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 Summary
Intramembrane proteolysis - hydrolysis of  membrane proteins within or close to their 
membrane-spanning regions - is a crucial cellular process that is conserved throughout all 
kingdoms of life. It is executed by distinct classes of polytopic membrane proteins, the 
intramembrane-cleaving proteases, that provide a hydrophilic, proteinaceous environment 
accommodating membrane protein substrates as well as water molecules within the 
hydrophobic membrane interior and catalyse peptide bond hydrolysis. In particular, 
intramembrane-cleaving aspartyl proteases have received attention as the presenilins, the 
catalytic subunits of  the γ-secretase complex, were identified as key players in Alzheimer's 
disease pathophysiology. In addition to presenilins, mammalian genomes harbour presenilin 
homologues which include signal peptide peptidase (SPP) and SPP-like (SPPL) proteases. 
Among these, the Golgi-resident protease SPPL3 stands out as it is highly conserved among 
metazoa and SPPL3 orthologues are also found in plants. However, due to the lack of known 
substrates, SPPL3 has thus far hardly been characterised. Hence, the purpose of this study 
was to identify its substrates and elucidate its physiological function(s).
In the first part of  this study, the foamy virus envelope glycoprotein (FVenv) was identified as the 
first substrate of  SPPL3. This allowed to study SPPL3's proteolytic activity in detail, with a focus 
on its substrate selectivity and sensitivity towards previously characterised inhibitors of 
intramembrane-cleaving aspartyl proteases. Importantly, this study revealed in addition that two 
other intramembrane-cleaving proteases, SPPL2a and SPPL2b, also endoproteolyse FVenv. 
SPPL2b in particular had been studied in detail before and therefore SPPL3- and SPPL2b-
mediated endoproteolysis of FVenv were examined in parallel to directly compare these 
phylogenetically related intramembrane-cleaving proteases. This uncovered an unexpected 
idiosyncrasy of  SPPL3 that clearly sets SPPL3 apart from other intramembrane-cleaving 
aspartyl proteases: SPPL3 endoproteolysed full-length FVenv and did not require the 
substrate's prior tailoring by another proteolytic activity - an otherwise common phenomenon 
among intramembrane-cleaving aspartyl proteases.
In the second part, the physiological function of SPPL3 was investigated. Alterations in the 
cellular levels of proteolytically active SPPL3 turned out to impact the composition of N-glycans 
attached to endogenous cellular glycoproteins. SPPL3 over-expression was accompanied by a 
decrease in glycoprotein molecular weight, i.e. a hypoglycosylation phenotype, while loss of 
SPPL3 expression in cell culture models but also in vivo resulted in a hyperglycosylation 
phenotype. This led to the identification of  Golgi glycan-modifying enzymes such as GnT-V and 
β3GnT1 as novel physiological substrates of SPPL3. Loss or reduction of SPPL3 expression, 
for instance, led to a marked intracellular accumulation of these enzymes, explaining the more 
extensive N-glycan elaboration and the hyperglycosylation phenotype observed under these 
conditions. At the same time secretion of these enzymes was reduced under these conditions. 
Together with additional observations such as the mapping of the SPPL3 cleavage site to the 
membrane-spanning region of GnT-V, this study demonstrates that SPPL3-mediated 
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intramembrane proteolysis of such glycan-modifying enzymes liberates their active site-
harbouring ectodomains. Acting in this manner, SPPL3 controls the intracellular pool of active 
glycan-modifying enzymes.
Importantly, the finding that SPPL3 proteolytically cleaves full-length glycan-modifying enzymes 
and sheds their ectodomains is well in line with the observations made for FVenv and 
suggested that SPPL3 acts functionally equivalent to classical sheddases or rhomboid 
proteases but much unlike all other characterised mammalian intramembrane-cleaving aspartyl 
proteases. To examine whether these observations hold also true on a global cellular scale, a 
proteomic approach was undertaken in the third part of the study to define the SPPL3 
degradome of HEK293 cells in conditions of SPPL3 over-expression. On the one hand, this led 
to the identification of  numerous novel, mostly Golgi-resident candidate SPPL3 substrates and, 
considering the physiological implications, suggests that SPPL3 is very intricately linked to Golgi 
function. On the other hand, this approach supports the initial hypothesis that SPPL3 acts as a 
cellular type II membrane protein-selective sheddase.
Taken together, this study provides the first in-depth characterisation of the intramembrane 
protease SPPL3 and reveals the cellular function of SPPL3. SPPL3 displays considerable and 
marked differences to other intramembrane-cleaving aspartyl proteases and emerges as a 
fundamental cellular sheddase that exhibits strong selectivity for type II-oriented, Golgi-resident 
membrane proteins. Products of SPPL3-mediated endoproteolysis of these Golgi factors are 
secreted and/or may be subject to intracellular degradation which compromises their catalytic 
activity. Thus, SPPL3 indirectly controls protein glycosylation in the Golgi apparatus.
2! Summary
 Zusammenfassung
Intramembranproteolyse, die hydrolytische Spaltung von Membranproteinen innerhalb ihrer 
Transmembrandomänen, ist ein wichtiger zellulärer Prozess, der in allen Reichen der 
Lebewesen konserviert ist. Die Intramembranproteolyse wird von unterschiedlichen Klassen 
von polytopen Membranproteinen, den Intramembranproteasen, ausgeführt, die eine hydrophile 
Proteinumgebung innerhalb des hydrophoben Bereichs der Membran bilden. In dieser 
Umgebung finden sowohl Membranproteinsubstrate als auch Wassermoleküle Platz und 
Hydrolyse der Peptidbindung wird durch die Intramembranproteasen katalysiert. Vor allem die 
Aspartylintramembranproteasen haben sehr viel Aufmerksamkeit auf sich gezogen, da die 
Preseniline, die katalytischen Untereinheiten des γ-Sekretasekomplexes, als Schlüsselenzyme 
in der Pathophysiologie der Alzheimer-Erkrankung identifiziert wurden. Neben den Presenilinen 
finden sich in Säugetiergenomen auch Presenilinhomologe, welche sowohl die 
Signalpeptidpeptidase (SPP) als auch SPP-ähnliche (SPP-like, SPPL) Proteasen umfassen.
Aus diesen sticht die im Golgi lokalisierte Protease SPPL3 heraus, da sie in vielzelligen Tieren 
hochkonserviert ist und sich SPPL3-Orthologe auch in Pflanzen finden. Gleichzeitig ist SPPL3 
jedoch, vor allem aufgrund der Tatsache, dass keine Substrate beschrieben wurden, bisher 
kaum charakterisiert. Daher war es das Ziel dieser Arbeit Substrate von SPPL3 zu identifizieren 
und seine physiologische Funktion(-en) aufzuklären.
Im ersten Teil dieser Arbeit wurde ein erstes SPPL3-Substrat, das foamy-virale Hüllglykoprotein 
(FVenv), identifiziert. Dies erlaubte die proteolytische Aktivität von SPPL3 und insbesondere 
seine Substratselektivität sowie seine Sensitivität gegenüber Inhibitoren von Aspartylintramem-
branproteasen im Detail zu untersuchen. Es konnte ebenfalls festgestellt werden, dass zwei 
weitere Intramembranproteasen, SPPL2a und SPPL2b, FVenv ebenfalls endoproteolytisch 
spalten. Vor allem SPPL2b war bereits zuvor im Detail untersucht worden und daher konnte die 
SPPL3- beziehungsweise SPPL2b-vermittelte Endoproteolyse von FVenv verglichen werden. 
Dies offenbarte eine unerwartete Eigenheit von SPPL3, welche SPPL3 deutlich von anderen 
Intramembranproteasen, vor allem den anderen Aspartylintramembraneproteasen, 
unterschiedet: SPPL3 spaltete das FVenv-Holoprotein und bedarf keinem vorherigen 
Zuschneiden des Substrates durch eine andere proteolytische Aktivität - ein sonst sehr 
verbreitetes Phänomen bei Intramembranproteasen.
Im zweiten Teil sollte die physiologischen Funktion von SPPL3 untersucht werden. Dabei zeigte 
sich, dass Änderungen in der zellulären SPPL3-Aktivität große Auswirkungen auf die 
Zusammensetzung der N-Glykane auf  endogenen zellulären Glykoproteinen haben. SPPL3-
Überexpression ging mit einer Reduktion des Molekulargewichts untersuchter Glykoproteine, 
einem so genannten Hypoglykosylierungsphänotyp, einher, während der Verlust der SPPL3-
Expression im Zellkulturmodell aber auch in vivo in einem Hyperglykosylierungsphänotyp 
resultierte. Dies führte zur Identifizierung von glykanmodifizierenden Enzymen im Golgi wie 
beispielsweise GnT-V und β3GnT1 als physiologische SPPL3-Substrate. Verlust oder 
Reduktion der SPPL3-Expression führte zu einer starken intrazellulären Akkumulation dieser 
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Substrate, was die unter diesen Bedingungen beobachtete umfassendere N-Glykan-
ausarbeitung sowie den Hyperglykosylierungsphänotyp erklärte. Gleichzeitig wurde die 
Sekretion dieser Enzyme unter diesen Bedingungen stark beeinträchtigt. Zusammen mit 
weiteren Beobachtungen wie der Bestimmung der SPPL3-Schnittstelle im Bereich der 
Transmembrandomäne von GnT-V zeigte diese Studie, dass die von SPPL3 vermittelte 
Intramembranproteolyse solcher glykan-modifizierenden Enzyme deren Ektodomainen freisetzt 
und SPPL3 folglich auf  diese Weise das intrazelluläre Reservoir aktiver glykan-modifizierender 
Enzyme kontrolliert.
Hervorzuheben ist dabei, dass diese Erkenntnis in guter Übereinstimmung mit den für FVenv 
gemachten Beobachtungen steht. Dies legt wiederum nahe, dass SPPL3 in funktioneller 
Hinsicht mit einer klassischen Sheddase oder einer Rhomboidprotease gleichgestellt ist, sich 
jedoch von allen anderen charakterisierten Aspartylintramembranproteasen in Säugetieren 
unterscheidet. Um herauszufinden, ob diese Beobachtungen auch auf globaler zellulärer Ebene 
Bestätigung finden, wurde eine Proteomanalyse im dritten Teil dieser Arbeit durchgeführt, um 
das SPPL3-Degradom in HEK293-Zellen unter Überexpressionsbedingungen zu definieren. 
Dies führte einerseits zur Identifizierung vieler weiterer neuer, zumeist im Golgi lokalisierter 
SPPL3-Substratkandidaten und legte andererseits unter physiologischen Gesichtspunkten 
nahe, dass SPPL3 sehr mit der Funktion des Golgi-Apparats verwoben ist. Andererseits 
unterstützten diese Ergebnisse sehr deutlich die formulierte Hypothese, dass SPPL3 als 
zelluläre Typ-II-Membranprotein-selektive Sheddase agiert.
Zusammengefasst liefert diese Arbeit die erste ausführliche Charakterisierung der Intramem-
branprotease SPPL3. SPPL3 zeigt erhebliche Unterschiede zu anderen Aspartylintramembran-
proteasen und erweist sich damit als bedeutende zelluläre Sheddase mit einer auffälligen 
Selektivität für Typ-II-orientierte, im Golgi lokalisierte Membranproteine. Produkte der 
Endoproteolyse dieser Golgi-Proteine werden sekretiert und/oder werden möglicherweise 
intrazellulär degradiert, was wiederum ihre eigentliche intrazelluläre Funktion beeinträchtigt. 
Folglich kontrolliert SPPL3 indirekt die Proteinglykosylierung im Golgi-Apparat.
4! Zusammenfassung
 1. Introduction
Physiological processes require tightly regulated and concerted activity of proteins. This is 
ensured by a number of  mechanisms, including the regulation of  gene expression, but on the 
post-translational level by regulation of  protein secretion or its sub-cellular localisation and 
trafficking as well as by post-translational modifications. Among the latter, hydrolytic cleavage of 
peptide bonds or proteolysis is special as it is a non-reversible process. Proteolytic processing 
of protein substrates allows for instance for the activation of catalytically inactive zymogens, the 
release of  bioactive factors from cells or scaffolds and the regulated degradation or inactivation 
of proteins (Turk et al, 2012).
Like extracellular and intracellular protein factors, membrane-anchored proteins are also subject 
to proteolytic processing, yet they harbour hydrophobic transmembrane domains (TMDs) which 
span the hydrophobic core of cellular membranes (Rath & Deber, 2012) and thus are hardly 
accessible to conventional proteases. It is meanwhile, however, established that proteolytic 
cleavage can in fact occur within membrane-spanning protein domains of numerous membrane 
proteins and that this process, also termed regulated intramembrane proteolysis (RIP) (Brown 
et al, 2000), is mediated by non-conventional proteases, the intramembrane-cleaving proteases 
(I-CLiPs) (Wolfe & Kopan, 2004).
1.1. Regulated Intramembrane Proteolysis
The term RIP was coined by Brown et al. in 2000 and describes a two-step proteolytic 
processing of  transmembrane proteins (Brown et al, 2000) which is schematically depicted for a 
single-pass membrane protein in Fig. 1.1. In an initiating step, transmembrane protein 
substrates are proteolytically cleaved within the juxtamembrane region. In case of  single-pass 
membrane proteins this liberates the bulk of  their respective ectodomain into the luminal and/or 
extracellular space, leaving behind a membrane-embedded fragment with a significantly 
shortened ectodomain. The subsequent secondary cleavage occurs within the substrate‘s TMD 
and liberates an additional luminal/extracellular protein fragment as well as a cytosolic peptide, 
the intracellular domain (ICD). In most cases the secondary cleavage depends on the preceding 
primary one as full-length membrane protein substrates cannot be processed by most 
intramembrane proteases catalysing the secondary cleavage. RIP is conserved from 
prokaryotes to mammals and proteolytic processing of numerous membrane protein substrates 
follows this basic principle (Brown et al, 2000). Importantly, RIP of a particular membrane 
protein substrate will generate distinct cleavage products which may be biologically active and 
have important (patho-)physiological functions (Brown et al, 2000; Lichtenthaler et al, 2011).
1.1.1. Primary Cleavage: Ectodomain Shedding
When considering type I or type II single-pass membrane protein RIP substrates, the primary 
cleavage event is termed shedding as it liberates the bulk of  the protein‘s ectodomain from its 
membrane anchor. Enzymes catalysing this proteolytic cleavage are referred to as sheddases. 
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Often, they belong to the a disintegrin and metalloprotease (ADAM) family of metzincin 
metalloproteases. These are type I membrane proteins which mediate ectodomain shedding of 
numerous membrane protein substrate proteins via their Zn2+-harbouring metalloprotease 
domain (reviewed in (Edwards et al, 2008)). Depending on the substrate's topology, ADAM-
mediated ectodomain shedding generates membrane-embedded N- or C-terminal fragments 
(NTFs or CTFs) that often are subject to subsequent intramembrane proteolysis. Alternatively, 
membrane-proximal ectodomain cleavage may also be catalysed by other proteases, for 
instance by aspartyl proteases (e.g. β-site of amyloid precursor protein cleaving enzyme 1 
(BACE), see 1.4.1.2.2), type II transmembrane serine proteases (Hooper et al, 2001), and 
others. 
Moreover, type III membrane proteins that comprise more than one TMD may similarly be 
subject to RIP (Brown et al, 2000). Unlike during RIP of  single-pass membrane proteins, 
cleavage products of  type III proteins generated by the primary cleavage event are not released 
from membranes or secreted. In this case the primary membrane-proximal cleavage that 
initiates RIP occurs within a lumenal loop between two TMDs and, accordingly, both cleavage 
products remain tethered to the membrane via these TMDs. 
1.1.2. Secondary Cleavage: Intramembrane Proteolysis
Following ectodomain removal, truncated membrane-embedded protein fragments may 
subsequently be endoproteolysed within their membrane-spanning domains by I-CLiPs. All I-
CLiPs are multi-pass membrane proteins and can, like conventional proteases (Hartley, 1960), 
be subcategorised according to the respective mechanism of catalysis (Wolfe, 2009). So far, 
intramembrane-cleaving metalloproteases (section 1.2) as well as serine (section 1.3) and 
aspartyl proteases (section 1.4) have been described. Currently, no intramembrane-cleaving 
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Fig. 1.1: Regulated intramembrane proteolysis (RIP). Membrane-spanning substrates are first 
endoproteolysed within their juxtamembrane region (shedding, (1)) generating a soluble ectodomain and 
a membrane-embedded protein fragment. The latter may then be subject to intramembrane proteolysis 
within its TMD (2), liberating a soluble fragment into the lumenal  or extracellular space and an ICD into 
the cytosol.
cysteine proteases are known but very recently a novel glutamate I-CLiP was identified 
(Manolaridis et al, 2013).
Intramembrane proteolysis, however, is clearly distinct from proteolysis catalysed by 
conventional proteases on soluble substrates. First, access to polar water molecules which are 
critically required for hydrolytic cleavage of peptide bonds is limited within the membrane‘s 
hydrophobic interior. However, structural studies on selected I-CLiPs have meanwhile 
established that these enzymes overcome this by providing a proteinaceous environment which 
enables water molecules to reach the scissile peptide bond allowing for proteolysis within the 
hydrophobic membrane plane (reviewed in (Urban & Shi, 2008)). Second, due to the 
hydrophobic nature of the membrane core, polar or charged amino acid residues are usually 
excluded from substrate TMDs (Heijne, 2006; Rath & Deber, 2012) and TMD peptides often 
adopt an α-helical conformation (Popot & Engelman, 2000; Rath & Deber, 2012) which would 
hinder proteases from accessing the peptide backbone and thus prevent proteolysis. It was 
therefore hypothesised that intramembrane proteolysis may only occur when substrate TMDs 
harbour an intrinsic structural flexibility or instability to support a local unfolding upon binding to 
an I-CLiP which then allows for proteolytic attack on scissile bonds (Lemberg & Martoglio, 
2004).
1.2. Intramembrane-cleaving metalloproteases
Intramembrane-cleaving metalloproteases were the first I-CLiPs identified. The human family 
member, S2P (Fig. 1.2a), was identified 1997 by complementation cloning as a factor facilitating 
liberation of  membrane-tethered transcription factors into the cytosol and the nucleus (Rawson 
et al, 1997). Human S2P and S2P-like I-CLiPs found in other species are multi-pass membrane 
proteins and harbour a HExxH motif1 characteristic of zinc-dependent metalloprotease in one of 
their TMDs and an additional LDG motif  in another one (Fig. 1.2a) (Brown et al, 2000; Wolfe, 
2009). These motifs are critically required for proteolytic activity and, therefore, were anticipated 
to co-ordinate the active site Zn2+ ion (Rawson et al, 1997; Zelenski et al, 1999). This notion 
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1 Here and in the following catalytically required active site residues are highlighted in bold.
Fig. 1.2: Intramembrane-cleaving metalloproteases. (a) Schematic depiction of the S2P which 
harbours six TMDs and has cytosolic  N- and C-termini. Catalytic consensus motifs in TMD2 and TMD4 
are highlighted in red, residues co-ordinating the active site Zn2+ in bold. (b) Processing of SREBPs by 
S1P and S2P proteases. SREBPs have a hair-pin topology and are successively cleaved by S1P within 
the lumenal loop and by S2P in their first TMD. The latter cleavage liberates the trans-activating domain 
(TF) that translocates to the nucleus. The regulatory domain (REG) binds to the cholesterol  sensor 
SCAP. S1P and S2P process other substrates in a similar fashion. Adapted from (Wolfe, 2009).
received strong support from a crystal structure that was recently reported for 
Methanocaldococcus jannaschii S2P (Feng et al, 2007).
S2P and S2P-like proteases facilitate proteolytic release of biologically active protein fragments 
from their membrane anchors (reviewed in (Brown et al, 2000; Wolfe, 2009; Chen & Zhang, 
2010)). In humans their substrates include membrane-bound transcription factors such as the 
human sterol regulatory element binding protein (SREBP) (Hua et al, 1995) and others that 
have a hairpin topology with two membrane-spanning segments (Fig. 1.2b). Importantly, S2P 
strictly follows the RIP scheme and requires its substrates to be cleaved within their lumenal 
loop prior to intramembrane cleavage. This is mediated by another protease, the site-1 protease 
(S1P), a substilisin-like serine protease (Shen & Prywes, 2004). In bacteria, S2P substrates are 
transcription factors that are tethered to the membrane by a single TMD but they likewise have 
to be tailored before being endoproteolysed by S2P. Unlike S2P, however, S1P is not conserved 
throughout species and in other organisms unrelated proteases possess a S1P activity (Chen & 
Zhang, 2010).
In mammals, the S1P-S2P proteolytic cascade was found to be crucially involved in the 
regulation of  cholesterol metabolism (Fig. 1.2b) (Brown et al, 2000; Wolfe, 2009; Chen & Zhang, 
2010). SREBPs are membrane-tethered transcription factors that, when translocated to the 
nucleus, regulate expression of genes involved in the biosynthesis of  cholesterol (Brown & 
Goldstein, 1997). Under normal conditions, SREBPs are retained in the ER by interaction with 
the membrane protein SCAP which at the same time functions as a cholesterol sensor. As S1P 
and S2P localise to post-ER compartments they cannot access their substrates. Consequently, 
SREBP signalling is prevented. Upon depletion of cellular cholesterol, however, SCAP facilitates 
anterograde transport of SREBPs to the Golgi compartment. There, S1P and S2P 
endoproteolyse SREBPs and their trans-activating domain is released from its membrane 
anchor, translocates to the nucleus, and up-regulates cholesterol biosynthesis (Brown et al, 
2000; Wolfe, 2009; Chen & Zhang, 2010). In a very similar manner the transcription factor ATF6 
is liberated from post-ER membranes as part of the unfolded protein response in eukaryotes 
(Kaufman et al, 2002) and bacterial S2P-like proteases liberate specific bacterial transcription 
initiation factors, the σ-factors, from membranes (Chen & Zhang, 2010).
1.3. Intramembrane-cleaving serine proteases
Intramembrane-cleaving serine proteases or rhomboids (Fig. 1.3) are present in all kingdoms of 
life and have evolved fundamental but at the same time highly diverse physiological functions. 
In bacteria rhomboids are implicated in quorum sensing, while in intracellular protozoan 
parasites rhomboids cleave adhesins and are required for host cell invasion (Urban, 2006; 
Freeman, 2008; Urban & Dickey, 2011). Being clearly crucial to epidermal growth factor (EGF) 
signalling in Drosophila, the rhomboids' role in other invertebrates and vertebrates is less well 
understood (Urban, 2006; Urban & Dickey, 2011). The mammalian rhomboid RHBDL4 was 
recently found to be up-regulated by ER stress and to function as an ubiquitin-dependent 
intramembrane proteases that cleaves unstable membrane proteins and initiates their 
degradation by the ER-associated degradation (ERAD) machinery (Fleig et al, 2012). The 
mitochondrial rhomboid protease PARL has been intricately linked to mitochondrial function, 
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mitophagy and apoptosis and may be involved in Parkinson‘s disease pathophysiology 
(reviewed in (Urban & Dickey, 2011)). Presently, however, the physiological role of  other 
mammalian rhomboid proteases remains largely unknown.
1.3.1 Catalytic mechanism, topology and structure of rhomboids
Rhomboids employ a catalytic serine-histidine dyad to catalyse peptide bond hydrolysis 
(Fig. 1.3a) (Lemberg et al, 2005). They are polytopic membrane proteins, but in silico topology 
analyses predict some degree of variation in rhomboid topology (Lemberg & Freeman, 2007a). 
All rhomboids comprise a six TMD core domain that harbours the residues of  the serine-
histidine dyad in TMD4 and TMD6, respectively. Some rhomboids, for example Drosophila 
Rhomboid-1 (Fig. 1.3a), contain an additional C-terminal TMD, while others like mitochondrial 
rhomboids have an additional TMD N-terminal of the six TMD core.
In recent years, a number of  crystal structures have been obtained for bacterial rhomboids 
(reviewed in (Lemberg & Freeman, 2007b; Freeman, 2008; Urban, 2010)). In sum, they 
revealed that the six TMD helices of  the rhomboid core form a tight bundle in the membrane 
plane and prove that proteolysis catalysed by rhomboids in fact occurs inside the membrane 
plane as the active site is buried within this core bundle. 
1.3.2 Substrate requirements and regulation of rhomboid activity
Rhomboids endoproteolyse type I membrane protein substrates (i.e. in Nout/Cin topology), such 
as EGF ligands like Drosophila Spitz (Urban, 2006; Lemberg & Freeman, 2007b; Freeman, 
2008). The topology of  mitochondrial rhomboids, however, is inverted and, accordingly, they 
cleave Nin/Cout substrates (Lemberg & Freeman, 2007a; 2007b). Cleavage within rhomboid 
substrates occurs in a region close to the membrane boundary and rhomboids in fact appear to 
exhibit some degree of specificity towards particular substrate regions (Urban & Freeman, 2003; 
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Fig. 1.3: Rhomboid I-CLiPs. (a) Schematic  depiction of Drosophila Rhomboid-1. Rhomboid-1 is a 
rhomboid with a 6+1 topology, containing a TMD C-terminal to the six TMD rhomboid core (dotted line). 
Catalytic residues in TMD4 and TMD6 are highlighted in bold. The catalytic serine is found in a 
conserved GxSx motif. (b) Schematic depiction of an iRhom, which - unlike active rhomboids - has an 
extended N-terminus, a large iRhom homology domain (IRHD) between TMD1 and TMD2 and a proline 
residue directly upstream of the catalytic  serine position. Active site serine and histidine residues may be 
missing in iRhoms (X). Adapted from (Freeman, 2008).
Strisovsky et al, 2009). Importantly, a recent study established that rhomboids recognise a 
rather specific sequence motif  within their substrates that harbours a small amino acid residue 
in the P1 position as well as hydrophobic and large ones in P4 and P2‘ positions making 
rhomboids sequence-specific I-CLiPs (Strisovsky et al, 2009).
Intriguingly, rhomboid I-CLiPs directly endoproteolyse full-length substrates and do not rely on 
prior substrate processing by another protease (Urban, 2006; Lemberg & Freeman, 2007b; 
Freeman, 2008). Hence, they do formally not follow  the RIP concept (see 1.1) as they are not 
regulated by a preceding proteolytic shedding event. In fact, rhomboids themselves act 
functionally equivalent to sheddases as they liberate membrane-bound precursors. Their activity 
seems to be controlled by regulation of gene expression (Urban, 2006) and by sub-cellular 
segregation of substrate and protease (reviewed in (Urban, 2006; Freeman, 2008)).
1.3.3 Proteolytically inactive rhomboid-like proteins
In addition to active rhomboid I-CLiPs, proteolytically inactive homologues, the so-called 
inactive rhomboids (iRhoms, Fig. 1.3b) and the derlins, have been identified (Lemberg & 
Freeman, 2007a; Adrain & Freeman, 2012). Sequence analysis of iRhoms revealed that they 
form a distinctive sub-clade of the rhomboid family (Lemberg & Freeman, 2007a) but also that 
some iRhoms lack either or both catalytic residues required for rhomboid proteolytic activity 
suggesting they are not proteolytically active (Lemberg & Freeman, 2007a; Adrain & Freeman, 
2012). iRhoms share with most mammalian rhomboids the characteristic topology. Unlike active 
rhomboids, they harbour, however, a conserved proline residue immediately upstream of the 
expected position of the catalytic serine and a characteristic insertion of  a conserved, cysteine-
rich and likely globular iRhom homology domain (IRHD) between TMD1 and TMD2 (Lemberg & 
Freeman, 2007a; Freeman, 2008). iRhoms are highly conserved in animals (Lemberg & 
Freeman, 2007a) and only recently have been characterised functionally (Zettl et al, 2011; 
Adrain et al, 2012; McIlwain et al, 2012). iRhoms apparently lack proteolytic activity towards 
transmembrane proteins yet retain their capacity to associate with such factors and appear to 
control ER-to-Golgi trafficking of  transmembrane proteins (Adrain & Freeman, 2012). In 
Drosophila, for instance, iRhom blocks ER-to-Golgi transport of growth factors (Zettl et al, 
2011), whereas in mice iRhom2 promotes ER export of certain membrane protein clients 
(Adrain et al, 2012; McIlwain et al, 2012). The existence of  inactive protease pseudo-enzymes 
is, however, a unique feature of rhomboid I-CLiPs and presently no proteolytically inactive 
homologues of other I-CLiPs have been described.
1.4. Intramembrane-cleaving aspartyl proteases
Intramembrane-cleaving aspartyl proteases constitute the third family of I-CLiPs2. In aspartyl I-
CLiPs, one of the catalytic aspartate residues is found within a conserved GxGD motif  and 
these proteases are therefore collectively referred to as GxGD proteases (Steiner et al, 2000). 
They include the presenilins (Steiner et al, 2000) (see 1.4.1), signal peptide peptidase (SPP) 
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2  Note that, herein, the terms "family" and "subfamily" are not used in accordance with the MEROPS peptidase database 
(merops.sanger.ac.uk). MEROPS lists GxGD proteases as two independent protease families with presenilins (A22A) and SPP/
SPPLs (A22B) each forming a subfamily of the protease family A22 and TFPPs (A24A) and PFPs (A24B) of the family A24.
and SPP-like (SPPL) proteases (Weihofen et al, 2002; Ponting et al, 2002; Grigorenko et al, 
2002) (see 1.4.2) as well as the bacterial type IV pre-pilin peptidases (TFPPs) (Steiner et al, 
2000; LaPointe & Taylor, 2000) and the Archaeal pre-flagellin peptidases (PFPs) (Bardy & 
Jarrell, 2003) (Fig. 1.4).
1.4.1 Presenilins and the γ-secretase complex
As early as 1995 it became apparent that mutations in PSEN1 and PSEN2, the genes encoding 
the two human presenilins, presenilin 1 (PS1) and presenilin 2 (PS2), respectively, are 
associated with early-onset, familial forms of  Alzheimer‘s disease (AD) (Rogaev et al, 1995; 
Sherrington et al, 1995; Levy-Lahad et al, 1995b; 1995a). Presenilins have since been subject 
to extensive examination and, hence, are without doubt the best-studied GxGD proteases. 
1.4.1.1 Presenilin topology and γ-secretase complex architecture
Presenilins are the catalytic subunits of the heterotetrameric γ-secretase complex (Fig. 1.5). In 
addition to presenilin (either PS1 or PS2 in mammals), the γ-secretase complex contains the 
single-span membrane protein Nicastrin as well as presenilin enhancer-2 (PEN-2) and an 
isoform of  the polytopic membrane protein anterior pharynx defective-1 (APH-1) (Haass, 2004). 
Most likely these subunits are found in the γ-secretase complex in a 1:1:1:1 stoichiometry (Sato 
et al, 2007). All four subunits are required but at the same time sufficient for assembly of  an 
active γ-secretase complex (Edbauer et al, 2003; Kimberly et al, 2003). In addition, studies 
observed co-isolation of  additional protein factors with the γ-secretase complex, e.g. of CD147 
(Zhou et al, 2005). However, in a subsequent study such factors failed to co-isolate with 
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Fig. 1.4: GxGD-type aspartyl ICLiPs. The family of GxGD-type intramembrane-cleaving aspartyl 
proteases comprises the presenilins (a), SPP/SPPLs (b), TFPPs (c), and PFPs (d). All these proteases 
are multi-pass membrane proteins harbouring an active site GxGD motif in one of their TMDs and a 
second catalytic aspartate residue in another TMD (purple arrowheads). Human GxGD proteases have a 
conserved PAL motif within their last TMD and in TFPPs and PFPs a conserved proline residue can be 
found at the very same site. Note that presenilins (a) and SPP/SPPLs (b) share a highly homologous 
structural organisation but their overall topology is inverted. Presenilins are not catalytically active in vivo 
unless found with additional co-factors within the γ-secretase complex (purple box). Structures depicted 
here resemble human PS1 (a), human SPP (b), Vibrio cholerae TcpJ (c), and Methanococcus 
maripaludis FlaK (d). Taken from (Voss et al, 2013).
catalytically active γ-secretase (Winkler et al, 2009), questioning their suspected roles as crucial 
complex components. 
Presenilin itself is a multi-pass membrane protein and adopts a nine TMD topology (Fig. 1.4a & 
Fig. 1.5a) (Henricson et al, 2005; Laudon et al, 2005; Spasic et al, 2006). Its proteolytic activity 
depends on two aspartate residues located in the adjacent TMD6 and TMD7, the first one within 
a conserved YD motif  (D257 in human PS1), the second within the GxGD motif  (D385 in human 
PS1) (Wolfe et al, 1999; Steiner et al, 1999; Laudon et al, 2004). In the native γ-secretase 
complex, these two residues were found to be facing each other in close proximity and to be 
accessible to water, supporting their role in catalysis (Tolia et al, 2006; Sato et al, 2006a). Also, 
the PAL motif  in the N-terminal region of TMD9 was shown to be accessible to water and to be 
located close to the catalytic aspartate residue D257 in TMD6 (Tolia et al, 2008; Sato et al, 
2008). Taken together, these biochemical data suggest that TMD6, TMD7, and TMD9 of 
presenilin tightly associate to form the hydrophilic active site of γ-secretase. Interestingly, a 
similar spatial arrangement of  TMD6, TMD7, and TMD9 is apparent in the crystal structures of 
Archaeal GxGD proteases (Hu et al, 2011; Li et al, 2013).
Presenilin is endoproteolysed within the extended cytosolic loop that connects TMD6 and TMD7 
by an at that time elusive "presenilinase" activity that generates presenilin NTF and CTF 
(Thinakaran et al, 1996). Presenilinase activity, however, is impaired when the catalytic 
aspartate residues are mutagenised (Wolfe et al, 1999) and presenilinase precision is affected 
by FAD mutations in presenilin (Fukumori et al, 2010), suggesting that endoproteolysis is in fact 
autocatalytic. Presenilin NTF and CTF remain tightly associated as heterodimer (Capell et al, 
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Fig. 1.5: Architecture of the human γ-secretase complex. (a) Active, mature γ-secretase is a 
heterotrimeric complex consisting of PEN-2 (yellow), either PS1 or PS2 (red), an APH-1 isoform (blue), 
and the glycoprotein Nicastrin (green). Active site motifs in presenilin are highlighted. Note that presenilin 
NTF and CTF are generated by endoproteolysis between TMD6 and TMD7. (b) Spatial subunit 
arrangement of native γ-secretase as determined by chemical cross-linking. Adapted from (Steiner et al, 
2008b).
1998) and are bound by transition state analogue inhibitors of  γ-secretase suggesting that the 
NTF/CTF heterodimer is the actual active subunit of γ-secretase (Esler et al, 2000).
Nicastrin was identified by co-immunoprecipitation with PS1 and PS2 in human cells (Yu et al, 
2000). It is a type I membrane protein with a large ectodomain and, in its mature form, harbours 
a number of  asparagine-linked complex glycans (Edbauer et al, 2002; Yang et al, 2002; Leem et 
al, 2002). Its ectodomain was proposed to serve as substrate receptor of  the γ-secretase 
complex (Shah et al, 2005), but this finding is currently debated (Chávez-Gutiérrez et al, 2008). 
PEN-2 is a small hairpin protein that stabilises the presenilin NTC/CTF heterodimer (Prokop et 
al, 2004). The fourth complex component is APH-1 which adopts a seven TMD topology (Fortna 
et al, 2004). Elaborate biochemical analysis using chemical cross-linking of  endogenous γ-
secretase complexes purified from cultured cells revealed an overall model of intra-complex 
interactions (Fig. 1.5b). According to this, PEN-2 associates with the respective presenilin NTF, 
which in turn is associated with the presenilin CTF. APH-1 was cross-linked to both the 
presenilin CTF and to Nicastrin suggesting a tight spatial interaction of these subunits (Steiner 
et al, 2008b).
As an oligomeric complex, γ-secretase has to be assembled in a concerted and stepwise 
manner and progress of  assembly can be examined experimentally by monitoring Nicastrin 
maturation and presenilin endoproteolysis. Experimental evidence (LaVoie et al, 2003; Takasugi 
et al, 2003; Capell et al, 2005) suggests that γ-secretase assembly proceeds as follows: In the 
ER, it is initiated by the formation of a Nicastrin and APH-1 heterodimer which subsequently 
binds the presenilin holoprotein. Association of PEN-2 with the Nicastrin-APH-1-presenilin 
heterotrimereric sub-complex then triggers presenilin endoproteolysis and the fully assembled 
heterotetrameric γ-secretase complex reaches the Golgi compartment where Nicastrin becomes 
complexly N-glycosylated. ER-localised γ-secretase appears to be catalytically inactive (Cupers 
et al, 2001) and proteolytically active γ-secretase complexes likely reside at the plasma 
membrane as well as within the endosomal/lysosomal compartment (Kaether et al, 2006). 
 
1.4.1.2 Physiological function of γ-secretase-mediated intramembrane proteolysis
Numerous (> 90) membrane proteins have been described to be hydrolysed by the γ-secretase 
complex (Kopan & Ilagan, 2004; Haapasalo & Kovacs, 2011) and more are being identified. γ-
secretase-mediated cleavage of such substrates liberates protein fragments from the 
membrane with potential biological activity. In some cases, it is well established that ICDs 
generated can potentially translocate to the nucleus and regulate transcription of  target genes. 
In such cases, RIP in fact constitutes a pathway of  signal transduction (Fortini, 2002). However, 
in light of  the large number of substrates identified and the apparent absence of  primary 
sequence-based substrate recognition motifs (Beel & Sanders, 2008), it was postulated that γ-
secretase acts as an intramembrane equivalent of the cytosolic proteasome and facilitates non-
selective degradative turn-over of type I membrane protein fragments (Kopan & Ilagan, 2004). 
However, proteomic datasets challenge this view  as only a minor fraction of proteins in HeLa 
cells were found to be subject to γ-secretase cleavage (Hemming et al, 2008) suggesting that 
not all type I membrane proteins are turned over by γ-secretase and γ-secretase displays a 
certain degree of substrate selectivity. Intramembrane cleavage of γ-secretase substrates has 
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been linked to various fundamental (patho-)physiological processes (reviewed in (Haapasalo & 
Kovacs, 2011), including Notch-dependent cell fate determination and differentiation (see 
1.4.1.2.1) and AD aetiology (see 1.4.1.2.2).
1.4.1.2.1 Notch regulated intramembrane proteolysis and cell fate determination
Notch signalling is a juxtacrine signalling pathway which determines cell fate specification in 
early ontogenic events as well as in adult organisms (reviewed in (Artavanis-Tsakonas et al, 
1999)). Notch receptors are type I transmembrane proteins that undergo extensive post-
translational modifications, including proteolytic processing (Fortini, 2002). Nascent Notch is 
subject to processing by furin in the Golgi network (S1 cleavage), is subsequently trafficked to 
the cell surface where, upon interaction with its membrane-anchored ligands on neighbouring 
cells, it is cleaved by ADAM proteases (S2 cleavage). Subsequent intramembrane cleavage of 
the membrane-embedded shedding product is mediated by the γ-secretase complex (S3 and 
S4 cleavages) (Fortini, 2002). This leads to the liberation of the Notch ICD (NICD) (Schroeter et 
al, 1998; De Strooper et al, 1999) as well as to secretion of  a Notch β-peptide (Okochi et al, 
2006). NICD translocates to the nucleus of  the signal-receiving cell and interacts with the DNA-
binding protein CSL (C promoter binding factor/suppressor of hairless/Lag-1) and the co-
activator Mastermind to promote transcription of  target genes (Fortini, 2002). The fundamental 
importance of Notch signalling in metazoan development is highlighted in animal models 
deficient in pathway components. In particular, mice that lack functional PS1 and PS2, PEN-2, 
Nicastrin, or the APH-1 isoform APH-1A die in utero and are characterised by severe 
developmental defects that resemble those observed for animals deficient in Notch (Wong et al, 
1997; Li et al, 2003; Serneels et al, 2005; Bammens et al, 2011).
1.4.1.2.2 APP intramembrane proteolysis and Alzheimer's Disease
The amyloid precursor protein (APP) is another type I membrane protein that is a γ-secretase 
substrate (reviewed in (Haass, 2004; Haapasalo & Kovacs, 2011; Lichtenthaler et al, 2011; 
Zhang et al, 2012)). The proteolytic processing of APP may either be amyloidogenic producing 
hydrophobic amyloid β (Aβ) peptides or non-amyloidogenic (Fig. 1.6) (Lichtenthaler et al, 2011; 
Zhang et al, 2012). Ectodomain shedding that initiates the amyloidogenic processing of  APP is 
executed by the β-site of  APP cleaving enzyme 1 (BACE1). BACE1 cleavage generates a 
soluble APP ectodomain (sAPPβ) and a membrane-embedded 99 amino acid CTF (CTFβ). The 
latter, in turn, is substrate to γ-secretase-mediated intramembrane proteolysis, which generates 
an APP ICD (AICD) as well as Aβ peptides (see below), the latter being key players in AD 
pathophysiology (Selkoe, 1991; Hardy & Higgins, 1992; Haass & Selkoe, 2007). The 
physiological function of  the AICD, however, is controversial (see discussion in (Lichtenthaler et 
al, 2011; Zhang et al, 2012)). Alternatively, APP is endoproteolysed by α-secretase activity 
(Esch et al, 1990), which is predominantly executed by ADAM10 (Kuhn et al, 2010). α-secretase 
shedding occurs within the Aβ domain of  APP and, thus, precludes Aβ peptide generation and is 
non-amyloidogenic (Lichtenthaler et al, 2011; Zhang et al, 2012). In addition to sAPPα, a 83 
amino acid CTFα is generated by α-secretase cleavage of APP and, like CTFβ, CTFα is subject 
to γ-secretase-catalysed intramembrane proteolysis leading to the generation of  the cytosolic 
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AICD and an additional secreted protein fragment, p3 (Lichtenthaler et al, 2011; Zhang et al, 
2012). p3 is significantly truncated compared to Aβ peptides, is less hydrophobic and less prone 
to form soluble oligomers (Dulin et al, 2008), which are considered the key synaptotoxic Aβ 
species (Haass & Selkoe, 2007).
AD is a devastating and - presently - inevitably progressive neurodegenerative disease that 
affects millions of ageing people worldwide (Jakob-Roetne & Jacobsen, 2009; Holtzman et al, 
2011; Ballard et al, 2011). It is accompanied by macroscopic brain atrophy and, 
histopathologically, by synapse loss and the presence of  two distinct types of proteinaceous 
aggregates, extracellular amyloid plaques and intracellular neurofibrillary tangles (reviewed in 
(Jakob-Roetne & Jacobsen, 2009; Holtzman et al, 2011)). Amyloid plaques are primarily found 
in cortical regions and their main constituents are Aβ peptides. It was hypothesised that Aβ 
peptides in fact constitute the pathogenic driver that initiates a cascade of pathophysiological 
events leading ultimately to AD pathology (amyloid cascade hypothesis) (Selkoe, 1991; Hardy & 
Higgins, 1992). Today, this notion is still regarded the key mechanism underlying AD pathology 
(discussed in (Karran et al, 2011)).
However, amyloidogenic processing of APP per se is not considered a pathological process. In 
fact, Aβ peptides can be found in bodily fluids (like cerebrospinal fluid) of healthy individuals 
demonstrating that Aβ generation is a normal physiological process (Seubert et al, 1992; Shoji 
et al, 1992). Importantly, γ-secretase cleavage of CTFβ generates Aβ peptides of  variable length 
ranging from 37 to 43 amino acids (Lichtenthaler et al, 2011; Holtzman et al, 2011). The most 
abundant product species under normal physiological conditions is Aβ40 that comprises 
residues 1 to 40 of the Aβ domain of  APP. Slightly longer species, in particular Aβ42, are 
likewise generated but only in minor amounts (roughly 10% of total Aβ) (Holtzman et al, 2011) 
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Fig. 1.6: RIP of APP. Schematic overview of non-amyloidogenic  (left) and amyloidogenic (right) 
proteolytic  processing of APP. Non-amyloidogenic processing is initiated (1) by an α-secretase (α) and 
the resulting CTFα is cleaved subsequently (2) by γ-secretase (γ). Amyloidogenic processing is initiated 
(1) by β-secretase (β) and the resulting CTFβ is also subsequently (2) cleaved by γ-secretase (γ). Note 
that γ-secretase-mediated cleavage of CTFβ results in heterogenous Aβ peptides that are variable in 
length (not depicted). Adapted from (Lichtenthaler et al, 2011).
yet the more hydrophobic Aβ42 is regarded as the major neurotoxic species and pathogenic 
factor initiating AD pathophysiology (reviewed in (Haass & Selkoe, 2007)). Recently, Aβ43 also 
(re-)emerged as highly neurotoxic Aβ species in vivo (Saito et al, 2011). Intriguingly, in a 
minority of AD cases (< 5%), referred to as familial AD (FAD), onset may occur rather early 
(age < 60 years) and these patients often harbour autosomal-dominant mutations in PSEN1 
(Rogaev et al, 1995; Sherrington et al, 1995) or, less frequently, in PSEN2 (Levy-Lahad et al, 
1995b; 1995a) and APP (Goate et al, 1991). A seminal study established that FAD mutations in 
PSEN1 or PSEN2 lead to increased secretion of  longer, neurotoxic Aβ species (i.e. Aβ42/Aβ43) 
(Scheuner et al, 1996) and elevated levels of  Aβ42/Aβ43 have since then been considered the 
underlying etiologic cause of FAD. FAD mutations can for instance cause an elevated overall Aβ 
production (including an absolute increase in Aβ42/Aβ43 abundance), e.g. in patients 
harbouring the "Swedish" M596L APP mutation at the BACE1 cleavage site (Citron et al, 1992). 
FAD mutations may also increase the Aβ42/Aβ43 to Aβ40 ratio, i.e. lead to an elevated Aβ42/
Aβ43 production at the expense of Aβ40 without a significant effect on total Aβ production 
(Suzuki et al, 1994). Taken together, long Aβ species such as Aβ42 and Aβ43 are considered 
key drivers of  AD pathology (Selkoe, 1991; Hardy & Higgins, 1992; Haass & Selkoe, 2007) and, 
hence, interference with APP intramembrane proteolysis has been considered a promising 
therapeutic strategy (see 1.4.4.4) (Karran et al, 2011). Importantly, however, FAD mutations in 
APP do not necessarily always affect APP processing and Aβ generation but can also change 
Aβ's biophysical properties, e.g. its propensity for aggregation or oligomerisation (Nilsberth et al, 
2001).
1.4.2 SPP and SPPLs
SPP and the SPPLs (Fig. 1.7) were identified in 2002 in three independent studies (Weihofen et 
al, 2002; Grigorenko et al, 2002; Ponting et al, 2002). In two of these studies bioinformatic 
database searches using PSI-BLAST and BLAST algorithms, respectively, were performed to 
find genes homologous to the presenilins and five such putative protein-coding genes were 
uncovered in humans (Ponting et al, 2002; Grigorenko et al, 2002). At the same time Weihofen 
et al. used a photocrosslinkable derivative of 1,3-di-(N-carboxybenzoyl-L-leucyl-L-leucyl)-amino 
acetone ((Z-LL)2 ketone), a compound that had been found to inhibit signal peptide 
endoproteolysis  in vitro before (Weihofen et al, 2000), to identify SPP as enzyme responsible for 
this activity and subsequently identified the related SPPL proteases (Weihofen et al, 2002). In 
humans and in rodents, the SPP/SPPL subfamily of  GxGD proteases comprises SPP and 
SPPL3 as well as SPPL2a, SPPL2b, and SPPL2c.
1.4.2.1 Key features of SPP/SPPL-type GxGD proteases
Sequence analyses of  all SPP/SPPLs predict a characteristic nine TMD topology resembling 
that of  presenilin (Fig. 1.7, see 1.4.1.1) (Weihofen et al, 2002; Ponting et al, 2002; Grigorenko et 
al, 2002; Friedmann et al, 2004). Strikingly, the predicted topology of  SPP/SPPLs is inverted 
compared to that of presenilins and experimental evidence supports the luminal and cytosolic 
localisation of SPP/SPPL N- and C-termini as well as the luminal accessibility of  the loop 
connecting TMD6 and TMD7 (Friedmann et al, 2004; Nyborg et al, 2004). All SPP/SPPL family 
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members harbour catalytic (Y/F)D and GxGD motifs in their predicted TMD6 and TMD7, 
respectively. In addition, they contain a QPALLY motif  in the tip region of  TMD9 that is similar to 
that found in presenilins (Weihofen et al, 2002; Grigorenko et al, 2002; Ponting et al, 2002). 
Amino acid substitutions in the proline, alanine or leucine residues of this motif  affect the 
proteolytic activity of  SPP (Wang et al, 2006) which was also observed for the corresponding 
mutations in presenilin (Tomita et al, 2001; Wang et al, 2004; 2006). Taken together, these 
observations suggest that key features of  the active site architecture are conserved among 
presenilin- and SPP/SPPL-type GxGD proteases (Voss et al, 2013).
In spite of these similarities, some differences between presenilins and SPP/SPPLs stand out: 
Exogenous expression of  SPP/SPPLs in cell culture leads to increased turnover of the 
respective substrates suggesting that SPP/SPPLs are proteolytically active as monomers or 
homomeric oligomers and do not require accessory cellular co-factors. Enzymatic activity of 
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Fig. 1.7: Human SPP/SPPL family members. In humans, the SPP/SPPL family comprises SPP (a), 
SPPL3 (b), SPPL2a (c), SPPL2b (d), and SPPL2c (e). All members share a nine TMD topology. They 
harbour catalytic YD and GxGD motifs as well  as a PALLYL motif (all  shown in purple, catalytic aspartates 
are given in bold and with their respective amino acid position). SPP (a) contains two putative consensus 
N-glycosylation sites as well as a C-terminal KKXX ER retention signal. SPPL3 (b) is not glycosylated, 
while SPPL2a (c), SPPL2b (d), and SPPL2c (e) harbour several  consensus N-glycosylation sites. SPP 
and SPPL3 lack N-terminal signal sequences. SPPL2 subfamily members contain N-terminal signal 
sequences that are post-translationally removed (Friedmann et al, 2004). These are highlighted in yellow 
according to the respective Uniprot entries and cleavage sites indicated by the black arrowheads. The 
SPPL2a C-terminus harbours a YKKΦ lysosomal  sorting signal. Two SPPL2b isoforms are conserved in 
humans and mice and they differ in the length of their cytoplasmic C-termini (shaded). Taken from (Voss 
et al, 2013).
SPP can be reconstituted by exogenous expression of solely human SPP in yeast (Weihofen et 
al, 2002), whereas reconstitution of γ-secretase in the same setting requires exogenous 
expression of all four complex components (Edbauer et al, 2003), indicating that SPP (and likely 
the SPPLs) do not require the formation of a γ-secretase-like complex to be active. Moreover, 
unlike presenilins (see 1.4.1.1), there is currently no conclusive evidence that SPP/SPPLs do 
undergo autocatalytic endoproteolysis.
1.4.2.2 Physiological functions of mammalian SPP/SPPL family members
There is unambiguous evidence that mammalian SPP/SPPL family members3  are active 
aspartyl I-CLiPs as their proteolytic activity is impaired by mutagenesis of the catalytically active 
aspartate residues or following treatment with transition state analogue inhibitors (Weihofen et 
al, 2002; Friedmann et al, 2006; Fluhrer et al, 2006; Martin et al, 2008), but additional non-
proteolytic functions of these protein cannot be excluded. In addition, several studies have 
contributed greatly to the present understanding their physiological function (Grigorenko et al, 
2004; Krawitz et al, 2005; Casso et al, 2005; Tang et al, 2010; Casso et al, 2012; 
Schneppenheim et al, 2013; Beisner et al, 2013; Bergmann et al, 2013; Bronckers et al, 2013; 
Schneppenheim et al, 2014) which will be discussed in the following sections. 
1.4.2.2.1 SPP
SPP is a glycosylated polytopic membrane protein (Weihofen et al, 2002), contains a C-terminal 
KKXX ER retention signal and, in line with this, was found to localise to the ER in human and 
murine cells (Urny et al, 2003; Krawitz et al, 2005; Friedmann et al, 2006). SPP appears to be of 
fundamental importance in vivo, in particular during metazoan development. For instance, 
Drosophila melanogaster larvae that lack spp, the Drosophila orthologue of human SPP, display 
a severe developmental phenotype, die early, and have abnormal tracheae (Casso et al, 2005). 
This phenotype was rescued by exogenous expression of active SPP, but not of the catalytically 
inactive mutant pointing to a fundamental role of  its aspartyl protease activity in development 
(Casso et al, 2005). SPP was initially identified due to its proteolytic activity towards signal 
peptides (Weihofen et al, 2000; 2002), but has meanwhile also been linked to the proteolytic 
processing of other substrates.  
N-terminal signal peptides ensure proper co-translational targeting of  nascent secretory and 
membrane pre-proteins (Paetzel et al, 2002). Subsequently, they are cleaved off the nascent 
pre-protein by the signal peptidase complex but remain embedded in the ER membrane due to 
their considerably high degree of hydrophobicity (Paetzel et al, 2002). By endoproteolysis within 
their hydrophobic membrane-spanning domain, signal peptides can be liberated from the ER 
membrane and may subsequently be subject to proteasomal degradation (Fig. 1.8a). For the 
prolactin signal peptide this proteolytic activity was initially found to be (Z-LL)2 ketone-sensitive 
(Weihofen et al, 2000) and was later attributed to SPP (Weihofen et al, 2002). Meanwhile, SPP 
has been described to endoproteolyse signal peptides of several other proteins after their 
liberation from nascent proteins by signal peptidase (reviewed in (Voss et al, 2013)). 
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3 Note that proteolytic activity of SPPL2c has not yet been observed, see section 1.4.2.2.2.
Importantly, together with signal peptidase activity, SPP can generate immunogenic peptide 
fragments of  MHC class I signal peptides (Lemberg et al, 2001; Bland et al, 2003) and of  non-
MHC signal peptides (Hage et al, 2008), thus contributing to immune surveillance and an 
alternative pathway of  generation of antigenic peptides for presentation via polymorphic MHC 
molecules.
In addition to the intramembrane cleavage of  signal peptides, SPP may - following pre-cleavage 
by the signal peptidase complex - also endoproteolyse internal membrane-spanning sequences 
(Fig. 1.8b). IgSF1, for instance, was found to be cleaved at an internal stop-transfer sequence 
in the ER membrane by signal peptidase and a (Z-LL)2 ketone-sensitive protease, most likely by 
SPP (Robakis et al, 2008). Signal peptidase and SPP also participate in proteolytic processing 
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Fig. 1.8: SPP-mediated intramembrane proteolysis. Schematic  overview of processes proteolytic  SPP 
activity was implicated in. (a) SPP-mediated signal peptide cleavage. Signal  peptides of nascent 
secretory proteins synthesised at the ER translocon are first cleaved off by signal peptidase (SP) and are 
subsequently endoproteolysed within their membrane-spanning hydrophobic  core by SPP. Note that in 
rare exceptions signal  peptide removal and cleavage may occur post-translationally (not depicted). (b) 
SPP cleaves within internal protein sequences. The hepatitis C virus core protein is liberated by stepwise 
proteolytic  processing of the viral  polyprotein precursor by SP and SPP. (c) SPP liberates cytosolic 
protein domains from tail-anchored ER membrane proteins. In contrast to processes depicted in a and b, 
liberation of tail-anchored proteins such as HO-1 from their membrane anchors does not require SP pre-
cleavage. Note that, depending on the individual  substrate, liberated protein fragments may face very 
diverse fates including degradation (e.g. of signal  peptide fragments), loading onto MHC complexes and 
recruitment to specific cellular sub-compartments (not depicted).
of the polyprotein precursor of  flaviviruses such as hepatitis C virus (Fig. 1.8b) (McLauchlan et 
al, 2002; Targett-Adams et al, 2006; Heimann et al, 2006). Importantly, this SPP-dependent 
cleavage is indispensable for proper virus propagation (Randall et al, 2007; Targett-Adams et al, 
2008; Okamoto et al, 2008).
Only recently, tail-anchored ER-resident membrane proteins were described as novel SPP 
substrate class (Hsu et al, 2014; Boname et al, 2014). The N-terminal cytosolic domains of such 
proteins are tethered to the ER membrane via C-terminal TMDs that are post-translationally 
inserted into the lipid bilayer (Shao & Hegde, 2011). SPP cleaves within such C-terminal TMDs, 
for instance of heme oxygenase-1 (HO-1) but also of  other tail-anchored proteins, liberating 
cytosolic domains from their ER membrane anchor and allowing for nuclear translocation or 
proteasomal degradation (Fig. 1.8c) (Hsu et al, 2014; Boname et al, 2014).
Finally, SPP has also been implicated in ER retrotranslocation and ERAD (Loureiro et al, 2006; 
Christianson et al, 2012; Harbut et al, 2012). Loureiro et al., for instance, reported that human 
cytomegalovirus US2 physically interacts with SPP and that this complex facilitates 
retrotranslocation of  MHC class I molecules from the ER leading to down regulation of  MHC 
class I surface expression and immune evasion (Loureiro et al, 2006) (though this was recently 
questioned (Boname et al, 2014)). Also, SPP was recently found to be part of the human ER 
retrotranslocation machinery (Christianson et al, 2012). In protozoan parasites this machinery is 
less complex than in mammals as they lack several orthologues of human pathway components 
(Harbut et al, 2012). Nonetheless, Harbut et al. found that Plasmodium falciparum SPP is 
involved in retrotranslocation and that treatment with small molecule inhibitors targeting SPP 
interferes with this activity and is toxic to Plasmodium (Nyborg et al, 2006; Harbut et al, 2012).
1.4.2.2.2 The SPPL2 subfamily
In humans and rodents, the SPPL2 subfamily comprises SPPL2a, SPPL2b, and SPPL2c 
(Weihofen et al, 2002; Grigorenko et al, 2002; Ponting et al, 2002). These have an N-terminal 
signal peptide (Friedmann et al, 2004) and comprise an extended and highly glycosylated N-
terminal exoplasmic region upstream of the conserved nine TMD core (Fig. 1.7) (Friedmann et 
al, 2004; Krawitz et al, 2005). 
SPPL2 subfamily members appear to be differentially localised in the cell: SPPL2a was found to 
harbour a lysosomal sorting signal within its lumenal C-terminus (Behnke et al, 2011) and, 
accordingly, both over-expressed (Friedmann et al, 2006; Behnke et al, 2011) as well as 
endogenous SPPL2a (Behnke et al, 2011) were primarily observed to localise to the lysosomal 
or late endosomal compartment. Conflicting results, however, have so far been obtained for 
over-expressed SPPL2b which was observed primarily at the cell surface (Friedmann et al, 
2004; Behnke et al, 2011), the Golgi (Martin et al, 2008), or in the lysosomal compartment 
(Krawitz et al, 2005).
In cell culture-based assays, SPPL2a and SPPL2b appear to have - to certain degree - an 
overlapping substrate repertoire as over-expressed tumour necrosis factor α (TNFα) (Fluhrer et 
al, 2006; Friedmann et al, 2006), Bri2 (Martin et al, 2008), CD74 NTFs (Schneppenheim et al, 
2014) and transmembrane protein 106B (TMEM106B) (Brady et al, 2014) are endoproteolysed 
both by over-expressed SPPL2a and SPPL2b. FasL and transferrin receptor 1 (TfR1) NTFs, 
20! Introduction
however, appear to be primarily processed by over-expressed SPPL2a (Kirkin et al, 2007) and 
SPPL2b (Zahn et al, 2013), respectively. Observations in such experimental settings, however, 
need to be considered with caution as in vivo SPPL2b appears not to contribute to CD74 NTF 
endoproteolysis and CD74 NTF cleavage is exclusively mediated by SPPL2a (Schneppenheim 
et al, 2014). Moreover, endogenous SPPL2a and SPPL2b are differentially expressed and 
localised suggesting that in vivo they likely do not assume redundant functions (Schneppenheim 
et al, 2014).
In a physiological context, SPPL2a/2b-mediated substrate intramembrane proteolysis serve 
either as a mechanism of  signal transduction or membrane protein degradation. For TNFα and 
FasL NTFs, for instance, it has been discussed that SPPL2a/2b-mediated cleavage generates 
ICDs that translocate to the nucleus and act as transcription factors that up-regulate target gene 
expression (Friedmann et al, 2006; Kirkin et al, 2007; Lückerath et al, 2011). In contrast, 
impaired turnover of the CD74 NTF causes a severe deficiency in mature B lymphocytes and 
CD8- dendritic cells in mice deficient in Sppl2a (Schneppenheim et al, 2013; Bergmann et al, 
2013; Beisner et al, 2013). In fact, accumulation of the CD74 NTF leads to massive intracellular 
ultrastructural changes and disturbed endocytic trafficking in Sppl2a-deficient cells 
(Schneppenheim et al, 2013) and to an early developmental arrest in splenic B cell maturation 
(Schneppenheim et al, 2013; Bergmann et al, 2013; Beisner et al, 2013). In animals deficient in 
both Sppl2a and Cd74, however, B lymphocyte and dendritic cell populations were found to be 
normal (Schneppenheim et al, 2013; Bergmann et al, 2013; Beisner et al, 2013).
For SPPL2c, no substrates have been identified and the SPPL2a/SPPL2b substrate TNFα is 
not processed by over-expressed SPPL2c (Friedmann et al, 2006). Hence, for the lack of  an 
identified substrate, it is currently unclear whether SPPL2c is actually an active protease. While, 
in theory, the SPPL2C ORF is functional and encodes a putative protein, it is intron-less and 
highly polymorphic in nature and could therefore constitute a recently evolved pseudogene 
(Golde et al, 2009).
1.4.2.2.3 SPPL3
With no known (physiological) substrate, SPPL3 is presently an orphan protease. It is the 
smallest member of  the SPP/SPPL family, is devoid of an N-terminal signal peptide and is not 
glycosylated (Friedmann et al, 2004). Its sub-cellular localisation is controversial since over-
expressed SPPL3 was observed to co-localise with ER markers (Krawitz et al, 2005), Golgi 
markers (Friedmann et al, 2006), or both (Casso et al, 2012). To complicate matters, early 
studies also attributed proteolytic activity observed towards artificial SPP model substrates in 
vitro to SPPL3 (Nyborg et al, 2006; Narayanan et al, 2007). Together with the ER localisation 
observed and the closer degree of homology of  SPPL3 to SPP than to the SPPL2 subfamily 
members, this led to the hypothesis that SPP and SPPL3 might in fact be functionally redundant 
(Krawitz et al, 2005; Nyborg et al, 2006). A more elaborate analysis, however, challenged this 
notion as catalytically inactive SPPL3 did not bind to a signal peptide-based substrate, while the 
respective SPP mutant did (Schrul et al, 2010). Similarly, there is no in vivo support for this 
notion as a D. melanogaster model that lacks functional spp and sppL genes (sppL is the 
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Drosophila orthologue of  mammalian SPPL3) does not exacerbated the phenotype observed in 
spp deficient animals before (Casso et al, 2012).
Importantly, however, SPPL3‘s high degree of evolutionary conservation in metazoa (Fig. 1.9) 
but its absence in single-celled organisms like Plasmodium point to an important physiological 
function that might have only evolved in multicellular organisms. Presently, however, such a 
function of SPPL3 remains completely enigmatic and SPPL3 deficient flies lack an overt 
phenotype (Casso et al, 2012). A Sppl3 genetrap mouse line generated by Tang et al. was also 
subject to an initial phenotypic analysis (Tang et al, 2010). Notably, on a B6;129S5 hybrid 
background homozygous Sppl3 knockout mice presented with reduced body size and weight, 
mild neurological abnormalities and sterility in males as well reduced numbers of 
natural killer (NK) cells (Tang et al, 2010).
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Fig. 1.9: Alignment of orthologues of human SPPL3. Protein sequences were aligned using the 
ClustalW algorithm implemented in the CLC Main Workbench 6 software platform. Non-conserved 
residues are highlight by a red background. Gallus gallus SPPL3 depicted here is a predicted gene 
product. Some species harbour an additional SPPL3 isoform that contains a roughly 30 amino acid 
insertion in the conserved SPPL3 backbone. This applies also to Xenopus laevis. Here, only the short 
isoform that does not contain this insertion is included. Sequence accension numbers are (in the order 
depicted) NP_620584, NP_083288, NP_001233544, XP_415261, CAJ83465, NP_001015068, 
NP_567918 and NP_001064518.
1.4.3 Archaeal presenilin homologues
In Archaea, a number of  putative genes were described that encode multi-pass membrane 
proteins which display homology to both eukaryotic presenilins and SPP/SPPLs (Ponting et al, 
2002; Grigorenko et al, 2002; Torres-Arancivia et al, 2010) and these are collectively referred to 
as presenilin/SPP homologues (PSHs). They likely share the nine TMD structure of mammalian 
GxGD proteases and harbour catalytic residues within YD and GxGD motifs in the predicted 
TMD6 and TMD7, respectively. Presently, Archaeal PSHs cannot be unambiguously classified 
into either the presenilin or the SPP/SPPL subfamily of  GxGD proteases. They may also 
constitute a common ancestors, making a clear distinction between the presenilin- and SPP/
SPPL-type GxGD protease only possible in higher organisms (Voss et al, 2013).
1.4.4 Common features of presenilin- and SPP/SPPL-type GxGD proteases
In light of the apparent homology of presenilins and SPP/SPPLs (as well as of PSHs) in 
sequence and in predicted membrane topology, it can be anticipated that key functional aspects 
of these proteases are in fact conserved. Therefore, protease structure (section 1.4.4.1), 
substrate requirements (section 1.4.4.2), mechanism of catalysis (section 1.4.4.3), and the 
development of  small molecule inhibitors (section 1.4.4.4) will be comparatively summarised for 
this protease family.
1.4.4.1 GxGD protease structure
Due to its nature, structural analyses of the fully assembled, proteolytically active γ-secretase 
complex have so far been restricted to electron microscopy (EM) and cryo-EM. The most recent 
study reported the cryo-EM structure of  detergent-solubilised γ-secretase produced 
recombinantly in HEK293 cells at a resolution of 4.5 Å (Lu et al, 2014). The structure nicely 
resolves 19 membrane-spanning peptide backbones (likely corresponding to the 19 TMD 
expected within the γ-secretase complex, Fig. 1.5) within a planar, membrane-embedded 
domain that adopts a horse shoe-like shape. This domain is caped by a large luminal structure, 
likely the Nicastrin ectodomain.
This restriction similarly applies to the SPP/SPPL subfamily of  I-CLiPs and the only structural 
data available for SPP is an EM study of  purified active human SPP tetramers (Miyashita et al, 
2011). However, Li et al. recently reported the first crystal structure of  an more distantly related 
Archaeal PSH (Li et al, 2013). They found that the PSH MCMJR1 adopts a previously 
unobserved fold and anticipate that presenilin- and SPP/SPPL-type GxGD protease will adopt a 
similar spatial structure. As predicted (Torres-Arancivia et al, 2010), MCMJR1 contains nine α-
helical TMDs connected by flexible loops. Of note and in line with prior biochemical analyses 
(see 1.4.1.1), TMD6 and TMD7, which harbour the catalytic residues, as well as TMD9 appear 
to be densely packed together forming the active site. This, in turn, is embedded in the 
membrane and is accessible to water. However, the crystal structure was obtained in an 
obviously inactive conformation as the catalytic aspartate residues are too far apart from each 
other to support catalysis. Therefore, structural changes might occur when the enzyme folds 
into an active conformation. 
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1.4.4.2 Substrate requirements of GxGD proteases
A striking distinction between presenilins and SPP/SPPLs is their apparent selectivity for a 
specific membrane protein topology: Presently, γ-secretase substrates identified are membrane 
proteins adopting a type I topology (i.e. Nout/Cin) ((Haapasalo & Kovacs, 2011) provide an 
overview  of  γ-secretase substrates reported). In contrast, all SPP/SPPL substrates identified are 
type II membrane proteins or signal peptides that adopt a type II orientation in the membrane 
(i.e. Nin/Cout) (Voss et al, 2013).
Presently, however, specific motifs in primary sequence that define whether and where 
intramembrane proteolysis of  a given membrane protein occurs have neither been identified for 
the presenilins nor for the SPP/SPPL subfamily (Beel & Sanders, 2008; Lemberg & Martoglio, 
2004). When discussing SPP substrate requirements, Lemberg and Martoglio proposed that 
two key features are required for a substrate to be cleaved (Lemberg & Martoglio, 2004): (i) 
Putative substrates have to be tailored for subsequent intramembrane proteolysis by a 
preceding proteolytic cleavage that removes the substrates ectodomain (i.e. shedding or a 
shedding-like event). (ii) SPP substrates have to exhibit structural flexibility within the scissile 
membrane-spanning region in order to be proteolytically accessible.
In fact, shedding is considered the regulative step of γ-secretase-mediated intramembrane 
proteolysis (section 1.1) (Brown et al, 2000). Both APP and Notch - but also numerous other γ-
secretase substrates identified - are subject to ectodomain shedding prior to intramembrane 
cleavage and the length of a substrate's ectodomain was found to negatively correlate with 
processing by the γ-secretase in vivo (Struhl & Adachi, 2000). Furthermore, APP CTFs but not 
full-length APP could be co-isolated with mature γ-secretase complexes (Xia et al, 2000). 
Similar requirements also seem to apply to the SPP homologue SPPL2b, which also requires its 
substrate Bri2 to be shed prior to cleavage and also in this case the substrate's ectodomain 
length negatively correlated with intramembrane cleavage (Martin et al, 2009). SPP substrates 
on the other hand do not undergo conventional ectodomain shedding, yet they are removed 
from nascent proteins by signal peptidase (Fig. 1.8a) (Paetzel et al, 2002) and Lemberg et al. 
demonstrated that SPP-mediated processing of  a signal peptide requires its prior liberation from 
the pre-protein by signal peptidase (Lemberg & Martoglio, 2002). The selectivity for substrates 
with a short luminal ectodomain of SPP was also corroborated in a recent study for tail-
anchored ER membrane proteins, another class of  SPP substrates (Fig. 1.8c) (Boname et al, 
2014). Taken together, shortening of  the luminal portion of a putative substrate is strictly 
required for γ-secretase- as well as for SPP- and SPPL2b-mediated intramembrane proteolysis. 
Helix-destabilising residues (e.g. proline or glycine) within TMDs were likewise found to be 
critically required for SPP-mediated signal peptide cleavage (Lemberg & Martoglio, 2002) and 
for SPPL2b-mediated endoproteolysis of the Bri2 NTF (Fluhrer et al, 2012). In line with this, it 
was also postulated that factors like structural flexibility and not the mere primary structure 
determine whether a particular protein is a γ-secretase substrate (Beel & Sanders, 2008). 
Finally, for both γ-secretase and SPPL2b substrates it has recently been shown that substrate 
juxtamembrane regions also affect intramembrane cleavage (Ren et al, 2007; Hemming et al, 
2008; Martin et al, 2009).
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1.4.4.3 Mechanism of GxGD protease-mediated intramembrane proteolysis
Conventional aspartyl proteases utilise two proximal aspartate residues in their active site to 
hydrolyse peptide bonds (Fig. 1.10) (Suguna et al, 1987). GxGD proteases likewise harbour two 
conserved aspartate residues in adjacent TMDs (e.g. D257 and D385 in human PS1) that are 
required for catalysis (Wolfe et al, 1999; Steiner et al, 1999; Laudon et al, 2004). In the native γ-
secretase complex these two residues were found to be facing each other in close proximity 
(Tolia et al, 2006; Sato et al, 2006a) suggesting that catalysis proceeds in a manner similar to 
that of conventional aspartyl proteases. 
In light of its link to AD, γ-secretase-mediated intramembrane processing of APP CTFs in 
particular has been studied extensively. Intriguingly, cleavage within APP CTFs is executed by 
γ-secretase at multiple positions (Fig. 1.11) (reviewed in (Takami & Funamoto, 2012)) and 
generates distinct product species that have only minor differences in length but profound 
differences in their biological activity (compare e.g. Aβ40 vs. Aβ42/Aβ43, see 1.4.1.2.2). In an 
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Fig. 1.10: Mechanism of aspartyl protease-mediated endoproteolysis. A protonated aspartate 
residue polarises the carbonyl  carbon of the scissile bond to become more susceptible to nucleophilic 
attack while the second de-protonated residue increases nucleophilicity of a water molecule close-by. 
This facilitates nucleophilic  attack of the polarised water molecule to the carbonyl carbon leading to 
formation of a tetrahedral intermediate and, upon reformation of the carbonyl carbon, to generation of a 
carboxylic acid (the newly formed C-terminus) and a primary amine (the newly formed N-terminus). 
Substrate peptide backbone is given in yellow, an active site water molecule in blue. Adapted from 
(Wolfe, 2009).
Fig. 1.11: Mechanism of γ-secretase-mediated intramembrane proteolysis of the APP CTFβ. Initial 
cleavage of γ-secretase at the ε-site liberates the AICD and generates either Aβ48 or Aβ49. Cleavage at 
ζ- and γ-sites trims the C-terminus of the long Aβ species and liberates tri- and tetrapeptides (not shown). 
Eventually, soluble Aβ peptides are released which may vary in length.
initial step, γ-secretase liberates the AICD in an endopeptidase-like fashion (ε-cleavage). ε-
cleavage may occur at two positions generating either AICD(49) or AICD(50) and corresponding 
Aβ48 and Aβ49 counterparts, respectively. The latter are substrate to downstream trimming by a 
carboxypeptidase-like activity of γ-secretase (referred to as ζ- and γ-cleavages) to eventually 
give rise to shorter peptides (Aβ37 to Aβ43) (Qi-Takahara et al, 2005). Detection of tri- and 
tetra-peptides that are released during Aβ processing strongly speaks in favour of this 
successive cleavage model (Takami et al, 2009; Takami & Funamoto, 2012). It was suggested 
that two independent Aβ product lines are initiated by ε-cleavage: The most abundant species 
Aβ40, for instance, is generated by successive cleavage of Aβ49 via Aβ46 and pathogenic 
Aβ43. Aβ48, on the other hand, is processed to Aβ45 which then gives rise to the pathogenic 
Aβ42 and eventually, by tetra-peptide release, to Aβ38 (Takami et al, 2009; Takami & Funamoto, 
2012). Recent work, however, suggests that there is no strict separation of the two product lines 
and that both product lines cross each other (Okochi et al, 2013; Matsumura et al, 2013).
Given the homology of  SPP/SPPLs and presenilins, the former may in fact utilise a similar 
successive proteolytic strategy. In support of this, SPPL2b-mediated TNFα intramembrane 
proteolysis produces multiple ICD and C-peptide cleavage products (Fluhrer et al, 2006). In 
contrast, SPP-mediated cleavage of  the prolactin signal peptide was shown to occur primarily at 
one single position and only minor amounts of additional cleavage products were observed 
(Sato et al, 2006b). Therefore, the exact mechanism of SPP/SPPL-mediated intramembrane 
proteolysis is currently not understood. 
1.4.4.4 GxGD protease inhibitors
Given the strong link of Aβ generation and AD pathophysiology, major efforts have been 
undertaken to pharmacologically interfere with its biogenesis. To this end numerous potent γ-
secretase inhibitors (GSIs) have been developed (Fig. 1.12) (reviewed in (Wolfe, 2012)). Such 
compounds are structurally diverse and include transition-state analogue inhibitors like the 
hydroxyethylamine L-685,458 (Shearman et al, 2000), the dipeptide-base N-[N-(3,5-
Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester (DAPT) (Dovey et al, 2001), or 
helical peptides (Bihel et al, 2004). Importantly, all these compounds as well as various 
derivatives thereof have allowed to functionally analyse the γ-secretase complex. As a transition 
state analogue inhibitor, L-685,458 is expected to bind to the enzyme's active site and indeed a 
photo-reactive derivative was found to target both presenilin NTF and CTF (Li et al, 2000b). 
Helical peptides similarly bound the presenilin NTF/CTF interface but competition experiments 
revealed that they interact with the so-called docking site which is clearly distinct from the active 
site (Kornilova et al, 2005). DAPT on the other hand was found to target yet another site and 
covalently labelled the PS1 CTF acting likely as an allosteric inhibitor of γ-secretase activity 
(Morohashi et al, 2006).
In light of  initially promising results, one GSI, semagacestat, entered clinical trials to treat AD but 
a phase III study recently had to be terminated before completion due serious adverse effects 
(Doody et al, 2013). These observations point to a major issue of  γ-secretase inhibition: Most 
GSIs affect γ-secretase activity in general and inhibit processing of all γ-secretase substrates. 
Hence, they also impair Notch signalling which could potentially account for the adverse effects 
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observed (Doody et al, 2013). In a distinct disease setting, however, interference with Notch 
signalling may in fact be desirable: Notch may have oncogenic properties and activating 
mutations within NOTCH1 can be found in 50 % of T cell acute lymphoblastic leukemias (Weng 
et al, 2004). Treatment of such patients with GSIs has been very promising (Real et al, 2009).
(Z-LL)2 ketone was the first inhibitor described to restrain SPP activity (Weihofen et al, 2000). 
Peptide aldehydes such as (Z-LL)2 ketone are typical serine/cysteine protease inhibitors (Wolfe, 
2012) and, accordingly, Weihofen et al. initially expected signal peptide endoproteolysis to be 
mediated by a cysteine protease (Weihofen et al, 2000). Yet in their ketal form, such 
compounds mimic the transition state of  aspartyl protease catalysis (Wolfe, 2012). When 
derivatised to a photo-reactive diazirine, (Z-LL)2 ketone was shown to cross-link to SPP 
(Weihofen et al, 2002) and this was reduced in a concentration-dependent manner when 
treated with the parental compound (Weihofen et al, 2003), suggesting that (Z-LL)2 ketone 
targets SPP‘s active site. Meanwhile, (Z-LL)2 ketone has been shown to inhibit activity of SPP of 
various organisms (Casso et al, 2005; Nyborg et al, 2006; Narayanan et al, 2007; Harbut et al, 
2012) and of human SPPL2a and SPPL2b (Fluhrer et al, 2006; Friedmann et al, 2006; Kirkin et 
al, 2007; Martin et al, 2008) in vitro as well as in cell culture, in most cases with IC50 values in 
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Fig. 1.12: Small molecule GSIs and GxGD protease inhibitors. N-[N-(3,5-Difluorophenacetyl)-L-
alanyl]-S-phenylglycine t-butyl ester (DAPT), 1,3-di-(N-carboxybenzoyl-L-leucyl-L-leucyl)-amino acetone 
((Z-LL)2 ketone). For details see section 1.4.4.4.
the micro-molar range. Only recently, more potent SPP inhibitors have been developed but 
details regarding their nature have not been disclosed (Harbut et al, 2012).
Interestingly, there is abundant experimental evidence that most active site-targeting GSIs 
impair the proteolytic activity of  both presenilin- as well as SPP/SPPL-type GxGD proteases 
and, hence, can in principle be considered general GxGD protease inhibitors. Labelling of  SPP 
with the photo-reactive (Z-LL)2 ketone derivative, for instance, was reduced by L-685,458 
(Weihofen et al, 2003). L-685,458 also inhibits proteolytic activity of SPP (Weihofen et al, 2003; 
Iben et al, 2007) as well as of  SPPL2a and SPPL2b (Fluhrer et al, 2006; Friedmann et al, 2006; 
Martin et al, 2008) suggesting that the active site architecture is conserved among presenilin- 
and SPP/SPPL-type GxGD proteases. In contrast, the allosteric GSI DAPT does neither impair 
SPP nor SPPL2b activity (Weihofen et al, 2003; Martin et al, 2008) and does not compete with 
active site labelling of  SPP (Weihofen et al, 2003) suggesting that the binding site of DAPT is 
not conserved among the two GxGD protease sub-families.
1.5. Foamy Viruses
In the course of this study, the foamy virus (FV) envelope glycoprotein (FVenv) was identified as 
first SPPL3 substrate. Foamy viruses (FVs) are complex retroviruses but several key features of 
their life cycles, clearly distinguish FVs from orthoretroviruses and, accordingly, they are 
grouped as separate Spumavirinae subfamily within the Retroviridae (Lecellier & Saïb, 2000; 
Rethwilm, 2010; Lindemann & Rethwilm, 2011). In vitro, FV exhibits an astonishingly broad 
tropism and can infect cell lines derived from various tissues and species (Hill et al, 1999). In 
line with this, the FV envelope glycoprotein (FVenv) mediates virus attachment to a highly 
ubiquitous receptor, the glycosaminoglycan (GAG) heparan sulphate (HS) (Plochmann et al, 
2012; Nasimuzzaman & Persons, 2012). 
FVs are endemic in various animal species, including non-human primates, cats, and others 
(Meiering & Linial, 2001). Prevalence in these host species is generally very high but may vary 
(Meiering & Linial, 2001). In infected animals, FVs establish a life-long persistent infection but 
there is no solid evidence for FV-associated disease (Meiering & Linial, 2001). FV transmission 
likely occurs by biting or licking (reviewed in (Meiering & Linial, 2001)) and in non-human 
primates virus replication is mostly restricted to superficial oropharyngeal epithelial cells (Murray 
et al, 2008).
Cases of  FV infections in humans have also been documented (Achong et al, 1971; Schweizer 
et al, 1997; Meiering & Linial, 2001; Betsem et al, 2011). These findings triggered extensive 
investigations to unravel potential link(s) of  FV infections in humans to disease but, in sum, 
there is presently no solid evidence supporting FV-associated aetiology of  human disease and, 
like in animal hosts, FVs are considered to be apathogenic (reviewed in (Meiering & Linial, 
2001)). Furthermore, humans appear to be dead-end hosts as no human-to-human FV 
transmission has been documented (Betsem et al, 2011). In line with this, the original "human" 
FV isolate (Achong et al, 1971) was found to be in fact highly homologous to a chimpanzee 
isolate of a simian FV (Herchenröder et al, 1994). Other human FV infection were exclusively 
observed in persons with (mostly occupational) contact to non-human primates (Heneine et al, 
1998; Schweizer et al, 1997), but there is no evidence for a wide-spread prevalence of  simian 
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FV in the general human population (Ali et al, 1996; Schweizer et al, 1995). However, a recent 
study showed that non-human primate-to-human FV transmission is frequently occurring locally 
among hunters in Central Africa (Betsem et al, 2011).
Due to their broad tissue tropism and their apathogenic nature FVs have become increasingly 
attractive as gene therapy vectors and FV particle-based systems were already successfully 
used to correct primary immunodeficiencies in animal models (Bauer et al, 2008; Uchiyama et 
al, 2012). Importantly, even after a > 4 year follow-up, no signs of malignant transformation of 
transplanted FV-transduced cells were observed, a problem commonly associated with gene 
therapeutic approaches (Bauer et al, 2013). Hence, FVs emerge as a safe alternative to γ-
retroviral vectors for gene therapy.
1.5.1 Foamy Virus envelope glycoprotein
Surface proteins of enveloped viruses are required to mediate attachment to host cells and to 
facilitate entry via fusion of  viral and host cell membranes. This also applies to retroviruses 
where the envelope (env) glycoprotein fulfils these two crucial functions (reviewed in 
(Blumenthal et al, 2012)). FVs likewise encode an env glycoprotein, FVenv (Lindemann & 
Rethwilm, 2011; Berka et al, 2013) (Fig. 1.13). It is synthesised as a pro-protein that requires 
proteolytic processing to generate the N-terminal leader peptide (LP, gp18LP) as well as the 
surface (SU, gp80SU) and the C-terminal transmembrane (TM, gp48TM) subunits (Lindemann & 
Goepfert, 2003; Berka et al, 2013). SU and TM subunits are highly conserved among 
retroviruses and mediate receptor binding and membrane fusion, respectively (Blumenthal et al, 
2012). Similar observations have been made for FVenv: FVenv SU was shown to be 
indispensable for receptor binding (Duda et al, 2006) and FVenv TM contains a hydrophobic 
! Introduction! 29
Fig. 1.13: Proteolytic processing of FVenv. FVenv is synthesised as a type III precursor and is 
subsequently endoproteolysed by furin or furin-like pro-protein convertases (PC) to generate its three 
subunits, LP (green), SU (yellow), and TM (red). As experimental evidence suggests that endoproteolysis 
at the indicated sites is mediated by distinct proteolytic  activities (Bansal et al, 2000), these have been 
designated PC and PC*.
stretch that is expected to function as fusion peptide (Wang & Mulligan, 1999; Berka et al, 
2013). Unlike other retroviral env proteins, however, the N-terminal LP is a unique features of 
FVenv (Lindemann & Goepfert, 2003; Berka et al, 2013). An N-terminal cytosolic stretch within 
LP of  FVs mediates interaction with the viral capsid (Lindemann et al, 2001; Wilk et al, 2001) 
pointing to a pivotal role of  the foamy viral LP subunit in particle assembly and budding 
(Lindemann & Rethwilm, 2011). 
The FVenv precursor initially adopts a type III topology, assembles into a tri-partite trimeric 
complex, and is subject to post-translational proteolytic processing (Berka et al, 2013). Furin or 
a furin-like pro-protein convertase (PC) separate LP and SU (Duda et al, 2004; Geiselhart et al, 
2004) as well as SU and TM (Bansal et al, 2000). Importantly, the latter cleavage is strictly 
required for viral infectivity (Bansal et al, 2000), whereas cleavage between LP and SU is not 
(Duda et al, 2004). Interestingly, the LP is incorporated into viral particles and is essential for 
egress of progeny virions from host cells while being dispensable for attachment and entry 
(Lindemann et al, 2001). Importantly, while both cleavages occur at primary sequence motifs 
that clearly correspond to consensus substrate motifs of furin/PC, the exact identity of the 
cellular protease(s) executing both cleavages, is presently elusive. Yet both cleavages have to 
be catalysed by distinct proteases as these cleavage events are differentially affected by 
mutations that alter the sub-cellular localisation of FVenv (Bansal et al, 2000).
Another striking difference of orthoretroviral envs and FVenv is a C-terminal ER retention signal 
found in the latter which ensures ER localisation of FVenv when expressed in the absence of 
other viral structural proteins (Goepfert et al, 1995; 1997). The exact role of this motif is 
presently unclear as it is not conserved among all FVs and is dispensable for virus propagation 
(Goepfert et al, 1999). Interestingly, initial observations pointed to assembly at and budding of 
FV particles from intracellular (possibly ER) membranes (Goepfert et al, 1999), but a more 
detailed study reported an interaction of gag and FVenv at the trans-Golgi network (TGN) (Yu et 
al, 2006). Accordingly, the exact identity of the site of intracellular particle assembly and egress 
remains elusive (Lindemann & Rethwilm, 2011).
1.6. Protein glycosylation
Numerous cellular proteins are subject to covalent post-translational modifications, including 
modifications by carbohydrate moieties termed glycosylation. Experimental work described in 
this study revealed that SPPL3 affected cellular glycosylation in vivo and in vitro. Glycosylation 
is common to transmembrane proteins and secreted proteins but also affects cytosolic and/or 
nuclear proteins (Moremen et al, 2012). Glycoproteins can be found in all kingdoms of  life, but, 
while simpler structures prevail in prokaryotes, eukaryotes and multicellular organisms in 
particular are characterised by a highly diversified glycome which may be subject to 
developmental and environmental changes. Glycan moieties may be covalently linked to 
proteins in multiple ways (Sears & Wong, 1998; Moremen et al, 2012). Mostly, however, glycans 
are attached to proteins in an N-glycosidic amide linkage via the side chains of  lumenal 
asparagine residues (N-glycosylation) or in an O-glycosidic fashion to serine or threonine 
residues (O-glycosylation).
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Several glycan structures are strictly required for multicellular life as animal models defective in 
normal glycosylation pathways often exhibit striking phenotypic abnormalities and inborn 
deficiencies in saccharide or glycosylation metabolism result in congenital disorders of 
glycosylation (CDGs) in man (reviewed in (Hennet, 2012)). Accordingly, protein glycosylation is 
crucial to cellular ER quality control, cell-cell interactions, intercellular signalling, tumour 
metastasis, and various other processes (Lowe & Marth, 2003; Moremen et al, 2012).   
1.6.1 Glycosyltransferase & glycosidases
Given their polyvalent nature and the unique chemistry of their anomeric centres, carbohydrates 
may be subject to diverse modifications and substitutions. In a cellular setting, such 
modifications are catalysed by the enzymatic activities of glycosyltransferases (GTs) and 
glycosidases as well as other glycan-modifying enzymes (GMEs). GTs employ mono-
saccharides conjugated to nucleoside or lipid phosphates as substrates to catalyse formation of 
glycosidic bonds (Paulson & Colley, 1989; Freeze & Elbein, 2009). Such activated sugar donors 
are synthesised from monosaccharide precursors within the cytosol and the nucleus and are 
subsequently transported to the ER and Golgi lumen (Freeze & Elbein, 2009).
Mammalian genomes contain numerous putative GMEs including roughly 200 GTs that each 
possess a certain specificity towards their donor and acceptor substrates (Stanley, 2011; 
Moremen et al, 2012). In fact, the presence of certain glycan structures in a cell reflects the 
expression levels of GTs involved in biosynthesis of these structures (Paulson & Colley, 1989). 
With only few  exceptions, most Golgi-localised GTs and other GMEs are type II transmembrane 
glycoproteins that comprise a short cytosolic N-terminal stretch followed by a TMD that at the 
same time functions as signal anchor and a lumenal stem region as well as the C-terminal 
catalytic domain (Paulson & Colley, 1989; Sears & Wong, 1998; Varki et al, 2009).
 
1.6.2 Cellular N-glycosylation
In vertebrates, a distinction is made between three types of N-linked glycans: (i) high mannose-
type glycans, (ii) complex glycans, and (iii) hybrid-type glycans (Fig. 1.14). Whereas they clearly 
differ in their degree of branching and, more importantly, in the extent and variety of  terminal 
modifications, all three types share a Man3GlcNAc2 core as they all derive from a common 
precursor. Hybrid-type and complex glycans differ in their degree of branching and the former 
contain no GlcNAc modifications on their α1,6-linked core mannose residue. Basic N-glycan 
structures (i.e. of  the high mannose-type) are highly conserved among eukaryotes and are 
essential to eukaryotic cellular viability as mediators of fundamental cellular ER quality control 
(Moremen et al, 2012). Accordingly, inhibition of  early steps of their biosynthesis, i.e. by 
treatment with the GlcNAc analogue tunicamycin, leads to cellular dysfunction and cell death 
(Lowe & Marth, 2003).
The biosynthesis of N-glycans has been extensively reviewed (Schachter, 1991; Sears & Wong, 
1998; Lowe & Marth, 2003; Stanley et al, 2009; Moremen et al, 2012). N-glycoslation 
commences at the rough ER membrane by attachment of a pre-assembled Glc3Man9GlcNAc2 
glycan to the side-chain amino group of an asparagine residue within the sequon Asn-X-Ser/Thr 
(X being any amino acid, but not proline; rarely, the sequon Asn-X-Cys is also glycosylated). 
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This reaction occurs co-translationally and is catalysed by the oligosaccharyltransferase 
complex that transfers Glc3Man9GlcNAc2 from its membrane-tethered dolichol pyrophosphate-
conjugated precursor to the nascent glycoprotein. Terminal glucose and mannose residues of 
Glc3Man9GlcNAc2 glycans are trimmed by ER-resident α-glucosidases as well as by Golgi α-
mannosidase I (Golgi Man I). This process is tightly linked to chaperone-assisted folding of 
nascent secretory and membrane proteins and, in case this fails, to ER quality control and ER 
retrotranslocation of  un- or mal-folded proteins (Moremen et al, 2012). Glycoproteins carrying 
trimmed N-glycans (i.e. Man5GlcNAc2) are then transported to the Golgi network for subsequent 
modifications. Importantly, glycoproteins that are ER-resident are not subject to these 
modifications and retain high mannose-type N-glycans. An example is the immature ER-
resident variant of  the γ-secretase complex component Nicastrin (Yang et al, 2002; Leem et al, 
2002). 
In the Golgi, a GlcNAc residue is attached in β-linkage to the C2 of the α1,3-linked mannose 
residue of the glycan core by N-acetylglucosaminyltransferase I (GnT-I), initiating synthesis of 
both hybrid and complex glycans (Fig. 1.15). GlcNAcMan5GlcNAc2 glycans generated by GnT-I 
may then be modified by Golgi α-mannosidase II which removes mannose residues bound to 
the core α1,6-linked mannose residue. The resulting structure, GlcNAcMan3GlcNAc2, acts as 
precursor for the generation of  multi-antennary, complex N-glycans: GnT-II, for instance, 
attaches GlcNAc to the α1,6-linked core mannose residue generating bi-antennary glycans. 
These, in turn, may then be subject to further elaboration through attachment of  additional 
GlcNAc residues to the two core mannose residues by GnT-IV, GnT-V and others. This process 
is collectively referred to as GlcNAc branching (Schachter, 2000). Hybrid-type glycans are 
generated when GlcNAcMan5GlcNAc2 glycans are not trimmed by α-mannosidase II.
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Fig. 1.14: Types of eukaryotic N-glycans. The Man3GlcNAc2 core structure that is common to all N-
glycans is shaded in grey. High-mannose glycans have not been subject to trimming in the ER. Hybrid 
glycans harbour an GlcNAc-initiated branch on the α1,3-initiated arm that is terminally modified. Complex 
glycans harbour GlcNAc branches also on the α1,6-initiated arm and may be highly and very diversely 
branched and core-fucosylated. Terminal modifications of the hybrid and the complex glycan depicted 
and GlcNAc branching of the complex glycan are exemplary. For clarity stereochemical details are largely 
omitted. Neu5Ac, sialic acid, Gal, galactose, GlcNAc, N-acetylglucosamine, Man, mannose, Fuc, fucose.
Following the branching of glycan cores mediated by the activity of GnTs, terminal GlcNAc 
residues in complex, yet also in hybrid-type glycans are subject to diverse additional 
modifications in the trans Golgi. These terminal modifications include the enzymatic addition of 
(poly-)N-acetyllactosamines in the medial/trans Golgi as well as fucosylation and terminal 
sialylation in the trans Golgi network (TGN) and these terminal glycan patterns often are alike 
on N-glycans, O-glycans, and glycolipids (Stanley & Cummings, 2009).
Importantly, the outlined biosynthetic route towards complex N-glycans is not strictly followed in 
a linear manner. The order of  action of  GMEs on glycan substrates is particularly important in 
determining the product structure as individual modifications may actually preclude or promote 
successive processing steps. Such modifications have been referred to as no-go and go signals 
(Schachter, 1991). Examples for the latter include α-mannosidase II that can only trim glycans 
that were acted on by GnT-I before and GnT-IV and GnT-V that require prior modification of 
their substrates by GnT-II. An important no-go signal is generated by GnT-III: GnT-III adds a so 
called bisecting GlcNAc residue in β1,4 linkage to the core mannose residue and this addition 
prevents further branching as bisected glycans cannot be processed by GnT-II, GnT-IV, and 
GnT-V. In addition, GMEs often compete for substrates. This results in a high diversity of glycan 
structures - even on the same protein - which is referred to as micro-heterogeneity (Schachter, 
1991; Moremen et al, 2012). Also, expression and activity of  enzymatic factors involved in 
glycan biosynthesis may be subject to regulation and, in light of the vast number of distinct 
enzymatic activities involved in glycan biosynthesis, glycan structures are specific for species, 
cell type as well as developmental stage (Ohtsubo & Marth, 2006).
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Fig. 1.15: Golgi GlcNAc branching. High-mannose precursor N-glycan on glycoproteins delivered from 
the ER to the Golgi are subject to GlcNAc branching that generates hybrid and complex glycans. For 
detailed description refer to main text. GlcNAc residues are added by numerous N-
acetylglucosaminyltransferases (GnTs) in distinct stereochemical manner (red). N-glycans are 
subsequently modified in the trans Golgi and the TGN (indicated by grey arrows) to obtain mature N-
glycans. Adapted from (Stanley et al, 2009).
1.6.3 Cellular O-glycosylation
Many cellular and secreted glycoproteins are extensively modified by O-glycosylation. These 
may be subject to modification by α-linked GalNAc as in mucin-type O-glycans, by β-linked 
xylose in GAG-carrying proteoglycans, by α-linked mannose found on α-dystroglycan and by 
other saccharides (Sears & Wong, 1998; Moremen et al, 2012; Brockhausen et al, 2009; 
Dobson et al, 2013). Depending on the exact type of O-glycosylation, the initial glycan 
attachment occurs in the ER or the Golgi and is catalysed by specific GTs that do not participate 
in N-glycosylation. The individual types of O-glycans are subsequently often elongated by 
stepwise action of  numerous additional pathway-specific, Golgi-resident GTs. However, terminal 
glycan structures of  N-glycans and mucin-type O-glycans - but not other types of  O-glycans - 
are often generated by the same set of trans Golgi and TGN GTs (Stanley & Cummings, 2009). 
While primary amino acid sequence motifs that define N-glycan attachment are well-described, 
similar motifs for O-glycosylation are not particularly well-defined (Sears & Wong, 1998; 
Brockhausen et al, 2009; Moremen et al, 2012).
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 2. Aims of the study
This study is focussed on SPPL3, an on the one hand highly conserved representative but on 
the other hand the least characterised one of  the SPP/SPPL proteases. With SPPL3 being an 
orphan protease, the primary aim of  the present study is to identify a SPPL3 substrate that 
allows to examine the protease's proteolytic activity in detail. As initial reports suggest a certain 
degree of  functional redundancy between SPPL3 and SPP (Krawitz et al, 2005; Nyborg et al, 
2006), atypical signal peptides such as of FVenv have become promising candidate substrates 
for SPPL3. Therefore, it is to be tested here whether SPPL3 is capable of  endoproteolysing 
FVenv. If  this does in fact apply, SPPL3-mediated endoproteolysis of FVenv should reveal the 
substrate requirements of SPPL3 and assess its sensitivity towards GSIs.
In addition to that, the physiological function of  SPPL3 will be investigated. To this end 
previously established cell culture models as well as a recently generated Sppl3-deficient gene-
trap mouse line (Tang et al, 2010) will be surveyed for phenotypic abnormalities. Assuming that 
SPPL3 exerts its biological function(s) first and foremost via its activity as a protease, in-depth 
analysis of phenotypic abnormalities in those models at hand should allow  to infer candidate 
SPPL3 substrates. Impaired proteolytic processing of such, e.g. in Sppl3-deficient mice, should 
then cause or contribute to the phenotypic abnormalities observed.
Finally, based on the insights obtained concerning SPPL3's substrate selectivity, a proteomic 
screen will be undertaken to completely define the SPPL3 degradome, i.e. its global substrate 
repertoire, which would then, in turn, help to understand the physiological role of SPPL3 in its 
entirety.
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 3. Materials & Methods
3.1 Materials
3.1.1 Laboratory equipment & reagents
Unless indicated otherwise in the respective detailed description of experimental procedures, 
standard laboratory equipment was used. Plastic consumables were from Sarstedt (Nümbrecht, 
Germany), greiner bio-one (Kremsmünster, Austria) and Thermo Fisher Scientific (Waltham, 
USA). Liquid and powder chemicals of  analytical grade were purchased from Merck (Darmstadt, 
Germany), Sigma-Aldrich (St. Louis, USA), Carl Roth (Karlsruhe, Germany), biomol (Hamburg, 
Germany), Serva (Heidelberg, Germany) or AppliChem (Darmstadt, Germany). Centrifuges, 
incubators and safety cabinets were from Eppendorf (Hamburg, Germany) and Thermo Fisher 
Scientific. Unless indicated otherwise, all buffers and reagents were prepared in or dissolved in 
double-distilled water.
3.1.2. Animals
B6;129S5-Sppl3Gt(OST279815)Lex/Mmucd mice had been generated by Lexicon Pharmaceuticals 
(The Woodlands, USA) and Genentech (San Francisco, USA) and kindly made available to the 
research community. They were obtained through the Mutant Mouse Regional Resource Center 
(MMRRC) at the University of California at Davis (USA).
3.1.4 Cell lines
Tab. 3.1 lists all clonal cell lines used throughout or generated in the course of  this study as well 
as their respective sources.
Tab. 3.1: Cell lines used and generated during the course of this study. Bold number in brackets 
refer to expression constructs cloned in this study and listed in Tab. 3.2. Continued on the following page.
Cell line stably transfected plasmid(s) antibiotic 
resistance
source
HeLa none none ATCC
HEK293 TetR/T-REx™ pcDNA6/TR blasticidin life technologies
HEK293 TetR SPPL2a-HA wt pcDNA6/TRpcDNA4/TO/SPPL2a-HA wt
blasticidin
zeocin
Dr Regina Fluhrer,
LMU Munich
(Martin et al, 2008)
HEK293 TetR SPPL2a-HA D412A pcDNA6/TRpcDNA4/TO/SPPL2a-HA D412A
blasticidin
zeocin
Dr Regina Fluhrer,
LMU Munich
(Martin et al, 2008)
HEK293 TetR SPPL2b-HA wt pcDNA6/TRpcDNA4/TO/SPPL2b-HA wt
blasticidin
zeocin
Dr Regina Fluhrer,
LMU Munich
(Martin et al, 2008)
HEK293 TetR SPPL2b-HA D421A pcDNA6/TRpcDNA4/TO/SPPL2b-HA D421A
blasticidin
zeocin
Dr Regina Fluhrer,
LMU Munich
(Martin et al, 2008)
HEK293 TetR SPPL3-HA wt
(isoform 2)
pcDNA6/TR
pcDNA4/TO/SPPL3-HA wt (isoform 2)
blasticidin
zeocin
Dr. Regina Fluhrer,
LMU Munich
(Martin et al, 2008)
HEK293 TetR SPPL3-HA wt 
(isoform 1)
pcDNA6/TR
pcDNA4/TO/SPPL3-HA wt (isoform 1), (7)
blasticidin
zeocin this study
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Cell line stably transfected plasmid(s) antibiotic 
resistance
source
HEK293 TetR SPPL3-HA D271A
(isoform 2)
pcDNA6/TR
pcDNA4/TO/SPPL3-HA D471A (isoform 2)
blasticidin
zeocin
Dr. Regina Fluhrer,
LMU Munich
(Martin et al, 2008)
HEK293 TetR SPPL3-HA D200N/D271N
(isoform 2)
pcDNA6/TR
pcDNA4/TO/SPPL3-HA D200N/D271N (isoform 2)
blasticidin
zeocin this study
HEK293 TetR SPPL2a-HA wt FVenv
pcDNA6/TR
pcDNA4/TO/SPPL2a-HA wt
pcDNA3.1hygro/FVenv (2)
blasticidin
zeocin
hygromycin
this study
HEK293 TetR SPPL2a-HA D412A FVenv
pcDNA6/TR
pcDNA4/TO/SPPL2a-HA D412A
pcDNA3.1hygro/FVenv (2)
blasticidin
zeocin
hygromycin
this study
HEK293 TetR SPPL2b-HA wt FVenv
pcDNA6/TR
pcDNA4/TO/SPPL2b-HA wt
pcDNA3.1hygro/FVenv (2)
blasticidin
zeocin
hygromycin
this study
HEK293 TetR SPPL2b-HA D421A FVenv
pcDNA6/TR
pcDNA4/TO/SPPL2b-HA D421A
pcDNA3.1hygro/FVenv (2)
blasticidin
zeocin
hygromycin
this study
HEK293 TetR SPPL3-HA wt
(isoform 2) FVenv
pcDNA6/TR
pcDNA4/TO/SPPL3-HA wt (isoform 2)
pcDNA3.1hygro/FVenv (2)
blasticidin
zeocin
hygromycin
this study
HEK293 TetR SPPL3-HA D271A
(isoform 2) FVenv
pcDNA6/TR
pcDNA4/TO/SPPL3-HA D471A (isoform 2)
pcDNA3.1hygro/FVenv (2)
blasticidin
zeocin
hygromycin
this study
HEK293 TetR FVenv ΔE pcDNA6/TRpcDNA3.1hygro/FVenv ΔE (5)
blasticidin
hygromycin this study
HEK293 TetR FVenv ΔE(AP) pcDNA6/TRpcDNA3.1hygro/FVenv ΔE(AP) (6)
blasticidin
hygromycin this study
HEK293 TetR Flag-GnT-V-V5 pcDNA6/TRpcDNA3.1hygro/Flag-GnT-V-V5 (10)
blasticidin
hygromycin this study
HEK293 TetR SPPL3-HA wt
(isoform 2) Flag-GnT-V-V5
pcDNA6/TR
pcDNA4/TO/SPPL3-HA wt (isoform 2)
pcDNA3.1hygro/Flag-GnT-V-V5 (10)
blasticidin
zeocin
hygromycin
this study
HEK293 TetR SPPL3-HA D200N/D271N
(isoform 2) Flag-GnT-V-V5
pcDNA6/TR
pcDNA4/TO/SPPL3-HA D200N/D271N (isoform 2)
pcDNA3.1hygro/Flag-GnT-V-V5 (10)
blasticidin
zeocin
hygromycin
this study
HEK293 TetR TRC2-pLKO.5-puroP pcDNA6/TRTRC2-pLKO.5-puroP
blasticidin
puromycin
Dr. Regina Fluhrer,
LMU Munich,
unpublished
HEK293 TetR TRC2-SPPL3-puroP pcDNA6/TRTRC2-pLKO.5-puroP
blasticidin
puromycin
Dr. Regina Fluhrer,
LMU Munich,
unpublished
MEF Sppl3+/+ E5 none none this study
MEF Sppl3-/- E2 none none this study
MEF PS1/PS2+/+ pMSSVLT none
Dr. Bart De Strooper, 
Leuven
(Herreman et al, 
2003)
MEF PS1/PS2-/- pMSSVLT none
Dr. Bart De Strooper, 
Leuven
(Herreman et al, 
2003)
3.1.4 Plasmids
pcDNA3.1hygro+ and pcDNA4/TO/myc-his A were purchased from life technologies (Carlsbad, 
USA). pCiES which includes the full-length coding sequence of FVenv of simian origin 
(SFVcpz(hu)) was kindly provided by David W. Russell (University of Washington, USA). The 
ORF shuttle clone OCABo5050G0617D/100061790 containing the human GnT-V coding 
sequence was obtained from Source BioScience, Nottingham, UK. C-terminally HA-tagged 
human SPPL3 (isoform 2) cloned into pcDNA4/TO had previously been generated in the 
laboratory of Dr. Regina Fluhrer (Ludwig-Maximilians University Munich) and the original 
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plasmid containing the coding sequence of  human SPPL3 (isoform 2) had kindly been provided 
by Dr. Bruno Martoglio (ETH Zurich, Switzerland). Plasmids encoding SPPL3-specific and non-
targeting control shRNAs were purchased from Sigma. Expression constructs cloned in this 
study are listed in Tab. 3.2.
3.2 Experimental procedures
3.2.1 Molecular cloning
3.2.1.1 Overview of expression constructs generated
Tab. 3.2 lists all constructs generated in this study that were subsequently used for expression 
in eukaryotic cells and give a brief description of the cloning strategy employed, including 
sequences of  primers used for amplification by polymerase chain reaction (PCR) and restriction 
enzymes used. Epitope tags as well as restriction enzyme cleavage sites were introduced via 
primers. All oligonucleotide primers were ordered from either Sigma or Thermo Fisher Scientific, 
obtained as lyophilisate and dissolve in sterile water (final molarity: 100 µM).
Tab. 3.2: Expression constructs generated. Primer sequences are listed in Tab. 3.3 under the primer 
number given here as reference. Primers used for site-directed mutagenesis (SDM) are listed in Tab. 3.4. 
*, These GnT-V expression constructs were cloned by Ulrike Künzel. Continued on the following page.
construc
t #
construct 
name
description vector 
backbone
enzyme 
strategy
primer 
number
1 ORF Flag V5 HindIII/XhoI
Generation of vector that enables HindIII/XhoI 
insertion of full-length FVenv cds; includes N-
terminal initiator ATG, Flag tag, HindIII site, spacing 
region, XhoI site, in-frame KKKNQ ER retention 
signal, stop codon; generated via pre-annealing of 
primers and cloning into NheI/PspOMI-opened 
pcDNA3.1hygro+
pcDNA3.1 
hygro+
NheI
PspOMI
P0
P-1
2 FVenv wt
Flag- and V5-tagged full-length FVenv, including C-
terminal ER retention signal; FVenv coding sequence 
(aa 2 to 983) cloned into ORF Flag V5 HindIII/XhoI 
via HindIII and XhoI; PCR template: pCiES
pcDNA3.1 
hygro+
HindIII
XhoI
P65
P66
3 FVenv mut
Full-length Flag- and V5-tagged full-length FVenv, 
harbouring R123A/R126A mutations; generated by 
SDM; PCR template: FVenv wt
pcDNA3.1 
hygro+
HindIII
XhoI Tab. 3.4
4 FVenv mut/
ΔKKXX
Full-length Flag- and V5-tagged full-length FVenv, 
harbouring R123A/R126A mutations, stop codon 
inserted upstream of C-terminal KKKNQ; generated 
by SDM; PCR template: FVenv mut
pcDNA3.1 
hygro+
HindIII
XhoI Tab. 3.4
5 FVenv ΔE
comprises FVenv amino acids 32 to 106, N-
terminally Flag-tagged, C-terminally V5-tagged; PCR 
template: pCiES 
pcDNA3.1 
hygro+
HindIII
XhoI
P42
P43
6 FVenv ΔE AP
comprises FVenv amino acids 32 to 106, N-
terminally V5-tagged, C-terminally Flag-tagged, ends 
with alanine-proline motif; tags introduced by PCR, 
AP motif by SDM; PCR template: FVenv ΔE
pcDNA3.1 
hygro+
HindIII
XhoI
P57
P59
Tab. 3.4
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construc
t #
construct 
name
description vector 
backbone
enzyme 
strategy
primer 
number
7 hsSPPL3 isoform 1
cloned overlap extension PCR with internal primers 
introducing the sequence differences to SPPL3 
isoform 2; first PCR: P-1 & P122; P-2 & P122; 
second PCR: P-1 & P-2; PCR template: SPPL3 
isoform 2 in pcDNA4/TO
pcDNA4/TO EcoRIXhoI
P-2
P-3
P121
P122
8
hsSPPL3 
isoform 2 
D200N/D271N
mutant of human SPPL3 isoform 2, generated by two 
successive site-directed mutagenesis reqctions; 
PCR template: SPPL3 isoform 2 in pcDNA4/TO
pcDNA4/TO EcoRIXhoI Tab. 3.4
9 GnT-V* untagged, full-length human GnT-V; PCR template: ORF shuttle clone OCABo5050G0617D/100061790
pcDNA3.1 
hygro+
KpnI
XhoI
P166
P167
10 Flag-GnT-V-V5* N-terminally Flag- and C-terminally V5-tagged full-length human GnT-V; PCR template: GnT-V
pcDNA3.1 
hygro+
KpnI
XhoI
P168
P169
11 GnT-V NTF*
comprises amino acids 2 to 61 of human GnT-V; N-
terminally V5-, C-terminally Flag-tagged, ends with 
alanine-proline motif; ; PCR template: GnT-V
pcDNA3.1 
hygro+
KpnI
XhoI
P176
P180
Tab. 3.3: Oligonucleotides used for molecular cloning. Continued on the following page.
primer names primer sequence (5' → 3')
P0/Flag-V5-KKxx-
NheI/PspOMI_fw
CTAGCACCATGGACTACAAGGACGACGACGACAAGAAGCTTCGCCTCGAGGGTAAGCCTATCCCTAACCCTCTCCT
CGGTCTCGATTCTACGACGAAAAAGAAGAATCAGTAGT
P-1/Flag-V5-KKxx-
NheI/PspOMI_rev
GGCCACTACTGATTCTTCTTTTTCGTCGTAGAATCGAGACCGAGGAGAGGGTTAGGGATAGGCTTACCCTCGAGGC
GAAGCTTCTTGTCGTCGTCGTCCTTGTAGTCCATGGTG
P65/pfoa2-Hind-for TCCAAGCTTGCACCACCAATGACACTGCAAC
P66/pfoa983-Xho-rev CGCTCGAGAGGAATCCATGATACAATCTTAA
P42/Flag-HindIII_for CTCCAAGCTTATGACTACAAGGACGACGACG
P43/V5-Stopp_rev CGCTCGAGGTCACGTAGAATCGAGACCGAGGAGAGGG
P57/pfoa32-Hind-V5-
for 
CTCCAAGCTTGACCATGGGTAAGCCTATCCCTAACCCTCTCCTCGGTCTCGATTCTACGCAGCAGAAGGAACAAAT
TATACTGGAC
P59/pfoa106-Flag- 
Xho-rev 
CGCTCGAGCGGCTACTTGTCGTCGTCGTCCTTGTAGTCTATTACAGGTCCTAATACCTGAATATC
P-2/Fluhrer - SPPL3 
fw EcoRI
CGGAATTCATGGCGGAGCAGACC
P-3/Fluhrer - SPPL3 
HA rw Xho neu
CCGCTCGAGTCAGGCGTAGTCGGGCACGTCGTAGGGGTAAGCTACTTCCAGGAATCGGGAGCTGCT
P121/hsSPPL3 iso 
1_fw
TTCAATGGGGAACAGGAACCAATAATTGGCTTCCAACCAATGGACTCTACCCGGGCTCGGTTCCTTCCAATGGGAG
CATGTGTCTCT
P122/hsSPPL3 iso 
1_rev
AGAGACACATGCTCCCATTGGAAGGAACCGAGCCCGGGTAGAGTCCATTGGTTGGAAGCCAATTATTGGTTCCTGT
TCCCCATTGAA
P166/hsMGAT5_fw GCTTGGTACCGACCATGGCTCTCTTCACTCCG
P167/hsMGAT5_rev CTCTAGACTCGAGCTATAGGCAGTCTTTGCAG
P168/
hsMGAT5_Flag_fw CTTGGTACCGACCATGGACTACAAGGACGACGACGACAAGGCTCTCTTCACTCCGTGGAAG
P169/
hsMGAT5_V5_rev
GGCCCTCTAGACTCGAGCTACGTAGAATCGAGACCGAGGAGAGGGTTAGGGATAGGCTTACCTAGGCAGTCTTTGC
AGAGAGCCAC
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primer names primer sequence (5' → 3')
P176/hsMGAT5-
V5_fw
GCTTGGTACCGACCATGGGTAAGCCTATCCCTAACCCTCTCCTCGGTCTCGATTCTACGGCTCTCTTCACTCCGTG
GAAG
P180/hsMGAT5-trunc-
Flag_rev CTCTAGACTCGAGCTAGGGGGCCTTGTCGTCGTCGTCCTTGTAGTCCAGTGCCTTGATGTACCTTTTG
3.2.1.2 Polymerase chain reaction
DNA was amplified by PCR with primers and templates indicated in Tab. 3.2 and 3.3 using the 
Pwo polymerase (PEQLAB, Erlangen, Germany). A 50 µl reaction mixture included 5 ng DNA 
template, 0.5 µM of each oligonucleotide primer, dNTPs at 400 µM (Roche, Rotkreuz, 
Switzerland), reaction buffer and 1 U Pwo Polymerase. Reactions were performed in an 
Eppendorf  Mastercycler personal with an initial denaturation for 5 min at 94°C followed by 
30 cycles of  1 min at 95°C, 1 min at 55°C and 4 min/1 kb at 68°C and a final incubation for 
10 min at 68°C. 
SPPL3 isoform 1 was cloned by overlap extension PCR using SPPL3 isoform 2 as a template 
and sequence alterations were included in the oligonucleotide primers. Two individual PCRs 
were performed using one terminally and one internally annealing primer. The individual two 
PCR products were then fused in another PCR using only flanking PCR primers.
3.2.1.3 Submerged agarose gel electrophoresis
TAE buffer (50x):   40 mM Tris pH 8.0, 20 mM Na(CH3COO)2, 2 mM EDTA
DNA sample buffer (10x):  100 mM Tris pH 9.0, 10 mM EDTA, 50% (v/v) glycerol, 0.5% (w/v) 
    Orange G
DNA fragments were analysed by submerged agarose gel electrophoresis (SAGE). To this end, 
samples were mixed with sample buffer and separated 1x TAE-buffered gels containing 0.5 to 
2 % (w/v) agarose (Invitrogen, Carlsbad, USA) containing 0.2 µg/ml ethidium bromide. Samples 
were compared to commercial DNA markers (Invitrogen, Carlsbad, USA) and analysed by UV 
illumination. For subsequent processing, DNA fragments of the expected size were excised 
from the gel and extracted using the NucleoSpin Gel and PCR clean-up kit (Macherey-Nagel, 
Düren, Germany) according to the manufacturer's instructions.
3.2.1.4 Restriction endonuclease digestion of DNA
Restriction endonucleases from commercial sources (Thermo Fisher Scientific or New  England 
Biolabs, Ipswich, USA) were used to digest DNA. To this end, DNA was diluted in water, 
supplemented with the respective reaction buffer, mixed with the respective enzymes (5 to 
20 U) according to the manufacturer's recommendations and incubated at 37°C for 2 to 16 h. 
Reaction products were purified as described in 3.2.1.3. Individual restriction enzymes used for 
cloning are listed in Tab. 3.2.
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3.2.1.5 Ligation
Ligations were performed using T4 DNA Ligase (Thermo Fisher Scientific) and the supplied 
reaction buffer. Reactions with a total volume of  20 µl containing roughly 50 to 100 ng restriction 
enzyme-digested target vector and 1 to 2 µg digested DNA fragments were incubated at room 
temperature for 2 h or alternatively at 14°C overnight.
3.2.1.6 Site-directed mutagenesis
Tab. 3.4 lists oligonucleotides used for site-directed mutagenesis. They were designed in strict 
accordance with guidelines from the QuikChange II Site-Directed Mutagenesis Kit (Agilent 
Technologies, Santa Clara, USA). A 50 µl reaction mixture included 10 ng DNA template, 125 ng 
of each oligonucleotide primer, dNTPs at 400 µM (Roche), 2,5 U Pfu turbo DNA polymerase 
(Agilent) and the reaction buffer supplied. Reactions were performed with an initial denaturation 
for 1 min at 95°C followed by 16 cycles of  30 s at 95°C, 30 s at 55°C and 2 min/1 kb at 68°C 
and a final incubation for 10 min at 68°C. Afterwards, 1 µl of  DpnI (New  England Biolabs) was 
added and the reaction mix was incubated at 37°C for 1.5 h to digest template DNA.
Tab. 3.4: Oligonucleotide primers used for site-directed mutagenesis. 
primer name sequence (5' → 3', mismatches bold) mutation target
P69/TAG_fw CGGTCTCGATTCTACGTAGACGAAAAAGAAGAATC stop codon 
insertion
FVenv
P70/TAG_rev GATTCTTCTTTTTCGTCTACGTAGAATCGAGACCG
P93/AP-mut-fw GACGACGACGACAAGGCCCCCTAGCCGCTCGAGTC alanine-proline 
insertion
FVenv
P94/AP-mut-rev GACTCGAGCGGCTAGGGGGCCTTGTCGTCGTCGTC
P73/RR123/126AAfw CCCTTACAGACTAGAGCCATTGCAGCCTCCCTTAGAATGCAGC R123A/R126A FVenv
P74/ RR123/126AArev GCTGCATTCTAAGGGAGGCTGCAATGGCTCTAGTCTGTAAGGG
P132_hSPPL3D-->N_fw CTCCATGTTGGGCATCGGAAACATCGTTATGCCTGGTCTCC D271N SPPL3
P133_hSPPL3D-->N_rev GGAGACCAGGCATAACGATGTTTCCGATGCCCAACATGGAG
P138-hSPPL3D-->N2_fw CTCTCAGGGCTTCTCATCTATAACGTCTTTTGGGTATTTTTCTC D200N SPPL3
P139-hSPPL3D-->N3_rev GAGAAAAATACCCAAAAGACGTTATAGATGAGAAGCCCTGAGAG
3.2.1.7 Transformation of E. coli
LB medium:   1% (w/v) bactotrypton, 0.5% (w/v) yeast extract, 1% (w/v) NaCl 
   autoclaved at 120°C and 1.2 bar for 20 min
CaCl2 buffer:  50 mM CaCl2, 10 mM Tris pH 8.0
LB agar plates:  LB medium supplemented with 15 g/l agar, autoclaved at 120°C at 1.2 bar 
   for 20 min, supplemented with 100 µg/ml ampicillin or spectinomycin
   following cooling, poured into plastic Petri dishes
To obtain heat shock-competent cells, an overnight culture of E. coli DH5α was diluted in fresh 
LB medium and incubated at 37°C and 250 rpm until an OD600 of  0.5 was reached. Cells were 
pelleted by centrifugation at 1,500g and 4°C for 5 min. They were then resuspended in ice-cold 
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CaCl2buffer and chilled on ice for 30 min. Cells were pelleted again, resuspended in 1 ml of 
CaCl2 and aliquots were stored at -80°C.
For transformation, 100 µl of  cells were thawed on ice and mixed with 10 µl of a ligation 
reaction, 1 µl of  a site-directed mutagenesis reaction or 50 ng intact plasmid DNA. Following 
incubation on ice for 10 min, the mixture was incubated at 42°C for 2 min and instantly chilled 
on ice for an additional 2 min. 1 ml of  sterile LB medium was added and samples were agitated 
for 1 h at 37°C. The mixture was then either plated on LB agar plates or used to inoculate sterile 
LB medium. In either case, media were supplemented with ampicillin or spectinomycin (100 µg/
µl, Carl Roth) to select for transformed cells.
3.2.1.8 Preparation of plasmid DNA
Plasmid DNA was isolated from bacterial cultures agitated overnight at 37°C using commercial 
kits according to the manufacturer's instructions (Macherey-Nagel). DNA concentration was 
determined photometrically using a UV-Vis NanoPhotometer (Implen, Munich, Germany) and 
plasmid identity was verified by restriction endonuclease digestion and SAGE.
3.2.1.9 Sequencing
Plasmid sequence identity was verified prior to use. To this end, plasmid samples were sent to 
GATC Biotech (Konstanz, Germany) and sequence information was obtained by Sanger 
sequencing using standard sequencing primers or, alternatively, internal sequencing primers 
(Tab. 3.5). Sequence analysis was performed using the CLC Main Workbench, v6.6 (CLC bio, 
Aarhus, Denmark).
Tab. 3.5: Oligonucleotide primers used for sequencing. Classical  sequencing primers provided by 
GATC  Biotech such as T7_for, CMV_for, BGH_rev etc. are not listed.
primer name sequence (5' → 3') target
P61/foa-env-2080_rev GTAGCTGTGGGAGAACTATG FVenv
P62/Foa-env-1400_for GGAACCCATAGTGGTGAAGG FVenv
P164/MmMGAT5_int TGGGTTCATTACCAGTGC MGAT5
P174/mmMGAT5_int_rev CACTGGTAATGAACCCAG MGAT5
P175/mmMGAT5_int_fw GATCCGGCGAATGGCTGACG MGAT5
3.2.2 Animal work
3.2.2.1 Animal housing and breeding
Mice were kept at specific pathogen-free conditions at the Institute of Immunology, Ludwig-
Maximilians University Munich, Munich, Germany. To maintain the mixed B6;129S5 background, 
heterozygous B6;129S5-Sppl3Gt(OST279815)Lex/Mmucd mice were inter-crossed. At the same time, 
B6;129S5-Sppl3Gt(OST279815)Lex/Mmucd were crossed back to the Institute of  Immunology's 
C57BL/6 strain for 5 generations. 
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3.2.2.2 Mouse genotyping
Tail lysis buffer:   100 mM Tris, pH 8.5, 5 mM EDTA, 0.2% (w/v) SDS, 200 mM 
    NaCl, freshly added proteinase K (100 µg/ml, Roche)
Mouse genotyping was conducted on genomic DNA isolated from tail clips or cultured cells. 
Samples were agitated in 500 µl tail lysis buffer overnight and debris was sedimented by 
centrifugation at 13 krpm for 5 min. DNA was precipitated from the supernatant by addition of 
0.8 volumes of  isopropanol, mixing, and centrifugation at 13 krpm and 4°C for 20 min. The pellet 
was washed once with 70% (v/v) ethanol. Next, the dried pellet was resuspended in 200 µl 
sterile water and incubated at 55°C for 1 h. The solution was refrigerated until use.
Primers used for genotyping PCRs are listed in Tab. 3.6. Reactions were set-up as described in 
3.2.1.2 but the GoTaqGreen polymerase and the supplied reaction buffer (Promega, Madison, 
USA) were used instead of Pwo polymerase. Correct insertion of  the genetrap into the SPPL3 
locus was tested by a touchdown PCR. An initial denaturation for 10 min at 94°C was followed 
by 10 PCR cycles (each 15 s at 95°C, 30 s at 65°C (decreased by 1°C every cycle) and 30 s at 
72°C). 30 additional cycles followed (each 15 s at 95°C, 30 s at 55°C and 30 s at 72°C) and the 
reaction was terminated after a final elongation of  5 min at 72°C. Presence of the intact wild-
type allele was checked by two additional PCR reactions (2 min at 95°C, 30 to 35 cycles (each 
1 min at 94°C, 30 s at 64°C, 1 min at 72°C, 10 min at 72°C). PCR products were separated by 
SAGE (3.2.1.3).
Tab. 3.6: Oligonucleotide primers used for genotyping.
primer name sequence (5' → 3') amplicon
P95/L3-KO-pair1_for GCAGGCATCTGCAGAACTCATG ca. 440 bp,
wt allele
P96/L3-KO-pair1_rev GCCGTGACACAGCAAGTGCA
P158/L3-KO-rev2 TTTACTAGGGAGAGGCGTCAT ca. 340 bp,
wt allele
P159/L3-KO-fw2 AAGTGCTGGGATTAAAGGCGA
P97/LTR2 AAATGGCGTTACTTAAGCTAGCTTGC ca. 220 bp,
inserted genetrap
P98/PRT340T2 3’ AAACCTTTACTAGGGAGAGGCGTCA
3.2.2.3 Tissue homogenisation
Homogenisation buffer:  5 mM Tris x HCl, pH 7.4, 250 mM sucrose, 5 mM EGTA, 
     supplemented with protease inhibitor mix (1:500, Sigma)
Organs were removed at necropsy of  sacrificed animals and frozen instantly on dry ice. Thawed 
organs were cut into pieces and homogenised in homogenisation buffer using a Wheaton tissue 
grinder (Thermo Fisher Scientific) and 23G needles afterwards. Homogenates were centrifuged 
for 5 min at 5 krpm and 4°C. Supernatants were transferred into an ultracentrifugation tube 
(Beckman-Coulter, Brea, USA) and subjected to centrifugation at 100,000g and 4°C for 1 h. 
Pellets were resuspended in homogenisation buffer containing 2% (v/v) Triton X-100 and 
incubated on ice for 30 min. Lysates were cleared by centrifugation (13 krpm, 4°C, 30 min). 
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Protein content was determined as detailed elsewhere (3.2.4.2) and samples were subjected to 
SDS-PAGE and Western blotting (3.2.4.7 to 3.2.4.9).
3.2.2.4 Generation of murine embryonic fibroblasts
basic medium:  DMEM GlutaMax® (life technologies) supplemented with 10% (v/v) FCS,
   2 mM L-glutamine, 50 U/ml penicillin and 50 µg/ml streptomycin
Murine embryonic fibroblasts (MEFs) were obtained from B6.129S5-Sppl3Gt(OST279815)Lex/Mmucd 
(N5) mice. Following mating with a heterozygous male, a heterozygous pregnant female was 
sacrificed and P13.5 embryos were taken from the corpse. Head and limbs as well as inner 
organs were removed from the embryo and the remaining material was cut in piece and 
resuspended in 1 ml sterile HBSS (life technologies, Carlsbad, USA). 2 ml sterile trypsin 
(0.05% (w/v))-EDTA (life technologies) was added and the tissue was digested for 20 min at 
37°C. 7 ml DMEM medium (GlutaMax®, life technologies) supplemented with 15% (v/v) fetal 
calf serum (Sigma), 2 mM L-glutamine (life technologies) and 50 U/ml penicillin/50 µg/ml 
streptomycin (life technologies) were added and cells were sedimented by centrifugation. Cell 
pellets were then resuspended in basic medium and cultivated as described elsewhere 
(3.2.3.1). Embryos were genotyped as described in 3.2.2.2 using the head to isolate genomic 
DNA. Primary MEFs were expanded and used for experiments. In addition, MEFs were 
immortalised as described earlier (Xu, 2005).
3.2.2.5 Flow cytometric analysis of NK cell counts
FACS medium:  DMEM (life technologies) supplemented with 10 mM Hepes and 1% (w/v) BSA
Inguinal, axillary and brachial lymph nodes were removed from sacrificed mice and taken up in 
5 ml FACS medium. They were homogenised between the rough edges of microscope slides 
and pipetted through a nylon mesh. Following centrifugation at 1,500 rpm for 5 min, the 
supernatant was removed, cells were resuspended in 1 ml FACS medium and counted using a 
Neubauer chamber. The removed spleen was treated similarly, but the cell suspension was 
underlaid with 3 ml Lympholyte M (Cedarlane Labs, Burlington, Canada) and centrifuged at 
2,000 rpm (i.e. 671 rcf) for 15 min without brake. Cells were collected from the interphase, 
mixed with 5 ml FACS medium and centrifuged again at 1,500 rpm for 5 min. The supernatant 
was discarded and cells were resuspended in 2 ml FACS medium and counted. For each 
staining, 1 to 5 million cells were used and staining was conducted in a 96-well plate. Fc 
receptors were blocked with an anti-mouse CD16/32 antibody (1:400 in FACS medium, 50 µl/
well; BioLegend, San Diego, USA) on ice for 10 min. Cells were sedimented and taken up in 
50 µl of the respective antibody solution. FITC-conjugated anti-mouse NKp46 (clone 29A1.4) 
and PE-conjugated anti-mouse CD49b (clone DX5) as well as the respective isotype control 
antibodies were obtained from eBioscience (San Diego, USA). They were pre-diluted 1:400 in 
FACS medium and centrifuged at 13 krpm for 5 min to remove aggregates. Antibody binding 
was done at 4°C in darkness for 20 to 30 min. Cells were washed once with 200 µl FACS 
medium and then taken up in 200 µl FACS buffer supplemented with DAPI. Measurements were 
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done using a FACSCanto™ (Becton Dickinson, Franklin Lanes, USA) and were analysed with 
the FlowJo software suite. These experiments were performed together with Anne Behrendt, 
Institute of Immunology, Ludwig-Maximilians University Munich.
3.2.2.5 In vitro differentiation of bone marrow-derived dendritic cells
PBS:   140 mM NaCl, 10 mM Na2HPO4, 1.75 mM KH2PO4, pH 7.4, 
   autoclaved at 120°C and 1.2 bar for 20 min
DC medium:  RPMI 1640 (life technologies) supplemented with 10% (v/v) FCS,
   2 mM L-glutamine, 50 U/ml penicillin and 50 µg/ml streptomycin
Bone marrow-derived dendritic cells (BMDCs) were generated by ex vivo generation of 
haematopoetic stem  cells in the presence of GM-CSF and IL-4. Femur and tibia were surgically 
removed from sacrificed mice, cleaned and briefly dipped into ethanol. Under sterile conditions, 
epiphyses were cut off  and bones diaphyses were rinsed with PBS to liberate bone marrow 
cells. The cell solution was collected and cells were pelleted by centrifugation (350g, 4°C, 
8 min). The cell pellet was resuspended in 5 ml 1x Pharm lyse (Becton-Dickinson) and 
incubated at room temperature for 3 min to lyse erythrocyte contaminants. 35 ml PBS were 
added and cells were pelleted again. Cells were resuspended in DC medium and plated in a 
T-75 tissue culture flask. Dendritic cell (DC) differentiation was started by addition of 0.1 µg/ml 
GM-CSF and 0.1 µg/ml IL-4 (both from PeproTech, Rocky Hill, USA). After 2 to 3 days, 10 ml of 
DC medium supplemented with GM-CSF and IL-4 were added. One week after plating, cells 
were counted and 5 x 106 cells were plated on fresh 10 cm dishes in 5 ml DC medium. Where 
indicated, cells were stimulated with CpG (Enzo) at 0.3 µM.
3.2.3 Cell biology
3.2.3.1 General techniques
basic medium:  DMEM GlutaMax® (life technologies) supplemented with 10% (v/v) FCS,
   2 mM L-glutamine, 50 U/ml penicillin and 50 µg/ml streptomycin
PBS:   140 mM NaCl, 10 mM Na2HPO4, 1.75 mM KH2PO4, pH 7.4
   autoclaved at 120°C and 1.2 bar for 20 min
All cells were cultivated in water-jacket incubators in a humidified atmosphere containing 5% (v/
v) CO2. All cells were cultivated in basic medium supplemented with 5 µg/ml blasticidin, 100 µg/
ml hygromycin, 1 µg/ml puromycin or 200 µg/ml zeocin (all from life technologies) according to 
Tab. 3.1 and passaged every 3 to 4 days. To this end, cells were washed once with phosphate-
buffered saline (PBS) and detached by incubation in trypsin(0.05%)-EDTA (life technologies). 
Following centrifugation at 1,000 rpm for 5 min, the cell pellet was resuspended in fresh medium 
and, when required, the cells were counted in a Neubauer chamber and plated.
All experiments were conducted on poly-L-lysine coated plates. To obtain these, culture dishes 
were covered with poly-L-lysine (Sigma) dissolved in PBS at 100 µg/ml. Following incubation for 
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1 h, the poly-L-lysine solution was removed and plates were washed three times with sterile 
PBS. Experiments were performed in DMEM medium supplemented solely with 10% (v/v) FCS. 
Over-expression of  tet operator-controlled wild-type or mutant SPPL2a, SPPL2b and SPPL3 
was induced by supplementing the culture medium with 1 µg/ml doxycycline (Carl Roth).
For subsequent analysis by biochemical methods, conditioned supernatants were collected, 
subjected to centrifugation at 13 krpm and 4°C for 20 min to remove detached cells and the 
supernatant was transferred into a new  reaction tube. It was either directly subjected to gel 
electrophoresis (see 3.2.4.7) or proteins were enriched by trichloroacetic acid precipitation (see 
3.2.4.6) Cells were washed once with ice-cold PBS, detached in 1 ml PBS using a cell scraper 
and sedimented by centrifugation. Material was either used directly or stored at -20°C or -80°C 
until further use.
3.2.3.2 Transfection with plasmid DNA
Cells were transfected with plasmid DNA using Lipofectamine 2000 (life technologies). For a 
single 6 or 10 cm dish, 8 µl Lipofectamine 2000 were pre-incubated in 500 µl Optimem (life 
technologies) at room temperature for 5 min. At the same time 4 to 8 µg plasmid DNA were 
mixed with 500 µl Optimem. Both solutions were mixed and incubated at room temperature for 
20 min before being added to the culture dish at roughly 75% confluency. Cells and conditioned 
supernatants were used for experimentation 48 h after transfection. To obtain stably transfected 
cells, cells were serially diluted into basic medium supplemented with the respective antibiotic to 
select for plasmid-encoded resistance genes. Resistant pooled cells or single cell-derived 
clones were expanded and analysed for exogenous protein expression as described.
3.2.3.3 RNAi
To reduce endogenous gene expression, cells were transiently transfected with siGENOME 
SMART pool siRNAs targeting SPPL2a (#M-006040-01), SPPL3 (#M-006042-02), B3GNT1 
(#M-012307-01), B4GALT1 (#M-012965-00), EXTL3 (#M-012578-00), XYLT2 (#M-013040-01), 
B3GALT6 (#M-021340-01), HS6ST1 (#M-011944-01), HS6ST2 (#M-015558-01), SGK196 
(#M-005321-00) or MGAT5 (#M-011334-01) obtained from Thermo Fisher Scientific. As control, 
cells were transfected with siGENOME non-targeting siRNA pool #2 (#D001206-14). SPPL2b-
targeting siRNA (#SI04256070) and a respective control siRNA were from Qiagen (Hilden, 
Germany). All siRNAs were dissolved in sterile, RNA-free water (Qiagen) at 20 µM. In a 6 cm 
dish, 1.2 ml Optimem, 3 µl siRNA (pool) and 12 µl Lipofectamine RNAiMax (life technologies) 
were incubated for 20 min. 1.6 to 2.0 x 106 cells (freshly trypsinised and diluted in 1.8 ml DMEM 
supplemented with 10% (v/v) FCS) were added. After 16 to 24 h the culture medium was 
changed and cells were analysed 3 to 5 days later.
3.2.3.4 Inhibitor treatment
In the course of this study, cells were treated with various small molecules. Compounds were 
diluted in culture medium, treatment was generally performed for 16 to 24 h and cells were 
directly harvested afterwards. Inhibitors used were: kifunensine (Santa Cruz Biotechnology, 
Dallas, USA), (Z-LL)2 ketone (Merck, Darmstadt, Germany), DAPT (Enzo) and L-685,458 
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(Merck). The compounds were used at concentrations indicated in the respective figure legend. 
Kifunensine was dissolved in sterile double-distilled water and all other inhibitors were dissolved 
in DMSO.
3.2.3.5 Immunocytochemistry and confocal microscopy
PBS:   140 mM NaCl, 10 mM Na2HPO4, 1.75 mM KH2PO4, pH 7.4
Mowiol:  6.0 g glycerol, 2.4 g Mowiol 4-88 (Carl Roth), 12.0 ml 0.2 M Tris x HCl pH 8.5
   6.0 ml double-distilled water, 25 mg/ml DABCO (Carl Roth)
   Glycerol and Mowiol were stirred for 1 h at room temperature, water was added
   and the mixture was stirred for another hour, following addition of Tris buffer, the
   mixture was incubated at 50°C for 2 h and stirred for 2 min every 20 min. After
   centrifugation for 15 min at 5,000 g, the supernatant was frozen until use.
4% (w/v) PFA:  4 g PFA (Sigma) were added to approximately 80 ml of heated (ca. 60°C)
   PBS; while being stirred 1 M NaOH was added dropwise until the solution
   cleared; following filtering and cooling the solution was adjusted to a pH of 
   approximately 6.9 using dilute HCl and a total volume of 100 ml with PBS
   
Sub-cellular localisation of individual proteins was analysed by immunofluorescence staining 
and confocal laser-scanning microscopy. Cells were grown on poly-L-lysine-coated glass 
coverslips in 6-well or 24-well cell culture dishes and transfected as described in 3.2.2.2. 
Medium was aspirated and cells were washed twice with PBS. Cells were fixed by incubation in 
4% (w/v) paraformaldehyde (PFA) dissolved in PBS for 20 min. The solution was discarded and 
fixed cells were washed three times with PBS. Cells were permeabilised in PBS supplemented 
with 0.2% (v/v) Triton X-100 and 50 mM NH4Cl for 20 min. Coverslips were washed again three 
times with PBS and incubated in PBS supplemented with 5% (w/v) BSA at room temperature for 
1 h. Coverslips were incubated in primary antibodies at ambient temperature for 1 h and 
afterwards washed six times with PBS. The procedure was repeated for fluorophore-conjugated 
secondary antibodies (anti-rabbit and anti-mouse, each conjugated to Alexa488 or Alexa555, 
1:500; life technologies). Finally, coverslips were washed once in water and embedded in 
Mowiol on microscope slides. Primary antibodies used are listed in Tab. 3.7. All antibodies were 
diluted in PBS containing 1% (w/v) BSA. For detection using the anti-Flag M2 mAb, cells were 
briefly (5 min) fixed in PFA and subsequently incubated for 1 min in methanol (-20°C). Following 
drying, cells were rehydrated in PBS for 10 min at room temperature and blocking as well as 
imumunodetection proceeded as described earlier. All samples were analysed using the 
510Meta confocal laser-scanning microscope (Carl Zeiss, Jena, Germany). Images were 
acquired in multi-channel scanning mode and processed using the LSM Image Browser (Carl 
Zeiss).
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Tab. 3.7: Primary antibodies used for immunocytochemical staining.
* For pAbs, the respective catalogue number is given.
antigen species & type clone #* dilution source
KDEL mouse, mAb 10C3 1:100 Enzo
V5 tag rabbit, pAb AB3792 1:400 Millipore
Flag tag mouse, mAb M2 1:800 Sigma
3.2.4 Biochemical methods
3.2.4.1 Preparation of cellular membranes
hypotonic buffer: 10 mM Tris pH 7.6, 1 mM EDTA, 1 mM EGTA, adjust pH to 7.6
   supplemented with protease inhibitor mix (1:500)
basic buffer:  40 mM Tris pH 7.8, 40 mM KCH3COO, 1.6 mM Mg(CH3COO)2, 
   100 mM sucrose, 0.8 mM DTT
sample buffer (2x): 20% (v/v) glycerol, 3% (w/v) SDS, 3% (w/v) DTT, bromophenol blue (traces)
   dissolved in 4x upper Tris buffer (see 3.2.4.7.3)
To obtain cellular membranes, cell pellets were resuspended in hypotonic buffer (800 µl/6 cm 
dish), vortexed and chilled on ice for 10 min. Following passing through a syringe with a 23G 
needle for 15 times, samples were subjected to centrifugation at 5 krpm and 4°C for 5 min to 
remove cellular debris and intact organelles such as nuclei and mitochondria. The post-nuclear 
supernatant was transferred into a new  reaction tube and centrifuged at 13 krpm and 4°C for 
45 min to sediment membranes. The supernatant was discarded and the membrane pellet was 
either lysed (see 3.2.4.2) or contained proteins were precipitated. In the latter case, pellets were 
resuspended in 40 µl basic buffer, mixed with 120 µl chloroform/methanol (1:2) and incubated 
on ice for 1 h. Following centrifugation (13 krpm, 4°C, 30 min), the supernatant was discarded. 
Protein precipitates were allowed to dry and were subsequently resuspended in 2x sample 
buffer.
3.2.4.2 Preparation of whole cell lysates
lysis buffer:  50 mM Tris pH 7.6, 150 mM NaCl, 2 mM EDTA, 1.2% (v/v) NP-40,
   1% (v/v) Triton X-100, supplemented with protease inhibitor mix (1:500)
sample buffer (5x): 50% (v/v) glycerol, 7.5% (w/v) SDS, 7.5% (w/v) DTT, 
   bromophenol blue (traces), dissolved in 4x upper Tris buffer (see 3.2.4.7.3)
Cell pellets were resuspended in lysis buffer (100 to 300 µl/pellet of  a 6 cm dish), vortexed 
extensively and incubated on ice for 30 to 60 min. Cell debris etc. was removed by 
centrifugation (13 krpm, 4°C, 30 min) and the supernatant was transferred into a new  reaction 
tube. Membrane pellets obtained as described (see 3.2.4.1) were treated similarly to extract 
proteins.
Protein concentrations in lysates were determined by means of  a bicinchoninic acid (BCA)-
based commercial kit (Interchim, Montluçon, France) according to the manufacturer's 
! Materials & Methods! 49
instructions. In brief, lysates were diluted and mixed with 200 µl reagent in a 96-well plate. 
Following incubation at 37°C for 15 to 30 min, the absorbance at 562 nm was measured 
photometrically in a plate reader (Power Wave XS, BioTek, Winooski, USA). A serial dilution of 
BSA was always measured in parallel as reference. Cell and membrane extracts were stored at 
-20°C for subsequent use, often supplemented with 5x sample buffer for SDS-PAGE (see 
3.2.4.7).
3.2.4.3. Immunoprecipitations
STEN buffer:  50 mM Tris pH 7.6, 150 mM NaCl, 2 mM EDTA, 0.2% (v/v) NP-40
sample buffer (2x): 20% (v/v) glycerol, 3% (w/v) SDS, 3% (w/v) DTT, bromophenol blue (traces)
   dissolved in 4x upper Tris buffer (see 3.2.4.7.3)
Cell or membrane lysates were either directly subjected to immunoprecipitation or were first 
adjusted to the same total protein content. All samples were brought to a final volume of 1 ml 
with STEN buffer. 25 to 50 µl protein A- or protein G-conjugated sepharose beads (GE 
Healthcare, Chalfont St Giles, UK) and the respective antibody (usually 1 µg, Tab. 3.8) were 
added. Alternatively, anti-Flag M2-conjugated agarose beads (Sigma) were used. 
Immunoprecipitations were agitated at 4°C overnight. Beads were sedimented by centrifugation 
(7 krpm, 4°C, 5 min) and washed five times with 1 ml STEN buffer. Finally, beads were dried by 
removing excess buffer with a 27G needle, resuspended in 2x sample buffer and subjected to 
SDS-PAGE (see 3.2.4.7).
Tab. 3.8: Antibodies used for immunoprecipitations. 
antigen antibody 
type
antibody 
species
clone/cat. 
#
quantity source
HA tag mAb rabbit 6908 1 µl Sigma
Nicastrin pAb rabbit N1660 6 µg Sigma
V5 tag pAb rabbit R960-25 1 µl Millipore
3.2.4.4 Co-immunoprecipitations
basic buffer:  40 mM Tris pH 7.8, 40 mM KCH3COO, 1.6 mM Mg(CH3COO)2, 
   100 mM sucrose, 0.8 mM DTT
sample buffer (5x): 50% (v/v) glycerol, 7.5% (w/v) SDS, 7.5% (w/v) DTT, 
   bromophenol blue (traces), dissolved in 4x upper Tris buffer (see 3.2.4.7.3)
sample buffer (2x): 20% (v/v) glycerol, 3% (w/v) SDS, 3% (w/v) DTT, bromophenol blue (traces)
   dissolved in 4x upper Tris buffer (see 3.2.4.7.3) 
For co-immunoprecipitation, cellular membranes (see 3.2.4.1) were lysed in basic buffer 
supplemented with 1% (w/v) CHAPSO (for FVenv co-immunprecipitations) on ice for 1 h. 
Following centrifugation at 13 krpm and 4°C for 45 min, 5% of the lysate's volume were mixed 
with 5x sample buffer. The remaining lysate was subjected to anti-Flag immunoprecipitation as 
described in 3.2.4.3. Beads were washed six times in the respective lysis buffer, dried, 
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resuspended in 2x sample buffer and subjected to SDS-PAGE and Western blot (see 3.2.4.7 to 
3.2.4.9) detection of co-precipitated proteins.
3.2.4.5 Enzymatic deglycosylation
deglycosylation buffer: 50 mM Na2PO4, pH 7.2, 12 mM EDTA, 0.4% (v/v) NP-40
sample buffer (5x):  50% (v/v) glycerol, 7.5% (w/v) SDS, 7.5% (w/v) DTT, 
    bromophenol blue (traces), dissolved in 4x upper Tris buffer
For enzymatic deglycosylation, lysates were supplemented with 1x glycoprotein denaturation 
buffer (New  England Biolabs) as well as additional 0.5% (w/v) SDS (1% (w/v) total) and 
incubated at 95°C for 10 min. They were subsequently diluted with deglycosylation buffer to 
adjust the total SDS concentrations to 0.1 to 0.2% (w/v). Diluted samples were divided and 1 to 
3 µl PNGase F (Roche) or Endo H were added. The reactions were incubated at 37°C overnight 
and stopped by addition of 5x sample buffer. As control, samples were incubated overnight 
without the addition of glycosidase.
3.2.4.6 Trichloroacetic acid precipitation
sample buffer (2x): 20% (v/v) glycerol, 3% (w/v) SDS, 3% (w/v) DTT, bromophenol blue (traces)
   dissolved in 4x upper Tris buffer (see 3.2.4.7.3)
To enrich secreted proteins in conditioned supernatants devoid of FCS for analysis by Western 
blotting, trichloroacetic acid (TCA) precipitations were performed. To this end, cells were 
washed twice with pre-warmed Optimem medium and cultivated in Optimem for 6 to 48 h. 
Media were collected as described (see 3.2.3.1). 800 µl conditioned supernatant were mixed 
with 200 µl freshly prepared aqueous 100% (w/v) TCA and incubated on ice for 1 h. Following 
centrifugation (13 krpm, 4°C, 30 min), pellets were washed twice with acetone (-20°C). After 
drying, precipitated proteins were resuspended in 2x sample buffer and the pH was adjusted by 
addition of  1 to 3 µl 1 M Tris x HCl, pH 7.8. Samples were incubated at 95°C for 10 to 15 min 
and stored at -20°C.
3.2.4.7 SDS-polyacrylamide gel electrophoresis
Depending on the protein size and the individual application protein samples were either 
separated on Tris-glycine- (see 3.2.4.7.3) or Tris-tricine-buffered (see 3.2.4.7.4) SDS-
polyacrylamide (SDS-PAGE) gels. In addition, to separate hydrophobic small molecular protein 
fragments urea tris-tricine gels were used (see 3.2.4.7.5).
3.2.4.7.1 Sample preparation
sample buffer (5x):  50% (v/v) glycerol, 7.5% (w/v) SDS, 7.5% (w/v) DTT, 
    bromophenol blue (traces), dissolved in 4x upper Tris buffer 
    (see 3.2.4.7.3)
sample buffer (2x):  20% (v/v) glycerol, 3% (w/v) SDS, 3% (w/v) DTT, bromophenol blue 
    (traces)
    dissolved in 4x upper Tris buffer (see 3.2.4.7.3)
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2x sample buffer (Wiltfang): 0.72 M Bis-Tris, 0.32 M Bicin, 2% (w/v) SDS, 5% β-mercaptoethanol,
    30% (w/v) sucrose, bromophenol blue (traces)
All samples that were subjected to electrophoretic separation were mixed with sample buffers 
as indicated. For Western blot applications that required non-reducing conditions sample buffers 
lacking DTT were used. All samples were heat-denatured by incubation at 95°C or 65°C for 10 
min prior to loading into gels.
For separation on urea tris-bicine gels (3.2.4.7.5), samples were mixed with the respective 
sample buffer and always denatured by incubation at 95°C for 5 min.
3.2.4.7.2 Gel casting and running equipment
Electrophoresis was performed using MINI-PROTEAN system (Bio-Rad, Hercules, USA) and 
gels with a thickness of  1.5 mm were cast between system-compatible glass plates. Tris-glycine 
separating gels were cast and overlaid with isopropanol for polymerisation. Tris-tricine 
separating and spacer gels (see were polymerised together, again overlaid with isopropanol. 
The respective stacking gels were polymerised in a second step and plastic combs were used 
to generate pockets. Electrophoresis was conducted in the indicated running buffer(s) at a 
constant voltage (70V during the stacking phase and 120V during separation) using PowerPack 
HC power supplies (Bio-Rad). Sea Blue pre-stained protein marker (life technologies) was used 
as molecular weight reference on every gel. Mighty small II chambers and the respective 
casting equipment (Hoefer, Holliston, USA) were used for Wiltfang (3.2.4.7.5) gels.
3.2.4.7.3 Tris-glycine SDS-PAGE
Lower Tris (4x): 1.5 M Tris, 0.4% (w/v) SDS, pH 8.8
Upper Tris (4x): 0.5 M Tris, 0.8% (w/v) SDS, pH 6.8
Running buffer: 25 mM Tris, 200 mM Glycine, 0.1 (w/v) SDS
Tab. 3.9 summarises the recipes for gels with 8%, 10%, 12% and 15% acrylamide content. 
Acrylamide  (40% (w/v), acrylamid/bisacrylamid ratio 37.5:1) was purchased from Serva. 
Mixtures were prepared as indicated and the polymerisation was initiated by addition of the 
indicated amount of  10% (w/v) ammonium persulphate and N, N, N', N'-tetramethylethylen-
diamine (Carl Roth). 
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Tab. 3.9: Tris-glycine composition. For 8 ml separating gel, sufficient for one 1.5 mm MINI-PROTEAN 
gel,  and 5 ml stacking gel.
separating gel
(8%)
separating gel
(10%)
separating gel
(12%)
separating gel
(15%)
stacking gel
H2O
acrylamide
lower Tris
upper Tris
TEMED
10% (w/v) APS
4.4 ml 4 ml 3.6 ml 3 ml 3.25 ml
1.6 ml 2 ml 2.4 ml 3 ml 0.5 ml
2 ml 2 ml 2 ml 2 ml -
- - - - 1.25 ml
15 µl 15 µl 15 µl 15 µl 15 µl
15 µl 15 µl 15 µl 15 µl 15 µl
3.2.4.7.4 Tris-tricine SDS-PAGE
Tris-tricine gel buffer:  3 M Tris x HCl, pH 8.45, 0.3% (w/v) SDS
acrylamide solution:  48 % (w/v) acrylamide, 1.5% (w/v) bisacrylamide
anode buffer:   200 mM Tris, pH 8.9
kathode buffer:  100 mM Tris, 100 mM tricine, 0.1% (w/v) SDS
For electrophoretic separation of small proteins and protein fragments below  16 kDa Tris-tricine 
gels were used which were prepared as summarised in Tab. 3.10. The spacing gel solution was 
carefully laid over the not yet polymerised separating gel solution to avoid mixing of the phases. 
The spacing gel solution was covered with isopropanol for polymerisation. The stacking gel was 
prepared as described earlier (see 3.2.4.7.2) using the mixture described in Tab. 3.10. 
Electrophoresis was performed in MINI-PROTEAN chambers (Bio-Rad) but distinct anode and 
kathode buffers were used.
Tab. 3.10: Tris-tricine gel composition. For two gels, 1.5 mm thickness.
separating gel
(16.5%)
spacing gel
(10%)
stacking gel
(4%)
H2O
acrylamide solution
Tris-tricine gel buffer
32% (v/v) glycerol
TEMED
10% (w/v) APS
- 3.5 ml 4.2 ml
3.5 ml 1.5 ml 0.5 ml
3.5 ml 2.5 ml 1.55 ml
3.5 ml - -
6.5 µl 8 µl 10 µl
65 µl 70 µl 50 µl
3.2.4.7.5 Urea tris-bicin gels after Wiltfang
separating gel buffer:  1.6 M Tris, 0.4 M H2SO4
spacing gel buffer:  0.8 Bis-Tris, 0.2 M H2SO4
stacking gel buffer:  0.72 M Bis-Tris, 0.32 M Bicin
anode buffer:   0.2 M Tris, 0.05 M H2SO4
kathode buffer:  0.2 M Bicin, 0.25% (w/v) SDS, 0.1 M NaOH
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Tab. 3.11: Urea tris-bicine or Wiltfang gel composition. For two gels, 1.5 mm thickness. * Urea, water 
and separating gel buffer were mixed and heated in the microwave until the urea was dissolved.
separating gel
(11%)
spacing gel stacking gel
urea
H2O
separating gel buffer
spacing gel buffer
stacking gel buffer
acrylamide/bisacrylamide
10% (w/v) APS
TEMED
9.6 g* - -
2 ml* 1.36 ml 0.74 ml
5 ml* - -
- 2 ml -
- - 1.5 ml
5.5 ml 0.6 ml 0.675 ml
80 µl 16 µl 18 µl
10 µl 4 µl 6 µl
Urea tris-bicin or Wiltfang gels were cast according to a modified version (Tab. 3.11) of  a 
previously published protocol (Wiltfang et al, 1997). The separating gel was cast first and was 
overlaid with isopropanol until it was polymerised. The spacing gel was prepared on top of the 
separating gel in a similar manner. Finally, a comb was polymerised in the stacking gel to obtain 
pockets for loading. Gels were wrapped into damp tissues and stored for one night at room 
temperature prior to use. 
3.2.4.8 Electroblotting
transfer buffer: 25 mM Tris, 200 mM glycine
Proteins separated by gel electrophoresis were transferred to polyvinylidenfluoride (PVDF; 
immobilon P transfer membrane, 0.45 µm pore width; Millipore, Billerica, USA) or nitrocellulose 
membranes (NC; Protran B 79, pore width 0.1 µm; GE Healthcare) by tank electroblotting using 
the MINI-PROTEAN system (Bio-Rad). To this end, gels were disassembled following 
electrophoreses, the stacking gel was discarded and the separating gel (in case of  Tris-tricine 
gels together with the spacing gel) were soaked in transfer buffer. Filter paper (GE Healthcare) 
and sponges were also soaked in transfer buffer. NC membranes were pre-incubated in the 
same buffer for 20 min, while PVDF membranes were first activated for 2 min in isopropanol, 
washed for 2 min in distilled water and then incubated in transfer puffer until use. Following 
assembly of the blotting apparatus, electroblotting was performed at a constant current of 
400 mA per chamber for 1 h generated by PowerPack HC power supplies (Bio-Rad). Gels were 
discarded and PVDF membranes were directly processed as described in 3.2.4.9. NC 
membranes, however, were boiled in PBS (see 3.2.3.1) for 5 min before Western blotting.
3.2.4.9 Protein detection by Western blotting
TBS-T:   50 mM Tris, 150 mM NaCl, 0.05% (v/v) Tween 20, pH 7.6
blocking solution: 2% (w/v) Tropix I-BLOCK™ (life technologies), 0.1% (v/v) Tween 20,
   dissolved in PBS (see 3.2.3.1)
stripping buffer: 62.5 mM Tris x HCl pH 6.7, 2% (w/v) SDS, 0.7% (v/v) β-mercaptoethanol
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Following electroblotting, membranes incubated in blocking solution either at room temperature 
for 1 h or at 4°C overnight. Next, membranes were incubated with the respective primary 
antibody (Tab. 3.12) at room temperature for 1 h or at 4°C overnight (up to 48 h). Membranes 
were washed three times for 15 min with TBS-T and then incubated with horseradish 
peroxidase (HRP)-conjugated secondary antibodies (Tab. 3.12) at room temperature for up to 
1 h. Subsequently, membranes were washed again three times for 15 min with TBS-T. All 
incubation and washing steps were conducted with light agitation and all antibodies were diluted 
in blocking solution as detailed in (Tab. 3.12). HRP-conjugated secondary anti-mouse (1:104) 
and anti-rabbit (1:104) antibodies were from Promega, anti-goat (1:4,000) from Santa Cruz 
Biotechnologies and anti-rat (1:5,000) antibodies were either from Promega or from Dianova 
(Hamburg, Germany). 
Antibody binding was visualised by means of enhanced chemical luminescence (ECL™) 
technology. Blots were incubated in either ECL™ (GE Healthcare), ECL Plus (Thermo Fisher 
Scientific) or ECL Prime (GE Healthcare) Western blot detection reagent according to the 
manufacturer's instructions. Signals were documented on medical X-ray films (Fujifilm, Tokio, 
Japan or Kodak, Rochester, USA) which were developed using an automated film developer 
(CAWOMAT 2000 IR; CAWO, Schrobenhausen, Germany). Developed films were digitalised 
with an Epson Perfection V700 PHOTO scanner (Epson, Suwa, Japan) and the supplied 
software. Images were cropped and edited in strict accordance with guidelines described in 
(Rossner & Yamada, 2004) using Adobe Photoshop CS5 (Adobe Systems, San Jose, USA).
For densitometric quantification of  Western blot intensities, ECL signals were acquired digitally 
using the Luminescent Image Analyzer LAS-4000 (Fujifilm) and intensities values were obtained 
using the supplied software package Multi Gauge v3.0. ICD ratios were calculated from signal 
intensities obtained from analysis of the very same Western blot. Statistical analyses were 
conducted with GraphPad Prism (Graphpad, La Jolla, USA) as indicated in the respective figure 
legends. The statistical significance is indicated in the results section with * (p < 0.5) and ** 
(p < 0.05).
To remove bound primary and secondary antibodies from membranes for redecoration, 
membranes were incubated in stripping buffer at 50°C for 30 to 40 min. Subsequently, they 
were washed multiple times with TBS-T. The immunodetection procedure was repeated as 
detailed above.
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Tab. 3.12: Antibodies used for Western blotting. #, non-reducing conditions required, I, HRP-
conjugated antibody, II, Developmental Studies Hybridoma Bank, Iowa City, USA, III, Santa Cruz 
Biotechnologies.   
antigen antibody 
type
antibody 
species
clone/cat. 
#
dilution/quantity source
APP mAb mouse 2D8 0.1 to 0.2 µg/ml Elisabeth Kremmer, Munich
APP pAb rabbit 6687 1:1,000 Eurogentec
β4GalT1 pAb goat AF3609 1:2,000 R&D
β3GalT6 pAb rabbit ab103375 1:1,000 Abcam
β3GnT1 mAb mouse 724057 1:1,000# R&D
Calnexin pAb rabbit - 1:3,000 Enzo
CD68 mAb rat FA-11 1:500# AbD serotec
ER α-mannosidase I mAb mouse 30-Y 1:500 to 1:1,000 SCBTIII
EXTL3 mAb mouse G-5 1:1,000 SCBTIII
Flag tag mAb mouse M2 1:1,000 Sigma
Flag tag pAb rabbit F7425 1:3,000 Sigma
GnT-V mAb mouse 706824 1:1,000 R&D
HA tagI mAb rat 3F10 1:1,000 Roche
HS6ST1 pAb sheep AF5057 1:500 R&D
HS6ST2 pAb rabbit HPA034625 1:500# Sigma
human Lamp2 mAb mouse H4B4 1:5,000 DSHBII
human Lamp2 pAb rabbit ab37024 1:1,000 Abcam
mouse Lamp2 mAb rat ABL-93c 1:2,000 DSHBII
N-cadherin mAb mouse 10C32 1:1,000 BD
Nicastrin mAb mouse 35 1:2,000 BD
Nicastrin pAb rabbit N1660 1:5,000 Sigma
Presenilin 1 pAb rabbit 2953 1:1,000 Eurogentec
Sgk196 mAb mouse S-23 1:500# SCBTIII
human SPPL2a mAb mouse 6E9 undiluted Elisabeth Kremmer, Munich
mouse SPPL2a pAb rabbit - 1:1,000 Bernd Schröder, Kiel
SPPL2b mAb mouse 3F9 undiluted Elisabeth Kremmer, Munich
SPPL3 mAb mouse 7F9 1:10 Elisabeth Kremmer, Munich
SPPL3 mAb mouse 6A2 1:10 Elisabeth Kremmer, Munich
V5 tag mAb mouse 2F11F7 1:1,000 life technologies
V5 tag pAb rabbit R960-25 1:1,000 Millipore
XylT2 mAb mouse G-1 1:1,000 SCBTIII
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3.2.4.10 Lectin blotting
lectin buffer:  10 mM HEPES pH 7.5, 150 mM NaCl, 0.1 mM CaCl2, 0.08% (w/v) NaN3
PBS-T:   0.05% (v/v) Tween 20 dissolved in PBS (see 3.2.3.1)
blocking solution: 5% (w/v) BSA in PBS-T
In order to visualise protein-conjugated glycans, biotinylated lectins were employed that had 
been purchased from Vector Laboratories (Burlingame, USA). anti-Nicastrin immunoprecipitates 
were separated by SDS-PAGE and electroblotted as described (see 3.2.4.7. and 3.2.4.8). 
Membranes were first incubated in blocking solution at 4°C overnight. They were then washed 
once with PBS-T and successively treated with streptavidin and biotin blocking solutions 
provided as a commercial kit (Vector Laboratories) according to the manufacturer's instructions. 
Following biotin blocking, membranes were incubated with the respective biotinylated lectins (2 
to 10 µg/ml, diluted in lectin buffer) at room temperature for 1 h. Membranes were washed three 
times for 10 min with PBS-T. Following incubation in 2 µg/µl streptavidin-HRP conjugated 
(diluted in PBS-T; Vector Laboratories) at room temperature for 30 min, membranes were 
washed again three times with PBS-T and lectin binding was visualised using ECL chemistry 
and X-ray film detection procedures as detailed earlier (see 3.2.4.9).
3.2.4.11 MALDI-TOF mass spectrometric analysis of C-peptide cleavage products
IP-MS buffer:   10 mM Tris pH 8.0, 140 mM NaCl, 5 mM EDTA, sterile filtered
    supplemented with 0.1% (w/v) octyl-β-D-glucopyranoside (Sigma)
Matrix:    0.3% (w/v) trifluoroacetic acid, 40% (v/v) acetonitrile,
    saturated with 4-hydroxycinnamic acid
To capture and purify Flag-tagged C-peptide species, conditioned supernatants from 6 to 10 cm 
dishes transfected with the respective substrate expression constructs were collected and 
subjected to anti-Flag M2 immunoprecipitation (10 µl beads, overnight, 4°C). Beads were 
washed six times with 1 ml IP-MS buffer and once with 1 ml fresh, sterile-filtered and double-
distilled water. Residual liquid was removed and dry beads were stored at -20°C until further 
analysis.
15 to 20 µl of the matrix solution were added to the sedimented beads, mixed gently and 
incubated  at room temperature for 5 min to eluted captured peptides. Beads were then 
sedimented by centrifugation (1 min, 13 krpm) and 1 to 2 µl of  the supernatant were spotted on 
the target plate (Assay sample plate, 96 spots, coat, Applied Biosystems). After drying, captured 
peptides were analysed by MALDI-TOF mass spectrometry using a Voyager DE STR (Applied 
Biosystems) mass spectrometer at the Center for Protein Analysis, Ludwig-Maximilians 
University Munich. For measurements, the mass spectrometer was set to linear mode but small 
peptides (1 to 5 kDa) were also analysed in reflector mode. Preset mass spectrometer 
parameters were used and grid voltage and delay time were set to 90-95% and 100-300 ns for 
the linear mode and 60-65% and 150-250 ns for the reflector mode, respectively. Data were 
analyzed using Data Explorer 4.3 (Applied Biosystems) and GPMAW 5.02 (Lighthouse data) 
software. Molecular masses were calibrated using the calibration mixture 2 of  the Sequazyme 
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Peptide Mass Standards Kit (Applied Biosystems) and relative peak intensities were determined 
in relation to peptide in the standard. Mass spectrometric measurements were performed by Dr 
Akio Fukumori, German Center for Neurodegenerative Diseases (DZNE) - Munich.
3.2.4.12 RNA isolation and quantitative RT-PCR
Total cellular RNA was isolated from cells using QIAshredder homogeniser columns and the 
RNeasy RNA isolation kit (Qiagen) following the manufacturer's instructions. RNA 
concentrations were determined by UV-Vis spectroscopy. Up to 2 µg total RNA was reverse-
transcribed with the high capacity reverse transcription kit (Applied Biosystems) according to the 
manufacturer's instructions and cDNA reaction products were stored at -20°C. Quantitative real-
time PCR was performed using 2x TaqMan master mix (Applied Biosystems) and pre-designed 
FAM-labelled 20x TaqMan probes targeting SPPL2a (Cat. # Hs01002698_g1) and SPPL2b 
(Cat. # Hs00292699_m1) mRNAs (Applied Biosystems). Reactions were performed with preset 
cycle settings in a 7500 Fast Real-Time PCR System (Applied Biosystems). Signals were 
normalised to levels of  ACTB mRNA obtained using VIC-labelled probes (Cat. # 4326315E) and 
relative mRNA levels were calculated with the ΔΔCT method.
3.2.4.13 Secretome analysis
To identify novel SPPL3 substrates, a recently developed protocol was applied which combines 
a novel technique to selectively isolate de novo synthesised secreted glycoproteins with 
quantitative mass spectrometry (Kuhn et al, 2012). SPPL3 over-expression was induced by 
supplementing the cell culture medium with 1 µg/ml doxycycline for 48 h prior to metabolic 
labelling. Cells were trypsinised and counted. For each sample, cells were plated in two T-75 
cell culture flasks (15 x 106 cells in 10 ml basic medium per flask) and media were 
supplemented with 50 µM tetraacetyl-N-azidoacetyl-mannosamine and 0.1 µg/ml doxycycline. 
As a control, uninduced cells were plated in parallel in an identical manner, yet omitting the 
supplementation with doxycycline. Cells were incubated for 48 h, the conditioned supernatants 
from the respective two flasks were collected and pooled. Following sterile filtration (filter pore 
width 0.2 µm), samples were frozen at -20°C for further processing. Samples were then 
subjected to the previously established protocol (Kuhn et al, 2012). In brief, non-metabolised 
tetraacetyl-N-azidoacetyl-mannosamine was washed out with PBS by ultrafiltration in VivaSpin 
20 columns with a molecular weight cut-off  of 30 kDa (GE Healthcare) that retained labelled 
proteins. Concentrated proteins were subjected to biotinylation with DBCO-PEG12-biotin (Click 
Chemistry Tools, Scottsdale, USA). Unreacted DBCO-PEG12-biotin was washed as detailed 
earlier. Biotinylated proteins in the concentrated retentate were then affinity-purified via 
streptavidin beads. Beads were washed with PBS and eluted for electrophoretic separation by 
SDS-PAGE. Proteins in cut out gel slices were trypsinised and samples were subjected to 
analyses by nanoLC coupled with high-resolution mass spectrometry and label-free 
quantification as detailed in (Kuhn et al, 2012). Click chemistry reactions, protein purification 
and analysis were performed by Dr. Peer-Hendrik Kuhn, PhD, from the German Center for 
Neurodegenerative Diseases (DZNE) - Munich.
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 4. Results
4.1 FVenv is substrate for intramembrane proteolysis by SPPL3 and SPPL2a/2b
4.1.1 Cloning and expression of epitope-tagged FVenv 
In light of  earlier studies that suggested a certain degree of functional redundancy between 
SPP and SPPL3 regarding signal peptide endoproteolysis (Krawitz et al, 2005; Nyborg et al, 
2006), atypical signal peptides were considered potential candidate SPPL3 substrates. As 
FVenv harbours such an atypical signal or leader peptide (see 1.5.1), it was tested whether it is 
proteolytically processed by SPPL3. In order to examine whether FVenv is subject to 
intramembrane proteolysis in a cellular model system, FVenv was cloned into an eukaryotic 
expression vector and terminal epitope tags were added to allow  for detection of  FVenv and 
proteolytic products thereof  with tag-specific antibodies. Similar strategies have been employed 
before to detect cleavage products of  SPPL2a- and/or SPPL2b-mediated intramembrane 
proteolysis (e.g. in (Martin et al, 2008)). At the FVenv N-terminus, immediately following the 
translation-initiating methionine residue, a Flag tag was introduced (Fig. 4.1a) allowing for 
detection of unprocessed full-length FVenv, the LP and LP-derived fragments generated by 
intramembrane proteolysis using anti-Flag antibodies. The C-terminal portion of  FVenv was 
likewise tagged with a V5 tag which was introduced right in front of the C-terminal KKKNQ ER 
retention signal in order not to interfere with proper sub-cellular targeting of  epitope-tagged 
FVenv (Fig. 4.1a). While in FV-infected cells FVenv is endoproteolysed at two sites (designated 
PC and PC* in Fig. 4.1a) leading to the generation of  the three individual subunits LP, SU and 
TM (Fig. 1.12), in cells solely expressing FVenv and no additional viral co-factors FVenv 
proteolysis proceeds in a distinct manner and no proteolytic cleavage between the SU and TM 
subunits (i.e. PC*) is observed (Bansal et al, 2000). To reduce generation of  LP two point 
mutations (R123A and R126A, Fig. 4.1b) were simultaneously introduced into the PC cleavage 
site as these had previously efficiently reduced LP generation (Duda et al, 2004). This FVenv 
mutant will subsequently be referred to as FVenv mut.
To ensure that the introduction of  these epitope tags did not interfere with proper expression, 
proteolytic processing or sub-cellular targeting of FVenv, these constructs were transiently 
transfected into HeLa cells and analysed by immunocytochemistry and confocal microscopy as 
well as Western blotting. FVenv wild-type localisation was assessed by staining with an anti-V5 
mAb (Fig. 4.1c, top row). Immunoreactivity was mainly observed in the perinuclear region and, 
to a lesser extent, in vesicular cytosolic structures. Anti-V5 immunoreactivity in cells transfected 
with tagged FVenv was found to be largely overlapping with an ER-specific staining of an anti-
KDEL directed pAb, suggesting that tagged FVenv wild-type mostly localises to the ER as 
observed earlier for over-expressed FVenv (Goepfert et al, 1997) and that introduction of  the 
epitope tags did not alter sub-cellular targeting. Staining with an anti-Flag antibody was similarly 
overlapping with anti-V5 immunoreactivity (Fig. 4.1c, second row), i.e. most likely also LP 
generated from the pre-protein by endoproteolysis remained localised to the ER. FVenv mut did 
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Fig. 4.1: Cloning and expression of epitope-tagged FVenv. (a) Schematic overview of FVenv. FVenv is 
proteolytically processed by furin and/or furin-like pro-protein convertases at two sites (PC and PC*) 
which generates its three subunits LP (green), SU (yellow), and TM (red). Putative N-glycosylation sites 
are indicated by "Y" (several additional ones in SU have been omitted for clarity). Epitope tags were 
introduced as indicated by the grey boxes. Not drawn to scale. (b) Sequence clip of the N-terminal PC 
cleavage site of FVenv and the R123A/R126A mutant (FVenv mut) used. FVenv mut is expected to be 
less efficiently processed at PC. (c) Sub-cellular localisation of FVenv constructs used. HeLa cells were 
transiently transfected as indicated, were subjected to immunocytochemical  staining and analysed by 
confocal laser-scanning microscopy. Note that untransfected cells were deliberately imaged next to 
transfected cells to show that anti-V5 and anti-Flag stainings are in fact specific. Scale bar = 20 µM. (d) 
Proteolytic  processing of FVenv constructs in HEK293 cells. HEK293 cells were transiently transfected as 
indicated and total  cell lysates were analysed for FVenv and fragments thereof by SDS-PAGE and 
Western blot (upper panel). For detection of LP, lysates had to be subjected to anti-Flag 
immunoprecipitation for enrichment. (e) Deglycosylation of FVenv and LP. Cell lysates and anti-Flag 
immunoprecipitates were enzymatically deglycosylated by endoglycosidase H (Endo H) or peptide-N-
glycosidase F (PNGase F) and analysed by SDS-PAGE and Western Blot. *, unspecific  band, **, IgG light 
chain, glyc, glycosylated species, deglyc, deglycosylated species.
not display an altered sub-cellular localisation (Fig. 4.1c, third row). As expected (Goepfert et al, 
1997), however, when the C-terminal ER retention motif  was removed by site-directed 
mutagenesis, anti-V5 immunoreactivity markedly changed and FVenv mut/ΔKKXX was 
observed on the cell surface as well as in cell surface protrusions, yet a perinuclear ER staining 
was still apparent (Fig. 4.1c, bottom row).
Proteolytic processing of FVenv was examined by SDS-PAGE and Western blot detection of  cell 
lysates from HEK293 cells transiently transfected with the expression constructs indicated 
(Fig. 4.1d). Importantly, FVenv wild-type was found to be proteolytically processed at the PC 
site as expected (Bansal et al, 2000), since in addition to an anti-V5 and anti-Flag 
immunoreactive high molecular weight band corresponding to full-length, unprocessed FVenv, 
an anti-V5 reactive, yet not anti-Flag reactive fragment of slightly lower molecular weight was 
observed in these cells. This additional fragment likely corresponds to the C-terminal SU-TM 
product generated by cleavage at PC. The corresponding N-terminal cleavage product, LP, was 
observed with a molecular weight of  roughly 18 kDa in anti-Flag immunoprecipitates of 
transfected cells. Levels of  both SU-TM and LP were drastically reduced in cell lysates 
transfected with FVenv mut and residual LP levels could only be detected following longer 
exposure. The reduction of  SU-TM and LP levels in these mutants further corroborates their 
biogenesis by endoproteolysis at this position. An anti-V5-reactive fragment of roughly 50 kDa 
that likely corresponds to the 48 kDa TM subunit was only observed in cells expressing the 
FVenv mut/ΔKKXX mutant. Hence, in line with previous observations (Bansal et al, 2000), 
cleavage at PC* only occurred when FVenv was not retained in the ER.
Following anti-Flag immunoprecipitation, an additional N-terminal protein fragment was detected 
that had a slightly lower molecular weight than LP (Fig. 4.1d, open arrowhead). FVenv is 
extensively modified post-translationally by N-glycosylation and the LP subunit contains two 
putative consensus N-glycosylation sites and one (N109) appears to be occupied in cultured 
cells (Lüftenegger et al, 2005). To examine whether this smaller anti-Flag-reactive fragments 
derives from subsequent endoproteolysis of LP or is merely due to non-quantitative cellular 
glycosylation at N109, lysates from HEK cells transfected with FVenv were subjected to 
treatment with peptide:N-glycosidase F (PNGase F) and endo-β-N-acetylglucosaminidase H 
(Endo H) (Fig. 4.1e). Glycosidase treatment led to reduction in molecular weight of both full-
length FVenv as well as immunoprecipitated LP, clearly showing that both species are modified 
by N-glycans. Of note, longer exposures of  blots of immunoprecipitated LP revealed that the 
previously observed LP fragment (Fig. 4.1d, open arrowhead) co-migrated with glycosidase-
digested LP and, therefore, likely corresponds to non-glycosylated LP and not to a proteolytic 
cleavage product. In addition, both FVenv as well as its N-terminal cleavage product LP were 
sensitive to treatment with Endo H which underpins their ER localisation.
Taken together, these experiments demonstrate that introduction of the terminal epitope tags 
does neither interfere with intracellular localisation and trafficking nor with proteolytic processing 
of FVenv as the tagged wild-type protein and tagged FVenv mutants behaved like untagged 
FVenv. Therefore, the tagged FVenv constructs used throughout subsequent experiments 
represent a valid model to assess intramembrane proteolysis of FVenv.
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4.1.2 FVenv leader peptide is endoproteolysed by over-expressed SPPL3 in HEK293 cells
To examine whether FVenv LP can be endoproteolysed by SPPL3, tagged FVenv was co-
expressed with HA-tagged catalytically active SPPL3 or a putatively inactive D271A mutant 
(Fig. 4.2). To this end, HEK293 T-Rex® (HEK293 TetR) cells that stably express active or 
mutant SPPL3 upon doxycycline induction were used. Upon stable co-expression of FVenv with 
proteolytically active SPPL3 a small anti-Flag-immunoreactive fragment, ICD(L3), was detected 
in immunoprecipitates. This fragment could neither be observed in immunoprecipitates of cells 
expressing only FVenv nor of  cells co-expressing FVenv and SPPL3 D271A. Instead a slight 
accumulation of LP became apparent under the latter conditions. These observations suggest 
that proteolytically active SPPL3 endoproteolyses FVenv in LP leading to the generation of an 
ICD, ICD(L3).
4.1.3 FVenv leader peptide is endoproteolysed by over-expressed SPPL2a and SPPL2b
To assess whether other SPPL intramembrane protease can also cleave FVenv, FVenv was 
similarly co-expressed with catalytically active SPPL2a (Fig. 4.3a) and SPPL2b (Fig. 4.3b) and 
the respective catalytically inactive mutants (SPPL2a D412A and SPPL2b D421A, respectively). 
Surprisingly, also in cells expressing FVenv and active SPPL2a an anti-Flag-reactive LP 
fragment was detected in immunoprecipitates which was termed ICD(L2) (Fig. 4.3a). In 
immunoprecipitates of  cells co-expressing inactive SPPL2a D412A and FVenv, however, no 
ICD(L2) was detected, but a drastic accumulation of LP was apparent. Such an accumulation of 
substrates upon co-expression of  inactive mutants had previously been observed, for instance 
for Bri2 (Martin et al, 2008). In addition to LP, other fragments likewise accumulated upon over-
expression of SPPL2a D412A. These fragments displayed a higher molecular weight than that 
of ICD(L2) but were smaller than LP. Processing of  FVenv in cells expressing SPPL2b 
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Fig. 4.2: SPPL3 endoproteolyses FVenv. HEK293 TetR cells that stably over-express HA-tagged active 
SPPL3 wild-type (wt) or inactive SPPL3 D271A (D/A) upon induction with doxycycline were stably 
transfected with FVenv. HEK293 TetR cells were used as controls. Cell  lysates were subjected to anti-
Flag (upper panels) or anti-HA immunoprecipitation (IP) (lower panel) to detect FVenv as well as smaller 
anti-Flag-reactive proteolytic  fragments thereof and the expressed protease species, respectively. SPPL3 
wild-type co-expression led to generation of an ICD, ICD(L3). Note that, depending on the gel resolution, 
ICD(L3) sometimes can be observed as a doublet.
(Fig. 4.3b) was similar to that observed for SPPL2a co-expression: In cells expressing FVenv 
and active SPPL2b an ICD was observed and in those expressing SPPL2b D421A this ICD was 
absent but instead LP and the previously observed additional fragments accumulated.
In order to check whether LP-derived fragments accumulating following SPPL2a D412A or 
SPPL2b D421A over-expression are generated by endogenous activity of SPPL3 or other 
endogenous proteases that turn over the accumulating LP, cells stably co-expressing 
SPPL2a D412A and FVenv were transfected with SPPL3-specific siRNA pools or a non-
targeting control siRNA pool to reduce endogenous SPPL3 levels (Fig. 4.4a). This led to a 
marked reduction of  one band accumulating in conditions of SPPL2a D412A expression 
showing that this band reflects in fact ICD(L3). Additional bands were unaffected by SPPL3 
siRNA transfection and, accordingly, most likely are due to another, presently elusive 
endogenous protease acting upon LP.
These observations also suggested that ICD(L3) observed upon co-expression of  FVenv and 
SPPL3 wild-type and the ICD species generated by SPPL2a and SPPL2b are in fact distinct. To 
underpin this, immunoprecipitates obtained from cells co-expressing FVenv with either 
biologically active SPPL3, SPPL2a, or SPPL2b were co-migrated (Fig. 4.4b). Interestingly, 
judged by their electrophoretic mobility, ICD species generated by SPPL2a and SPPL2b appear 
to be identical and are therefore collectively referred to as ICD(L2). ICD(L3) generated by 
SPPL3, however, displayed a slightly higher molecular weight than ICD(L2), showing that it 
represents a distinct ICD species.
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Fig. 4.3: SPPL2a and SPPL2b endoproteolyse FVenv. HEK293 TetR cells that stably over-express HA-
tagged active SPPL2a wild-type (wt) or inactive SPPL2a D412A (D/A) (a) or HA-tagged active SPPL2b wt 
or inactive SPPL2b D421A (D/A) (b) upon induction with doxycycline were stably transfected with FVenv. 
Cell lysates were subjected to anti-Flag (upper panels) or anti-HA (lower panel) immunoprecipitation (IP) 
to detect FVenv as well as smaller anti-Flag-reactive proteolytic  fragments thereof and the expressed 
protease species, respectively. Expression of active SPPL2a and SPPL2b led to detection of an ICD, 
ICD(L2) (grey). Upon co-expression of the respective D/A mutants, however, a marked accumulation of 
glycosylated and unglycosylated LP (closed and open arrowheads) as well  as of other fragments (*) and 
ICD(L3) was observed.
4.2 FVenv proteolysis reveals unique properties of SPPL3
Taken together, these observations collectively show  that FVenv is subject to endoproteolysis 
mediated by both SPPL3 and SPPL2a/SPPL2b when co-expressed in cultured cells. 
Importantly, FVenv represents the first transmembrane protein substrate of  SPPL3 and, hence, 
allows for more detailed mechanistic analyses of  this so far hardly characterised protease. At 
the same time FVenv is also a substrate of SPPL2a/SPPL2b, but endoproteolysis by SPPL3 
and SPPL2a/SPPL2b leads to the generation of distinct product species. Therefore, analyses of 
the proteolytic processing of FVenv allowed for direct comparison of these distinct proteases.
4.2.1 SPPL3-mediated cleavage of FVenv is independent of shedding
Furin/PC-mediated endoproteolysis of the FVenv separates the N-terminal LP moiety from SU-
TM and this cleavage occurs C-terminally of amino acid residue R126 (Duda et al, 2004; 
Geiselhart et al, 2004), i.e. in a distance of  < 40 amino acids (aa) from the predicted first TMD4 . 
Hence, this cleavage event is reminiscent of  a classical membrane-proximal shedding event of 
a single-pass transmembrane protein that is crucially required for subsequent intramembrane 
proteolysis by SPP, SPPL2b and the presenilins (see 1.1). To experimentally address whether 
FVenv intramembrane proteolysis by SPPL2b and by SPPL3 is likewise dependent on the 
shedding-like furin/PC-mediated pre-cleavage of full-length FVenv, the R123A/R126A mutant of 
FVenv (FVenv mut) was employed. When expressed in HEK293 cells, generation of  LP and SU-
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4  According to Uniprot annotations (entry ID: P14351) the type II-oriented TMD1 comprises amino acids 66 to 88 in SFVcpz(hu) 
FVenv. TMHMM 2.0 (http://www.cbs.dtu.dk/services/TMHMM/), however, predicts amino acids 69 to 91 as membrane-spanning 
region.
Fig. 4.4: ICD(L3) and ICD(L2) are distinct ICD species. (a) ICD(L3) accumulates upon over-expression 
of inactive SPPL2a. Endogenous SPPL3 levels were reduced in HEK293 TetR cells that stably over-
express inactive SPPL2a (D412A) (D/A) by transfection with a SPPL3-specific  siRNA pool (20 nM) and a 
non-targeting siRNA pool (ctrl, 20 nM). Reduction of SPPL3 was monitored by Western blot of cell  lysates 
with an anti-SPPL3 mAb. Calnexin signals were used as loading control. FVenv-derived LP fragments 
were analysed following anti-Flag immunoprecipitation of cell  lysates. *, LP-derived fragment of elusive 
nature, **, IgG light chain. (b) Co-migration of ICD(L3) and ICD(L2). ICD species were anti-Flag 
immunoprecipitated from lysates of cells stably co-expressing FVenv and active SPPL3, SPPL2a, and 
SPPL2b, respectively. Note that upon longer exposure of anti-Flag immunoprecipitates ICD(L3) may also 
be detected in cells only expressing FVenv (black arrowhead in image).
TM from FVenv mut was markedly reduced compared to cells transfected with FVenv wild-type 
(Fig. 4.1d & Fig. 4.5). Thus, FVenv mut represents a valid model for a substrate that does not 
undergo membrane-proximal shedding.
Protease activity on FVenv mut and the FVenv wild-type control substrate was assessed by 
quantification of ICD(L2) and ICD(L3) levels in immunoprecipitates from cells co-expressing 
these substrates with active SPPL2b and SPPL3, respectively (Fig. 4.5a). In line with previous 
observations (Martin et al, 2009), SPPL2b-mediated generation of ICD(L2) was reduced in cells 
expressing FVenv mut and only faint amounts of  ICD(L2) could be detected. These, however, 
correlated with the level of residual LP generated from FVenv mut and quantification of three 
independent experiments revealed that the ICD-to-LP ratio was unchanged in cells co-
expressing SPPL2b with either FVenv wild-type or FVenv mut, suggesting that SPPL2b can only 
produce ICD(L2) from LP, i.e. relies on FVenv cleavage by furin/PC. Strikingly, however, in cells 
co-expressing SPPL3 and FVenv mut substantial amounts of ICD(L3) were still detectable yet 
LP generation was reduced as expected. In fact, amounts of ICD(L3) generated from FVenv 
and FVenv mut were very similar. Also, significant changes in the ICD-to-LP ratio could be 
observed suggesting that SPPL3 is capable of processing full-length FVenv independent of  a 
membrane-proximal pre-cleavage. This was corroborated by the detection of  an anti-V5 
reactive, yet not anti-Flag reactive high molecular weight FVenv fragment in lysates of cells co-
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Fig. 4.5: SPPL3-mediated cleavage of FVenv  is independent of shedding. SPPL2b or SPPL3 
expression was induced by doxycycline treatment in the respective stably transfected HEK293 TetR cells. 
FVenv wild-type or FVenv R123A/R126A (FVenv mut) were transiently co-transfected and cells were 
lysed 48 h after transfection to monitor generation of ICD species in anti-Flag immunoprecipitates (a) or 
of high molecular weight FVenv species in straight lysates (b). Western blots signals of 
immunoprecipitates were quantified and the ICD-to-LP ratio ([ICD]/[LP]) was determined in three 
independent experiments. Data represent means ± SEM. *, p < 0.049 (Student's unpaired t test). (c) 
Schematic  model  of proteolytic  processing of full-length FVenv by either furin/PC (PC, to right side) or 
SPPL3 (to left side). Putative cleavage products detected in a & b are also depicted.
transfected with SPPL3 and FVenv mut but not of  cells transfected with FVenv mut alone or with 
SPPL2b and FVenv mut (Fig. 4.5b). This SPPL3-specific fragment was devoid of its original N-
terminus and had a molecular weight lower than full-length FVenv but slightly higher than SU-
TM generated by furin/PC cleavage (Fig. 4.5c). Therefore, this fragment, termed TMD-SU-TM, 
presumably is generated by intramembrane cleavage of  full-length FVenv together with ICD(L3). 
Importantly, this fragment was also observed upon co-expression of SPPL3 with FVenv wild-
type. Hence, even when truncated LP is available, full-length FVenv is endoproteolysed by 
SPPL3.
These observations point to strikingly distinct substrate preferences of SPPL2b and SPPL3. To 
support this, catalytically inactive protease mutants were over-expressed in HEK293 cells and 
used to co-immunoprecipitate co-expressed FVenv species from cell lysates obtained (Fig. 4.6). 
SPPL2b D421A co-precipitated LP but failed to co-precipitate detectable amounts of  full-length 
FVenv (Fig. 4.6a). SPPL3 D271A on the other hand preferentially co-isolated full-length FVenv 
and only faint amounts of  LP (Fig. 4.6b). Therefore, it was conclusively shown that SPPL2b can 
only accept pre-cleaved FVenv LP that has a sufficiently shortened ectodomain as a substrate. 
LP can similarly be endoproteolysed by SPPL3 but SPPL3 appears to preferentially accept full-
length FVenv as a substrate. Moreover, the co-immunoprecipitation experiments revealed a 
physical interaction of  SPPL2b and SPPL3 with their respective substrates suggesting that 
these protease directly endoproteolyse FVenv and arguing against FVenv endoproteolysis being 
an indirect consequence of SPPL2b or SPPL3 expression.
4.2.2 SPPL3-mediated cleavage of FVenv is insensitive to GxGD protease inhibitors
Several compounds are known to inhibit proteolytic processing of  transmembrane protein 
substrates by GxGD I-CLiPs (see 1.4.4.1). (Z-LL)2 ketone and the GSI L-685,458, for instance, 
inhibit proteolytic activity of SPP as well as SPPL2a/SPPL2b (Weihofen et al, 2000; 2003; 
Fluhrer et al, 2006; Friedmann et al, 2006; Kirkin et al, 2007; Martin et al, 2008), while DAPT 
does not block SPP or SPPL2b activity (Martin et al, 2008; Weihofen et al, 2003). For lack of  a 
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Fig. 4.6: Co-immunoprecipitation of FVenv  by catalytically inactive SPPL2b and SPPL3 mutants. 
CHAPSO lysates of membranes isolated from HEK293 TetR cells stably expressing HA-tagged SPPL2b 
D421A (D/A) (a) or SPPL3 D271A (D/A) (b) were subjected to anti-HA 6908 immunoprecipitation (IP). 
Alternatively, to check for unspecific binding, anti-HA serum was omitted and lysates were only incubated 
with protein A-conjugated sepharose beads (beads). To determine the amount of protein 
immunoprecipitated 5% of the IP input (input) were co-migrated.
known transmembrane protein substrate the effect of these compounds on SPPL3 activity has 
so far not been studied. Therefore, these inhibitors were assessed for their potency to inhibit 
SPPL2b- and SPPL3-mediated proteolytic processing of FVenv.
To this end, HEK293 cells stably co-expressing FVenv and catalytically active SPPL2b 
(Fig. 4.7a) or SPPL3 (Fig. 4.7b) were treated with increasing concentrations of  (Z-LL)2 ketone, 
L-685,458 or DAPT and ICD(L2) and ICD(L3) levels, respectively, were analysed. As expected, 
SPPL2b-mediated generation of ICD(L2) from FVenv LP was blocked in a concentration-
dependent manner by both (Z-LL)2 ketone and L-685,458 (Fig. 4.7a). Treatment with both 
compounds also led to an accumulation of LP and of ICD(L3) as well as another LP degradation 
product, mimicking the effect previously observed upon over-expression of  catalytically inactive 
SPPL2b D421A (Fig. 4.3b). DAPT, however, did not affect SPPL2b-mediated processing as 
neither an accumulation of LP nor a reduction in ICD(L2) levels were observed. DAPT also did 
not affect SPPL3-mediated processing of FVenv (Fig. 4.7b). Similarly, neither (Z-LL)2 ketone nor 
L-685,458 affected LP levels in cells co-expressing FVenv and SPPL3 and both compounds 
also failed to block production of  ICD(L3) at concentrations of  up to 50 µM. This is in stark 
contrast to the observations made for SPPL2b (Fig. 4.7a) and clearly shows that, unlike SPP as 
well as SPPL2a/SPPL2b, SPPL3 - in an over-expression setting - appears to be insensitive to 
treatment with the GxGD protease inhibitors at the concentrations tested. Strikingly, however, 
treatment of FVenv- and SPPL3-expressing cells with (Z-LL)2 ketone and L-685,458 was 
accompanied by inhibitor dose-dependent accumulation of ICD(L3) (Fig. 4.7b).
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Fig. 4.7: Effects of GxGD protease inhibitor treatment on SPPL2b- and SPPL3-mediated 
processing of FVenv. HEK293 cells stably co-expressing FVenv and either active SPPL2b (a) or active 
SPPL3 (b) were treated with increasing concentrations of (Z-LL)2 ketone ((Z-LL)2), L-685,458, or DAPT 
as well  as DMSO (vh, vehicle) for 16 h before lysis. anti-Flag immunoprecipitates of cell  lysates were 
analysed by SDS-PAGE and Western blot for ICD generation. Note that, similar to SPPL2b(D421A) co-
expression in Fig. 4.3b, ICD(L3) and a LP-derived fragment of unclear origin (*) accumulated with 
increasing concentrations of (Z-LL)2 ketone ((Z-LL)2) or L-685,458. **, IgG light chain.
4.2.3 SPPL2a/SPPL2b endoproteolyse the SPPL3 cleavage product ICD(L3)
A possible explanation for the striking accumulation of ICD(L3) upon (Z-LL)2 ketone or 
L-685,458 treatment (Fig. 4.7b) is that these compounds not only fail to inhibit SPPL3's activity 
but instead promote or activate it. Alternatively, these inhibitors block the activity of (an) 
endogenous protease(s) that is capable of further processing and/or degrading ICD(L3) 
generated by SPPL3.
In the experiments described previously Tris-Tricine gels were used to analyse anti-Flag 
immunoprecipitates by Western blot. These failed, however, to resolve ICD(L3) generated in 
cells co-expressing SPPL3 and FVenv into a sharp band. The ICD(L3) signal observed 
appeared rather smeary. ICD(L2) on the other hand was clearly detectable as a distinct protein 
band (compare for instance ICD(L3) and ICD(L2) bands in (Fig. 4.5a)). These observations 
suggested that the previously described ICD(L3) band could contain in fact additional smaller 
protein fragments that represent degradation products. To clarify this, immunoprecipitates 
obtained from cells co-expressing FVenv with either SPPL2b or SPPL3 were separated in 
parallel in Tris-Tricine gels (Fig. 4.8a) as previously and in Tris-Glycine gels (Fig. 4.8b). 
Strikingly, Tris-Glycine gels achieved a much higher resolution of  the ICD species and revealed 
that lysates obtained from cells expressing SPPL3 and FVenv contain two distinct anti-Flag 
reactive ICD species, genuine ICD(L3) as well as a smaller ICD. Notably, the latter ICD co-
migrated with ICD(L2) generated in cells stably expressing SPPL2b and FVenv. Next, stably 
SPPL3- and FVenv-transfected cells were treated with GxGD protease inhibitors (Fig. 4.9a) to 
determine whether ICD(L2) generation observed in these cells is dependent on endogenous 
SPPL2a and/or SPPL2b activity. Of  note, generation of ICD(L3) and ICD(L2) upon SPPL3 over-
expression appeared to be very efficient and detection in cell lysates was possible even without 
prior enrichment by immunoprecipitation. Indeed, (Z-LL)2 ketone as well as L-685,458 treatment 
resulted in a reduction of  ICD(L2) and a concomitant accumulation of  ICD(L3), yet levels of the 
corresponding TMD-SU-TM cleavage product did not change (Fig. 4.9a). In contrast, neither 
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Fig. 4.8: SPPL3 expression leads to generation of both ICD(L3) as well as ICD(L2). Tris-Tricine (a), 
which had been used to separate FVenv ICD species in all preceding experiments shown, and Tris-
Glycine (b) gels were tested for their capacity to separate ICD species from immunoprecipitates (IP) of 
HEK293 cells stably co-expressing FVenv and active SPPL2b or active SPPL3. Tris-Glycine gels clearly 
separated the previously observed ICD(L3) into ICD(L3) and ICD(L2). Note that ICD(L2) generation in 
SPPL3-expressing cells was highly efficient as less lysate input (40% IP input) was sufficient to detect 
amounts of ICD(L2) similar to those in SPPL2b-expressing cells. **, IgG light chain.
DAPT nor DMSO treatment led to changes in ICD(L2) levels. In support of prior observations 
(Fig. 4.7b), this unambiguously shows that inhibitor treatment does not directly affect SPPL3 
activity but instead targets ICD(L3) downstream processing by a protease activity that has an 
inhibitor sensitivity profile reminiscent of  other GxGD proteases. Moreover, reduction of 
endogenous SPPL2a and SPPL2b levels by siRNA transfection likewise slightly reduced 
ICD(L2) and concomitantly ICD(L3) accumulated (Fig. 4.9b). Treatment with SPPL3-specific 
siRNA reduced the levels of the products generated by SPPL3-mediated FVenv cleavage, TMD-
SU-TM and ICD(L3). Interestingly, however, this was accompanied by a reduction in ICD(L2) 
levels.
In all experiments performed proteolytic processing of FVenv was examined under conditions of 
SPPL3 or SPPL2a/SPPL2b over-expression conditions. Hence, it remained to be examined 
tested whether FVenv is similarly endoproteolysed by endogenous SPPL proteases and 
whether under these conditions ICD(L3) generated by SPPL3 is likewise turned over into 
ICD(L2). Therefore, FVenv ICD generation was analysed in HEK293 cells that stably express 
FVenv but do not over-express SPPL proteases (Fig. 4.10). By means of a two-step 
immunoprecipitation strategy low  levels of ICD(L3) and ICD(L2) generated by endogenous 
cellular protease activities could be observed. siRNA-mediated reduction of  endogenous 
SPPL2a and SPPL2b resulted in loss of ICD(L2) signals while ICD(L3) was still produced. 
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Fig. 4.9: ICD(L2) is produced from ICD(L3) by endogenous SPPL2a/SPPL2b. HEK293 cells stably 
co-expressing FVenv and active SPPL3 were treated with GxGD protease inhibitors (a) or transfected 
with siRNAs (b) to examine generation of ICD(L3) and ICD(L2). For inhibitor treatment, media were 
supplemented with the inhibitors as indicated at a concentration of 10 µM for 16 h. For SPPL2a/SPPL2b 
and SPPL3 knock-downs, cells were reversely transfected with either SPPL2a- and SPPL2b- or SPPL3-
specific siRNA pool as well  as a non-targeting control siRNA pool (ctrl) and analysed after four days in 
culture. Cells were lysed and 80 µg total protein were subjected to Tris-Glycine SDS-PAGE and Western 
Blot. Knock-down of SPPL3 was monitored by Western blot and of SPPL2a/SPPL2b by quantitative 
TaqMan RT-PCR using specific probes. mRNA levels were normalised to β-actin levels and relative 
mRNA changes were calculated using the ΔΔCT method. (Experimental  work presented herein was 
performed by Ulrike Künzel.)
Reduction of  endogenous SPPL3, however, resulted in decreased detection of  both ICD(L3) 
and ICD(L2).
Taken together, this suggests that ICD(L3) is efficiently turned over by endogenous SPPL2a/
SPPL2b to produce ICD(L2). In order to unambiguously show  that ICD(L2) is in fact generated 
by a direct turnover of  ICD(L3), SPPL3-over-expressing cells were transfected with FVenv mut 
or the FVenv wild-type control and ICD(L2) generation was monitored (Fig. 4.11). Due to 
impaired furin/PC cleavage, LP is hardly available as a substrate for SPPL2a/SPPL2b-mediated 
intramembrane proteolysis in cells expressing FVenv mut (Fig. 4.5 & Fig. 4.11a). However, cell 
lysates of FVenv mut-transfected and SPPL3-co-expressing cells still contained substantial 
amounts of  both ICD(L3) and ICD(L2) and the ICD(L2)/ICD(L3) ratio was not changed 
compared to cells expressing SPPL3 and FVenv wild-type (Fig. 4.11b & c). This demonstrates 
that ICD(L2) observed in FVenv mut-expressing cells was not generated by SPPL2a/SPPL2b-
mediated turnover of  LP but of  ICD(L3). Consequently, FVenv-derived substrates accepted for 
intramembrane proteolysis by SPPL2a/SPPL2b can either be generated by membrane-proximal 
furin/PC cleavage or, alternatively, by prior cleavage mediated by SPPL3. Moreover, it has to be 
highlighted that processing of ICD(L3) by endogenous SPPL2a/SPPL2b activity appears to be 
highly efficient. In fact, ICD(L2) generation from ICD(L3) appears to be more efficient than from 
LP: ICD(L2) levels were readily detectable when 80 µg total protein from cell lysates of  cells co-
expressing FVenv and SPPL3 wild-type were analysed (Fig. 4.9), while in  cells co-expressing 
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Fig. 4.10: Proteolytic processing of FVenv  by endogenous SPPL3 and SPPL2a/SPPL2b. HEK293 
cells stably expressing FVenv were reversely transfected with SPPL2a/SPPL2b- and SPPL3-specific 
siRNA as well as respective non-targeting controls (ctrl) as indicated (10 nM each) and analysed five 
days later. Knock-down efficiency was assessed by Western blot for SPPL3 (Calnexin was used as a 
loading control) and by quantitative TaqMan RT-PCR for SPPL2a and SPPL2b using specific  probes 
(right panels). mRNA levels were normalised to β-actin levels and relative mRNA changes were 
calculated using the ΔΔCT method. To detect endogenously produced ICD species in cell lysates (left 
panels) a two-step immunoprecipitation (IP) strategy was employed: First, lysates with equal amounts of 
total  protein (see actin levels in input) were cleared from full-length FVenv by anti-V5 immunoprecipitation 
and subsequently lysates were subjected to anti-Flag immunoprecipitation. The latter were analysed by 
Tris-Glycine SDS-PAGE and Western blot. *, degradation product of LP, see Fig. 4.3.
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Fig. 4.11: ICD(L2) is produced by endogenous SPPL2a/SPPL2b from ICD(L3) when SPPL3 is over-
expressed. (a) Overview of possible mechanisms how ICD(L2) can be generated in cells over-
expressing SPPL3. Full-length FVenv wild-type (centre of top row) is either directly endoproteolysed by 
SPPL3 (arrow to the left) which leads to the generation of ICD(L3) which is then turned over by SPPL2a 
or SPPL2b to obtain ICD(L2) or it is cleaved by PC (arrow to the right) generating LP18 which may then 
be converted to ICD(L2) by SPPL2a or SPPL2b. Full-length FVenv mut is not substantially turned over by 
PC, i.e. the majority of ICD(L2) will be generated by conversion of the SPPL3 cleavage product , ICD(L3). 
(b) Analysis of ICD(L2) generation from FVenv wild-type and FVenv mut in SPPL3 over-expressing cells. 
HEK293 cells stably expressing active SPPL3 were transfected with either FVenv wild-type or FVenv mut 
bearing the R123A/R126A substitutions and proteolytic  processing was monitored by Western blot. To 
this end 80 µg protein from total  cell lysates were subjected to Tris-Glycine SDS-PAGE. (c) Quantification 
of FVenv cleavage products. Western blot signals were quantified in three independent experiments and 
the ratios of FVenv species abundance were calculated as depicted (right panels). While the ICD(L2)-to-
ICD(L3) ratio was not significantly different in cells expressing either FVenv wild-type or FVenv mut, the 
LP-to-ICD(total) ratio was (**, p < 0.004 (Student's unpaired t test)). Data represent means ± SEM.
SPPL2a or SPPL2b and FVenv ICD(L2) was only detected following enrichment by 
immunoprecipitation (Fig. 4.3).
4.2.4 Determination of SPPL cleavage sites in FVenv
In sum, these observations point to a consecutive proteolytic processing of FVenv by the 
intramembrane proteases SPPL3 and SPPL2a/SPPL2b. Since collaborative processing of a 
substrate by different GxGD protease has not been observed previously, this raises additional 
mechanistic questions, in particular, how  consecutive intramembrane proteolysis proceeds and 
where cleavage by the two apparently very distinct proteolytic activities occurs. To address this, 
the exact amino acid residue(s) at which cleavage of FVenv by either SPPL3 or SPPL2a/
SPPL2b occurs were determined by MALDI-TOF mass spectrometry. To this end a truncated 
FVenv model substrate, FVenv ΔE, was cloned (Fig. 4.12a). FVenv ΔE includes an N-terminal 
Flag tag as well as a C-terminal V5 tag to allow  for detection of  ICDs in cell lysates and C-
peptides in conditioned cell culture supernatant, respectively. Such cleavage products were 
expected to be produced by intramembrane proteolysis of this construct. Similar substrate 
72! Results
Fig. 4.12: Proteolytic processing of FVenv  ΔE by SPPL intramembrane proteases. (a) Schematic 
overview of FVenv ΔE. This construct is derived from the FVenv coding sequence and comprises amino 
acids 32 to 106 and, hence, harbours the first, type II-oriented TMD1 (amino acids 66 to 88, green 
cylinder, the construct is not drawn to scale). Terminal  tags were introduced (grey boxes). It was 
anticipated that this construct is directly endoproteolysed by SPPL3 or SPPL2a/SPPL2b to generate 
secreted, V5-tagged C-peptides (Cp) and intracellular Flag-tagged ICDs. (b) Transient expression of 
FVenv ΔE in HEK293 cells. Conditioned supernatants were harvested and subjected to anti-V5 
immunoprecipitation (IP) (top panel) while cells were lysed and lysates subjected to anti-Flag 
immunoprecipitation (bottom panel). Precipitates were loaded on Wiltfang (top panel) or Tris-Tricine gels 
(bottom panel) and analysed by Western blot. FVenv ΔE represents the uncleaved substrate; cleavage 
products are labelled according to results from (c). Note that Wiltfang gels do not separate proteins 
according to their molecular weight, i.e. the faster migrating C-peptide species must not necessarily be 
the smallest. (c) SPPL2a/SPPL2b and SPPL3 generate distinct cleavage products from FVenv ΔE. 
HEK293 cells stably expressing FVenv ΔE were reversely transfected with non-targeting (ctrl) or SPPL3-
specific (SPPL3) siRNA pools (10 nM). 72 h post transfection cells were treated with either DMSO or (Z-
LL)2 ketone (10 µM) for 16 h. Conditioned media and cells were analysed as described for (b). Cp(L3) 
and ICD(L3) represent SPPL3-specific cleavage products, Cp(L2) and ICD(L2) are specific  for SPPL2a/
SPPL2b. SPPL3 knock-down efficiency was analysed by quantitative TaqMan RT-PCR (right panel). 
SPPL3  mRNA levels were normalised to β-actin levels and relative mRNA changes were calculated using 
the ΔΔCT method. Transfection with SPPL3-specific siRNAs resulted in loss of  > 95% of endogenous 
SPPL3 mRNA. Bars represent mean values from three technical replicates, error bars the SD.
constructs have already been used in previous studies in particular since they allow  for direct 
analysis of γ-secretase- or SPPL-mediated intramembrane proteolysis due to their substantially 
shortened ectodomains (Kopan et al, 1996; Fluhrer et al, 2006; Martin et al, 2008; Zahn et al, 
2013). Indeed, following FVenv ΔE expression in HEK293 cells three putative C-peptide bands 
were detected in conditioned media as well as two distinct putative ICD species in cell lysates 
(Fig. 4.12b), the latter being reminiscent of  ICD(L3) and ICD(L2) generated by intramembrane 
proteolysis of full-length FVenv. To attribute these cleavage products to the proteolytic activity of 
either SPPL3 or SPPL2a/SPPL2b, stably FVenv ΔE-expressing HEK293 cells were transfected 
with SPPL3-specific siRNAs and at the same time subjected to (Z-LL)2 ketone treatment to 
inhibit SPPL2a/SPPL2b activity (Fig. 4.12c). (Z-LL)2 ketone treatment markedly reduced the 
amounts of one C-peptide in cell culture supernatants and of  the smaller ICD species in cell 
lysates. As these bands were unaffected by SPPL3-specific siRNA transfection, they likely 
derive from endogenous SPPL2a/SPPL2b activity in HEK293 cells and, hence, are referred to 
as Cp(L2) and ICD(L2), respectively. Reduction of endogenous SPPL3 by RNAi similarly 
resulted in reduction of two C-peptide bands collectively named Cp(L3). Interestingly, even in 
cells transfected with non-targeting siRNAs, (Z-LL)2 ketone also led to accumulation of  both the 
larger ICD as well as of  the educt band, FVenv ΔE. Accumulation of the ICD was markedly 
decreased following SPPL3 knock-down, showing that this ICD, ICD(L3), is an SPPL3-specific 
cleavage product. FVenv ΔE has a shortened ectodomain and also lacks the furin/PC cleavage, 
suggesting that it can be directly accepted as a substrate of SPPL2a/SPPL2b and SPPL3. 
Indeed, the observed accumulation of the FVenv ΔE educt as well as of  ICD(L3) in cell lysates 
following inhibitor treatment demonstrate that both species can in fact be turned over by 
SPPL2a/SPPL2b. Taken together, FVenv ΔE is endoproteolysed by SPPL2a/SPPL2b and 
SPPL3 similar to full-length FVenv. Unlike full-length FVenv, however, FVenv ΔE can also be 
directly cleaved by SPPL2a/SPPL2b independent of prior proteolysis by either furin/PC or 
SPPL3.
To identify the exact site(s) at which SPPL-mediated endoproteolysis of FVenv occurs, C-
peptide species were analysed by MALDI-TOF mass spectrometry. To this end, another 
truncated FVenv substrate was constructed, FVenv ΔEinv. Unlike FVenv ΔE, however, this 
construct was C-terminally Flag-tagged to achieve secretion of Flag-tagged FVenv-derived C-
peptides generates by SPPL activity in transfected cells. These peptides were affinity-purified 
via their epitope tag and subsequently analysed by MALDI-TOF MS analysis. In initial 
experiments detection of such peptides, however, was hampered by C-terminal degradation 
which was attributed to the activity of secreted cellular or serum exopeptidase(s) (data not 
shown). To circumvent this technical problem, an alanine and a proline residue were added to 
the construct's C-terminus to prevent carboxypeptidase attack. This construct, FVenv ΔEinv(AP), 
was stably transfected into HEK293 cells. These were treated with either DMSO or (Z-LL)2 
ketone to inhibit SPPL2a/SPPL2b activity and conditioned media were subjected to anti-Flag 
immunoprecipitation to purify Flag-tagged C-peptides generated by endogenous protease 
activities. Four distinct peaks, a very prominent one and three less intense ones, were observed 
in immunoprecipitates analysed by mass spectrometry (Fig. 4.13a). Their observed mass was 
well in line with the calculated mass of four peptides originating in the annotated TMD and 
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comprising the intact C-terminus (Fig. 4.13a & b). Interestingly, all four peptides disappeared 
when cells were treated with (Z-LL)2 ketone (Fig. 4.13a), suggesting that they were generated 
by endogenous SPPL2a/SPPL2b activity. Collectively, these data point to SPPL2a/SPPL2b-
mediated cleavage of FVenv occurring close to the lumenal border of its TMD. SPPL3-specific 
C-peptide species, however, could not be detected using FVenv ΔEinv(AP). Moreover, mass 
spectrometric analysis of ICD species generated by SPPL2a/SPPL2b or SPPL3 activity was not 
successful, in spite of various experimental approaches (data not shown).
4.2.5 SPPL3 isoform 1 exhibits no proteolytic activity towards FVenv
Databases list two isoforms of human SPPL3: isoform 15, which encodes a putative 385 aa 
protein (GenBank entry CAD13135.1), and isoform 2, encoding a 384 aa protein (GenBank 
RefSeq entry NP_620584.2). In all the prior experiments (and in the one described in 
sections 4.3 and 4.4) over-expressed HA-tagged SPPL3 was exclusively isoform 2. Both 
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5 Isoform numbering is adopted from the human SPPL3 Uniprot entry (Q8TCT6), retrieved on March 12th 2014.
Fig. 4.13: Mass spectrometric analysis of C-peptides generated by SPPL-mediated intramembrane 
proteolysis. To allow for detection of FVenv-derived C-peptide species, a modified variant of FVenv ΔE 
(see Fig. 4.12), FVenv ΔEinv(AP), was used. Unlike FVenv ΔE, this construct's terminal tags were 
inverted, i.e. C-peptides secreted are Flag-tagged. Also, C-terminal to the Flag tag two residues (alanine 
and proline, given in italics in (b)) were added in order to prevent degradation by carboxypeptidases. 
Identification of (Z-LL)2 ketone-sensitive C-peptides (a). HEK293 cells stably transfected with 
FVenv ΔEinv(AP) were treated with DMSO or 50 µM (Z-LL)2 ketone for 48 h. Conditioned supernatants 
were subjected to anti-Flag immunoprecipitation (IP) and immunoprecipitates were analysed by MALDI-
TOF mass spectrometry together with angiotensin 1 peptide as a reference. Note that four (Z-LL)2 
ketone-sensitive peptides were detected within a m/z range of 3,000 and 4,000 (numbered coloured 
arrowheads). Mapping of the observed peptides to the FVenv ΔEinv(AP) sequence (b, c). FVenv TMD in 
(b) is highlighted in bold according to TMHMM 2.0 predictions, numbering is according to the untagged 
FVenv sequence. (Z-LL)2 ketone treatment of FVenv ΔEinv(AP)-transfected cells was accompanied by 
accumulation of higher molecular weight peptides (green bracket) that could not be mapped to the FVenv 
sequence. (Mass spectrometric measurements were performed by Dr Akio Fukumori, DZNE Munich.)
isoforms are highly homologous and differ only in a small stretch comprising the lumenal 
juxtamembrane region preceding TMD1 up to the middle of TMD1 (Fig. 4.14a). To examine 
whether SPPL3 isoform 1 is also capable of endoproteolysing FVenv in a manner similar to 
SPPL3 isoform 2, both isoforms were co-expressed with FVenv in HEK293 cells (Fig. 4.14b). As 
expected, expression of SPPL3 isoform 2 led to generation of TMD-SU-TM as well of ICD(L3) 
and the down-stream cleavage product ICD(L2). Upon expression of SPPL3 isoform 1, 
however, neither ICD(L3) and ICD(L2) nor TMD-SU-TM could be detected. Taken together, 
these observations suggest that SPPL3 isoform 1 is not proteolytically active on FVenv.
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Fig. 4.14: Comparison of human SPPL3 isoforms. (a) ClustalW protein sequence alignment of human 
SPPL3 isoform 1 and isoform 2. Sequences were obtained from GenBank with the given entry ID. 
Putative TMDs are highlighted in green according to Uniprot annotations. Note that isoform 1 and isoform 
solely differ in region comprising the lumenal  juxtamembrane region close to TMD1 and the first half of 
TMD2. Residues in isoform 1 differing from the respective ones in isoform 2 are depicted with a red 
background.  (b) Co-expression of FVenv and SPPL3 wild-type isoform 1 and isoform 2. Stably 
transfected HEK TetR cells inducibly over-expressing the respective SPPL3 isoform were transiently 
transfected with FVenv. FVenv cleavage was monitored by Western blot detection of TMD-SU-TM and 
ICD(L3)/ICD(L2). Note that both SPPL3 isoforms are expressed at comparable levels, yet only SPPL3 
isoform 2 induction led to changes in ICD production and detection of TMD-SU-TM.
4.3 SPPL3 affects cellular N-glycosylation under physiological conditions
SPPL3 appears to be one of the most ancient SPP homologues and is highly conserved in 
metazoa (Fig. 1.9) (Golde et al, 2009; Voss et al, 2013). Such high degree of  conservation could 
point to a crucial physiological function in multicellular organisms. Presently, however, this has 
remained enigmatic, mostly for the lack of (a) known physiological substrate(s). Hence, in order 
to investigate its physiological function(s) in mammals, SPPL3-deficient mice were examined for 
a phenotype.
4.3.1 Characterisation of Sppl3-deficient mice 
To examine the physiological function of  SPPL3 a previously established mouse line deficient in 
Sppl3, B6;129S5-Sppl3Gt(OST279815)Lex/Mmucd, was used (Tang et al, 2010). This mouse line 
harbours a genetrap insertion between exons 6 and 7 of  the Sppl3 open reading frame leading 
to an absence of Sppl3 transcripts in homozygous mutant animals (Tang et al, 2010). 
Phenotypic analyses by Tang et al. revealed that homozygous B6;129S5-Sppl3Gt(OST279815)Lex/
Mmucd mice were viable but both Sppl3-deficient males and females exhibited signs of  growth 
retardation such as decreased body weight and size (Tang et al, 2010). Behavioural 
abnormalities such as decreased exploratory activity and depression-like responses were also 
noted in homozygous Sppl3 mutants and, importantly, mutant males were found to be 
compromised in fertility. Moreover, Sppl3 knock-out animals had markedly reduced levels of  NK 
cells in spleen, lymph node, and peripheral blood (by up to 75% compared to homozygous wild-
type litter-mates).
As expected from these published observations, breeding performance of  homozygous knock-
out animals appeared to be very poor. Similar to observations made by Tang et al. male knock-
outs were observed to be not fertile (Tang et al, 2010) and female knock-out mice produced 
very small litters (data not shown). Hence, to nevertheless obtain homozygous knock-out 
animals, heterozygous litter-mates were mated (Tab. 4.1). Genotyping of the F1 offspring 
obtained from such heterozygous breeding pairs revealed that viable Sppl3-/- could be obtained, 
yet at a lower percentage than expected (8% vs. 25%). Macroscopically, animals deficient in 
Sppl3 were phenotypically inapparent. To reproduce the previously observed NK cell deficiency 
(Tang et al, 2010), lymph nodes and spleen were removed from sacrificed B6;129S5 Sppl3 
knock-out animals and wild-type litter-mate controls and analysed by flow  cytometry. To detect 
mature NK cells, surface expression of two NK cell markers, the integrin CD49b (Arase et al, 
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Tab. 4.1: F1 genotypes of Sppl3+/- x Sppl3+/- matings. After separation from the parents the F1 
offspring of Sppl3+/- x Sppl3+/- matings from both Sppl3-deficient mouse lines was genotyped by PCR. 
Note that following back-crossing to the C57BL/6 background no Sppl3-/- animals could be obtained. nx/x, 
absolute number of animals of a given genotype, ntotal, total number of F1 animals genotyped.
Sppl3+/+ Sppl3+/- Sppl3-/-
mouse line n+/+ % n+/- % n-/- % ntotal
B6;129S5-Sppl3Gt(OST279815)Lex/Mmucd 43 28.67 95 63.33 12 8.00 150
B6.129S5-Sppl3Gt(OST279815)Lex/Mmucd (N5) 30 37.04 51 62.94 0 0.00 81
2001) and the NK cell activating receptor NKp46 (Walzer et al, 2007), was analysed (Fig. 4.15). 
While Sppl3+/+ spleen and lymph nodes contained a minor population of  CD49b+ NKp46+ 
double-positive cells (0.38 and 0.78% in spleen and roughly 0.2% in lymph node), the relative 
abundance of this population in Sppl3 knock-out animals was substantially reduced (< 0.06%), 
clearly supporting the previous observations (Tang et al, 2010) and demonstrating that reduced 
NK cell counts are a distinctive feature of B6;129S5 mice lacking Sppl3.
A mixed genetic background could in principle affect the degree of severity of  such a phenotype 
and could lead to variance within the population of  animals studied. Therefore, Sppl3-deficient 
animals were back-crossed to the C57BL/6 inbred mouse strain. Heterozygous B6.129S5-
Sppl3Gt(OST279815)Lex/Mmucd (N5) mutants were then similarly inter-crossed to obtain Sppl3-
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Fig. 4.15: Flow  cytometric analysis of NK cells in Sppl3-/- mice. Splenic  lymphocytes (a) and pooled 
lymphocytes from axillary, brachial, and inguinal  lymph nodes (b) from two individual  animals (#1 and #2) 
of each genotype (Sppl3+/+, Sppl3+/-, and Sppl3-/-) were examined for NKp46 and CD49b surface 
expression. Percentages are indicated for each quadrant. Both NKp46 (Walzer et al, 2007) as well as 
CD49b (Arase et al, 2001) are well  established NK cell markers, yet they may also be found on other 
minor lymphocyte subpopulations such as γδ T cells (Walzer et al, 2007) and NKT  cells (Ortaldo et al, 
1998), respectively. To exclude these populations, NKp46+ CD49b+ cells were analysed. (c) depicts the 
gating strategy for Sppl3+/+ #1 spleen. Duplets were excluded and viable, i.e. DAPI-negative, lymphocytic 
cells were analysed. Percentages of cells in gate are given. (Flow cytometric analyses were performed 
together with Anne Behrendt, Institute of Immunology, LMU Munich.)
deficient animals. However, no homozygous Sppl3 mutants were observed in numerous litters 
produced by heterozygous parents (Tab. 4.1), suggesting that, on the C57BL/6 background, 
SPPL3 deficiency is associated with embryonic or early post-natal lethality. At the pre-natal 
developmental stage E13.5, however, homozygous knock-out embryos and wild-type controls 
exhibited no gross macroscopic phenotypic differences and were indistinguishable (not shown). 
4.3.2 SPPL3 affects the electrophoretic mobility of cellular glycoproteins
Primary MEFs were prepared from E13.5 embryos of  B6.129S5-Sppl3Gt(OST279815)Lex/ Mmucd 
(N5) mice. Genotyping by PCR revealed that two MEF preparations were in fact obtained from 
Sppl3-/- embryos (Fig. 4.16a). In line with this, no SPPL3 protein expression was detected in 
lysates of  these MEF preparations by Western blot, while SPPL3 protein expression was 
observed in MEFs obtained from a litter-mate Sppl3+/+ embryo (Fig. 4.16b, top panels). Striking 
differences between knock-out MEFs and wild-type MEFs became apparent when the running 
behaviour of endogenous glycoproteins, for instance of mature Nicastrin (NCTmat), was 
analysed (Fig. 4.16b, lower panels) in these cells. NCTmat displayed a slightly lower 
electrophoretic mobility in SDS-PAGE gels in cells devoid of Sppl3 than in wild-type MEFs, 
suggesting it has a higher molecular weight in cells lacking Sppl3. Interestingly, endogenous 
SPPL2a and the neuronal cell adhesion molecule N-cadherin behaved similarly and exhibited a 
slightly higher molecular weight in Sppl3-/- MEFs than in Sppl3+/+ cells. Similar observations 
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Fig. 4.16: Analysis of Sppl3-deficient MEFs. Genotyping of primary MEFs (a). Genomic DNA was 
isolated from primary MEFs and analysed by PCR for the genetrap insertion in the Sppl3 locus (top 
panel) or for the wild-type locus (bottom panel). Analysis of primary (b) and immortalised (c) MEFs by 
SDS-Page and Western blot to monitor the absence of detectable SPPL3 expression in Sppl3-/- MEFs 
(-/-) compared to wild-type control MEFs (+/+) (top two panels). In addition, selected glycoproteins were 
analysed (lower panels). *, unspecific bands.
were made in MEFs following immortalisation (Fig. 4.16c). In immortalised Sppl3-/- MEFs, 
NCTmat as well as the neuronal cell adhesion molecule N-cadherin and the lysosomal 
membrane protein Lamp2 displayed a slightly increased molecular weight compared to their 
respective molecular weight observed in lysates obtained from Sppl3+/+ MEFs.
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Fig. 4.17: Analysis of endogenous glycoproteins in Sppl3-/- mice and litter-mate controls. 
Homogenates of spleen (a), lung (b), brain (c), and kidney (d) obtained from age- and sex-matched 
B6;129S5 mice were examined for expression of SPPL3 (lower panels) and for the running behaviour of 
endogenous glycoproteins by SDS-PAGE and Western blot (top panels). Bone marrow-derived dendritic 
cells (BMDC, e) were generated by ex vivo differentiation of bone marrow-resident haematopoetic  stem 
cells obtained from age- and sex-matched Sppl3-/- mice and litter-mate controls and left unstimulated or 
were stimulated with CpG overnight. #, upper blot was redecorated with anti-Calnexin antibody (lower 
blot) as loading control.
To address whether this phenotype also prevails in living, adult Sppl3-deficient mice, tissue 
homogenates obtained from B6;129S5-Sppl3Gt(OST279815)Lex/Mmucd mice were examined by 
SDS-PAGE and Western blotting to assess for electrophoretic mobility of  endogenous 
glycoproteins (Fig. 4.17). As expected, Sppl3-/- mice lacked any detectable SPPL3 expression 
and SPPL3 levels were also reduced in Sppl3+/- compared to wild-type litter-mate controls. 
NCTmat was found to have a slightly higher molecular weight in spleen homogenates of  Sppl3-/- 
mice compared to homogenates of  Sppl3+/+ animals, while immature Nicastrin (NCTim) of all 
animals analysed had a highly similar running behaviour (Fig. 4.17a). While the extent of 
complex glycosylation of NCTmat clearly differs in a tissue-specific manner, the increased 
molecular weight of NCTmat associated with loss of  Sppl3 was consistently observed also in 
other tissues such as lung (Fig. 4.17b), brain (Fig. 4.17c), and kidney (Fig. 4.17d). Dendritic 
cells generated by ex vivo differentiation from Sppl3-/- bone marrow  exhibited a similar alteration 
in NCTmat molecular weight (Fig. 4.17e). In addition to NCTmat, other endogenous and 
ubiquitously expressed glycoproteins such as Lamp2 and SPPL2a also displayed a higher 
molecular weight in tissues of Sppl3-/- than in samples obtained from wild-type litter-mates 
(Fig. 4.17). Finally, the running behaviour of glycoproteins that are expressed in a tissue-specific 
manner was also examined. Like NCTmat, these proteins, for instance the monocytic marker 
CD68 expressed in spleen (Fig. 4.17a) or the neuronal cell adhesion factor N-cadherin 
expressed in the brain (Fig. 4.17c), displayed a lower electrophoretic mobility in animals that 
lacked SPPL3 expression.
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Fig. 4.18: Glycoprotein analysis following RNAi-mediated SPPL3 knock-down in HEK293 cells. 
Endogenous SPPL3 expression in HEK293 TetR cells was reduced by transient transfection with SPPL3-
specific siRNAs (a) or by stable expression of a SPPL3-specific  shRNA (b). For siRNA transfections (a), 
cells were reversely transfected with 20 nM of a non-targeting siRNA pool  (ctrl), with SPPL3- or SPPL2a-
specific siRNA pools or were left untransfected (none). Cells were harvested four days after transfection. 
Membranes were isolated from cells (a & b) and membrane lysates were examined by SDS-PAGE and 
Western blotting for SPPL3 expression levels (left panels) and glycoprotein electrophoretic  mobility (right 
panels). #, upper blot was redecorated with anti-Calnexin antibody (lower blot) as loading control.
Taken together, Sppl3 deficiency in mice in vivo and ex vivo is accompanied by an increase in 
molecular weight of selected glycoproteins. To investigate whether such effects are also 
associated with the human orthologue, SPPL3 expression levels were modified in human 
HEK293 TetR cells. First, to mimic the murine knock-out setting (Fig. 4.16 & 4.17), endogenous 
SPPL3 expression was reduced by RNAi. Transient transfection with SPPL3-specific siRNA 
pools resulted in a marked reduction in SPPL3 protein levels compared to cells transfected with 
non-targeting control oligonucleotides (Fig. 4.18a). This, in turn, was accompanied by an 
increase in molecular weight of NCTmat, SPPL2a and N-cadherin. A similar change was 
observed in cells that express substantially less endogenous SPPL3 due to a stable expression 
of a SPPL3-specific shRNA (Fig. 4.18b). Hence, reduction of endogenous human SPPL3 in 
HEK293 TetR cells mirrors the effects observed following genomic ablation of Sppl3 in murine 
cells. 
Next, exogenous SPPL3 over-expression was induced in stably transfected HEK293 TetR cells 
to check whether this has the opposite effect on endogenous cellular glycoproteins (Fig. 4.19a). 
Indeed, SPPL3 wild-type over-expression had a profound impact on NCTmat, N-cadherin, Lamp2 
and SPPL2a. It led to a reduction in molecular weight of these glycoproteins and, interestingly, 
the extent of the molecular weight shift was even more pronounced than the increase in 
molecular weight associated with loss of SPPL3 expression. Moreover, no changes in 
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Fig. 4.19: Glycoprotein analysis following SPPL3 over-expression in HEK293 cells. Cell lysates of 
HEK TetR cells stably over-expressing SPPL3 wild-type (wt) or the active site D200N/D271N mutant (DD/
NN) were analysed by SDS-PAGE and Western blot to monitor changes in the molecular weight of 
endogenous glycoproteins such as Nicastrin (NCT), N-cadherin, SPPL2a, and Lamp2 (a). To exclude 
clone-specific  effects, the experiment depicted in (a) was repeated with individual  single cell-derived 
clones (C#) of cells expressing SPPL3 wt and SPPL3 D200N/D271N (DD/NN). In addition, cells 
expressing the D271A mutant (D/A) were analysed. #, upper blot was redecorated with anti-Calnexin 
antibody (lower blot) as loading control.
glycoprotein molecular weight were associated with exogenous expression of  the SPPL3 active 
site mutant D200N/D271N, suggesting that proteolytic activity of  SPPL3 is crucially required to 
affect cellular glycoproteins. To exclude that these observations are simply due to an unspecific 
phenotype solely observed in one single cell-derived clone, two additional cell clones over-
expressing SPPL3 wild-type and SPPL3 D200N/D271N, respectively, were examined 
(Fig. 4.19b). In both SPPL3 wild-type-expressing clones the glycoprotein molecular weight shift 
became apparent, while in clones expressing SPPL3 D200N/D271N glycoprotein molecular 
weights were unchanged. In addition, glycoprotein running behaviour in cell lysates obtained 
from cells expressing the SPPL3 D271A active site mutant was also examined and was found to 
be slightly changed upon expression of the mutant, yet the differences in molecular weight 
following doxycycline treatment in these cells were not as substantial as in SPPL3 wild-type-
expressing cells (Fig. 4.19b).
4.3.3 SPPL3 alters cellular glycosylation of post-ER-localised glycoproteins
Interestingly, while changes in SPPL3 expression clearly affected NCTmat, SPPL2a, N-Cadherin, 
and Lamp2, the ER chaperone calnexin was not affected (Fig. 4.16 to 4.19). Unlike Calnexin, 
which is not glycosylated, NCTmat, SPPL2a, N-Cadherin, and Lamp2 are all membrane proteins 
that harbour several Nx(S/T) N-glycosylation sequons within their lumenal ectodomains. In fact, 
there is abundant experimental evidence that these proteins are post-translationally modified by 
N-glycosylation (Yu et al, 2000; Leem et al, 2002; Friedmann et al, 2004; Guo et al, 2009; 
Carlsson et al, 1988). Accordingly, the assumption emerged that SPPL3 does not affect the 
glycoproteins themselves but instead alters cellular N-glycosylation globally which then leads to 
the molecular weight changes observed. To test this, lysates from cells over-expressing active 
or inactive SPPL3 were subjected to glycosidase treatment to remove N-glycans attached. 
PNGase F removes most N-glycan structures, including complex ones, by hydrolysing the β-N-
glycosidic amide bond connecting the Asn side chain and the first GlcNAc residue of the N-
glycan (Maley et al, 1989). Accordingly, PNGase F treatment reduced the molecular weight of 
N-cadherin, SPPL2a, and Lamp2 due to the removal of attached N-glycans (Fig. 4.20a). 
Strikingly, however, whereas in untreated cell lysates SPPL3 over-expression affected the 
glycoproteins' molecular weight as observed earlier, in lysates treated with PNGase F the 
SPPL3-mediated change in molecular weight was lost. Likewise, the molecular weight 
difference of  NCTmat and N-cadherin observed earlier in tissues from Sppl3-/- animals compared 
to wild-type litter-mates (Fig. 4.17b), was not apparent anymore in PNGase F-treated brain 
homogenates (Fig. 4.20b). Also, in PNGase F-treated lysates of Sppl3+/+ and Sppl3-/- MEFs 
neither N-cadherin nor SPPL2a exhibited any differences in molecular weight, while in untreated 
lysates both glycoproteins had a slightly higher molecular weight in Sppl3-deficient cells than in 
Sppl3+/+ MEFs (Fig. 4.20c). Taken together, this clearly shows that changes in SPPL3 
expression levels lead to alterations in the pattern and/or extent of glycosylation on the proteins 
analysed. In addition, to dissect at which step(s) SPPL3 interferes with the cellular synthesis of 
N-glycans, HEK cell lysates were digested with Endo H (Fig. 4.20a & b). Endo H hydrolyses the 
β1,4-glycosidic bond within the chitobiose core of  N-glycans. N-glycans that were acted upon by 
α-mannosidase II, however, become resistant to Endo H hydrolysis and, therefore, Endo H fails 
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to remove complex glycan structures from glycopeptides (Maley et al, 1989). Endogenous 
NCTmat, N-cadherin, SPPL2a, and Lamp2 in HEK293 cells (Fig. 4.20a) and NCTmat and N-
cadherin in brain homogenates (Fig. 4.20b) appear to be extensively modified by such complex 
glycans, as they were largely resistant to Endo H activity. Interestingly, though, these Endo H-
digested glycoproteins were affected by alterations in SPPL3 expression as this led to changes 
in their electrophoretic mobility. In contrast to this, in cells treated with the alkaloid kifunensine, 
exogenously expressed active SPPL3 lost its ability to alter the electrophoretic mobility of 
NCTmat, N-cadherin, SPPL2a, and Lamp2 (Fig. 4.21a). Kifunensine very potently inhibits α-
mannosidase I activity and, as a result, cells fail to produce complex- as well as hybrid-type 
glycans and, consequently, high-mannose glycans prevail (Elbein et al, 1990). Hence, following 
kifunensine treatment, glycoproteins such as N-cadherin and SPPL2a become sensitive to 
Endo H hydrolysis (Fig. 4.21b). Moreover, it was also examined whether the ER-resident, 
glycosylated FVenv is affected by SPPL3 over-expression. In line with the earlier observations, 
FVenv wild-type was found to be Endo H-sensitive and its molecular weight was unchanged in 
cells expressing exogenous SPPL3 (Fig. 4.22). In cells expressing the ER retention signal 
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Fig. 4.20: Enzymatic N-deglycosylation. Lysates of HEK TetR cells stably over-expressing SPPL3 wild-
type (wt) upon doxycycline (+ Dox) treatment (a), of wild-type (+/+) or Sppl3-deficient (-/-) mouse brain (b) 
and of immortalised MEFs (c) were subjected to endoglycosidase digestion by PNGase F (a, b, c) or 
Endo H (a, b) as indicated. Electrophoretic mobility of endogenous glycoproteins was analysed as 
depicted earlier. Note that PNGase F-digested N-Cadherin and SPPL2a were not affected by changes in 
SPPL3 expression anymore, while glycoproteins resistant to Endo H treatment were. PNGase F-treated 
human Lamp2 could not be detected using the anti-H4B4 antibody anymore, but instead was detected 
using another anti-Lamp2 antibody that in turn only recognised N-deglycosylation human Lamp2. glyc, 
glycosylated species, deglyc, N-deglycosylated species.
mutant of FVenv, FVenv mut ΔΚΚΧΧ, however, LP-SU and TM were generated due to  cleavage 
at the PC* site of  the FVenv holoprotein. LP-SU was found to be complexly glycosylated as it 
was Endo H-resistant and glycosylated LP-SU exhibited a lower molecular weight in cells over-
expressing SPPL3 than in control cells. In sum, SPPL3 was shown to profoundly change the 
degree of N-glycosylation of  complexly glycosylated, post-ER localised glycoproteins. This is 
also in line with the very initial observation that SPPL3 only affected NCTmat and not NCTimmat, 
as only the former species is complexly glycosylated (Leem et al, 2002; Yang et al, 2002; 
Edbauer et al, 2002).
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Fig. 4.21: Kifunensine treatment of HEK293 cells over-expressing SPPL3. Lysates of HEK TetR cells 
as well as uninduced (-) and doxycycline-induced (+) HEK TetR SPPL3 wild-type cells (SPPL3) were 
examined for changes in glycoprotein molecular weight by SDS-PAGE and Western blot (a). SPPL3 
expression was induced for 48 h and cells were in parallel  treated with 4 µg/ml kifunensine (KF) or were 
left untreated. Note that kifunensine treatment globally changed the extent of glycosylation as Nicastrin 
maturation is impaired and N-Cadherin, SPPL2a, and Lamp2 feature a lower molecular weight following 
treatment. Enzymatic de-glycosylation of cell  lysates following kifunensine treatment (b). Samples from 
(a) were treated with Endo H or PNGase F prior to electrophoresis to assess for effective kifunensine 
treatment. Note that following kifunensine treatment N-cadherin and SPPL2a were Endo H-sensitive. 
glyc, glycosylated glycoprotein species, deglyc, N-de-glycosylated species.
4.3.4 SPPL3 facilitates secretion of GnT-V
The experiments presented suggest that SPPL3 modulates the extent and nature of  cellular 
Golgi N-glycosylation. Importantly, glycoproteins modified by high-mannose type glycans, such 
as NCTimmat, glycoproteins in cells treated with kifunensine (Fig. 4.21) or ER-resident 
glycoproteins (Fig. 4.22), are not affected by SPPL3, suggesting that SPPL3 does not interfere 
with early steps of the N-glycan synthesis. In contrast, glycosylation of Endo H-resistant 
glycoproteins clearly is altered by SPPL3 over-expression (Fig. 4.20). In sum, these 
observations suggest that SPPL3 intervenes in the N-glycosylation pathway downstream of α-
mannosidase II. Following α-mannosidase II cleavage, N-glycans are subject to extensive 
branching of  the glycan core mediated by GnTs and to elongations and terminal modifications of 
such branches by various other GTs (see 1.6.2). As most of  these enzymes are type II 
membrane proteins, they represent candidate SPPL3 substrates and, therefore, it was 
investigated experimentally whether SPPL3 may affect cellular glycosylation by catalysing 
endoproteolysis of GTs and other GMEs.
β1,6-N-acetylglucosaminyltransferase V (GnT-V) emerged as very promising substrate 
candidate. GnT-V is encoded by MGAT5. It is involved in GlcNAc branching of complex N-
glycans and is crucially required for the formation of tetra-antennary complex glycans (reviewed 
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Fig. 4.22: Analysis of FVenv and FVenv mut ΔKKXX in cells over-expressing SPPL3. FVenv wild-
type or FVenv mut ΔKKXX were transiently transfected in control HEK293 TetR cells or in cells over-
expressing SPPL3. Cell lysates were left untreated (U) or were treated with either Endo H (E) or 
PNGase F (P) and were subsequently separated by SDS-PAGE and analysed by Western blot. FVenv 
mut ΔKKXX was endoproteolysed by PC* generating LP-SU (upper panel) and TM (lower panel). ER-
resident, Endo H-sensitive full-length FVenv was not affected by SPPL3 over-expression. LP-SU, 
however, was exported from the ER, thus became Endo H-resistant and was affected by SPPL3 over-
expression (compare bands with black asterisks with those with red ones). TM was observed to be 
Endo H-sensitive, suggesting that it is either not successfully exported from the ER or is not complexly 
glycosylated. Note that it is not affected by SPPL3 over-expression. glyc, glycosylated glycoprotein 
species, deglyc, N-deglycosylated species. Schematic illustrations of the respective epitope-tagged 
FVenv species analysed in this experiment are given on the right.
in (Dennis et al, 2002)). An anti-GnT-V mAb detected a prominent protein band with a molecular 
weight of  roughly 100 kDa in both cell lysates and in conditioned media of HEK293 cells 
(Fig. 4.23a). In cells transfected with MGAT5-specific siRNAs, however, levels of this protein 
were reduced substantiating that the mAb is in fact specific for human GnT-V and that GnT-V is 
endogenously expressed and secreted in HEK293 cells. Next, it was tested whether reduction 
of endogenous SPPL3 levels by RNAi or SPPL3 over-expression affected endogenous GnT-V 
in HEK293 cells (Fig. 4.23b). Similar to cells transfected with MGAT5 siRNA, levels of  secreted 
GnT-V (sGnT-V) in the cell culture supernatant were profoundly reduced by transfection with 
SPPL3-specific siRNA compared to cells transfected with a non-targeting control. In the cell 
lysate, however, two alterations were observed upon SPPL3 knock-down: First, GnT-V exhibited 
a slightly higher molecular weight than in the control sample. This is likely due to the 
glycosylation changes that accompany a SPPL3 knock-down (see 4.3.2) as GnT-V itself  is 
complexly glycosylated (Kamar et al, 2004). Second, GnT-V markedly accumulated in SPPL3 
knock-down cells. These observations are in favour of the notion that SPPL3 facilitates 
shedding and thus secretion of GnT-V. Moreover, over-expression of biologically active SPPL3 
resulted in a pronounced reduction in intracellular levels of  endogenous GnT-V. sGnT-V 
appeared to exhibit a slightly lower molecular weight in induced HEK293 TetR SPPL3 wild-type 
cells than in non-induced cells, yet its level in the conditioned supernatant did not change 
markedly.
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Fig. 4.23: Effects of SPPL3 on secretion and intracellular levels of endogenous GnT-V in HEK293. 
(a) HEK293 cells endogenously express and secrete GnT-V which is specifically detected by the anti-
GnT-V mAb. GnT-V expression in lysates (bottom panels) and conditioned supernatants (top panel) was 
examined using a commercial anti-GnT-V antibody. To check for specificity of the mAb, cells were 
transiently transfected with MGAT5-specific siRNA pools or a non-MGAT5-targeting control  (20 nM each). 
sGnT-V, secreted GnT-V. (b) GnT-V secretion is affected by SPPL3. HEK TetR cells were transiently 
transfected with indicated siRNA pools  or a non-targeting control pool (ctrl) (20 nM each). In parallel, 
SPPL3 expression was induced in HEK TetR SPPL3 wild-type (wt) cells by supplementing the media with 
doxycycline (+ Dox). Cell culture supernatants were conditioned for 48 h and GnT-V secretion was 
monitored by SDS-PAGE and Western blotting. At the same time cellular GnT-V as well as SPPL3 levels 
were analysed in cell  lysates. #, upper blot was redecorated with anti-Calnexin antibody (lower blot) as 
loading control.
Similar observations were made when GnT-V was over-expressed in HEK293 cells 
(Fig. 4.24a & b). Interestingly, unlike endogenous GnT-V, exogenously expressed GnT-V was 
detected as a double band in lysates of  transfected cells. Enzymatic deglycosylation revealed 
that, whereas the upper GnT-V band was resistant to Endo H treatment, the lower molecular 
weight GnT-V band was Endo H sensitive (Fig. 4.24c). Hence, this band likely corresponds to 
immature, ER-resident GnT-V that accumulates following its over-expression. In line with this, 
alterations in cellular complex N-glycosylation upon co-expression of  active SPPL3 or SPPL3 
knock-down by RNAi did not affect immature GnT-V, while mature, Endo H-resistant GnT-V was 
subject to such changes (Fig. 4.24a & b). Moreover, co-expression of GnT-V and active SPPL3 
reduced levels of  mature GnT-V in cell lysates and at the same time led to a profound 
accumulation of  sGnT-V in conditioned supernatants (Fig. 4.24a). Over-expression of the 
SPPL3 D200N/D271N mutant, however, was rather associated with slight accumulation of  GnT-
V in cell lysates. At the same time, sGnT-V was still detectable in amounts comparable to those 
secreted by untransfected cells and the SPPL3 D200N/D271N mutant did not alter the 
molecular weight of  GnT-V. In cells that have markedly reduced endogenous SPPL3 due to 
stable expression of a SPPL3-specific shRNA exogenously expressed GnT-V displayed a 
slightly higher molecular weight (Fig. 4.24b). At the same time, sGnT-V levels in the supernatant 
of these cells were reduced, while mature GnT-V accumulated inside the cells compared to cells 
expressing non-targeting or SPPL2a-specific shRNAs. In sum, these observations demonstrate 
that, in HEK293 cells, SPPL3 selectively facilitates shedding of GnT-V and that this depends on 
its proteolytic activity.
! Results! 87
Fig. 4.24: Co-expression of human GnT-V and SPPL3 in HEK293 cells. HEK293 TetR cells were 
transiently transfected with human GnT-V-encoding expression constructs as indicated and conditioned 
cell  culture supernatants and cell  lysates were analysed for GnT-V secretion and expression, 
respectively, by Western blotting. To examine GnT-V processing by exogenously expressed SPPL3 
HEK293 TetR cells were employed that over-express active SPPL3 wild-type (wt) or the active site 
mutant SPPL3 D200N/D271N (DD/NN) (a). In parallel, GnT-V was analysed in cells stably expressing 
non-targeting (ctrl), SPPL3- or SPPL2a-specific  shRNA pools (b). To differentiate between mature GnT-V 
(GnT-Vmat) and immature (GnT-Vim) lysates of transfected cells were subjected to enzymatic 
deglycosylation (c). GnT-Vdeglyc, deglycosylated GnT-V. #, upper blot was redecorated with anti-Calnexin 
antibody (lower blot) as loading control. (Experimental  work presented herein was performed by Ulrike 
Künzel.)
In order to determine whether GnT-V secretion is - as suggested earlier (Nakahara et al, 2006) - 
a proteolytic process, N-terminally Flag- and C-terminally V5-tagged GnT-V (Flag-GnT-V-V5) 
was cloned and expressed in HEK293 cells (Fig. 4.25). In lysates of transfected cells immature 
and mature GnT-V (compare with Fig. 4.24c) were detected using an anti-V5 and an anti-Flag 
antibody as well as an antibody directed against the GnT-V ectodomain (Fig. 4.25), indicating 
that these cellular Flag-GnT-V-V5 species correspond to the full-length protein that had not 
been subject to limited proteolysis. Co-expression of Flag-GnT-V-V5 with SPPL3 led to a 
reduction of  the intracellular mature species as observed earlier with untagged GnT-V. At the 
same time, over-expressed GnT-V was also detected with anti-V5 and anti-GnT-V antibodies in 
conditioned cell culture supernatants. This secreted GnT-V species was much more abundant 
(and had a slightly lower molecular weight) in cells over-expressing active SPPL3. Notably, 
however, sGnT-V generated from Flag-GnT-V-V5 in these cells lacked anti-Flag-reactivity, 
demonstrating that it had been N-terminally truncated.
Finally, to examine whether SPPL3 similarly impacts GnT-V under physiological conditions, 
GnT-V levels in immortalised Sppl3-deficient MEFs were analysed and compared to Sppl3+/+ 
control cells (Fig. 4.26). In the former intracellular GnT-V levels were strongly increased 
compared to wild-type MEFs. Moreover, sGnT-V levels in the conditioned supernatants of 
Sppl3-/- MEFs were substantially reduced, yet sGnT-V was not completely absent from these 
samples. These observations support the notion that SPPL3 facilitates GnT-V secretion under 
physiological conditions.
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Fig. 4.25: Over-expression of epitope-tagged GnT-V in HEK293 cells. HEK293 TetR cells and 
HEK293 TetR cells over-expressing SPPL3 (SPPL3) were stably transfected with human N-terminally 
Flag- and C-terminally V5-tagged GnT-V (Flag-GnT-V-V5)-encoding expression constructs as indicated 
and conditioned cell culture supernatants (right panel) and cell  lysates (left panel) were analysed for GnT-
V secretion and expression, respectively. n.t., not transfected, *, unspecific band. #, upper blot was 
redecorated with anti-Calnexin antibody (lower blot) as loading control. (Experimental  work presented in 
panel a was performed by Ulrike Künzel.)
4.3.5 SPPL3-mediated GnT-V endoproteolysis occurs close to the lipid bilayer boundary
Recent structural studies demonstrated that the active centres of GxGD proteases are 
positioned within the lipid bilayer plane (Hu et al, 2011; Li et al, 2013) and in line with this these 
proteases are expected to cleave their substrates within or close to their respective membrane-
spanning regions. To support that secretion of GnT-V is mediated by the intramembrane-
cleaving activity of  SPPL3, the site(s) at that GnT-V endoproteolysis occurs were determined by 
MALDI-TOF mass spectrometry (Fig. 4.27). To obtain GnT-V-derived peptidic cleavage products 
that can be reliably analysed and identified using this method, a strategy similar to the one 
described in section 4.2.4 was used. A GnT-V-based expression construct, GnT-V NTF, was 
cloned as depicted in Fig. 4.27a. It encodes the V5-tagged N-terminus of GnT-V (comprising aa 
2 to 61 of  human GnT-V) including the predicted TMD (residues 14 to 30 (Shoreibah et al, 
1993)) but lacks most of  GnT-V's ectodomain. At the C-terminus, the protein comprises a Flag 
epitope tag and terminates with an alanine-proline motif (described earlier, see 4.2.4). Hence, it 
allowed for immunoprecipitation of  secreted cleavage products from conditioned supernatants 
of cells expressing GnT-V NTF. These immunoprecipitates were then analysed by mass 
spectrometry.
In immunoprecipitates from conditioned supernatants of GnT-V NTF-transfected HEK293 TetR 
cells and of  non-induced control cells five unique peaks were observed (Fig. 4.27b). Their 
molecular weight corresponded well with the molecular weight of peptides generated by 
endoproteolysis of GnT-V between residues Met 28 and Thr 33 (Fig. 4.27a & c). The most 
prominent peaks corresponded to peptides commencing with Leu 29 and His 31, respectively, 
whereas only minor amounts of the three additional peptides (commencing with Leu 30, Phe 32 
and Thr 33, respectively) were observed. These peaks were not detected in immunoprecipitates 
from supernatant of non-transfected cells proving that they are genuine cleavage products of 
GnT-V NTF. While co-expression of the inactive SPPL3 mutant did not affect the peak 
intensities, all five cleavage products appeared to be more abundant in supernatants collected 
from cells over-expressing SPPL3 wild-type (Fig. 4.27b). The peptide-to-peptide ratios, 
however, remained largely unaltered. Notably, the detected peptides originate in a stretch of 
GnT-V that is predicted to lie at the interface of  the lipid bilayer and the lumenal or extracellular 
space (Fig. 27a). These cleavage sites are likely not accessible to conventional proteases and it 
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Fig. 4.26: Secretion of endogenous GnT-V in Sppl3-deficient MEFs. Levels of endogenous GnT-V in 
TCA-precipitated conditioned supernatants (sGnT-V) and in whole-cell  lysates (GnT-V) of Sppl3-deficient 
(-/-) and wild-type (+/+) MEFs were analysed by Western blotting.
is therefore well conceivable that cleavage is mediated by an I-CLiP. Hence, the identification of 
the GnT-V cleavage sites at the TMD boundary strongly corroborates that the five peptides 
observed constitute cleavage products generated by GnT-V endoproteolysis mediated directly 
by SPPL3.
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Fig. 4.27: Identification of GnT-V cleavage sites. (a) Schematic overview of GnT-V NTF. The encoded 
protein is tagged with a V5 epitope tag following its initiator methionine. It comprises amino acids 2 to 61 
of the human GnT-V protein including its predicted TMD (grey background sketch). TMD prediction is 
based on the Uniprot annotation of human GnT-V (entry Q09328, version 119, May 14, 2014). A C-
terminal Ala-Pro motif suppresses degradation by carboxypeptidases and the Flag tag allows for affinity 
purification of cleavage products from cell  culture supernatants. Peptides detected experimentally are 
labelled with coloured arrowheads as in b and c. (b) Analysis of Flag immunoprecipitates by MALDI-TOF 
mass spectrometry. anti-Flag immunoprecipitates from conditioned supernatants of HEK293 cells (left) as 
well as cells over-expressing SPPL3 wild-type (wt, middle) or D200N/D271N (DD/NN, right) upon 
doxycycline induction (induced) were analysed by mass spectrometry using the ACTH 7 to 38 peptide as 
reference. Unique peaks are labelled with coloured arrowheads. (c) Peak assignment. Peaks observed 
and labelled in b are assigned to GnT-V NTF-derived peptides according to their observed mass (obs. 
mass). Peaks are colour-coded and correspond to arrowheads in a and b. calc. mass, calculated mass. 
(d) Expression control of transfected GnT-V NTF and doxycycline (Dox)-induced SPPL3 over-expression. 
Cells lysates were analysed by SDS-PAGE and Western blotting. Calnexin was used as loading control. 
(Mass spectrometry measurement of samples used here was performed by Dr. Akio Fukumori.)
4.3.6 GnT-V is not a γ-secretase substrate
An earlier study reported that secreted GnT-V is generated by γ-secretase-mediated 
intramembrane cleavage (Nakahara et al, 2006). This, however, is incompatible with the 
apparent selectivity of γ-secretase for type I transmembrane protein substrates (Haapasalo & 
Kovacs, 2011) and also contrasts with the findings presented here (see 4.3.4 & 4.3.5). To 
validate those previous observations, HEK293 TetR cells were treated with two structurally 
distinct GSIs and secretion of endogenous GnT-V was monitored (Fig. 4.28a). At the same time, 
proteolytic processing of endogenous APP by γ-secretase was analysed to ensure that inhibitor 
treatment was effective. At a final concentration of 10 µM, DAPT potently inhibited APP 
intramembrane proteolysis resulting in a strong decrease in Aβ secretion and a concomitant 
accumulation of  APP CTFs (Fig. 4.28a, lower panels), while APP full-length levels were 
unaffected. The effect of DAPT on APP intramembrane proteolysis was clearly concentration-
dependent and at a concentration of  0.1 µM DAPT treatment did not results in APP CTF 
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Fig. 4.28: Impact of loss of γ-secretase activity on GnT-V secretion and on cellular N-
glycosylation. (a) Pharmacological inhibition of γ-secretase activity. HEK293 TetR cells were treated with 
indicated concentrations of DAPT, L-685,458 or with vehicle only (DMSO). Levels of secreted GnT-V 
(sGnT-V) in conditioned supernatants and cellular GnT-V in whole-cell lysates were analysed by Western 
blotting. To control for efficient inhibition of cellular γ-secretase activity, APP processing was analysed. To 
this end, Aβ was immunoprecipitated from conditioned supernatants. Levels of full-length APP and APP 
C-terminal fragments (CTF) were examined in cell lysates. (b) Electrophoretic  mobility of endogenous 
glycoproteins was assessed by SDS-PAGE and Western blotting in lysates of PS1/PS2-deficient (-/-) and 
Sppl3-deficient (-/-) MEFs and the respective wild-type controls (+/+). PS1/PS1-deficient MEFs lack PS1 
N-terminal fragments (NTF) and mature Nicastrin. (c) GnT-V levels in TCA-precipitated conditioned 
supernatants and lysates of PS1/PS2-deficient cells. Samples used in (c) were the same used in (b), 
hence see (b) for presenilin expression controls. #, upper blot was redecorated with anti-Calnexin 
antibody (lower blot) as loading control.
accumulation and Aβ production was even stronger than in vehicle-treated cells, an effect that 
has already been previously observed for a number of GSIs (discussed in (Shen & Kelleher, 
2007)). L-685,458 inhibited APP processing in a similar fashion, yet was not as potent an 
inhibitor as DAPT (Fig. 4.28a). Importantly, neither compound had a strong and concentration-
dependent effect on secretion of  endogenous GnT-V as both levels of cellular and sGnT-V were 
not markedly altered following inhibitor treatment (Fig. 4.28a, top panels). Assuming that γ-
secretase endoproteolysed GnT-V, resulting in its premature secretion and, thus, interfering with 
its cellular function as postulated (Nakahara et al, 2006), it had to be expected that loss of γ-
secretase activity leads to an intracellular accumulation of GnT-V and, hence, a 
hyperglycosylation in γ-secretase-deficient cells. To test this, electrophoretic mobility of 
endogenous glycoproteins in PS1/PS2-deficient MEFs that lack γ-secretase activity (Herreman 
et al, 2003) was analysed by SDS-PAGE and Western blotting and directly compared to Sppl3-/- 
MEFs (Fig. 4.28b). As observed before (Fig. 4.16), Sppl3-deficient MEFs presented with an 
hypoglycosylation phenotype that became apparent when analysing the running behaviour of 
NCTmat, N-cadherin and Lamp2 (Fig. 4.28b). In contrast, loss of γ-secretase activity was not 
associated with such an effect in PS1/PS2-deficient MEFs (Fig. 4.28b), arguing against GnT-V 
secretion being mediated by the γ-secretase complex. To finally exclude any direct effect of γ-
secretase on GnT-V secretion, GnT-V levels in lysates and conditioned supernatants of PS1/
PS2-deficient and wild-type control MEFs were analysed (Fig. 4.28c). Contrasting starkly with 
the results reported by Nakahara et al. (Nakahara et al, 2006), substantial amounts of GnT-V 
were secreted from PS1/PS2-/- cells. Sppl3-deficiency in MEFs, however, was associated with 
almost complete loss of GnT-V secretion (Fig. 4.26). Collectively, these observations clearly 
disprove the assumption that γ-secretase facilitates GnT-V secretion.
4.3.7 SPPL3 modulates cellular GnT-V activity
The above presented experimental evidence substantiates that SPPL3 facilitates GnT-V 
secretion in a manner that relies on its proteolytic activity. Therefore, it was addressed whether 
SPPL3-induced alterations in cellular GnT-V levels ultimately lead to changes in cellular GnT-V 
activity and whether this could explain the phenotypic observations made in vivo and in cell 
culture (see 4.3.3). GnT-V is fundamentally required for the production of highly branched 
complex glycans (Sears & Wong, 1998; Schachter, 1991; Dennis et al, 2002; Stanley et al, 
2009). More specifically, GnT-V catalyses the β1,6-glycosidic addition of GlcNAc to the α1,6-
linked core mannose residue of N-glycans (Cummings et al, 1982). To directly assess whether 
glycoproteins synthesised in cells over-expressing active SPPL3 exhibit any alterations in the 
abundance of glycan structures formed by GnT-V activity, the leucoagglutinin PHA-L, a plant 
lectin from Phaseolus vulgaris, was used to analyse N-glycans. PHA-L preferentially binds the 
Galβ1,4GlcNAcβ1,6[Galβ1,4GlcNAcβ1,2]Man moiety in complex N-glycans (Cummings & 
Kornfeld, 1982). Thus, its binding motif contains the GlcNAcβ1,6Man product of GnT-V activity, 
and cell lines that lack normal GnT-V activity are resistant to PHA-L-mediated agglutination 
(Cummings et al, 1982; Stanley et al, 1975; Chaney et al, 1989). Nicastrin N-glycosylation was 
analysed following its immunoprecipitation from HEK293 cell lysates by Western and lectin 
blotting (Fig. 4.29). As control, hybrid and complex N-glycosylation was blocked by kifunensine 
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treatment. As expected, kifunensine treatment interfered with Nicastrin maturation and hardly 
any NCTmat was observed in the anti-Nicastrin Western blot of these immunoprecipitates. 
Nicastrin maturation was likewise affected by SPPL3 over-expression which led to a reduction 
in the molecular weight of NCTmat. Analysis of immunoprecipitated Nicastrin by lectin staining 
revealed that PHA-L preferentially bound complexly glycosylated NCTmat and only exhibited 
weak reactivity towards NCTimmat. As expected, PHA-L reactivity was markedly reduced in cells 
treated with kifunensine. Interestingly, in cells expressing exogenous active SPPL3, PHA-L 
reactivity was also reduced supporting the notion that SPPL3 promotes GnT-V release and thus 
interferes with the generation of  GlcNAcβ1,6[GlcNAcβ1,4]Man-modified glycans. To test 
whether alterations in lectin binding observed are specific for PHA-L, reactivity of Nicastrin 
glycans with Concanavalin A (Con A) was monitored in parallel. Con A has broad reactivity 
towards mannose-containing glycans and binds high mannose glycans with high affinity, while 
complex and hybrid glycans can also be bound yet with lower affinity (Cummings & Etzler, 
2009). SPPL3 over-expression failed to interfere with Con A binding. Taken together, enhanced 
GnT-V secretion facilitated by SPPL3 over-expression results in decreased cellular GnT-V 
activity and, thus, alters the composition of cellular complex glycans.
4.3.8 Impact of SPPL3 on cellular N-glycosylation is not solely due to effects on GnT-V
As SPPL3 impacts cellular GnT-V activity (Fig. 4.29), it is conceivable that the alterations in 
cellular N-glycosylation observed upon exogenous expression of  proteolytically active SPPL3 
are due to SPPL3-mediated endoproteolysis of  GnT-V (Fig. 4.19), since impaired intracellular 
GnT-V activity and consequently a less extensive GlcNAc branching associated with SPPL3 
over-expression (Fig. 4.29) could explain the hypoglycosylation phenotype observed following 
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Fig. 4.29: Analysis of lectin binding to Nicastrin from cells over-expressing SPPL3. Endogenous 
Nicastrin was immunoprecipitated (IP) from lysates of either non-transfected HEK293 TetR cells or 
HEK293 TetR cells stably expressing SPPL3 wild-type upon doxycycline treatment (+ Dox). 
Immunoprecipitates were probed using an anti-Nicastrin mAb (first panel) or the lectins ConA (second 
panel) and PHA-L (third panel), respectively. To control for SPPL3 over-expression, lysates were directly 
analysed by Western blotting (bottommost panels). Kifunensine treatment (+ KF) was used to control  for 
lectin binding specificity.
SPPL3 over-expression (Fig. 4.20). Assuming that SPPL3-induced alterations in N-glycosylation 
exclusively depend on proteolytic processing of  GnT-V, SPPL3 over-expression should 
phenocopy the alterations in N-glycosylation associated with loss of  cellular MGAT5 expression. 
As expected, GnT-V expression levels were reduced in HEK293 cells transiently transfected 
with a siRNA pool targeting MGAT5 (Fig. 4.30). This came along with alterations in glycoprotein 
running behaviour. More precisely, NCTmat, N-cadherin, SPPL2a and Lamp2 had a slightly lower 
molecular weight in these cells compared to cells transfected with non-targeting siRNAs 
(Fig. 4.30), indicating a less pronounced N-glycosylation or hypoglycosylation that most likely is 
due to impaired GlcNAc branching. As observed earlier, SPPL3 over-expression similarly shifted 
endogenous glycoproteins to a lower molecular weight (Fig. 4.30). Importantly, however, the 
molecular weight alteration was much stronger in cells over-expressing SPPL3 than in cells 
transfected with MGAT5-specific siRNAs, even though low  GnT-V expression levels were still 
apparent in the former. This clearly shows that SPPL3 over-expression does not phenocopy the 
MGAT5 knock-down situation in HEK293 cells and that SPPL3 over-expression results in glycan 
structure alterations that are not restricted to mere GlcNAc branching. This suggests that 
SPPL3 may also affect other enzymes involved in cellular N-glycan biosynthesis, e.g. other GTs 
or GMEs apart from GnT-V.
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Fig. 4.30: Comparison of alterations in cellular N-glycosylation caused by SPPL3 over-expression 
and MGAT5 siRNA transfection. Endogenous cellular glycoproteins (left panels) were analysed by 
SDS-PAGE and Western blotting in lysates of HEK293 TetR cells transiently transfected with siRNA pools 
(20 µM each) directed against SPPL3 and MGAT5, respectively, and of cells that over-expressed SPPL3 
following induction with doxycycline (+ Dox). In parallel, SPPL3 and GnT-V expression levels were 
monitored (right panels). Note that, even though residual  GnT-V expression is higher following SPPL3 
over-expression, the alteration in glycoprotein running behaviour is more pronounced in this condition 
than in cells transfected with MGAT5 siRNAs.
4.3.9 SPPL3 facilitates β3GnT1 and β4GalT1 secretion
β1,3 N-acetylglucosaminyltransferase 1 (β3GnT1, gene name: B3GNT1) catalyses the 
formation of a β1,3 bond between a GlcNAc and a galactose residue, the latter being within a 
Galβ1,4GlcNAc motif, a motif frequently found on N-glycans (Sasaki et al, 1997). In HEK293 
TetR cells, alterations in SPPL3 expression levels affected intracellular β3GnT1 levels as well 
as the secretion of soluble β3GnT1 (sβ3GnT1) in a manner that is reminiscent of SPPL3's 
effects on GnT-V levels and GnT-V secretion. Endogenous β3GnT1 was detected as a roughly 
55 kDa protein in cell lysates of HEK293 TetR cells (Fig. 4.31a). In addition, sβ3GnT1 was 
detected in TCA-precipitated conditioned cell culture supernatants. Signals for both protein 
species were diminished following transient transfection of a B3GNT1-targeting siRNA pool 
indicating that the mAb employed specifically detected β3GnT1. Following SPPL3 knock-down, 
intracellular β3GnT1 accumulated substantially and less sβ3GnT1 was secreted. Over-
expression of catalytically active SPPL3 reduced intracellular β3GnT1 levels but sβ3GnT1 was 
only slightly more abundant in the supernatant of SPPL3 over-expressing cells compared to 
non-induced control cells. β3GnT1 bears two potential N-glycosylation sites (Sasaki et al, 1997) 
and, as a Golgi-resident enzyme (Buysse et al, 2013), it is likely complexly glycosylated itself, 
and, accordingly, in addition to changes in β3GnT1 levels, alterations in SPPL3 expression were 
accompanied with slight changes in β3GnT1 running behaviour (Fig. 4.31a). SPPL3 knock-
down, for instance, resulted in β3GnT1 hyperglycosylation whereas SPPL3 over-expression 
was accompanied by a hypoglycosylation of sβ3GnT1. Next, β3GnT1 levels in Sppl3-/- MEFs 
were analysed (Fig. 4.31b). β3GnT1 was more abundant in MEFs deficient in Sppl3 than in 
control Sppl3+/+ cells. This suggests that β3GnT1 secretion is reduced in Sppl3-/- MEFs due to 
the lack of  the protease facilitating its proteolysis and hence the intact holoprotein accumulates. 
sβ3GnT1 could however not be detected in TCA-precipitated supernatants of  these cells and 
accordingly it could not be directly examined whether impaired β3GnT1 in fact accounts for its 
intracellular accumulation.
In a manner similar to GnT-V and β3GnT1, secretion of β1,4 galactosyltransferase 1 (β4GalT1, 
gene name: B4GALT1), another Golgi GT, in HEK293 TetR cells was also affected by SPPL3 
(Fig. 4.31c). In immunoblots of  TCA-precipitated conditioned cell culture supernatants of 
HEK293 cells, an antiserum specifically detected constitutively secreted β4GalT1 (sβ4GalT1) 
which was absent from supernatants of cells transfected with B4GALT1-targeting siRNA. 
SPPL3 knockdown led to a marked reduction in β4GalT1 secretion. In contrast, SPPL3 over-
expression did not alter sβ4GalT1 levels but sβ4GalT1 was shifted to a slightly lower molecular 
weight, hence also sβ4GalT1 was hypoglycosylated under these conditions. SPPL3 also 
affected intracellular β4GalT1 protein levels as assessed by immunoblotting of cell lysates 
(Fig. 4.31c). Transfection of  SPPL3-targeting siRNAs resulted in an accumulation of intracellular 
β4GalT1 and at the same time β4GalT1 displayed signs of  hyperglycosylation as it exhibited a 
slightly lower electrophoretic mobility than β4GalT1 in control cells. Moreover, SPPL3 over-
expression was accompanied by a pronounced reduction in intracellular β4GalT1 levels. Finally, 
β4GalT1 levels were examined in Sppl3-/- MEFs (Fig. 4.31c). Also in wild-type MEFs sβ4GalT1 
was readily detectable in Western blots of  TCA-precipitated supernatants. In cells lacking intact 
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Sppl3, however, generation of  sβ4GalT1 was almost completely abolished and at the same time 
the β4GalT1 holoprotein was found to be more abundant in lysates of these cells compared to 
wild-type control cells.
Collectively, the Golgi GTs β3GnT1 and β4GalT1 behaved essentially identically to GnT-V as 
their secretion was also impaired following SPPL3 knock-down or Sppl3 knock-out and their 
intracellular levels were reduced following SPPL3 over-expression, suggesting that both GTs 
are likely additional novel SPPL3 substrates.
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Fig. 4.31: Analysis of β3GnT1 and β4GalT1 secretion in cells lacking or over-expressing SPPL3. 
(a) β3GnT1 secretion was monitored in HEK293 cells. HEK293 TetR cells were transfected with siRNA 
pools targeting B3GNT1 or SPPL3 (20 nM each). In addition, a non-targeting siRNA pool was used as 
control  (CTRL). In parallel, SPPL3 over-expression was induced by doxycycline treatment (+ Dox) in 
stably transfected cells. Levels of secreted β3GnT1 (sβ3GnT1) in the TCA-precipitated conditioned 
supernatant and of β3GnT1 in whole-cell lysates were analysed by SDS-PAGE and Western blotting. 
SPPL3 expression levels were likewise documented. (b) β3GnT1 levels in Sppl3-deficient MEFs. β3GnT1 
and SPPL3 protein expression were examined in lysates of Sppl3-deficient (-/-) and wild-type control (+/
+) MEFs. (c) β4GalT1 secretion was monitored in HEK293 cells. Similar to the experiment depicted in (a), 
levels of secreted (sβ4GalT1) were analysed in TCA-precipitated conditioned supernatants and in whole 
cell  lysates of cells transfected with non-, B4GALT1- or SPPL3-targeting siRNA pools (20 nM each) or of 
cells that over-expressed SPPL3. (d) Levels of secreted and intracellular β4GalT1 in Sppl3-deficient 
MEFs. TCA-precipitated supernatants and whole cell lysates of Sppl3-/- and wild-type control MEFs were 
probed for β4GalT1 by Western blotting. In all experiments calnexin was used as loading control.
4.4 SPPL3 facilitates secretion of type II membrane protein ectodomains
FVenv was identified as the first SPPL3 substrate (see 4.1) and it was subsequently found that 
SPPL3-mediated intramembrane cleavage of  FVenv is independent of prior membrane-proximal 
pre-cleavage or shedding (see 4.2.1). In light of these observations it is postulated that SPPL3 
in fact could act on full-length protein substrates and, thus would facilitate proteolytic release or 
shedding of  type II membrane protein ectodomains. This hypothesis receives strong support 
from the finding that SPPL3 facilitates proteolytic secretion of GnT-V and β3GnT1 (see 4.3.4) 
under physiological conditions. To further corroborate these findings a proteome-wide analysis 
was performed to define the SPPL3 degradome in more detail.
4.4.1 SPECS analysis identifies new potential SPPL3 substrates 
Numerous - though not all - secreted proteins are glycoproteins and are post-translationally 
modified by de novo assembled N- and O-glycans (see 1.6). The cellular secretome comprises 
proteins that are either directly synthesised as soluble lumenal factors and are subsequently 
secreted by exocytosis or, alternatively, proteins that are derived from membrane-anchored pre-
proteins subjected to proteolytic processing. One major challenge when analysing secretomes 
of cultured cells is to differentiate between de novo synthesised cell-derived factors and 
exogenously added, serum-derived protein factors and to enrich for the former. Kuhn et al. 
successfully achieved this by developing a technique termed secretome protein enrichment with 
click sugars (SPECS, Fig. 4.32) (Kuhn et al, 2012). In brief, the authors supplemented media 
with tetraacetyl-N-azidoacetyl-mannosamine (ManAz). This compound is cell-permeable and is 
intracellularly converted into an azido-modified sialic acid derivative. This, in turn, is 
incorporated terminally into N- and O-glycans on de novo synthesised and secreted proteins 
and allows for selective biotin-labelling of such proteins by means of copper-free click chemistry. 
Biotin-conjugated de novo synthesised glycoproteins are then purified from cell culture 
supernatants and subsequently analysed by quantitative mass spectrometry (Fig. 4.32).
Here, this technique was employed to analyse and compare secretomes of  HEK293 that 
express active human SPPL3 upon induction with doxycycline and of  non-induced control cells 
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Fig. 4.32: SPECS workflow. Cell  culture media are supplemented with peracetylated N-azidoacetyl 
mannosamine (ManAz). Due to its peracetylation, this compound is membrane permeable, is 
deacetylated by intracellular esterases and enzymatically converted into an N-azidoacetyl neuraminic 
acid (azido-Neu5Ac) (step 1). This, in turn, is incorporated terminally into glycans (red circles) on de novo 
synthesised secreted proteins by cellular sialyltransferases (step 2). Using click chemistry, azido-labelled 
secreted glycoproteins are conjugated to alkyne-linked biotin and can be purified using streptavidin 
beads. Proteins purified in this manner are subjected to quantitative mass spectrometry (step 3).
(Fig. 4.33). One important consideration has to be taken into account when applying this 
method to this setup, though. Experiments presented in sections 4.3.2 & 4.3.3 demonstrated 
that SPPL3 over-expression interferes with cellular N-glycosylation due to its effects on the 
cellular activity of  certain Golgi GTs implicated in N-glycosylation. Therefore, SPPL3 over-
expression indirectly leads to alterations, for example in the extent of  N-glycan GlcNAc 
branching. This could theoretically result in reduction of  terminal N-glycan sialylation. Therefore, 
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Fig. 4.33: SPECS analysis of HEK293 cells over-expressing active SPPL3. HEK293 TetR SPPL3 
wild-type cells were either pre-treated with doxycycline to induce SPPL3 over-expression or left 
untreated. Labelling was performed by supplementing cell culture media with 50 µM ManAz for 48 h and 
samples were subjected to the SPECS workflow. Data are represented in a volcano plot. The y-axis 
shows the negative decadic logarithm of the p-values for five biological replicates (two-tailed t-test, 
unequal variance). The relative abundance of respective secreted proteins in cells over-expressing 
SPPL3 compared to control  cells is plotted on the x-axis (binary logarithm of fold change). Green dots 
represent proteins that are more abundantly secreted following SPPL3 over-expression whereas red dots 
highlight proteins that are secreted less following SPPL3 over-expression. Gene names are given for 
selected proteins. (Data depicted in this figure were obtained in close collaboration with Dr. Peer-Hendrik 
Kuhn, DZNE Munich.)
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Tab. 4.2: Candidate SPPL3 substrates identified in HEK293 cells over-expressing active SPPL3 
using SPECS. This table lists all  proteins that were significantly more secreted in doxycycline-induced 
HEK293 TetR SPPL3 wt cells compared to non-induced control  cells. Gene names and Uniprot IDs are 
given for the human orthologues. Topology entries are given based on Uniprot annotations or - indicated 
by an asterisks - by topology predictions, e.g. using Phobius (http://phobius.sbc.su.se). (Data 
summarised in this table were obtained in close collaboration with Dr. Peer-Hendrik Kuhn, DZNE 
Munich.)
gene 
name
Uniprot 
ID
protein name topology fold 
change
p-value
GGT7 Q9UJ14 γ-glutamyltransferase 7 II 317.43 1.799 x 10-2
ASPH Q12797 Aspartyl/asparaginyl β-hydroxylase II 287.58 3.226 x 10-3
TOR1AIP1 Q5JTV8 Torsin-1A-interacting protein 1 II* 134.34 2.112 x 10-2
EXTL3 O43909 Exostosin-like 3 II 26.56 1.971 x 10-4
ITFG3 Q9H0X4 Protein ITFG3 II 12.89 3.611 x 10-3
ATP1B1 P05026 Na+/K+-transporting ATPase subunit β-1 II 9.93 7.917 x 10-3
CKAP4 Q07065 Cytoskeleton-associated protein 4 II 9.82 3.487 x 10-2
SGK196 Q9H5K3 Probable inactive protein kinase-like protein SgK196 II 7.35 3.314 x 10-3
MAN1B1 Q9UKM7 ER mannosyl-oligosaccharide 1,2-α-mannosidase II 6.99 5.714 x 10-3
GLG1 Q92896 Golgi apparatus protein 1 I 5.09 3.271 x 10-2
HS6ST2 Q96MM7 Heparan-sulfate 6-O-sulfotransferase 2 II 5.05 2.870 x 10-3
B4GALT7 Q9UBV7 β1,4-galactosyltransferase 7 II 5.00 4.909 x 10-6
NHLRC3 Q5JS37 NHL repeat-containing protein 3 secreted 4.96 3.996 x 10-3
OGFOD3 Q6PK18 2-oxoglutarate and iron-dependent oxygenase 
domain-containing protein 3
II 4.30 1.858 x 10-4
B3GALT6 Q96L58 β1,3-galactosyltransferase 6 II 3.92 3.708 x 10-3
XYLT2 Q9H1B5 Xylosyltransferase 2 II 3.84 1.866 x 10-2
GAA P10253 Lysosomal α-glucosidase II* 3.53 5.893 x 10-3
CHST10 O43529 Carbohydrate sulfotransferase 10 II 3.43 3.485 x 10-2
MAN2A2 P49641 α-mannosidase 2x II 3.18 1.652 x 10-2
ST3GAL6 Q9Y274 Type 2 lactosamine α2,3-sialyltransferase II 3.08 1.083 x 10-2
NDST1 P52848 Bifunctional heparan sulfate N-deacetylase/N-
sulfotransferase 1
II 3.05 1.751 x 10-4
ECE1 P42892 Endothelin-converting enzyme 1 II 2.76 5.670 x 10-3
ENTPD6 O75354 Ectonucleoside triphosphate diphosphohydrolase 6 II 2.71 1.198 x 10-2
QPCTL Q9NXS2 Glutaminyl-peptide cyclotransferase-like protein II* 2.51 3.617 x 10-2
VCAN P13611 Versican core protein secreted 2.38 5.571 x 10-3
MGAT1 P26572 α1,3-mannosyl-glycoprotein 2-β-N-
acetylglucosaminyltransferase
II 2.38 4.638 x 10-2
NDST2 P52849 Bifunctional heparan sulfate N-deacetylase/N-
sulfotransferase 2
II 1.90 5.394 x 10-2
click sugar labelling could potentially suffer from poor efficiency in cells over-expressing SPPL3 
compared to control cells, making absolute quantification of differences in secretomes 
impossible.
Results from five independent experiments are depicted in Fig. 4.33. The abundance of 
numerous proteins detected in conditioned supernatants from HEK293 cells was found to be 
altered significantly following over-expression of catalytically active SPPL3 (red and green dots 
in Fig. 4.33). Importantly, in most cases secretion of  proteins was found to be reduced following 
SPPL3 over-expression. While it can presently be not completely ruled out that this is due to 
inhibitory effects of SPPL3 on secretion of these protein factors, this apparent reduction in 
secretion is most likely due to a reduced efficacy of  azido-sialic acid labelling and not due to a 
genuine reduction in protein secretion (see above). In contrast, a selected number of other 
proteins were found to be more abundant in conditioned supernatants of  HEK293 TetR cells 
over-expressing SPPL3 than in conditioned supernatants of control cells (Fig. 4.33). A total 
number of 27 proteins were reliably (p < 5.4 x 10-2) observed to be > 1.9 fold more abundant in 
supernatants of  cells over-expressing SPPL3 (Tab. 4.2 and green dots in Fig. 4.33). The 
increase in secretion of  these hits following SPPL3 over-expression, however, was rather 
variable. Some proteins, for instance γ-glutaminyltransferase 7 and aspartyl-/asparaginyl β-
hydroxylase, were > 250-fold more abundant in conditioned supernatants in cells that over-
express SPPL3 than in control cells, while most other hits were only mildly affected and altered 
two- to five-fold (Tab. 4.2). Interestingly, analysis of  candidate substrate hits using the QARIP 
web server (Ivankov et al, 2013) revealed that unique peptides detected experimentally map 
exclusively to extracellular and/or lumenal regions of the hits (Fig. 4.34), indicating that proteins 
detected in the conditioned supernatants had properly been secreted and did not derive from 
dead or damaged cells or other experimental flaws. In addition, these extracellular/lumenal 
peptides are in most cases (25 of  27 hits) derived from annotated (or predicted) transmembrane 
proteins (Fig. 4.35a) and, with a single exception (Golgi apparatus protein 1), are known or 
predicted to display a type II topology (Tab. 4.2 & Fig. 4.35b). Therefore, a total number 24 
novel potential candidate SPPL3 substrates could be identified.
Where available, additional GO information suggests that the majority of  these type II 
transmembrane proteins localises to Golgi membranes, the ER, and/or the plasma membrane 
(Fig. 4.35c). From a functional perspective, hits include proteins implicated in quite diverse 
cellular processes, such as enzymes involved in glutathione metabolism like γ-
glutaminyltransferase 7, the bifunctional Ca2+ sensor aspartyl-/asparaginyl β-hydroxylase, the 
metalloprotease endothelin-converting enzyme 1 that generates the vasoconstrictive peptide 
hormone endothelin 1, the β-1 subunit of  the cell surface Na+/K+ ATPase that regulates the 
number of  active Na+/K+ ATPase at the cell surface, and several others. Strikingly, however, the 
majority of candidate SPPL3 substrates identified have GO annotations that link them to 
carbohydrate metabolism and protein glycosylation (Fig. 4.35d). Seven candidates appear to be 
involved in GAG biosynthesis (Fig. 4.35e).
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Fig. 4.34: QARIP analysis of tryptic peptides identified using SPECS. SPPL3 candidate substrates 
(Fig. 4.33 and Tab. 4.2) were analysed using the QARIP web server (Ivankov et al, 2013). Protein 
topology is depicted schematically according to Uniprot annotations or to Phobius predictions as 
indicated. Tryptic peptides detected experimentally are mapped to the respective candidate substrates 
(black bars). Note that exclusively peptides derived from the respective proteins extracellular domains 
were detected. (Data depicted in this figure were obtained in close collaboration with Dr. Peer-Hendrik 
Kuhn, DZNE Munich.)
4.4.2 Validation of selected newly identified candidate SPPL3 substrates
A major caveat of  the method employed to identify novel SPPL3 substrates is that only the 
abundance of  secreted proteins and protein fragments in conditioned cell culture supernatants 
is assessed. Therefore, it needs to be excluded that alterations in the abundance of these 
simply relate back to an altered expression of  the respective gene due to indirect effects of 
SPPL3 over-expression. Hence, all candidate SPPL3 substrates identified here (see 4.4.1) 
require further validation.
To this end, levels of seven candidate SPPL3 substrates in lysates and conditioned 
supernatants were analysed in conditions of  altered SPPL3 expression by Western blotting 
(Fig. 4.36). These included GTs such as the N-acteylglucosaminyltransferase EXTL3 
(Fig. 4.36a), the xylosyltransferase XylT2 (Fig. 4.36b) and the galactosyltransferase β3GalT6 
(Fig. 4.36d) and in addition other GMEs like ER Man I (Fig. 4.36c) and the heparan sulphate 
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Fig. 4.35: Gene ontology (GO) analysis of candidate SPPL3 substrates. GO (a, c to e) and topology 
(b) information deposited in Uniprot for candidate SPPL3 substrates identified in HEK293 cells (see 
Fig. 4.33 and Tab. 4.2 for the hits and the respective entry IDs) are summarised. Subfigures a and c 
contain GO  "cellular_component" terms concerning membrane integrity and localisation in sub-cellular 
membranous compartments, respectively. (b) depicts the distribution of membrane topology among 
candidate substrates. (d) and (e) highlight selected functional annotations regarding glycosylation and 
carbohydrate mechanism in general  and glycosaminoglycan biosynthesis, respectively (GO 
"biological_process").
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Fig. 4.36: Validation of candidate SPPL3 substrates uncovered by the proteome-wide approach. 
Effects of alterations in SPPL3 expression levels on secreted and intracellular levels of EXTL3 (a), XylT2 
(b), ER α-mannosidase I (ER Man I, c), β3GalT6 (d), HS6ST1 (e), HS6ST2 (f) and Sgk196 (g) were 
monitored. HEK293 TetR cells were transfected with siRNA pools targeting SPPL3 or a non-targeting 
control  siRNA pool  (ctrl) (20 nM each). siRNA pools targeting the individual candidate substrates were 
used to test for specificity of the antibodies used for immunoblotting. In parallel, SPPL3 over-expression 
was induced by doxycycline treatment (+ Dox) in stably transfected cells. Levels of secreted protein 
species (sEXTL3, sXylT2, sER Man I, sβ3GalT6, sHS6ST1, sHS6ST2 and sSgk196 respectively) in the 
TCA-precipitated (a and b, d to g) or crude (c) conditioned supernatant and of the respective holoproteins 
in whole-cell lysates were analysed by SDS-PAGE and Western blotting. SPPL3 expression levels were 
similarly analysed. Loaded supernatant samples were normalised to total protein content of cell lysates. 
#, upper blot was redecorated with anti-Calnexin antibody (lower blot) as loading control. **, Sgk196 
fragment(s) of unknown origin.
sulphotransferases HS6ST1 (Fig. 4.36e) and HS6ST2 (Fig. 4.36f) as well as Sgk196 
(Fig. 4.36g). All candidate substrates were detected in lysates and conditioned supernatants of 
HEK293 TetR cells indicating that they are constitutively secreted. Importantly, proteins detected 
were absent when cells had been transfected with siRNA pools targeting the respective mRNA 
(Fig. 4.36a & b, d-g, not shown for ER α-Man I), demonstrating that the ectodomain-specific 
commercial mAbs used for immunoblot detection were specific. For all six candidate substrates 
secreted species were found to be more abundant in supernatants of  cells over-expressing 
active SPPL3 (Fig. 4.36), confirming the previous observations by SPECS and mass 
spectrometry. In addition, siRNA-mediated knockdown of  SPPL3 expression led to reduced 
secretion of EXTL3 (Fig. 4.36a), XylT2 (Fig. 4.36b) and HS6ST1 (Fig. 4.36e). Similar to other 
SPPL3 substrates identified here, intracellular levels of the candidate substrates were likewise 
affected by alterations in SPPL3 expression levels. EXTL3 (Fig. 4.36a), ER Man I (Fig. 4.36b), 
HS6ST1 (Fig. 4.36e) and Sgk196 (Fig. 4.36g) for instance were less abundant in cell lysates 
following SPPL3 over-expression, while ER Man I (Fig. 4.36c), HS6ST1 (Fig. 4.36e) and 
HS6ST2 (Fig. 4.36f) accumulated intracellularly in cells transfected with SPPL3-targeting 
siRNA. For Sgk196 (Fig. 4.36g), protein fragments were specifically detected with a Sgk196-
specific mAb that displayed a slightly lower molecular weight than the holoprotein. Interestingly, 
this fragment was reduced in cells transfected with SPPL3-specific siRNA and remained present 
in SPPL3 over-expressing cells but its nature and its generation is currently unclear.
In sum, this preliminary validation of  a selected number of candidate SPPL3 substrates 
recapitulates the earlier observation that SPPL3 over-expression promotes their secretion. At 
the same time, the reduction of their respective intracellular levels argues in favour of  a SPPL3-
dependent proteolytic secretion of  these candidate substrates. Moreover, in most cases 
secretion and/or intracellular levels of  these candidate substrates were also changed upon 
reduction of cellular SPPL3 activity indicating that their proteolytic secretion proceeds in a 
SPPL3-dependent fashion under physiological conditions. Strikingly, however, these 
observations made here for the candidate substrates identified using the proteomics approach 
contrast with the observations made for e.g. GnT-V (see 4.3.4) in a similar experimental setting. 
Over-expression of SPPL3 for instance reduced intracellular levels of  GnT-V much stronger 
than it did of most of the candidate substrates validated. At the same time, however, secretion of 
endogenous GnT-V was hardly increased following SPPL3 over-expression whereas the 
validated candidate substrate were much more efficiently secreted in cells over-expressing 
proteolytically active SPPL3. This similarly applies to knockdown experiments: Reduced SPPL3 
expression for instance impaired secretion of GnT-V and β3GnT1 and at the same time led to 
an intracellular accumulation of  these GTs. Similar effects were observed for the candidate 
substrates yet they were not as pronounced. Taken together, these experiments support that the 
candidate SPPL3 substrates identified using the proteomics approach are genuine SPPL3 
substrates like e.g. GnT-V, but also indicate that not all SPPL3 substrates in HEK293 cells are 
endoproteolysed in the very same manner.
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 5. Discussion
In 2002, the intramembrane protease SPP and its homologues, the SPPLs, were described for 
the first time (Weihofen et al, 2002; Ponting et al, 2002; Grigorenko et al, 2002). Since then, a 
number of  substrates have been identified that are endoproteolysed by SPP, SPPL2a or 
SPPL2b in vitro or in cultured cells but also in vivo. SPPL3, on the other hand, has not been 
studied in detail. In particular, the physiological function of  SPPL3 has remained unclear and to 
date no physiological substrates have been reported.
Herein, an initial in-depth characterisation of SPPL3 is provided and potential implications of 
these observations are discussed in the following. First, FVenv is identified as the first SPPL3 
substrate (section 5.1) and subsequent detailed analyses of  FVenv's intramembrane proteolytic 
processing by SPPL3 reveal unexpected properties of this protease (section 5.1.5). Second, 
SPPL3 emerges as a cellular type II membrane protein-selective sheddase as a number of 
type II membrane proteins are identified as novel SPPL3 substrates in this study and SPPL3 
appears to facilitate proteolytic secretion of  these substrates' ectodomain (section 5.2). Finally, 
this study reveals that SPPL3 fundamentally affects cellular N-glycosylation by facilitating 
proteolytic shedding of  Golgi GTs and glycosidases (section 5.3.1). In light of  these novel 
insights, SPPL3's potential physiological functions (section 5.3.2) as well as upcoming 
questions (section 5.4. & 5.5) will be discussed.
5.1 Identification of FVenv as the first SPPL3 substrate
Based on the meanwhile strongly challenged (Schrul et al, 2010; Casso et al, 2012) assumption 
of functional redundancy between SPP and SPPL3 (see 1.4.2.2.3), signal peptides were 
examined as potential SPPL3 substrates leading to the identification of  FVenv, more specifically 
its N-terminal LP, as first SPPL3 substrate.
5.1.1 FVenv LP: signal peptide or type III membrane protein signal anchor?
N-terminal signal peptides that ensure proper targeting of nascent secretory and membrane 
proteins to the ER often exhibit no obvious primary sequence homology, but feature a highly 
conserved modular structure with (i) an N-terminal positively charged n-region, variable in 
length, (ii) a central hydrophobic h-region, 7 to 15 aa in length, and (iii) a C-terminal polar c-
region harbouring the signal peptidase cleavage site (Paetzel et al, 2002). In most cases, signal 
peptides are cleaved off the pre-protein co-translationally by signal peptidase (Paetzel et al, 
2002). Most liberated signal peptides are short-lived and will be quickly degraded, but some are 
discussed to be rather stable and to fulfil downstream, so-called post-targeting functions 
(reviewed in (Kapp et al, 2009)). 
The N-terminus of the FVenv pre-protein was initially described as such a conventional - albeit 
rather long - signal peptide and, accordingly, FVenv as a type I membrane protein (Wang & 
Mulligan, 1999; Lindemann et al, 2001). Proteolytic removal of the N-terminus, however, occurs 
post-translationally as full-length FVenv was detected in Western blots with an antiserum 
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directed against the N-terminal LP (Lindemann et al, 2001). Moreover, it has meanwhile been 
established that FVenv LP is an integral component of mature virions and is essential for 
progeny virion egress (Lindemann et al, 2001; Wilk et al, 2001), likely because it physically 
interacts with the viral capsid (Wilk et al, 2001; Geiselhart et al, 2003). Importantly, release of 
LP from full-length FVenv is not - as initially suspected (Wang & Mulligan, 1999; Lindemann et 
al, 2001) - mediated by signal peptidase but instead by furin- or a furin-like PC (Duda et al, 
2004; Geiselhart et al, 2004). In sum, these observations suggest that the term signal peptide is 
misleading and does not adequately apply to FVenv LP. Instead, FVenv should be considered a 
type III membrane protein (Lindemann & Rethwilm, 2011) and LP a genuine FVenv subunit that 
is liberated post-translationally from the holoprotein. The hydrophobic, membrane-spanning 
stretch in FVenv LP thus represents a conventional type II-oriented TMD that at the same time 
acts as a type III signal anchor sequence. Such sequences ensure insertion into the ER 
translocon and anchoring in the membrane (Goder & Spiess, 2001).
5.1.2 FVenv is endoproteolysed by SPPL3 and SPPL2a/SPPL2b
Upon co-expression of  FVenv and active human SPPL3 a FVenv-derived ICD(L3) was detected 
which was absent from cells that co-expressed FVenv and the SPPL3 D271A mutant (Fig. 4.2). 
Moreover, the SPPL3 D271A mutant co-immunoprecipitated FVenv (Fig. 4.6), i.e. FVenv, and 
SPPL3 interact physically. Collectively, these data demonstrate that SPPL3 endoproteolyses 
FVenv and that FVenv is a novel SPPL3 substrate. To date, proteolytic activity of  SPPL3 has 
only been observed using a synthetic peptide based on the bovine prolactin signal peptide 
(Narayanan et al, 2007) or an artificial signal peptide-based fusion protein (Nyborg et al, 2006) 
(discussed in 5.1.5.2). As no epitope tags were introduced into membrane-proximal regions of 
FVenv and epitope-tagging of FVenv did not interfere with its cellular processing and trafficking 
(Fig. 4.1), FVenv represents the first authentic SPPL3 substrate identified. It needs to be 
emphasised, though, that SPPL3-mediated FVenv endoproteolysis was primarily analysed in 
conditions of SPPL3 over-expression.
While proteolysis also occurs in cells that solely harbour endogenous SPPL3 activity (Fig. 4.10) 
and seems to follow  the same basic principle (see 5.1.5), generation of ICD(L3) under such 
conditions is not as efficient as e.g. proteolysis of other newly identified SPPL3 substrates such 
as the GT GnT-V and others. This may well be explained with the differential sub-cellular 
localisation of these proteins. As a primarily ER-resident protein (Fig. 4.1), only a minor fraction 
of FVenv will co-localise with endogenous, likely Golgi-resident SPPL3 and consequently 
ICD(L3) generation is not very efficient. It is, however, conceivable that sub-cellular localisation 
of over-expressed SPPL3 is not as tightly restricted to the Golgi and, hence, under these 
conditions FVenv and SPPL3 may be more likely to meet, explaining the efficient ICD(L3) 
generation under these conditions.
Surprisingly, the data presented here demonstrate that FVenv is also a SPPL2a/SPPL2b 
substrate: Co-expression of FVenv with active SPPL2a or SPPL2b was similarly accompanied 
by endoproteolysis of  FVenv and generation of  ICDL2. Physical interaction of  FVenv LP with an 
inactive SPPL2b mutant was verified by co-immunoprecipitation (Fig. 4.6). ICD(L2) generated 
by either SPPL2a or SPPL2b is likely identical in nature (Fig. 4.4b), suggesting that SPPL2a 
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and SPPL2b endoproteolyse FVenv LP in a similar manner under over-expression conditions. In 
line with this, SPPL2a and SPPL2b both cleave NTFs of TNFα (Friedmann et al, 2006; Fluhrer 
et al, 2006), Bri2 (Martin et al, 2008) and CD74 (Schneppenheim et al, 2014) in a similar 
manner when over-expressed suggesting that under these conditions both protease can 
process the same substrates. In addition, FVenv LP accumulated in cells over-expressing 
catalytically inactive mutants of  SPPL2a or SPPL2b (Fig. 4.3), a phenomenon that had also 
been observed in previous studies for TNFα (Fluhrer et al, 2006; Friedmann et al, 2006) and 
Bri2 (Martin et al, 2008) and, in these studies, has been attributed to a possible dominant-
negative effect of such mutants on the endogenous SPPL2a or SPPL2b pool, respectively. 
Importantly, cleavage products (i.e. ICD and C-peptide species) observed following 
intramembrane proteolysis of FVenv mediated by either SPPL2a/SPPL2b or SPPL3 are not 
identical as they display a different molecular weight (Fig. 4.4b), suggesting that SPPL2a/
SPPL2b and SPPL3 endoproteolyse FVenv at different sites.
The finding that the rather distinct SPP/SPPL family members SPPL2a/SPPL2b and SPPL3 
proteolytically process FVenv within or in the vicinity of  its first, type II-oriented TMD is in fact 
surprising. Presently, no SPPL2a/SPPL2b substrate has been reported that is at the same time 
cleaved by SPPL3. In fact, two studies addressed this experimentally but in cells co-expressing 
SPPL2a and/or SPPL2b substrates with active SPPL3 no ICD generation and/or substrate 
turnover was documented (Martin et al, 2008; Zahn et al, 2013). Furthermore, SPPL3 also fails 
to process another type III membrane protein, the type III splice variant of the EGF-like growth 
factor Neuregulin 1(IIINrg1), that was recently identified as a new  SPPL2a/SPPL2b substrate 
(Fleck et al., unpublished), demonstrating that the proteolytic processing by both SPPL2a/
SPPL2b and SPPL3 is not generally applying for type III membrane proteins.
5.1.3 Implications of FVenv intramembrane proteolysis for the virus life cycle
Compared to other retroviral surface glycoproteins FVenv is unique due to its N-terminal leader 
peptide (Lindemann & Goepfert, 2003) which also plays a fundamental role during virus egress 
(Lindemann & Rethwilm, 2011). Accordingly, cells expressing N-terminally truncated FVenv 
mutants produce substantially less infectious virus particles (Lindemann et al, 2001). Unlike 
their orthoretroviral counterparts, foamy viral gag proteins lack a membrane-targeting signal 
and, hence, fail to induce budding of virus-like particles (Lindemann & Rethwilm, 2011). Instead, 
FVenv LP mediates physical interaction with gag via its N-terminal cytosolic portion and recruits 
viral capsids to the membrane to ensure proper virus assembly and budding (Lindemann et al, 
2001; Wilk et al, 2001; Lindemann & Rethwilm, 2011). Taken together, these observations 
highlight the fundamental role of FVenv LP in the viral life cycle. At the same time, however, it is 
clear that in order to fulfil its function and to recruit viral capsids to the membrane FVenv LP 
must be firmly anchored in the membrane.
Intramembrane proteolysis of a given transmembrane protein substrate may result in the 
generation of soluble products (see 1.4.1.2.2). Therefore, intramembrane proteolysis of FVenv 
LP by SPPL2a/SPPL2b and/or SPPL3 could in principle release the cytosolic LP N-terminus 
from its membrane anchor. Hence, promotion of  FVenv LP intramembrane proteolysis could 
impair gag recruitment (Fig. 5.1), interfere with FV particle egress and, ultimately, restrict FV 
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propagation. Several aspects, however, have to be taken into account when considering such 
potential implications of SPPL-mediated intramembrane proteolysis for the FV life cycle: (i) 
Does FVenv LP intramembrane proteolysis occur under physiological conditions? In HEK293 
cells, generation of ICD(L2) and ICD(L3) produced by SPPL2a/SPPL2b and SPPL3, 
respectively, was readily observed when the respective proteases were over-expressed 
(Fig. 4.2 & 4.3). ICD generation by endogenous protease activity, however, appeared to be 
much less efficient. Therefore, it needs to be investigated whether and to what extent FVenv LP 
is turned over by SPPLs under physiologically conditions. In naturally infected rhesus monkeys 
active virus replication is mainly restricted to superficial epithelial layers of  the oral mucosa 
(Murray et al, 2008). Expression levels of SPPL2a/SPPL2b and SPPL3 in these tissues could 
be analysed and, using antisera directed against the simian FVenv N-terminus (Lindemann et 
al, 2001), FVenv ICD generation could be monitored directly in homogenates of  these tissues in 
infected animals. Assuming that SPPL-mediated endoproteolysis of FVenv interferes with its 
propagation, such permissive host tissues should harbour low  endogenous activity of SPPL2a/
SPPL2b or SPPL3. Up-regulation of their expression may then be expected to suppress virus 
propagation. Similarly, FVs can be propagated in mice (Schmidt et al, 1997) and FV infections 
could be examined in detail in SPPL-deficient or transgenic mouse models. (ii) Are FVenv ICDs 
released from the membrane? It needs to be examined whether FVenv ICDs are released from 
membranes or whether they remain integral to the membrane and are incorporated into virus 
particles like LP in order to assess whether ICDs can still fulfil FVenv LP's function. (iii) Do 
SPPLs interfere with the generation of  FV particles? Ultimately, this question has to be 
addressed experimentally. Using established vector systems (described e.g. in (Trobridge et al, 
2002)), release of  recombinant FV particles could be monitored in HEK293 cells that over-
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Fig. 5.1: FVenv  LP intramembrane proteolysis could interfere with membrane recruitment of gag. 
Under normal conditions (a), cytosolic FV gag (purple) is recruited to the host cell plasma membrane 
(black dashed arrow) by interacting with the membrane-integral FVenv LP (green) and then initiates virion 
assembly and packaging. Assuming that FVenv LP is quantitatively endoproteolysed by either SPPL3 or 
SPPL2a/SPPL2b and that the cleavage product (ICD) is not tightly anchored in the membrane bilayer (b), 
this would impair proper membrane recruitment of gag. FVenv SU, yellow, FVenv TM, red.
express catalytically active SPPL3 or that were transfected with SPPL3-targeting siRNA or 
shRNA.
5.1.4 Signal/leader peptides of other retroviral env proteins 
As discussed in 5.1.1, FVenv LP cannot be considered a conventional signal peptide. 
Interestingly, env proteins of several other retroviruses also have N-terminal signal or leader 
peptides that display unusual characteristics. In contrast to conventional signal peptides, 
retroviruses have evolved signal peptides that appear to exert intricate post-targeting functions 
as they serve important purposes during the viral life cycle. Also, such retroviral signal peptides 
are often cleaved post-translationally. Therefore, it is tempting to speculate that SPP/SPPL 
intramembrane proteases could also be involved in proteolytic processing of these peptides. 
Exemplary retroviral env proteins will be discussed in the following.
The human immunodeficiency virus (HIV) surface glycoprotein precursor gp160 is predicted to 
have an N-terminal signal peptide of approximately 30 aa (Martoglio & Dobberstein, 1998), but 
its length may vary. In contrast to the commonly co-translational removal of N-terminal signal 
sequences from pre-proteins, HIV-1 env's leader peptide is removed post-translationally (Li et 
al, 1994; 2000a; Land et al, 2003) and this process is slow  and inefficient (Martoglio et al, 1997; 
Li et al, 2000a). Moreover, the HIV-1 signal peptide serves purposes beyond protein targeting 
and modulates the association of gp160 with ER chaperones such as calnexin (Li et al, 1996) 
and the folding state of gp160 critically determines whether and when removal of the leader 
peptide occurs (Land et al, 2003). Importantly, while N-terminal HIV-1 gp160 leader peptide 
fragments were released enzymatically from microsomal membranes in vitro (Martoglio et al, 
1997), the exact nature of  the proteases involved in HIV-1 gp160 signal peptide removal and its 
liberation from ER membranes has not been unambiguously determined. 
While the HIV-1 gp160 signal peptide is already exceptionally long for a conventional signal 
sequence, other lentiviral env glycoproteins such as those of ungulate lentiviruses or of the 
feline immunodeficiency virus (FIV) harbour much longer leader peptides. FIV env, for instance, 
comprises a roughly 20 kDa N-terminal leader peptide that includes two hydrophobic stretches 
(Verschoor et al, 1993). This leader peptide is post-translationally removed by an elusive 
proteolytic activity (Verschoor et al, 1993). Small N-terminal truncations of FIV env are well 
tolerated and do not affect the protein synthesis and maturation, but deletion of  most of  env's 
leader peptide led to profoundly impaired protein maturation (Stephens et al, 1992). In sum, FIV 
env proteolytic processing and the nature of its leader peptide resemble that of FVenv. 
However, the exact role of  FIV env's leader peptide in the viral life cycle remains largely 
enigmatic. In addition, several studies report that β-retroviral signal/leader peptides, being 
initially targeted to the ER as part of  the env holoprotein, subsequently translocate to the cytosol 
and/or the nucleus. Examples include the env signal peptides of the human endogenous 
retrovirus HERV-K(HML-2), which is associated with seminoma incidence in young adults 
(Ruggieri et al, 2009), and of  the Jaagsiekte sheep retrovirus (JSRV), a β-retrovirus that causes 
transmissible lung adenocarcinomas in sheep (Caporale et al, 2009). 
Taken together, it is obvious that retroviral signal or leader peptides often display rather unusual 
stability and at the same time possess important, yet also very diverse functions beyond the 
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mere targeting of  nascent proteins to the secretory pathway. In light of  the finding that the 
FVenv leader is subject to SPPL-mediated intramembrane proteolysis (see 5.1.2), other 
retroviral leader peptides could, in principle, also constitute interesting SPPL substrates. 
Whether this in fact is the case remains to be determined.
5.1.5 Analysis of SPPL3-mediated intramembrane proteolysis of FVenv
Having identified the a novel substrate that is endoproteolysed by SPPL3 in a cellular setting 
allowed to examine SPPL3-mediated intramembrane proteolysis in more detail. As FVenv is at 
the same time subject to intramembrane cleavage mediated by SPPL2b, the characteristics of 
these proteases could be directly compared. Key characteristics of  SPPL2b such as its 
substrate requirements (Martin et al, 2009; Fluhrer et al, 2012) and its sensitivity towards 
various small molecule inhibitors (Fluhrer et al, 2006; Friedmann et al, 2006; Martin et al, 2008) 
had already been studied before and, taken together with similar studies on SPP as well as on 
γ-secretase, revealed conserved characteristic features of  mammalian GxGD proteases (see 
1.4.4). Therefore, comparison of  SPPL3- and SPPL2b-mediated intramembrane proteolysis of 
FVenv directly allowed to examine whether the poorly characterised protease SPPL3 likewise 
shares these conserved characteristics.
5.1.5.1 SPPL3 is hardly sensitive to transition state analogue GxGD protease inhibitors
A common and apparently conserved characteristic of GxGD proteases analysed is their 
sensitivity towards active site-directed GSIs and the peptidomimetic (Z-LL)2 ketone (see 
1.4.4.4). SPPL2b-mediated intramembrane proteolysis of  the TNFα NTF and the Bri2 NTF, for 
instance, is impaired following treatment with either (Z-LL)2 ketone or L-685,458 (Fluhrer et al, 
2006; Friedmann et al, 2004; Martin et al, 2008). In line with this, SPPL2b-mediated FVenv 
cleavage was also inhibited in a concentration-dependent manner by both inhibitors (Fig. 4.7a) 
and both compounds inhibited subsequent proteolytic processing of  the SPPL3-specific 
cleavage product ICD(L3) by endogenous SPPL2a/SPPL2b activity (Fig. 4.7b, see 5.1.5.3). In 
contrast, the GSI DAPT failed to impair SPPL2b-mediated processing of FVenv LP as well as 
the SPPL2a-/SPPL2b-dependent processing of  ICD(L3). Similarly, DAPT neither inhibits 
SPPL2b-mediated processing of the Bri2 NTF (Martin et al, 2008) nor SPP activity (Weihofen et 
al, 2003), suggesting that the DAPT binding site, which is not the active site in presenilin 
(Morohashi et al, 2006), is not conserved among GxGD proteases. Taken together the results 
obtained for SPPL2b-mediated processing of  FVenv LP nicely conform with the inhibitor profile 
of SPP/SPPL-type GxGD proteases.
Unexpectedly, SPPL3-dependent production of ICD(L3) from FVenv was inhibited neither by the 
active site-directed inhibitors (Z-LL)2 ketone or L-685,458 nor by DAPT (Fig. 4.7b). In fact, 
ICD(L3) was found to accumulate in a dose-dependent manner following (Z-LL)2 ketone and 
L-685,458 treatment. This, however, appears to be due the inhibition of  endogenous SPPL2a 
and SPPL2b activity resulting in a block of ICD(L3) processing by SPPL2a/SPPL2b (discussed 
in 5.1.5.3). Therefore, in sum, SPPL3 activity on FVenv is not affected by these active site-
directed compounds. 
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While - in light of the conserved GxGD protease inhibitor profile - the inefficacy of DAPT 
treatment to inhibit SPPL3 activity was expected, the lack of  SPPL3 inhibition following (Z-
LL)2 ketone or L-685,458 treatment was not and also contrasts with earlier observations. In the 
assumption that SPPL3 and SPP are to some degree functionally redundant, two studies 
claimed having observed proteolytic activity of SPPL3 towards artificially engineered signal 
peptide-based substrates (Nyborg et al, 2006; Narayanan et al, 2007). Narayanan et al. 
recombinantly expressed the Drosophila orthologue of human SPPL3 in E. coli  and monitored 
activity of solubilised E. coli membranes towards an epitope-tagged reporter substrate based on 
a mutant of the prolactin signal peptide (Narayanan et al, 2007) that had been used before to 
monitor SPP activity (Sato et al, 2006b). They observed proteolytic turn-over of the substrate 
that was impaired following addition of  10 µM (Z-LL)2 ketone (Narayanan et al, 2007). Nyborg et 
al. transiently over-expressed SPPL3 in HEK293T cells and employed a cellular reporter assay 
to monitor intramembrane cleavage (Nyborg et al, 2006). This assay had been developed 
earlier and employs a fusion protein that comprises the membrane-spanning region of the 
cytomegaloviral gpUL40 signal sequence (Nyborg et al, 2004). This signal sequence, however, 
is resistant to SPP-mediated intramembrane proteolysis and only is turned into a SPP substrate 
following mutagenesis (Lemberg & Martoglio, 2002). In cells expressing the mutated reporter 
substrate, Nyborg et al. documented reporter activity that was boosted dose-dependently when 
co-expressing SPPL3 and that was impaired following (Z-LL)2 ketone treatment (Nyborg et al, 
2006). Taken together, both studies suggest that human SPPL3 is sensitive towards (Z-
LL)2 ketone treatment and, hence, contrast with observations presented herein. Notably, FVenv 
is the first "native" SPPL3 substrate identified and the terminal epitope tags introduced to allow 
for detection of cleavage products do not interfere with the protein's normal intracellular 
trafficking and proteolytic processing by pro-protein convertases (Fig. 4.1) and do presumably 
not interfere with intramembrane processing. In contrast, the assay substrate used in the study 
of Narayanan et al. and in particular the fusion protein used by Nyborg et al. are no natural 
SPPL3 substrates and are highly artificial in nature. Therefore, examination of SPPL3 activity by 
means of such substrates may be artefact-prone. Moreover, Narayanan et al. who reported 
proteolytic activity of recombinantly expressed human SPPL3 in E. coli membranes cannot rule 
out that the observed (Z-LL)2 ketone-sensitive proteolytic activity towards the prolactin signal 
peptide substrate is due to an endogenous bacterial protease. Finally, however, it can presently 
not be excluded that the characteristics of SPPL3 are perhaps also dependent on the substrate 
employed to study its proteolytic activity. Therefore, examination of the secretion of the 
numerous new  candidate SPPL3 substrates identified herein (see 5.2) will likely reveal on a 
proteome-wide scale whether SPPL3 is in general not sensitive towards treatment with active 
site GSIs or less sensitive than other GxGD proteases.
Importantly, this is a particularly pressing question considering that GSIs have been developed 
as drug candidates for prevention of AD development and progression (see 1.4.4.4). Cross-
reactivity of these compounds with the SPP/SPPL family members and inhibition of  their 
physiological function(s) may therefore pose a certain risk and may contribute to potential side-
effects of GSI therapy. With that said, the observed lower sensitivity of  SPPL3 towards transition 
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state analogue GSIs may in fact be promising and could suggest that GSI therapy does not 
interfere with SPPL3's physiological function. 
Moreover, the lower sensitivity or possibly insensitivity of  SPPL3 towards substrate-mimicking 
active site-targeting GSIs observed raises the question whether SPPL3's active site architecture 
is fundamentally distinct, e.g. regarding the spatial dimension of peptide side chain 
accommodating pockets, from that of most other mammalian GxGD proteases. L-685,458 and 
(Z-LL)2 ketone are both peptidomimetics, i.e. the more they resembled a natural, physiological 
substrate, the better their binding into the target enzyme's active site would be. Therefore, a 
promising approach to identify inhibitors that would efficiently impair SPPL3 activity could be to 
screen peptidomimetics that display a greater variety in amino acid side chain-mimicking 
moieties or design such compounds according to the cleavage site features of the newly 
identified SPPL3 substrates (see 5.2).
5.1.5.2 SPPL3 cleaves a full-length membrane protein substrate
Another common characteristic of  GxGD proteases is that they can only catalyse 
intramembrane proteolysis of membrane protein substrates with sufficiently shortened 
ectodomains and, in most instances, these particular substrates are cleaved by (an)other 
protease(s) prior to intramembrane cleavage (Struhl & Adachi, 2000; Lemberg & Martoglio, 
2002; Hemming et al, 2008; Martin et al, 2009). FVenv is endoproteolysed in its TMD1-proximal 
region by a furin-like PC (Duda et al, 2004; Geiselhart et al, 2004), leaving behind LP with an 
approximately 40 amino acid lumenal moiety. PC cleavage of FVenv therefore constitutes a 
shedding-like event, the difference from conventional shedding being that the FVenv 
ectodomain (SU-TM) is not released from the cell but remains cell-attached due to its C-terminal 
TMD. To reproduce earlier findings for the SPPL2b substrate Bri2 (Martin et al, 2009), the PC 
cleavage site was mutagenised to abolish generation of LP and SU-TM. Notably, this mutant 
was not endoproteolysed by SPPL2b (Fig. 4.5), which is in good agreement with the data 
obtained by Martin et al. and suggests that the selectivity for substrates with a short ectodomain 
is a general requirement of SPPL2b and not a substrate-specific phenomenon.
Unexpectedly, however, SPPL3-mediated processing of  FVenv was unimpaired when the same 
PC cleavage site mutant was analysed (Fig. 4.5) and, hence, contrasts with the observations 
made for substrates of  SPP (Lemberg & Martoglio, 2002; Boname et al, 2014) and of SPPL2b 
(Martin et al, 2008). A possible explanation is that SPPL3 does not necessarily only accept 
substrates with short lumenal domains but instead readily proteolyses full-length substrates. 
Subsequent experimental data strongly favour this explanation. First, co-immunoprecipitation 
studies revealed that a SPPL3 mutant preferentially associates with FVenv full-length and only 
to a minor extent with FVenv LP, the truncated substrate available in the cell (Fig. 4.6b). 
Second, an additional high molecular weight cleavage product, TMD-SU-TM, was identified that 
is generated together with ICD(L3) when SPPL3 cleaves full-length FVenv (Fig. 4.5). Moreover, 
in light of TMD-SU-TM also being generated in conditions where FVenv LP is available as a 
substrate and in light of  the co-immunoprecipitation results it appears that SPPL3 exhibits 
indeed a preference for the full-length substrate. Finally, SPPL3 was found to facilitate secretion 
of a number of  other full-length substrate proteins (discussed in section 5.2), implying that the 
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processing of a full-length substrate is not specific for FVenv but rather a general feature of 
SPPL3.
It is presently unclear why SPPL3 lacks the preference for substrates with short ectodomains 
that is typical of other mammalian GxGD proteases. In fact, even for the latter the exact 
molecular mechanism underlying the substrate selectivity is enigmatic. An initial study proposed 
that Nicastrin with its large, highly glycosylated lumenal ectodomains functions as a γ-secretase 
substrate receptor by associating with the N-terminus of substrate stubs (Shah et al, 2005). This 
study, however, has subsequently been challenged (Chávez-Gutiérrez et al, 2008). Hence, to 
date no protease-intrinsic domain has been identified to ensure selectivity for substrates with 
truncated ectodomains. It has to be emphasised, though, that SPPL3 is probably the most 
primitive mammalian GxGD protease as its lumenal and cytosolic N- and C-termini, 
respectively, are extremely short as are the internal loops connecting the nine individual TMDs. 
It could therefore lack domains ensuring selectivity for substrates of a particular ectodomain 
size, but this in turn raises the question whether and how  SPPL3 selectivity is regulated 
(see 5.4).
5.1.5.3 SPPL2a/SPPL2b cleave the SPPL3 cleavage product
In-depth analyses of ICD(L3) running behaviour on different gel systems revealed that 
generation of ICD(L3) in cells over-expressing active SPPL3 was accompanied by production of 
a smaller N-terminal fragment (Fig. 4.8). This fragment co-migrated with ICD(L2) generated in 
cells co-expressing SPPL2b and FVenv. Moreover, its generation was substantially impaired in 
cells treated with (Z-LL)2 ketone or L-685,458 or in cells transfected with SPPL2a- and SPPL2b-
specific siRNAs. At the same time ICD(L3) accumulated (Fig. 4.8). ICD(L2) was also observed 
in cells co-expressing SPPL3 and the furin/PC cleavage site mutant of  FVenv (Fig. 4.11). Under 
these conditions, FVenv LP is hardly produced, but SPPL3-expression was still accompanied by 
production of  both species. Therefore, this particular experiment provides evidence that ICD(L2) 
is in fact produced from ICD(L3). Collectively, these data unambiguously show  that, following its 
generation by SPPL3, ICD(L3) can subsequently be processed by SPPL2a and/or SPPL2b.
In the present study a region within the first FVenv TMD in which intramembrane proteolysis 
occurs could be defined by analysis of the C-peptides released (Fig. 4.13). Their production was 
abolished following (Z-LL)2 ketone treatment suggesting that they were generated in a SPPL2a/
SPPL2b-dependent fashion. These C-peptides originate in a region close to the C-terminal, i.e. 
lumenal border of the predicted TMD1 of  FVenv. Since ICD(L3) has a slightly higher molecular 
weight than the ICD(L2) (Fig. 4.4b), it has to be anticipated that endoproteolysis mediated by 
SPPL3 occurs C-terminal to the putative SPPL2b cleavage site. Therefore, it presently cannot 
be excluded that SPPL3 cleaves FVenv C-terminal of its TMD, e.g. in the lumenal 
juxtamembrane region. Importantly, this does not contradict the intramembrane proteolysis 
concept as other I-CLiPs, e.g. the rhomboids, may also cleave substrates outside of their 
membrane-spanning stretches, likely by folding into the membrane-buried active site (Strisovsky 
et al, 2009). Ultimately, however, this requires experimental verification and the exact SPPL3 
cleavage site has to be determined in FVenv.
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The finding that ICD(L3) is subject to proteolytic processing by SPPL2a/SPPL2b is rather 
unexpected as processing of  a GxGD protease cleavage product by another, distinct GxGD 
protease has not been previously reported. Moreover, it raises numerous mechanistic 
questions, in particular how  a given TMD can be subject to endoproteolysis by two distinct 
proteolytic activities and how  the product of the first intramembrane cleavage is efficiently 
recruited as a substrate for the protease(s) catalysing the second cleavage event, in particular 
as these distinct protease are differentially localised within the cell. Assuming SPPL3-mediated 
FVenv endoproteolysis occurs in the C-terminal (i.e. luminal) portion of the TMD (see above), 
ICD(L3) would retain a large degree of hydrophobicity and could therefore remain firmly 
embedded in the lipid bilayer. It may then display mobility due to lateral diffusion in the 
membrane which could in turn allow  ICD(L3) to traffic from from the active site of SPPL3 to the 
respective on in either SPPL2a or SPPL2b. Alternatively, SPPL3 could also interact physically 
with either SPPL2a or SPPL2b which would enable direct delivery from one enzyme to the 
other. The latter model, however, seems less likely in light of the reported differential sub-
cellular localisation of the proteases involved (Krawitz et al, 2005; Friedmann et al, 2006).
5.1.5.4 Comparison of SPPL3 and other intramembrane proteases
Tab. 5.1 summarises the observations made for SPPL3-mediated intramembrane proteolysis of 
FVenv and compares those features to other proteases. As expected, SPPL3 appears to display 
selectivity towards type II transmembrane proteins (see also section 4.4) like other SPP/SPPL 
proteases. Unlike all other mammalian GxGD proteases characterised (i.e. SPP, SPPL2a, 
SPPL2b and the γ-secretase complex), SPPL3 activity seems not to be profoundly impaired by 
treatment with substrate analogous active site-targeting GSIs. In addition, SPPL3 clearly differs 
from other mammalian GxGD protease regarding its ability to endoproteolyse membrane protein 
substrates with intact (and bulky) ectodomains. In sum, significant differences between SPPL3 
and other mammalian GxGD proteases regarding inhibitor sensitivity and substrate 
requirements become evident. Instead, the independence of  substrate truncation is a key 
feature of  the rhomboid I-CLiPs (see 1.3) and thus there seems to be striking similarity of 
rhomboids and SPPL3 in that regard.
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Tab. 5.1: Comparison of SPPL3 with other intramembrane proteases. Results obtained in this study 
are indicated including a reference to respective section. n.a., not applicable; * The strict topological 
selectivity of rhomboids for type I membrane proteins has recently been questioned.
SPPL3 SPP SPPL2b γ-secretase rhomboids
substrate topology type II type II type II type I type I*
sensitivity towards GSIs no (4.2.2) yes yes yes n.a.
substrate truncation required no (4.2.1) yes yes yes no
5.2 SPPL3 facilitates secretion of selected type II membrane proteins
The identification of  FVenv as SPPL3 substrate allowed for the first time to functionally 
characterise SPPL3 and this revealed properties not expected for a mammalian GxGD protease 
(discussed in 5.1.5), most importantly that SPPL3 does not require a shedding-like event that 
tailors its substrate FVenv for intramembrane proteolysis and instead endoproteolyses full-
length FVenv directly (5.1.5.3). This finding led to the hypothesis that SPPL3 could act as 
membrane protein convertase that liberates protein ectodomains from their membrane anchor, 
i.e. acting functionally similar to classical sheddases (see 1.1) or rhomboid I-CLiPs (see 1.3)  
5.2.1 SPPL3 acts as a type II membrane-selective protein convertase or sheddase
The viral protein FVenv is certainly not the only SPPL3 substrate. Instead, in light of SPPL3's 
high degree of evolutionary conservation (Fig. 1.9), it has to be anticipated that there are vital 
cell-intrinsic SPPL3 substrates. Since another type III protein is not endoproteolysed by SPPL3 
(Fleck et al., unpublished) and since multi-pass membrane proteins are generally less abundant 
than single-pass proteins (Almén et al, 2009; Fagerberg et al, 2010), it was hypothesised that 
SPPL3 could similarly endoproteolyse full-length single-pass type II membrane proteins 
(Fig. 5.2). SPPL3-mediated endoproteolysis of  a given type II protein would then result in 
disengagement of the substrate's ectodomain from its membrane anchor and its liberation into 
the Golgi lumen (and possibly into the extracellular space). At the same time SPPL3 cleavage 
produces a membrane-embedded substrate stub which, in analogy to the FVenv ICD(L3), could 
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Fig. 5.2: Hypothetical model of SPPL3 acting as a type II membrane protein-selective sheddase. 
SPPL3-mediated cleavage of a given type II membrane protein substrate in a stretch close to the 
interface of the membrane and the Golgi  lumen could liberate a substrate's ectodomain from its 
membrane anchor. It can subsequently be trafficked intracellularly, secreted or degraded (not depicted). 
The putative TMD cleavage product could remain within the membrane and may potentially be subject to 
downstream intramembrane cleavage by SPPL2a/SPPL2b resulting in the release of indicated cleavage 
products from the membrane.
be subsequently endoproteolysed by SPPL2a or SPPL2b. SPPL3 would then act in a manner 
reminiscent of a classical sheddase (compare with Fig. 1.1) as it facilitates release of a soluble 
ectodomain of  a given substrate and allows for subsequent intramembrane proteolysis 
(Fig. 5.2).
This hypothesis receives strong support from the identification of  several novel (candidate) 
SPPL3 substrates in this study using two distinct approaches, a candidate-based approach (see 
4.3.4 & 4.3.9) and a less biased proteome-wide approach (see 4.4). Obviously, SPPL3 
substrates are expected to (i) adopt a type II topology, (ii) co-localise sub-cellularly with SPPL3, 
and (iii) physically interact with the protease. Regarding the topology, it is well-documented that 
SPP/SPPL I-CLiPs exclusively endoproteolyse membrane protein substrates that adopt a type II 
orientation (Voss et al, 2013) and SPPL3 apparently shares this characteristic as the FVenv N-
terminus also spans the membrane in a type II orientation. In addition, it is obvious that 
protease and substrate have (at least transiently) to co-localise sub-cellularly and to interact 
physically for proteolysis to occur. In view  of this, the results obtained and the (candidate) 
substrates identified will be discussed in the following, while the physiological implications of 
their proteolytic processing by SPPL3 will be subject to in-depth discussion later (section 5.3). 
The finding that FVenv ICD(L3) generated by SPPL3 activity is subsequently also 
endoproteolysed by SPPL2a/SPPL2b (see 5.1.5.4) of course raises the question whether this 
likewise happens to the newly identified candidate SPPL3 substrates (Fig. 5.2). Presently, 
however, this can neither be disproven nor verified as no ICD species have yet been observed 
for these new substrates.
5.2.2 SPPL3 substrates identified by a candidate-based approach
In light of  the observation that alterations in SPPL3 levels in cultured cells and in vivo translate 
into global changes in cellular N-glycosylation (discussed in 5.3.1), Golgi-localised GTs were 
examined as candidate SPPL3 substrates and the experimental data strongly support that 
SPPL3 proteolytically cleaves the GTs GnT-V, β3GnT1 and β4GalT1.
In accordance with an earlier study (Nakahara et al, 2006), secretion of GnT-V was observed to 
be a proteolytic process that leads to N-terminal truncation of  the full-length protein (Fig. 4.25 
& 4.27). In cells lacking endogenous SPPL3 activity, GnT-V secretion is almost completely 
abolished and the full-length protein accumulates intracellularly (Figs. 4.23 & 4.26) which could 
be attributed to impaired proteolytic liberation of GnT-V from its membrane anchor. In cells over-
expressing active SPPL3, intracellular levels of  endogenous GnT-V are drastically reduced 
(Fig. 4.23), but no marked increase in GnT-V secretion could be detected under these 
conditions suggesting that, following its cleavage by SPPL3, GnT-V could be also subject to 
degradation. SPPL3 over-expression did only lead to enhanced GnT-V secretion following co-
expression of exogenous GnT-V (Figs. 4.24 & 4.25), indicating that excessive amounts of GnT-
V saturate its degradation and under these conditions SPPL3 over-expression then results in 
increased GnT-V secretion. Taken together, these observations are in fact in line with SPPL3 
catalysing GnT-V shedding. In addition, two other type II membrane proteins implicated in 
cellular N-glycosylation, β3GnT1 and β4GalT1, were found to be affected by SPPL3 in a 
manner similar to GnT-V (see 4.3.9). Importantly, knock-down of endogenous SPPL3 using 
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RNAi or genomic ablation of SPPL3 expression in MEFs nearly abolished secretion of GnT-V, 
β3GnT1 and β4GalT1, strengthening that these GTs are subject to SPPL3-mediated cleavage 
under physiological conditions.
GnT-V, β3GnT1 and β4GalT1 all lack N-terminal signal peptides and are predicted to adopt a 
type II topology (Shoreibah et al, 1993; Sasaki et al, 1997; Masri et al, 1988), being well 
compatible with the expected topological substrate preference of SPPL3. SPPL3 is considered 
a Golgi-resident protease as over-expressed, epitope-tagged SPPL3 co-localised with the Golgi 
marker Giantin (Friedmann et al, 2006). Based on their catalytic activity on N-glycans, GnT-V, 
β3GnT1 and β4GalT1 are considered medial/trans Golgi enzymes (Roth, 2002) and 
endogenous β4GalT1 (Roth & Berger, 1982) as well as over-expressed GnT-V and β3GnT1 
(Chaney et al, 1989; Chen et al, 1995; Buysse et al, 2013) co-localise with Golgi markers. This 
suggests that SPPL3 co-localises with the substrates identified and that GT endoproteolysis 
occurs within the Golgi. This receives additional strong support from experiments with 
exogenously expressed GnT-V (Figs. 4.24 & 4.25): In HEK293 cells, two distinct species of 
over-expressed GnT-V were detected and enzymatic deglycosylation revealed that the higher 
molecular weight species localises to post-ER compartments whereas the other species is ER-
resident. Exclusively the Endo H-resistant, Golgi-resident GnT-V species was affected by loss of 
SPPL3 expression or SPPL3 over-expression, indicating that SPPL3 endoproteolyses GnT-V in 
the Golgi network (or later). 
Taken together, the experimental evidence points to GnT-V, βGnT1 and β4GalT1 being genuine 
SPPL3 substrates. However, while the model outlined here (Fig. 5.2) suggests a direct 
proteolytic effect of SPPL3 on the GT substrates leading to their liberation, this direct effect of 
SPPL3 on the GT substrates still requires experimental support and it can presently not be 
completely ruled out that the effects on substrate secretion are indirect. SPPL3, for instance, 
could proteolytically activate another proteases that in turn mediates ectodomain shedding of 
such substrates, but alternative indirect mechanism can also be imagined (e.g. an effect of 
SPPL3 (intra-)Golgi trafficking etc.). To clarify this matter, it is essential to unambiguously 
demonstrate that SPPL3 directly acts on substrates, for instance by monitoring proteolytic 
activity of SPPL3 towards its substrate(s) in an in vitro assay. Given that SPPL3 is an I-CLiP, it 
is a rather challenging task to establish such an assay. First, both the polytopic protease SPPL3 
and the membrane-spanning substrate protein must be expressed recombinantly and purified in 
an active conformation. Then, recombinant protease and substrate have to be reconstituted into 
an environment containing specific lipids and/or detergents that adequately support catalysis. 
For rhomboid I-CLiPs for example such assays have been developed (Urban & Wolfe, 2005; 
Lemberg et al, 2005; Maegawa et al, 2005) and have been valuable tools to study their catalytic 
properties and validate substrates identified. Alternatively, co-immunoprecipitation assays of an 
inactive mutant of SPPL3 and the respective substrate could be established. The latter 
approach, however, requires careful validation to ensure that the interaction is specific. Of  note, 
such co-precipitation assays only allow  to examine whether a physical interaction of substrate 
and protease is possible but they do not unequivocally exclude that other factors contribute to 
the proteolytic cleavage.
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5.2.3 SPPL3 substrates identified by a proteome-wide approach
In addition, a proteomics approach was undertaken to identify novel SPPL3 substrates. This 
revealed that over-expression of catalytically active SPPL3 is accompanied by enhanced 
secretion of a number of  protein factors (Fig. 4.33 & Tab. 4.2) which constitute candidate SPPL3 
substrates. Importantly, as this method only assesses the abundance of secreted protein and as 
higher protein levels in the conditioned supernatant can in principle also be due to an overall 
increase in expression of  a given substrate protein, candidate SPPL3 substrates require careful 
validation by Western blot analysis of  both conditioned supernatants and cell lysates. Such 
experiments were performed for a selection of the candidate SPPL3 substrates in HEK293 cells 
(Fig. 4.36) and indeed revealed that SPPL3 over-expression promoted secretion of these 
candidate substrates while there was no indication of  a higher expression of these proteins in 
cells that over-express SPPL3. Moreover, secretion of  some of the candidate substrates (e.g. of 
EXTL3, Fig. 36a) was reduced in cells transfected with SPPL3-targeting siRNA pools, 
suggesting that their secretion under normal conditions is likewise dependent on SPPL3. 
Collectively, these experiment support the notion that secretion of  these candidate SPPL3 
substrates is facilitated by SPPL3.
Notably, most of the candidate SPPL3 substrates identified on a proteome-wide scale also 
conform with SPPL3's expected substrate selectivity. With only few  exceptions, those factors 
are single-span membrane proteins with an annotated or predicted type II topology, i.e. adopt 
the topology expected for SPP/SPPL substrates (reviewed in (Voss et al, 2013)). However, it 
should still be assessed why and how  SPPL3 over-expression affected secretion of the one 
type I protein, Golgi apparatus protein 1 (Fig. 4.33 & Tab. 4.2). For rhomboids, for instance, the 
suspected strict selectivity for type I membrane protein substrates (Urban, 2006; Freeman, 
2008) has been questioned by recent studies identifying also type II and multi-pass rhomboid 
substrates (Tsruya et al, 2007; Erez & Bibi, 2009).
Regarding the sub-cellular localisation of the SPPL3 candidate substrates identified in this 
manner, in particular in view  of a potential sub-cellular co-localisation of protease and substrate, 
the situation is much more complex than for the three GT substrates discussed earlier 
(see 5.2.2). Database annotations suggest predominantly a Golgi localisation of the majority of 
the candidate substrates identified, yet several of these proteins are considered to localise to 
other non-Golgi membranes such as the lysosomal membrane (e.g. lysosomal α-glucosidase) 
or the plasma membrane (e.g. the β-1 subunit of the Na+/K+ ATPase) (Fig. 4.35). However, in 
several cases the exact sub-cellular localisation is controversial. Xylosyltransferase activity, for 
example, has been observed in either the ER or the Golgi network (discussed in (Schön et al, 
2006)), while XylT1 and XylT2 were observed to localise to the Golgi when analysed by 
immunocytochemistry (Schön et al, 2006). It is, however, important to scrutinise how  the sub-
cellular localisation of a given candidate substrate was determined because often such 
experiments are performed by immunocytochemistry following over-expression of epitope-
tagged proteins or chimeric GFP fusion proteins; rarely such an annotation is based on the 
localisation of endogenous protein. Over-expression may cause artefacts e.g. due to an "over-
spill" of cellular compartments (discussed in (Multhaupt & Couchman, 2012)) and, hence, 
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results from such experiments may not necessarily reflect the sub-cellular localisation of  a given 
protein under physiological conditions. This not only applies to the candidate substrates, but at 
the same time also to SPPL3 itself as its Golgi localisation has so far also only been observed 
following over-expression of an epitope-tagged variant (Friedmann et al, 2006). Therefore, it 
remains to be carefully re-evaluated (e.g. by biochemical sub-cellular fractionation) whether and 
where SPPL3 and the newly identified candidate substrates co-localise. Moreover, candidate 
substrates identified by this approach require in-depth validation to unambiguously show  that 
these proteins are endoproteolysed by SPPL3 under physiological conditions.
5.2.4 Two distinct classes of SPPL3 substrates
As delineated earlier (see 5.2.2 and 5.2.3), novel SPPL3 substrates and candidate substrates 
uncovered in this study conform with the expected selectivity of  SPPL3 for type II proteins. 
However, a closer look at their SPPL3-mediated processing in cultured cells reveals that there 
are marked differences between the substrates uncovered by these two distinct approaches 
and the substrates can therefore be categorised accordingly.
Secretion of class I substrates - being those identified by the candidate-based approach, i.e. 
endogenous GnT-V, β3GnT1 and β4GalT1 - is strongly impaired in cells that lack or express 
substantially less SPPL3, yet SPPL3 over-expression does not strongly promote secretion of 
these proteins and, hence, they did not come up as candidate substrates when the secretomes 
of cells over-expressing catalytically active SPPL3 and of  control cells were compared (see 4.4). 
At the same time, alterations in SPPL3 expression levels are accompanied by strong effects on 
the intracellular levels of these substrates as SPPL3 knockdown or knockout and over-
expression results in robust intracellular accumulation and loss of  the intracellular substrate 
species, respectively. Consequently, it follows that (i) following their disengagement from their 
membrane anchor, cleaved, lumenal substrates may be subject to degradation, explaining why 
SPPL3 over-expression does not promote release of more secreted substrates, that (ii) 
cleavage of these substrates by endogenous SPPL3 occurs most likely also under physiological 
conditions, and that (iii) SPPL3-mediated cleavage of these substrates probably impacts cellular 
glycosylation as the intracellular levels, i.e. the active intracellular pool of  these enzymes, are 
strongly affected (which then, in turn, explains the glycosylation phenotypes discussed in 
section 5.3.1). It is tempting to speculate that other endogenous cellular proteins also belong to 
this category of  SPPL3 substrates and they could for instance be identified by applying the 
proteome-wide SPECS approach to a SPPL3 knockdown or knockout setting.
In contrast, secretion of class II substrates - i.e. candidate substrates identified by the 
proteome-wide approach - is strongly promoted by SPPL3 over-expression which is associated 
with rather mild (yet variable) reduction in their intracellular levels, depending on the individual 
candidate substrate. SPPL3 knockdown also had variable effects on secretion, ranging from a 
markedly reduced secretion observed for EXTL3 (Fig. 4.36b) to a rather unaffected secretion of 
HS6ST2 (Fig. 4.36f). Following liberation from their membrane anchors, these substrates are 
likely not subject to degradation and appear to be directly secreted. It is, however, questionable 
whether endoproteolysis of  these substrates catalysed by SPPL3 affects their intracellular 
function as alterations in SPPL3 expression levels hardly affected intracellular levels of these 
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substrates. Moreover, as these substrates are primarily affected by SPPL3 over-expression it 
also remains to be examined to which extent these substrates are endoproteolysed by SPPL3 
under physiological conditions and whether this is a direct effect of SPPL3 on the candidate 
substrate. In fact, it is well conceivable that these proteins are only processed by SPPL3 in 
substantial amounts following SPPL3 mis-localisation which could be a consequence of  the 
protease's over-expression (discussed in 5.2.3).
In sum and in spite of these open questions, the newly identified candidate SPPL3 substrates 
underpin the initial hypothesis (Fig. 5.2) that SPPL3 acts as a type II membrane protein-
selective sheddase that cleaves full-length type II membrane proteins leading, in turn, to the 
secretion of their ectodomains. Notably, the apparent selectivity of  SPPL3-facilitated secretion 
for type II membrane proteins is already indicative that the observed effects are not due to 
global cellular effects that SPPL3 has on, for instance, the secretory pathway or intracellular 
trafficking.
5.3 Physiological function(s) of SPPL3
Single-celled organisms lack orthologues of  mammalian SPPL3 but such orthologues are 
present in multi-cellular organisms (Golde et al, 2009; Voss et al, 2013) and, astonishingly, there 
is hardly variation in SPPL3's primary structure in metazoa6  (Fig. 1.9). Such high degree of 
conservation implies a strong selective pressure on SPPL3 which, in turn, points to an 
indispensable physiological function fulfilled by SPPL3 in metazoa. Primarily due to the lack of 
adequate in vivo models and of known substrates this physiological function has remained 
completely enigmatic. Here, the putative implications of this study regarding SPPL3's function in 
cellulo and in vivo will be discussed.
5.3.1 SPPL3 is a global cellular regulator of complex N-glycosylation
This study demonstrates that changes in cellular SPPL3 expression and/or activity result in 
alterations in the composition of  N-glycan moieties attached to endogenous cellular 
glycoproteins in cultured cells and in vivo. To be more specific, a hypo-glycosylation phenotype 
was observed following over-expression of active SPPL3 (Fig. 4.19), whereas loss of 
endogenous SPPL3 activity in cultured murine (Fig. 4.16) or humans (Fig. 4.18) cells or in 
mouse tissues (Fig. 4.17) was accompanied by a hyper-glycosylation. 
Several experiments were performed in order to dissect the cellular N-glycosylation pathway in 
more detail and to identify the steps in N-glycan metabolism SPPL3 is interfering with. 
Kifunensine treatment, for instance, prevented SPPL3 over-expression to cause any alterations 
in glycoprotein running behaviour (Fig. 4.21), indicating that the generation of  high-mannose 
glycans in the ER is not affected. Additional data point to SPPL3 affecting primarily post-ER 
localised glycoproteins and interfering with complex N-glycosylation in the Golgi, the cellular 
compartment in which active SPPL3 is expected to be localised (Friedmann et al, 2006). 
Transition from ER N-glycan precursors to complex glycans is catalysed by a number cellular 
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6  Note that this high degree of conservation exclusively applies to isoform 2 of human SPPL3. Uniprot also lists another isoform, 
isoform 1 (Fig. 4.14a, www.uniprot.org, query: SPPL3_HUMAN, entry ID: Q8TCT6, information retrieved August 28, 2013). A 
discernible orthologue of isoform 1, however, is not conserved in other species species and also appears to be not catalytically 
active towards FVenv (Fig. 4.14b).
GTs and glycosidases (Fig. 1.15). These are almost exclusively type II transmembrane proteins 
and localise to the Golgi network (reviewed in (Paulson & Colley, 1989; Sears & Wong, 1998; 
Ohtsubo & Marth, 2006)), hence they fulfil two major requirements one would impose on a 
SPPL3 substrate (discussed in 5.2.1). Moreover, a hypothetical model postulating that SPPL3 is 
engaged in GT and/or glycosidase endoproteolysis and secretion could in fact well explain the 
alterations in N-glycosylation observed (Fig. 5.3): In conditions of  SPPL3 over-expression, 
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Fig. 5.3: Model explaining the observed glycosylation phenotypes by SPPL3-mediated proteolytic 
glycosyltransferase secretion. (a) Under physiological conditions, a certain fraction of the Golgi 
glycosyltransferase pool (GT) is proteolytically cleaved off its membrane anchor by SPPL3 and 
subsequently secreted (left bold black arrow) or intracellularly degraded (not depicted). Unaffected GT 
molecules reach their destination within the Golgi  and catalyse glycan modifications (depicted here: GnT-
V-mediated β1,6-GlcNAc  branching). (b) In cells over-expressing active SPPL3, GT cleavage is nearly 
quantitative and no active GT is available for glycan elaboration leading to the hypoglycosylation 
phenotype observed. (c) In cells lacking SPPL3, no GT  secretion is catalysed and hence active GT 
molecules accumulate in the Golgi leading to hyperglycosylation. This may similarly affect the activity of 
other Golgi glycan-modifying enzymes.
cleavage and thus secretion of  a given GT is promoted and likely occurs prematurely, leading to 
a reduction in intracellular GT levels and precluding the transferase to fulfil its normal 
physiological function. This then results in less extensively modified glycans on glycoproteins, 
i.e. the hypoglycosylation phenotype associated with SPPL3 over-expression. In contrast, loss 
of SPPL3 expression leads to profoundly impaired GT cleavage. Consequently, cells 
accumulate active GT which then leads to a more extensive N-glycosylation and, hence, the 
hyperglycosylation phenotype observed. Under physiological conditions, however, SPPL3-
mediated GT secretion is at equilibrium allowing for a normal extent of N-glycan elaboration. 
Altogether, this suggests that SPPL3 indirectly alters the extent of cellular glycosylation by 
endoproteolysing such GTs and/or other GMEs, thereby interfering with their cellular activity in 
glycan assembly.
5.3.1.1 Glycosyltransferase proteolysis
Secretion of  cellular GTs that is ascribed to proteolytic liberation of  these GTs from their 
membrane anchors is a well-known phenomenon, yet the physiological consequences and 
implications of this process are unclear (Paulson & Colley, 1989; Ohtsubo & Marth, 2006; Varki 
et al, 2009). Several studies have already reported enzymatic activities of distinct GTs in bodily 
fluids such as human (Kim et al, 1972a; 1972b; Hosomi et al, 1984) and porcine (Hudgin & 
Schachter, 1971a; 1971b; 1971c) serum as well as bovine colostrum (Elhammer & Kornfeld, 
1986). Moreover, using antibodies generated against GT ectodomains, secreted variants of 
specific GTs were identified in and purified from such biological samples, respectively 
(Elhammer & Kornfeld, 1986; Kitazume et al, 2009). In addition, soluble GTs were found to be 
released from cultured cells (Borsig et al, 1998; Saito et al, 2002; El-Battari et al, 2003). 
Most GTs (but also also other GMEs) involved in the assembly of  Golgi (N-)glycans have a 
type II topology and their C-terminal lumenal catalytic domain is tethered to its membrane 
anchor, the TMD, via a so-called stem region (Paulson & Colley, 1989; Varki et al, 2009) 
(Fig. 5.4). The N-terminal cytosolic regions are usually rather short (< 30 aa). Soluble GTs are 
generally believed to be generated via proteolytic cleavage of their membrane-anchored 
precursor and subsequent secretion of  the liberated ectodomain (Paulson & Colley, 1989; 
Ohtsubo & Marth, 2006; Varki et al, 2009) as sequence analyses of secreted individual GTs 
purified from tissue homogenates or cell culture media revealed N-terminal truncation 
(Weinstein et al, 1987; Kitazume et al, 2001; 2003; Nakahara et al, 2006). Whether a GT is 
subject to endoproteolysis appears to be defined by a region comprising its cytosolic stretch, the 
TMD and the stem region, often collectively referred to as CTS region (Grabenhorst & Conradt, 
1999).
Interestingly, however, the protease(s) involved in this wide-spread shedding of GTs have less 
well been defined and the few  studies investigating this matter have been somewhat 
contradictory. Importantly, to date no single protease has been defined that globally and 
exclusively mediates GT proteolysis. One study addressed the proteolytic liberation of GnT-V 
from its membrane anchor and claims that this is mediated by the γ-secretase complex 
(Nakahara et al, 2006) (discussed in 5.3.1.2). Several other studies have focussed on the 
proteolytic release of TGN sialyltransferases. Initially, α2,6-sialyltransferase 1 (ST6Gal1) 
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liberation had been attributed to a cathepsin D-like protease (Lammers & Jamieson, 1988; 
McCaffrey & Jamieson, 1993), which had similar been implicated in proteolytic release of 
another GT (Jaskiewicz et al, 1996). Subsequent studies, however, suggest that ST6Gal1 is 
endoproteolysed by BACE1 in vitro and in cultured cell lines (Kitazume et al, 2001) as well as, 
to a certain extent, in vivo (Kitazume et al, 2005). BACE1 is also suspected of endoproteolysing 
other sialyltransferases (Kitazume et al, 2006). Importantly, while BACE1-mediated ST6Gal1 
release occurs in vivo, substantial amounts of secreted ST6Gal1 could still be detected in 
plasma of Bace1-deficient mice (Kitazume et al, 2005). A proteome-wide secretome analysis 
also found that proteolytic secretion of  another sialyltransferase, ST3Gal1, was reduced 
following inhibition of BACE1 activity, but its release was not blocked completely (Kuhn et al, 
2012), underscoring that BACE1 is not the only protease that liberates these sialyltransferase 
substrates. Importantly, apart from ST3Gal1, no other BACE1 substrates implicated in 
(N-)glycosylation were identified in two independent proteomic studies (Hemming et al, 2009; 
Kuhn et al, 2012).
As shedding is such a conserved feature among Golgi GTs, it is tempting to speculate that it is 
of particular physiological importance. Secreted variants of GTs comprise the enzymes' active 
sites and, accordingly, retain their catalytic activity in vitro when reactions are supplemented 
with nucleotide-conjugated monosaccharides (Elhammer & Kornfeld, 1986). To catalyse 
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Fig. 5.4: Structure and proteolytic processing of Golgi GTs and GMEs. Golgi GTs and GMEs are 
type II transmembrane proteins that feature a characteristic  domain structure. Their catalytic ectodomains 
are tethered to the lumenal membrane via their CTS region. This comprises a short N-terminal cytosolic 
domain, a TMD and a lumenal  stem region. The CTS region also controls intracellularly trafficking and the 
sub-cellular localisation of GTs and GMEs. In addition, most Golgi  GTs and GMEs undergo proteolytic 
cleavage within a membrane-proximal stretch in their stem regions (scissors). Cleavage liberates the GT/
GME ectodomain into the lumenal  space and leaves behind a presently uncharacterised putative CTS 
fragment (black arrow). Liberated GT or GME ectodomains may subsequently be secreted or 
proteolytically degraded. Individual domain lengths are not drawn to scale.
glycosidic bond formation, GTs strictly require such nucleotide-conjugated monosaccharides as 
donors. In vivo, these are generally believed not to be present extracellularly in adequate 
concentrations for GT catalysis and, hence, GTs are expected not to be catalytically active 
following secretion in a physiological setting (Colley, 1997; Varki et al, 2009; Stanley, 2011). 
Proteolytic liberation of GTs from their membrane tethers is therefore considered a way to 
negatively regulate intracellular GT activity (Varki et al, 2009; Ohtsubo & Marth, 2006). Formal 
and conclusive prove for this concept is, however, still missing. Moreover, there is evidence that 
in certain micro-environments sufficient amounts of  sugar donors can be provided to fuel 
extracellular GT activity. Interestingly, secretion of ST6Gal1 from liver, for instance, is known to 
be triggered by inflammatory hepatopathological conditions and during acute phase response 
(Lammers & Jamieson, 1988; McCaffrey & Jamieson, 1993; Kitazume et al, 2005; 2009), 
indicating that GT proteolysis is in fact a dynamic process under physiological conditions. 
Importantly, GTs may fulfil functions in the extracellular space that are independent of  their 
catalytic activity (Saito et al, 2002).
5.3.1.2 SPPL3 facilitates GnT-V secretion
As delineated earlier (see 5.2.2), this study identifies GnT-V as a novel SPPL3 substrate. 
Importantly, its processing essentially follows the previously proposed model (Fig. 5.3) and, 
hence, could contribute to SPPL3's effect on cellular N-glycosylation. GnT-V activity generates 
tri- and tetraantennary N-glycans by transferring β1,6-linked GlcNAc to the N-glycan core 
(Cummings et al, 1982; Dennis et al, 2002) and GnT-V products are specifically bound by the 
plant lectin PHA-L (Cummings & Kornfeld, 1982). In fact, SPPL3 over-expression was 
accompanied by an overt reduction in PHA-L reactivity towards NCT (Fig. 4.29), demonstrating 
that SPPL3 not only affects cellular GnT-V levels but also GnT-V activity. This supports the 
assumption that proteolytic GT secretion can negatively regulate intracellular GT activity (see 
5.3.1.1).
GnT-V is a type II membrane protein (Shoreibah et al, 1993) and localises to the Golgi 
apparatus (Chaney et al, 1989; Chen et al, 1995). Given its action late during N-glycan 
biosynthesis, it most likely resides in the medial or trans Golgi (Roth, 2002) and could therefore, 
in principle, co-localise with SPPL3. Intriguingly, GnT-V had already been reported before to be 
secreted from cultured cells (Saito et al, 2002; Nakahara et al, 2006), likely due to a proteolytic 
activity since secreted GnT-V was found to lack its cytosolic N-terminus as well as the adjacent 
TMD (Nakahara et al, 2006). It can therefore be postulated that SPPL3 proteolytically cleaves 
membrane-anchored GnT-V upon encounter in the Golgi network, liberating the GnT-V 
ectodomain from its membrane anchor which then could be trafficking to the cell surface and be 
secreted. In addition, however, the data also point to (likely intracellular) degradation of cleaved 
GnT-V (discussed in 5.2.2).
The finding that SPPL3 endoproteolyses GnT-V contrasts starkly with a previous study which 
claims that GnT-V is liberated by γ-secretase (Nakahara et al, 2006). This is rather puzzling as, 
apart from GnT-V, all γ-secretase substrates identified are type I membrane proteins 
(Haapasalo & Kovacs (Haapasalo & Kovacs, 2011) provide a detailed list) and a proteomic 
screen for novel γ-secretase substrates also uncovered exclusively type I membrane proteins 
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as novel substrate candidates (Hemming et al, 2008) and, accordingly, γ-secretase is 
considered a type I membrane-protein selective protease (Steiner et al, 2008a). Moreover, 
experimental data presented by Nakahara et al. (Nakahara et al, 2006) in order to support their 
findings are not convincing. The authors observed that GnT-V secretion from cells was blocked 
by treatment with the GSI DFK167 (Nakahara et al, 2006). In contrast, in the present studies 
two other highly potent GSIs were found to neither affect GnT-V secretion nor intracellular GnT-
V levels, while at the same time APP CTFβ processing was clearly inhibited indicating that 
cellular γ-secretase activity was inhibited (Fig. 4.28a). Moreover, Nakahara et al. reported a loss 
of GnT-V secretion in MEFs lacking PS1 and PS2 (Nakahara et al, 2006). Using the very same 
cells, GnT-V secretion was found to be unaltered compared to the respective control cell line 
obtained from PS1/PS2+/+ embryos in this study (Fig. 4.28b). Experiments performed in the 
course of  this study therefore disprove Nakahara et al.'s assertion that γ-secretase mediates 
GnT-V secretion. 
Irrespective of the conclusion that GnT-V cleavage is γ-secretase-dependent, Nakahara et al. 
also show  that secreted GnT-V commences at residue His 31 (Nakahara et al, 2006). In this 
study, a different experimental strategy was adopted to determine the SPPL3 cleavage sites 
within GnT-V (Fig. 4.27). The data obtained suggest that SPPL3 cleaves GnT-V within stretch 
predicted to lie close to the membrane boundary, hence in a region that could well be 
accessible to an I-CLiP. Moreover, it suggests that SPPL3-mediated intramembrane proteolysis 
is not entirely precise explaining the five distinct cleavage products observed. It can, however, 
presently not be excluded that a single cleavage product generated by SPPL3 is subject to 
exopeptidase digestion giving rise to the successively trimmed cleavage products observed. 
Importantly, the cleavage product described earlier (Nakahara et al, 2006) was also observed, 
confirming the observations made here and indicating that the cleavage site(s) identified using 
the truncated GnT-V construct likely correspond to the respective cleavage(s) of physiological, 
full-length GnT-V. However, in this setting another cleavage product, commencing at Leu 29, 
was found to be most abundant. This discrepancy may originate in the different cell lines used 
or in the different approaches employed. In addition, it remains unclear whether SPPL3 cleaves 
GnT-V at the five sites identified here with variable efficiency or whether cleavage occurs at one 
site and the cleavage product is successively trimmed.
5.3.1.3 SPPL3 facilitates secretion of β3GnT1 and β4GalT1
While SPPL3 affects cellular N-glycan synthesis by modulating cellular GnT-V activity, SPPL3's 
effects were not entirely due to GnT-V (Fig. 4.30), indicating that SPPL3 might act similarly on 
other Golgi GTs or GMEs leading to more profound alterations in cellular N-glycosylation. 
Indeed, such other additional SPPL3 (candidate) substrates could be identified and will be 
discussed in the following.
Experiments in human and murine cells (Fig. 4.31a & b) demonstrate that secretion of β3GnT1 
is also affected by SPPL3. β3GnT1 was predicted to adopt a type II topology (Sasaki et al, 
1997) and over-expressed β3GnT1 was reported to co-localise with Giantin and, therefore, 
likely resides in the Golgi network (Buysse et al, 2013). β3GnT1 hence matches the expected 
SPPL3 substrate requirements. β3GnT1 is critically involved in the generation poly-N-
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acetyllactosamines (poly-LacNAc) moieties on N- and O-glycans (Sasaki et al, 1997; Ujita et al, 
1999). Until now, secreted β3GnT1 has not been observed using specific antibodies, but an N-
acetyllactosamine (LacNAc)-modifying, β1,3-N-acetylglucosaminyltransferase activity in human 
serum was already described in 1984 (Hosomi et al, 1984), which could be attributed to 
β3GnT1. Indeed, β3GnT1 was constitutively secreted from HEK293 cells (Fig. 4.31a).
Loss of  SPPL3 led to an accumulation of  intracellular β3GnT1 and at the same time β3GnT1 
secretion was reduced (Fig. 4.31). Thus, β3GnT1 secretion is affected by alterations in SPPL3 
expression levels in a manner reminiscent of GnT-V and, hence, follows the model proposed for 
SPPL3's impact on GTs (Fig. 5.3). Importantly, also β3GnT1 secretion is only slightly increased 
following SPPL3 over-expression, while the intracellular β3GnT1 signal is strongly reduced, 
suggesting that, similar to GnT-V, β3GnT1 may be subject to degradation following disengaged 
from its membrane anchor. Collectively, these observations support that β3GnT1 is another 
newly identified SPPL3 substrate (even though the formal proof of this concept e.g. using an in 
vitro cleavage assay is currently missing).
Constitutive secretion of the galactosyltransferase β4GalT1, like of GnT-V and β3GnT1, was 
also found to be reduced in HEK293 cells following transfection with SPPL3-targeting siRNAs 
(Fig. 4.31c) and almost abolished in Sppl3-deficient MEFs (Fig. 4.31d). At the same time, the 
intracellular β4GalT1 levels were elevated pointing to an intracellular accumulation of  the 
holoprotein due to impaired proteolytic secretion. As for GnT-V and β3GnT1, intracellular 
β4GalT1 was reduced following SPPL3 over-expression in HEK 293. In sum, this points to 
β4GalT1 being another endogenous Golgi GT that is a substrate of SPPL3. Cellular βGalT1 
produces LacNAc and, in tandem with β3GnT1, poly-LacNAc moieties (Ujita et al, 1999; 2000). 
Interestingly, there is also indication that β3GnT1 and β4GalT1 interact physically (Lee et al, 
2009). 
Taken together, SPPL3-mediated proteolysis of  β3GnT1 and β4GalT1 could also hinder the 
physiological function of  these GTs and thus likely contributes to the N-glycosylation phenotypes 
associated with SPPL3 over-expression or loss of SPPL3 expression. Furthermore, in light of 
β3GnT1 and β4GalT1 being involved in the formation of  LacNAc and poly-LacNAc moieties that 
can also be found on mucin-type O-glycans and glycolipids, this may imply that SPPL3 could 
likewise interfere with the generation of these glycoconjugates.
5.3.1.4 Other glycan-modifying SPPL3 substrates and candidate substrates
The comparison of  secretomes of  SPPL3 over-expressing cells and control cells by quantitative 
proteomics revealed a number of candidate SPPL3 substrates (Tab. 4.2 and Fig. 4.33) that are 
also involved in cellular glycoconjugate anabolism and therefore could likewise contribute to the 
alterations in glycan composition associated with loss of  SPPL3 expression or SPPL3 over-
expression (see 5.3.1). Regarding cellular Golgi N-glycosylation these include β1,2-N-
acetylglucosaminyltransferase 1 (GnT-I, gene name: MGAT1) and α-mannosidase IIx (α-
Man IIx, gene name: MAN2A2) that are both crucially involved in cellular N-glycosylation, the 
former being required for the generation of  both hybrid and complex N-glycans, the latter being 
required for the generation of  complex N-glycans (Schachter, 1991; Sears & Wong, 1998; 
Stanley et al, 2009). Secretion of ER Man I (gene name: MAN1B1) was likewise affected by 
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SPPL3 over-expression. Its name, however, is rather misleading as ER Man I is a type II 
membrane protein (Gonzalez et al, 1999) involved in targeting of ERAD substrates (Pan et al, 
2011; Moremen et al, 2012) yet it localises to the Golgi network (Pan et al, 2011). In addition, 
the list of candidate substrates includes additional GTs such as the N-acetylglucosaminyl-
transferase exostosin-like 3 (EXTL3), β1,4-galactosyltransferase 7 (β4GalT7, gene name: 
B4GALT7), β1,3-galactosyltransferase 6 (β3GalT6, gene name: B3GALT6) and 
xylosyltransferase II (XT-II, gene name: XYLT2), which are all involved in GAG biosynthesis 
(Almeida et al, 1999; Götting et al, 2000; Bai et al, 2001), as well as the α2,3-
sialyltransferase VI (ST3GAL6, gene name: ST3GAL6). Finally, other GMEs, in particular 
several sulphotransferases were observed to be more abundantly secreted in SPPL3-over-
expressing cells. Interestingly, all these candidate substrates brought up are (predicted) type II 
membrane proteins (Tab. 4.2) and localise to the Golgi compartment (Bai et al, 2001; Schön et 
al, 2006; Humphries et al, 1997; Pan et al, 2011). Collectively, the identification of these 
candidate SPPL3 substrates underscores the notion that SPPL3 facilitates proteolytic secretion 
of (primarily) Golgi-localised glycan-modifying type II membrane proteins.
5.3.1.5 SPPL3 may serve as global cellular Golgi enzyme sheddase
Taken together, SPPL3 emerges as novel sheddase of Golgi-localised GTs and GMEs. Indeed, 
there is strong evidence from Sppl3 knockout MEFs that constitutive secretion of GnT-V is 
largely SPPL3-dependent (Fig. 4.26). Moreover, SPPL3 is capable of  facilitating secretion of a 
variety of other Golgi-resident enzymes pointing to a fundamental function of SPPL3-mediated 
GME secretion in Golgi proteostasis (discussed in 6.2). It remains, however, to be worked out to 
what extent SPPL3 affects secretion of an individual GME and whether there is competition with 
other proteases, e.g. BACE1 (see 5.3.1.1).
Moreover, it has to be carefully tested, in principle for every individual substrate, that SPPL3 
directly mediates endoproteolysis to exclude indirect effects of SPPL3, e.g. on intra-Golgi 
trafficking. In particular, future experiments should examine integrity of  the conserved oligomeric 
Golgi (COG) complex as COG complex defects, e.g. in CDG patients, are well known to cause 
Golgi enzyme mis-localisation and alter cellular glycosylation (reviewed in (Reynders et al, 
2011)).
5.3.2 Potential physiological implications of other newly identified SPPL3 substrates
This study unveiled several new  (candidate) SPPL3 substrates implicated in very diverse 
cellular pathways (Tab. 4.2). Assuming that these proteins are genuine SPPL3 substrates and 
are endoproteolysed under physiological conditions, they could contribute to SPPL3's 
physiological functions. In the following, SPPL3's potential physiological role(s) in three distinct 
cellular pathways - the formation of (poly-)LacNAc-bearing N- and O-glycans (section 5.3.2.1), 
GAG biosynthesis (section 5.3.2.2) and O-mannosylation (section 5.3.2.3) - will be discussed. 
Furthermore, alterations in glycosylation may affect the individual function of the various cellular 
glycoproteins that are subject to such post-translational modifications (see section 5.3.2.4).
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5.3.2.1 SPPL3 may control integrity of the glycoprotein-galectin lattice
Glycoprotein-linked mature N-glycans but also mucin-type O-glycans often harbour specific 
disaccharidic patterns, the LacNAc units (Galβ1,4GlcNAc or Galβ1,3GlcNAc) (Stanley & 
Cummings, 2009). On β1,6GlcNAc N-glycan branches in particular, these units can be found as 
polymers, poly-LacNAc ([-3Galβ1,4GlcNAcβ1-]n) (Dennis et al, 2009; Stanley & Cummings, 
2009; Boscher et al, 2011). These structures are preferred binding sites for lectins, primarily for 
members of the galectin family, such as galectin-3 (Boscher et al, 2011). Galectins form a family 
of evolutionary conserved lectins. They are produced in the cytosol and are secreted via a non-
conventional, ER-/Golgi-independent export pathway (Boscher et al, 2011). Interactions of 
multivalent galectins with their ligands, primarily branched, poly-LacNAc-bearing N-glycans on 
cell surface glycoproteins are considered to form a supramolecular lattice, the so-called 
glycoprotein-galectin lattice that fundamentally affects the motility and versatility of N-
glycosylated cell surface membrane proteins, e.g. it restricts their oligomerisation, their 
recruitment into lipid raft membrane microdomains or their endocytosis (reviewed in (Dennis et 
al, 2002; Grigorian et al, 2009; Dennis et al, 2009; Boscher et al, 2011)). The glycoprotein-
galectin lattice has received particular attention as it appears to be intricately linked to 
tumourigenesis (reviewed in (Lau & Dennis, 2008)) as well as T cell biology (reviewed in 
(Grigorian et al, 2009)) and is subject to nutritional regulation (Lau et al, 2007; Grigorian et al, 
2007).
Interestingly, three GTs identified here as novel SPPL3 substrates are implicated in the 
generation of poly-LacNAc motifs. GnT-V catalyses the transfer of GlcNAc from the cellular 
UDP-GlcNAc donor to the C6 hydroxy group of  the α1,6-linked core mannose residue that is 
part of the cellular precursor of  complex N-glycans (Cummings et al, 1982) and is thus crucial to 
the formation of  tri- and tetraantennary N-glycans. N-glycans harbouring a GlcNAcβ1,2-
(GlcNAcβ1,6)Manα1,6 motif  generated by enzymatic activities of both GnT-V and GnT-II, are 
preferentially extended by poly-LacNAcs (van den Eijnden et al, 1988; Ujita et al, 1999). 
LacNAc repeating units are added to GlcNAcβ1,2(GlcNAcβ1,6)Manα1,6-carrying N-glycans (but 
also to mucin-type O-glycans) by the repetitive action of β4GalT1 and β3GnT1, leading to the 
formation of linear poly-LacNAc structures (Sasaki et al, 1997; Ujita et al, 1999; 2000). As 
SPPL3 can control the intracellular active pool of GnT-V, β3GnT1 and β4GalT1 and in this way 
affect the composition and structure of  cellular glycans, it is conceivable that alterations in 
SPPL3 expression levels may also specifically alter a given cell surface glycoprotein's capacity 
to integrate into the glycoprotein-galectin lattice. Over-expression of  the active protease 
interferes, for instance, with cellular GnT-V activity (Fig. 4.29) and can similarly be expected to 
reduce β3GnT1 and β4GalT1 activity, which would then result in a reduction of galectin binding 
to carbohydrates on the cellular glycoproteins. In contrast, loss or reduction of  active cellular 
SPPL3 could lead to a higher abundance of  galectin binding motifs, i.e. a higher affinity of the 
cellular N-glycan pool for the lattice. Presently, however, this is merely speculative and it 
remains to be examined whether alterations of  SPPL3 expression levels really alter the cellular 
affinity for galectins. This could be tested by assessing for instance binding of labelled 
recombinant galectins to cells over-expressing or lacking SPPL3. 
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In particular, the newly identified SPPL3 substrate GnT-V has recently attracted strong attention 
as a crucial regulator of the glycoprotein-galectin lattice, in particular in the context of cellular 
malignancies and T cell biology (reviewed in (Lau & Dennis, 2008; Dennis et al, 2009; Grigorian 
et al, 2009)). Tumours, for instance, often display profoundly up-regulated MGAT5 expression 
(Dennis et al, 2002; Lau & Dennis, 2008) and, in fact, expression levels may correlate with 
tumour metastatic potential and patient prognosis (Murata et al, 2000). In line with this, in an 
oncogene-driven mouse mammary tumour model, tumour growth and metastic potential was 
reduced in Mgat5-/- animals (Granovsky et al, 2000). GnT-V also negatively regulates T cell 
receptor (TCR) signalling by controlling the recruitment of the TCR and co-receptors into 
glycoprotein-galectin lattice (Demetriou et al, 2001; Lau et al, 2007) and loss of GnT-V was 
therefore associated with autoimmunity in mice (Demetriou et al, 2001; Lee et al, 2007). 
Therefore, it is particularly worthwhile to consider that due to its capacity to control GnT-V 
activity SPPL3 may functionally be tightly linked to such pathophysiological conditions.
5.3.2.2 SPPL3 may affect glycosaminoglycan biosynthesis
CAGs are linear, high-molecular weight polysaccharides with a disaccharidic repeating unit. As 
integral components of the extracellular matrix (ECM) they fulfil diverse physiological functions 
in multicellular organisms (Esko et al, 2009). Depending on the underlying disaccharide, a 
distinction is made between hyaluronan, dermatan sulphate (DS), keratan sulphate (KS), 
chondroitin sulphate (CS) (including several subtypes), and heparan sulphate (HS). Hyaluronan 
aside, which will not be considered here any further as it is synthesised via a completely distinct 
pathway (Hascall & Esko, 2009), CAGs are often highly sulphated and are found covalently 
attached to secreted or membrane-bound proteins, the so-called proteoglycans. KS is 
essentially a sulphated poly-LacNAc and, accordingly, is attached to proteoglycans via N-
glycans or a mucin-type O-glycans (Esko et al, 2009). Its synthesis strictly relies on the 
formation of  poly-LacNAc precursors (see 5.3.2.1) (Esko et al, 2009). In contrast, HS, CS, and 
DS are linked to proteoglycan serine residues via a tetrasaccharide linker (GAG-
GlcAβ1,3Galβ1,3Galβ1,4Xylβ1-Ser) (Sugahara & Kitagawa, 2002; Esko et al, 2009). Hence, 
biosynthesis of these types of GAGs occurs via a common cellular pathway (depicted in 
Fig. 5.5). Following completion of the tetrasaccharide linker synthesis of either HS or CS is 
initiated by distinct Golgi enzymes (Fig. 5.5).
Biosynthesis of sulphated GAGs is generally thought to occur predominantly within the cis/
medial Golgi compartment as this is the cellular compartment in which most enzymes implicated 
in their biosynthesis reside (Sugahara & Kitagawa, 2002; Multhaupt & Couchman, 2012; 
Kreuger & Kjellén, 2012). It has, however, been somewhat controversial (see discussion in 
(Schön et al, 2006; Multhaupt & Couchman, 2012)) where exactly the first step - the xylosylation 
- occurs, but both exogenously expressed XylT1 and XylT2 appear to co-localise with α-Man II 
in the Golgi compartment (Schön et al, 2006). Similar findings were reported for β3GalT6 (Bai et 
al, 2001), NDST1 (Humphries et al, 1997), the EXT1/EXT2 complex (McCormick et al, 2000), 
heparan sulphate 6-O sulphotransferases (Nagai et al, 2004), and others. Hence, like complex 
N-glycosylation, sulphated GAG biosynthesis is another crucial cellular process proceeding in 
the Golgi network that is executed by type II membrane proteins and could also be modulated 
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Fig. 5.5: Heparan sulphate biosynthesis. Biosynthesis of heparan sulphate (HS) as well  as dermatan 
sulphate (DS) and chondroitin sulphate (CS) proceeds initially via a common pathway and diverges later. 
Initially, a tetra-saccharide linker is generated. A xylosyltransferase, of which there are two isoforms, 
XylT1 and XylT2, transfers a xylose to the proteoglycan's serine residue. Other sugar residues are then 
successively added by β1,4-galactosyltransferase 7 (β4GalT7, gene name: B4GALT7), β1,3-
galactosyltransferase 6 (β6GalT6, gene name: B6GALT6) and finally by β1,3-glucuronosyltransferase 3 
(β3GlcAT3, gene name: B3GAT3). The tetrasaccharide linker may then be subject to sub-stoichiometrical 
phosphorylation and/or sulphation by undefined kinases and sulphotransferases, respectively (not 
depicted). Depending on the enzyme acting next on the linker, biosynthesis of either CS/DS or HS is 
initiated. In case of the former, β1,4-N-acetylgalatosaminyl transferase 1 attaches an N-
acetylgalactosamine (GlcNAc) residue to the terminal glucuronic  acid (GlcA). In contrast, the N-
acetylglucosaminyltransferase exostosin-like 3 (EXTL3, gene name: EXTL3) takes up HS biosynthesis by 
attaching α1,4-linked GlcNAc. HS polymerisation is then performed by a co-polymerising heterodimeric 
enzyme complex of EXT1 and EXT2 that successively adds β1,4-linked GlcA and α1,4-linked GlcNAc to 
the nascent HS chain. In addition, the HS precursor is subject to GlcA epimerisation and extensive 
sulphation. Sulphation at C2 of GlcNAc residues is performed by the bifunctional heparan sulphate N-
deacetylases/N-sulphtotransferases (NDST) 1 (gene name: NDST1) or NDST1 isoforms, while distinct 
sulphotransferases catalyse sulphation at other sites. Adapted from (Sugahara & Kitagawa, 2002; Esko 
et al, 2009).
by SPPL3 activity.
Indeed, the secretome analysis (see 4.4) supports this assumption. It revealed that, upon 
SPPL3 over-expression, a number of key enzymes implicated in the biosynthesis of CS (XylT2, 
β4GalT7, β3GalT6) and, even more strikingly, HS (XylT2, β4GalT7, β3GalT6, EXTL3, NDST1, 
NDST2 and HS6ST2) were more abundantly secreted, raising the possibility that SPPL3 
facilitates their proteolytic secretion. While the identification of such a number of candidate 
substrates implicated in the very same cellular pathway is indeed surprising, it is unlikely that 
this is merely a coincidental finding. Rather, this underscores that HS biosynthesis might indeed 
be tightly controlled by SPPL3 activity. It should be directly assessed (e.g. with HS composition-
specific antibodies (van Kuppevelt et al, 1998)) whether altered secretion of these enzymes 
associated with changes in SPPL3 expression translates into alterations in HS formation in 
cultured cells and in vivo.
There is conclusive evidence that HS biosynthesis is tightly regulated as there are, for instance, 
tissue-specific HS modification patterns (van Kuppevelt et al, 1998; Kreuger & Kjellén, 2012). It 
is unclear, however, by which mechanisms its regulation is ensured but several possibilities 
including regulation on a transcriptional level as well as sub-cellular localisation/targeting have 
been discussed (Kreuger & Kjellén, 2012; Multhaupt & Couchman, 2012). As for GTs (see 
5.3.1.1), proteolytic liberation of  membrane-anchored enzymes involved in HS biosynthesis is 
likewise a plausible mechanism by which this process could be concerted. Indeed, activity of 
enzymes involved in HS biosynthesis has already been reported in extracellular samples. For 
instance, xylosyltransferase activity was observed in conditioned supernatants of  human dermal 
fibroblasts and in human and murine serum (Götting et al, 1999; Condac et al, 2009). It is 
attributed to secretion of XylT1 and XylT2 (Götting et al, 1999; Condac et al, 2009). As these 
proteins are expected to be membrane-anchored (Götting et al, 2000), their secretion is 
considered a proteolytic process. The protease(s) generating secreted variants thereof  are 
unknown. Also, an enzyme with heparan sulphate 6-O sulphotransferase activity was purified 
from conditioned supernatants of  CHO cells (Habuchi et al, 1995) and this arises from 
proteolytic cleavage in the luminal membrane proximal region of  the type II membrane-
anchored precursor (Nagai et al, 2007). One study reported a reduction in secretion of C-
terminally GFP-tagged over-expressed HS6ST3 following treatment with a BACE1 inhibitor 
(Nagai et al, 2007). This finding is interesting as BACE1 has also been discussed to liberate 
sialyltransferases from their membrane anchors (see 5.3.1). Notably, however, the isoenzymes 
HS6ST2 (which was identified as a candidate SPPL3 substrate here) and HS6ST1 remained 
unaffected by inhibitor treatment and the authors failed to conclusively show  that BACE1 
directly acts on HS6ST3 (Nagai et al, 2007). Hence, their findings could likewise be explained 
by BACE1-independent effects of the inhibitor used. It is therefore crucial to verify the findings 
of the proteomic screen in order to firmly establish whether - and to what extent - SPPL3 
mediates proteolytic release of  enzymes implicated in the generation of  sulphated GAGs under 
physiological conditions and what the consequences of altered GAG are.
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5.3.2.3 SPPL3 may affect O-mannosylation
Apart from N-glycosylation and mucin-type O-glycosylation, a variety other types of 
glycosylation are known, including the covalent attachment of mannose to Ser/Thr residues, the 
so-called O-mannosylation. Numerous studies have been conducted to unravel the cellular 
pathway leading to O-mannosylation of α-dystroglycan, since disruptions in this pathway are 
linked to congenital muscular dystrophies (CMDs) in humans (Barresi & Campbell, 2006; 
Dobson et al, 2013). Clinically, CMDs are rather heterogenous ranging from patients presenting 
with mild muscle wasting that does not lower life expectancy to patients suffering from Walker-
Warburg syndrome (WWS), a condition diagnosed in new-borns that is characterised by severe 
developmental defects such as neurological and ophthalmological abnormalities and a life 
expectancy of usually only a few months after birth.
α-dystroglycan is part of a multi-protein complex, the dystrophin-glycoprotein complex, that links 
structural ECM components of  the basal lamina to the cellular cytoskeleton (Barresi & 
Campbell, 2006; Dobson et al, 2013). α-dystroglycan associates non-covalently with the 
membrane-spanning β-dystroglycan which in turn is tethered to the actin network. Development 
of mice lacking α- and β-dystroglycan is severely compromised and ceases early in utero 
underscoring its physiological importance (Williamson et al, 1997). α-dystroglycan is heavily 
glycosylated, predominantly by O-mannosylation, and the interaction of  ECM proteins such as 
laminin with α-dystroglycan is strictly dependent on this post-translational modification (Barresi 
& Campbell, 2006; Dobson et al, 2013). O-mannosylation is initiated by ER-resident 
mannosyltransferases which transfer a mannose residue from a dolichol-linked precursor to a 
Ser/Thr residue. O-linked mannose is then subject to further modifications in the Golgi 
apparatus.
In this study, two enzymes implicated in protein O-mannosylation were identified as candidate 
SPPL3 substrates. On the one hand, Sgk196 secretion was found to be elevated > 7-fold 
following SPPL3 over-expression in HEK293 cells (Tab. 4.2). This observation could be 
reproduced by Western blotting and SPPL3 over-expression was also accompanied by a 
reduction in intracellular Sgk196 levels (Fig. 4.36g). Sgk196 presumably matches SPPL3's 
substrate requirements as sequence analysis predicts a type II topology. It remains, however, to 
be tested whether Sgk196 is also secreted in an SPPL3-dependent fashion under physiological 
conditions. This is indeed needed as Sgk196 likely resides in the ER (Yoshida-Moriguchi et al, 
2013). In contrast, it was also conclusively shown that secretion of β3GnT1 is dependent on 
endogenous levels of SPPL3 (see 5.3.1.3). Notably, both Sgk196 and β3GnT1 have only 
recently been linked to α-dystroglycan O-mannosylation when mutations in SGK196 (Jae et al, 
2013) and B3GNT1 (Buysse et al, 2013; Shaheen et al, 2013), respectively, were uncovered in 
families with WWS-afflicted patients. While it was meanwhile demonstrated that SGK196 
encodes a kinase that generates 6-O-phoshorylated mannose within the core laminin-binding 
glycan moiety of  α-dystroglycan (Yoshida-Moriguchi et al, 2013), the role of  β3GnT1 in O-
mannosylation remains elusive. Interestingly, also GnT-V was recently shown to contribute to 
some extent to β1,6-GlcNAc branching of  O-mannosyl glycans in brain (Lee et al, 2012). To 
establish that SPPL3 controls cellular O-mannosylation via GT/GME shedding, it has to be 
examined whether alterations in SPPL3 expression levels also lead to changes in O-
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mannosylation patterns, for instance using α-dystroglycan glycoepitope-specific antibodies, and 
whether this also has functional consequences regarding in particular dystrophin-glycoprotein 
complex integrity and cell-basal membrane interactions.
5.3.2.4 Effects on the biological activity of cellular glycoproteins
It is important to bear in mind that glycosylation is a very common cellular post-translational 
modification. Numerous proteins are modified by glycans and, in many cases, their biological 
function is markedly affected by or dependent on the nature, i.e. the stereochemical 
composition, of  these glycans (Ohtsubo & Marth, 2006; Marth & Grewal, 2008; Dennis et al, 
2009; Moremen et al, 2012). Hence, in addition to the cellular pathways discussed in the 
previous section, alterations in SPPL3 expression levels and the concomitant changes in 
glycosylation could - in principle - affect the physiological function(s) of many cellular 
glycoproteins.
There is abundant body of evidence that altered glycosylation may interfere with or alter a given 
glycoproteins physiological function. The cell adhesion molecule N-cadherin, for instance, 
mediates cell-cell adhesion and is post-translationally modified by N-glycosylation at several 
NxS/T sites (Guo et al, 2009). Interestingly, N-cadherin-dependent cell-cell adhesion and 
outside-in signalling are strongly affected by N-alterations in N-glycan composition, e.g. by 
changes in the extent of GnT-V-mediated β1,6GlcNAc branching (Guo et al, 2003; 2009). 
Elevated GnT-V levels, for instance, led to decreased cell adhesion in a cell culture model (Guo 
et al, 2003), an effect that may be in part responsible for GnT-V's role in tumour invasiveness. 
Here, it was demonstrated that SPPL3 clearly alters the extent of N-glycosylation of N-cadherin 
(Figs. 4.16 to 4.20), therefore SPPL3 could also regulate N-cadherin function. In addition, other 
glycosylated proteins may likewise be affected in their physiological functions by SPPL3.
5.3.3 Sppl3 deficiency in mice
Animals models often are very useful to elucidate the physiological function of a gene product of 
interest. Only recently, for example, Sppl2a knockout mouse models revealed previously 
unknown roles of  this I-CLiP in B lymphocyte development (Schneppenheim et al, 2013; 
Beisner et al, 2013; Bergmann et al, 2013). Accordingly, such models could similarly be helpful 
to study SPPL3's in vivo function and to examine the potential physiological implications of 
SPPL3-mediated processing of  substrates identified here (section 5.2 & 5.3). As discussed 
earlier (section 5.3.1), this study revealed that loss of  SPPL3 causes hyperglycosylation in vivo. 
Therefore, the key question is whether and to what extent the hyperglycosylation contributes to 
or accounts for the phenotypic abnormalities associated with loss of murine Sppl3, specifically 
NK cell deficiency (5.3.3.2), male infertility (5.3.3.3) and the apparently strain-dependent 
problems in embryonic or early post-natal development (5.3.3.4).
5.3.3.1 General considerations
Proteases exhibit proteolytic activity towards a number of distinct substrates in vivo - the entire 
substrate repertoire of a given protease being referred to as substrate degradome (López-Otín 
& Overall, 2002). A major challenge, therefore, is to attribute phenotypic abnormalities caused 
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by e.g. knockout of  a protease of  interest to impaired proteolytic processing of  a certain 
substrate within the substrate degradome of that particular protease. The vast number of 
candidate SPPL3 substrates identified (see 5.2), however, might complicate analysis of  the 
molecular mechanisms underlying phenotypic abnormalities in Sppl3-/- mice. While this study at 
the same time provides evidence that impaired proteolytic processing of  GnT-V, β3GnT1 and 
β4GalT1 contributes to the hypoglycosylation phenotype associated with loss of  Sppl3, it can 
presently not be excluded that phenotypic abnormalities are entirely independent of  SPPL3's 
effect on glycosylation and relate back to impaired processing of other, non-GT/GME 
substrates.
Another obstacle is that, considering substrate biological function(s), knowledge of such is often 
based on animal models or other model systems deficient in substrate expression and/or 
bioactivity. This similarly applies to the glycobiology field, in which on the one hand several 
mouse lines have been generated that lack enzymes implicated in glycan biosynthesis 
(reviewed in (Lowe & Marth, 2003; Sarrazin et al, 2011; Dobson et al, 2013)) and on the other 
hand clinical human CDG models are at hand (Hennet, 2012). While such models allow  crucial 
insight into a given substrate's biological function, they cannot directly be phenotypically 
compared to the Sppl3-deficient mouse line used here as lack of  Sppl3 is expected to result in 
blocked substrate turnover and concomitant substrate accumulation. Hence, Sppl3 deficiency 
will likely rather mimic substrate over-expression. Therefore, mice lacking Sppl3 may potentially 
phenocopy transgenic over-expression models of certain GT substrates, yet only few  such 
models are available for direct comparison and parallel analysis.
5.3.3.2 NK cell deficiency
Initial in-depth characterisation of  a Sppl3 genetrap mouse line established that both male and 
female homozygous Sppl3 knockout mice display reduced NK cell numbers when kept on a 
mixed background (Tang et al, 2010). Using the established NK cell markers CD49b and NKp46 
(Arase et al, 2001; Walzer et al, 2007), substantially reduced numbers of  CD49b+ NKp46+ 
mature NK cells were detected in spleen and lymph node homogenates of Sppl3-/- animals 
compared to controls (Fig. 4.15) and, hence, the observations of Tang et al. could be 
reproduced. When kept under specific pathogen-free housing conditions, NK cell deficiency 
appears to be relatively well tolerated in vivo as Sppl3-/- animals can survive into adulthood. As 
NK cells are effector cells of the innate immune system equipped to combat viral infections and 
malignancies (Vivier et al, 2008), an open question is how  animals lacking Sppl3 can cope with 
such challenges in an experimental setting. 
Mature NK cells are of lymphoid origin, i.e. they ultimately derive from haematopoetic stem cells 
that eventually differentiate into committed NK cell precursors in the bone marrow  (reviewed in 
(Di Santo, 2006; Huntington et al, 2007; Yu et al, 2013)). There, but also in extra-medullary 
tissues, NK cell precursors develop into mature, CD49b+ NKp46+ NK cells which then reach 
peripheral tissues and, upon proper stimulation, exert their effector functions (e.g. cytotoxicity 
and cytokine release) (Huntington et al, 2007; Yu et al, 2013).
Therefore, either differentiation of  progenitors into mature NK cells is interrupted or homeostasis 
of mature NK cells is severely disturbed in Sppl3-deficient mice. Of note, the severity of  NK cell 
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deficiency observed in Sppl3 knockouts is well comparable with for example mice lacking IL-15 
(Kennedy et al, 2000), a key cytokine during NK differentiation (Yu et al, 2013). It is therefore of 
particular interest, to examine NK cell function and specifically NK cell development in more 
detail in the Sppl3 genetrap mouse line. Additional cell surface markers (e.g. CD122, CD117, 
CD127 and NKG2D) that allow  for detection of and discrimination between committed NK cell 
precursors and immature NK cells in the bone marrow  by multi-colour flow  cytometry could be 
employed to assess whether such developmental intermediates exist under Sppl3-/- conditions. 
Also, parallel in vitro differentiation of  Sppl3+/+ and Sppl3-/- bone marrow  progenitors into mature 
NK cells (Williams et al, 1999; Fathman et al, 2011) could allow  to elucidate potential 
disturbances due to the loss of Sppl3.
Another pressing question is what the physiological role of SPPL3 in NK cells or NK cell 
precursors is and how  its loss leads to the drastic reduction in NK cells numbers observed. Data 
showing an elevated expression of  murine Sppl3 in NK cells compared to other tissues and 
blood cell populations7  argue against an essential function of stromal cell SPPL3 expression 
during NK cell development but rather point to an important NK cell-intrinsic function of murine 
Sppl3 during NK cell development or in homeostasis of  mature NK cells. In that regard, it needs 
to be examined whether SPPL3's role in NK cell biology is linked to its function as regulator of 
glycosylation. Not unexpectedly, many NK cell-specific surface molecules are glycosylated and 
their glycosylation appears to be of functional relevance (McCoy & Chambers, 1991). In fact, 
human NK cells feature a glycosylation pattern distinct from that of  other peripheral blood cells 
as assessed by binding of plant lectins: Maackia amurensis lectin that displays binding 
specificity for α2,3-sialylated LacNAc moieties (Knibbs et al, 1991) strongly binds NK cells 
(McCoy & Chambers, 1991) whereas Erythrina cristagalli  lectin that binds asialo-
Galβ1,4GlcNAc structures (Teneberg et al, 1994) neglects NK cells (Harris et al, 1987; McCoy & 
Chambers, 1991). Interestingly, the degree of  sialylation of  individual NK cell receptors has 
been subject to investigation recently and seems to be of  functional importance (Margraf-
Schönfeld et al, 2011; Bar-On et al, 2013). Taken together, this could imply that NK cells require 
fine-tuned sialylation of  their cell surface receptors for proper development and function. It is 
possible that this can be achieved by regulating SPPL3 expression, assuming that SPPL3 could 
control the extent of  sialylation (e.g. by endoproteolysing sialyltransferases such as ST3Gal6, a 
candidate substrate identified here, Tab. 4.2, or by affecting GnT-V-mediated GlcNAc branching 
and hence indirectly the abundance of  sialylation sites). Alternatively, it is conceivable that 
SPPL3 exerts a pivotal function independent of its effect on glycosylation and GTs, i.e. by 
endoproteolysing other type II membrane proteins crucially required in NK cell progenitors or 
NK cells.
5.3.3.3 Male infertility
On a mixed background, no offspring is obtained from Sppl3-/- males suggesting that loss of 
Sppl3 leads to male infertility (Tang et al, 2010). Obviously, future experiments need to follow  up 
on this phenotypic abnormality to elucidate why and how  loss of  Sppl3 compromises male 
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7 available online via www.biogps.com and http://www.immgen.org/databrowser/index.html, queried by "SPPL3".
fertility. In principle, disturbances in spermatogenesis but also in downstream processes 
including epididymal maturation, capacitation and motility of  spermatozoa but also their egg-
binding and egg-fusion capacity are conceivable explanations for this phenotype.
Interestingly, however, a considerable body of evidence suggests that glycosylation plays a 
fundamental role during spermatogenesis in mammals (reviewed in (Benoff, 1997)), raising the 
possibility that alterations in glycosylation associated with Sppl3 inactivation can be considered 
responsible for the infertility phenotype. In male Mgat2 knockout mice that lack complex N-
glycans, for instance, no spermatozoa were found in testicular seminiferous tubules and 
spermatogenesis ceased at the spermatocyte stage pointing to a crucial role of  either GnT-II or 
complex N-glycosylation in spermatogenesis (Wang et al, 2001). Following spermatogenesis, 
spermatozoa pass through and mature in the epididymis and this is accompanied by 
remodelling of surface N-glycans (Benoff, 1997; Tulsiani, 2006). Interestingly, the epididymal 
luminal fluid was reported to be rich in soluble GTs and sugars and it was hypothesised - 
contrasting with the general assumption that secreted GTs are inactive in bodily fluids (see 
5.3.1.1) - that secreted GTs enriched in the epididymal luminal fluid have a fundamental 
physiological function and act catalytically on maturing spermatozoa to remodel their surface 
glycans (Tulsiani, 2006). This is particularly interesting in light of SPPL3's role in proteolytic GT 
secretion (see 5.3.1). Accordingly, loss of Sppl3 would preclude GT secretion into the 
epididymal lumen and, in line with the aforementioned hypothesis, this could lead to impaired 
spermatozoan maturation and infertility. Interestingly, catalytic activity attributed to secreted 
xylosyltransferase (XylT2 being likely a SPPL3 substrate, Tab. 4.2 & Fig. 3.36) was also 
described in seminal plasma of healthy human donors, but was significantly reduced in infertile 
men (Götting et al, 2002). 
In addition to spermatogenesis, another essential step during fertilisation, the binding of a 
spermatozoon to an oocyte, is similarly dependent on cell surface glycosylation (reviewed in 
(Benoff, 1997)). A factor implicated in mediating sperm-oocyte binding is the 
galactosyltransferase β4GalT1: Spermatozoa exclusively express a unique long β4GalT1 
isoform that is, unlike the commonly expressed short isoform (Roth & Berger, 1982), present on 
the cell surface where it engages in a lectin-like fashion as cell adhesion molecule that mediates 
binding to the oocyte zona pelucida glycans. The exact significance of this interaction in vivo is, 
however, not entirely clear. Sperm from mice lacking β4GalT1 displays a reduced acrosome 
reaction in vitro but B4galt1-/- males are still fertile (reviewed in (Shur et al, 2006)). Interestingly, 
β4GalT1 is also a novel candidate SPPL3 substrate (Fig. 31c) and can consequently be 
expected to accumulate in cells lacking SPPL3. Elevated β4GalT1 levels in spermatozoa also 
restrain egg binding due to precocious acrosome reactions (Youakim et al, 1994). This could 
likewise explain the observed infertility in Sppl3-/- mice. 
Taken together, the exact mechanism underlying the male infertility associated with loss of 
Sppl3 in mice remains to be elucidated. However, mammalian fertilisation seems to rely heavily 
on tightly controlled cell surface glycosylation, a process that may be subject to regulation by 
SPPL3.
136! Discussion
5.3.3.4 Strain-dependency of the Sppl3 knockout phenotype
On a mixed B6;129S5 background, homozygous animals of  the previously described Sppl3 
genetrap mouse line display the phenotypic abnormalities described in sections 5.3.3.2 and 
5.3.3.3 (Tang et al, 2010). Importantly, however, Sppl3-/- offspring on this particular genetic 
background is not obtained at expected Mendelian ratios (see 4.3.1) pointing to potential 
difficulties during embryonal or early postnatal development linked to loss of Sppl3 expression, 
a notion supported by the early of expression sppl3 mRNA in zebrafish embryos (Krawitz et al, 
2005). Moreover, when crossed back into the C57BL/6 background, no viable Sppl3-/- mice were 
obtained from matings of heterozygous males with heterozygous females (see 4.3.1), clearly 
indicating that the phenotype associated with loss of  Sppl3 is strain-dependent - which is a 
general caveat of  inbred mouse models (Ermann & Glimcher, 2012). Therefore, in order to 
entirely dissect the Sppl3-/- phenotype, more elaborate animal studies are required. First, mice 
carrying the Sppl3 genetrap insertion should be crossed into other inbred backgrounds. 
Previous observations for instance suggest that the 129S5 background harbours protective 
alleles (see 4.3.1), but the effects of loss of SPPL3 expression should similarly be assessed in 
other inbred mouse strains as this could uncover additional important physiological functions of 
SPPL3. Also, information on the nature of such protective alleles could provide crucial insight, in 
particular since the hypoglycosylation phenotype appears to be independent of the genetic 
background used as it was encountered both in living Sppl3-/- mice on a B6;129S5 background 
but also in MEFs obtained from Sppl3-/- embryos of a mouse line crossed back to the C57BL/6 
background. Second, development of Sppl3-deficient embryos in utero should be carefully 
followed, in particular in B6.129S5 mice, to determine which developmental processes or 
pathways are defective due to lack of SPPL3 expression and how  this leads to embryonic or 
early post-natal lethality.
Interestingly, similar to the observations made here for Sppl3, phenotypes of  mouse lines 
deficient in genes implicated in complex N-glycosylation seem to be often critically dependent 
on the (inbred) mouse strain used. Strain-dependent severity and nature of  phenotypic 
abnormalities was reported for instance for mice deficient in Mgat5 (Dennis et al, 2002; Lee et 
al, 2007). Another particularly interesting example is a mouse model that lacks complex N-
glycans due a deficiency in Mgat2, which codes for GnT-II (Wang et al, 2001). Mgat2-deficient 
embryos were found at lower frequencies than expected in utero and born mice died early 
postnatally due to severe gastrointestinal, haematological and osteogenic abnormalities (Wang 
et al, 2001). When crossed into an outbred mouse strain, however, Mgat2-deficient mice lived 
much longer, however, like Sppl3-/- mice on a mixed background, male Mgat2-/- mice failed to 
generate mature spermatids and were found to be infertile (Wang et al, 2001). Taken together, 
there appear to be interesting parallels between such glycosylation mouse models and Sppl3-
deficient mice.
5.3.3.5 Other SPPL3 in vivo models
Orthologues of  human SPPL3 are highly conserved in many multicellular eukaryotes (Fig. 1.9). 
Apart from murine Sppl3 ((Tang et al, 2010) and this study), however, the physiological 
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functions of SPPL3 orthologues have presently only been under investigation in zebrafish and in 
Drosophila.
In zebrafish, sppl3 mRNA is ubiquitously expressed during early embryonal developmental 
stages, even before onset of zygotic transcription suggesting maternal inheritance (Krawitz et 
al, 2005). To elucidate sppl3's role during embryonal development antisense technology was 
used to reduce endogenous sppl3 expression levels (Krawitz et al, 2005). sppl3 knockdown led 
to a phenotype characterised by neuronal cell death in brain and spinal cord (Krawitz et al, 
2005). This supports the previously discussed notion of a pivotal role of  SPPL3 during 
embryonal development (see 5.3.3.4). It is presently unclear whether reduction of cellular 
SPPL3 activity also alters N-glycosylation in zebrafish and whether this accounts for the 
phenotypic observation. Knowledge of glycosylation pathways in zebrafish is rather scarce, but, 
in principle, complex N-glycosylation occurs (Guérardel et al, 2006).
Insect genomes also harbour a conserved orthologue of human SPPL3 referred to as sppL 
(Casso et al, 2005; 2012) but loss of  this gene was phenotypically inapparent (Casso et al, 
2012). This contrasts with the previously discussed studies in mice and zebrafish. Hence, either 
a phenotype has so far been overlooked or more rigorous phenotypic characterisation of sppL-
deficient flies is required (e.g. looking into glycosylation patterns). Alternatively, sppL's function 
in Drosophila may not be as fundamentally required as in vertebrates. In that regard it is 
important to note that, while Drosophila can in principal synthesise complex N-glycans, such 
structures can only be detected in trace amounts and the Drosophila glycome is dominated by 
high-mannose- and paucimannose-type N-glycans (North et al, 2006). Hence, unlike 
vertebrates in which complex N-glycans prevail, insects appear to lack substantial amounts of 
triantennary, (poly-)LacNAc-modified glycans that are affected by changes in SPPL3 expression 
in vertebrates. This, in turn, could explain the discrepancy between arthropod and vertebrate 
models deficient in SPPL3.
5.4 How is SPPL3 activity regulated?
This study provides an initial insight into the cellular and physiological function(s) of SPPL3 and 
identifies first physiological substrates of  this protease. This, however, inevitably raises the 
question of how SPPL3 activity is regulated.
Unlike other post-translational modifications, proteolysis is an irreversible process and, hence, 
has to be tightly controlled in a physiological context. Nature has evolved a myriad of 
mechanisms to control protease activity, including regulation of protease gene expression, the 
production of protease zymogens, the expression of endogenous protease inhibitors and many 
others (reviewed in (Turk et al, 2012)). This study revealed that, unlike other mammalian GxGD 
proteases, SPPL3 catalyses endoproteolysis of  full-length substrates and, thus, this process 
appears not to be regulated in a cascade-like fashion by a preceding proteolytic cleavage as 
described earlier (see 1.1). The fundamental implication of  this is that SPPL3 may in principle 
be constitutively active towards its substrates. A pressing question therefore is how  SPPL3 
activity is regulated.
In light of its capability to endoproteolyse full-length membrane proteins, SPPL3 bears strong 
resemblance to rhomboids (see 5.1.5.5). These particular I-CLiPs are likewise constitutively 
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active and liberate membrane protein ectodomains from their TMD anchors. Nonetheless their 
activity is tightly regulated by compartmentalisation in Drosophila (Fig. 5.7). Active Drosophila 
rhomboid-1, for example, resides in the Golgi compartment. Its substrate, the EGFR ligand 
Spitz, is, however, actively retained in the ER, i.e. it is not accessible to the active rhomboid. 
Only upon expression of  Star, another membrane protein, Spitz is trafficked to the Golgi. There, 
it is cleaved off its membrane anchor by rhomboid-1 and is subsequently secreted (reviewed in 
(Urban, 2006; Freeman, 2008)). A similar mechanism of  regulation could likewise be employed 
to ensure controlled activity of SPPL3. Interestingly, the observation that distinct candidate 
SPPL3 substrates are differentially affected by either SPPL3 knockdown or over-expression 
points to a certain importance of SPPL3's sub-cellular localisation in determining whether and to 
what extent a given substrate is endoproteolysed by SPPL3.
While SPPL3 appears to be constitutively expressed, microarray datasets show  that there is a 
certain degree of variation in the expression profile of SPPL3 (Friedmann et al, 2004)8, which is 
exemplified by the higher abundance of Sppl3 mRNA in murine NK cells compared to other 
lymphocyte populations and tissues (see 5.3.3.2). This suggests that expression of  SPPL3 may 
indeed be subject to regulation on the transcriptional or post-transcriptional level. Future efforts 
should therefore be directed at identifying potential transcription factor binding sites conserved 
in SPPL3 promoter regions or binding sites of  regulatory factors within SPPL3 mRNA 
untranslated regions.
Moreover, there is indication that SPPL3 could itself  be subject to post-translational 
modification. In cultured human and murine cells, SPPL3-directed mAbs reliably detect a small 
molecular weight fragment of SPPL3 that accumulates following inhibition of  lysosomal 
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queried by "SPPL3".
Fig. 5.7: Rhomboid activity is regulated by sub-cellular compartmentalisation. In the absence of 
Star, the Drosophila  EGFR ligand Spitz is retained in the ER. Only upon encounter with Star, Spitz 
reaches the Golgi. There it is endoproteolysed by rhomboid-1, secreted and initiates EGFR signalling in a 
target cell (top). Adapted from (Freeman, 2008).
acidification (Fluhrer et al., unpublished). The abundance of this fragment - in particular in 
relation to full-length SPPL3 detected with the very same mAbs in parallel - appears to be 
different in distinct murine tissue homogenates analysed. A possible explanation for these 
observations is that the cellular pool of  active SPPL3 could be controlled by the holoprotein's 
lysosomal degradation. Given its nature as multi-pass membrane protein, this could proceed via 
an ubiquitin- and ESCRT-dependent recruitment into endocytic multivesicular bodies, the 
primary site of the cell's membrane protein degradative machinery (Hanson & Cashikar, 2012), 
but this requires experimentally verification.
5.5 Does SPPL3 have a role in Golgi proteostasis?
SPPL3 is highly conserved (Fig. 1.9) and, hence, likely fulfils a very pivotal cellular function. The 
identification of individual GTs and GMEs as novel SPPL3 substrates and the alterations in 
glycosylation following reduction or elevation of SPPL3 levels in an experimental setting 
obviously raise the possibility that the cell can control specific aspects of  glycan biosynthesis, 
for example the extent of GlcNAc branching via SPPL3-mediated GnT-V endoproteolysis. 
Astonishingly, however, employing a proteomics approach, this study does not solely identify 
selected individual GTs as novel SPPL3 substrate. On the contrary, the list of  newly identified 
(candidate) SPPL3 substrates includes a multitude of mostly Golgi-localised GTs and GMEs 
(but also other Golgi-localised proteins) and is certainly not yet complete. In fact, this study fails 
to identify any GT or GME of which secretion is not affected by SPPL3 (a possible candidate 
being fucosyltransferase VII that is not secreted (Grabenhorst & Conradt, 1999; de Vries et al, 
2001; El-Battari et al, 2003)). Together with the wide-spread phenomenon of proteolytic 
secretion among most post-ER-localised glycan-modifying enzymes (Paulson & Colley, 1989; 
Varki et al, 2009) and the lack of a known and generally accepted physiological function of  their 
secreted ectodomains, this can also imply that SPPL3 may fulfil a rather general function within 
the Golgi cisternae.
In an eukaryotic cell, the Golgi network is integral part of  the secretory pathway and serves as 
central hub that receives protein and lipid input cargo from the ER, post-translationally 
processes these macromolecules and orchestrates their ultimate intracellular targeting 
(Mellman & Simons, 1992). In spite of  the Golgi's first description more than 100 years ago, key 
aspects of Golgi biology - in particular how  protein cargo is trafficked from cis Golgi through the 
organelle to the TGN and at the same time organelle-resident enzymes are kept in place - are 
presently not completely understood (discussed in (Glick & Luini, 2011; Morriswood & Warren, 
2013)) and new  models such as the recently proposed rim progression model (Lavieu et al, 
2013) keep emerging. In fact, recent observations suggest that several Golgi trafficking modes 
exist in parallel and that it depends on the nature of the respective cargo which route of 
trafficking within the Golgi is used (Beznoussenko et al, 2014).
GTs and other type II-oriented GMEs constitute the majority of  Golgi-resident proteins that 
catalytically act on the transiting cargo. Interestingly, they are arranged in an orderly fashion 
within the polarised Golgi stack that corresponds well with the order in which these individual 
enzymes act on their glycan substrates, e.g. N-acetylglucosaminyltransferase involved in 
GlcNAc branching reside in the medial and/or trans Golgi whereas most sialyl- and 
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fucosyltransferases that catalyse terminal glycan modifications are found in the TGN (Colley, 
1997; Tu & Banfield, 2010). In fact, it is well established that these enzymes harbour intrinsic 
determinants mapping to their CTS region that govern their steady-state localisation within the 
respective Golgi sub-compartment, the exact underlying mechanisms that ensure sub-
compartment-specific protein targeting and retention, however, are still under debate and none 
of the in-depth characterised targeting motifs can explain global GT and GME localisation9 
(Colley, 1997; Tu & Banfield, 2010). Of  note, the length of a membrane protein's TMD appears 
to be a strong determinant of  its sub-cellular localisation and TMDs of Golgi-resident factors are 
generally shorter than those of  for instance plasma membrane proteins (Sharpe et al, 2010). In 
addition, proper Golgi localisation can also be ensured by protein-protein interactions via the 
GTs' N-terminal cytosolic domain. In yeast, for instance, the majority of Golgi-localised GTs 
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(reviewed in (Berger, 2002).)
Fig. 5.8: Model of SPPL3's function within the Golgi complex. To explain the differential  effects of 
endogenous and over-expressed SPPL3 on distinct Golgi-resident GMEs the existence of a SPPL3-
enriched Golgi sub-compartment is proposed. Under physiological  conditions (a), this could explain why 
only a certain fraction of GMEs (such as GnT-V or other medial/trans Golgi  GTs) is affected by SPPL3-
mediated endoproteolysis. This would for instance restrict intra-Golgi trafficking (e.g. of cis GMEs). 
Whether and how such an SPPL3-enriched sub-compartment can be reconciled with current Golgi 
models remains to be established. On condition of SPPL3 over-expression (b), it can be assumed that 
localisation of exogenous SPPL3 is less well  restricted and, hence, SPPL3 may encounter other Golgi 
GMEs (such as trans or cis GMEs) more readily leading to much more pronounced secretion of such 
factors. Intra-Golgi and post-Golgi vesicular trafficking is indicated by dashed arrows.
interact with Vps74p via their N-termini and Vps74p mediates retention of  such enzymes in the 
Golgi (Tu et al, 2008).
Another feature of GTs and GMEs that is defined by determinants residing in their CTS regions 
is whether they are subject to endoproteolysis (Grabenhorst & Conradt, 1999). Disengagement 
of GTs and other GMEs from their membrane anchors essentially excludes the ectodomain 
cleavage products from the reach of the machinery that ensures proper Golgi protein targeting 
and retention (see above). Accordingly, they can be secreted or intracellularly degraded. Hence, 
SPPL3 activity may in fact control Golgi proteostasis by mediating GT and GME shedding, i.e. 
catalysing the first (and possible rate-limiting) step of their disposal. In theory, a Golgi sub-
compartment enriched in SPPL3 (Fig. 5.8a), for instance, may serve such a purpose by 
initiating disposal of mal-sorted or corrupt proteins. This would limit intra-Golgi trafficking of such 
enzymes and control functional Golgi sub-compartmentalisation. This assumption, however, 
requires proper validation and it has to be assessed how  this can be reconciled with the current 
understanding of Golgi trafficking.
The vast number and diversity of  candidate SPPL3 substrates identified here demonstrates that 
many Golgi-resident factors harbour in principle an intrinsic susceptibility to SPPL3-mediated 
processing. At the same time, however, these substrates are differentially affected by SPPL3 
knock-down or over-expression (see 5.2.4) and this could be due to the exact sub-cellular co-
localisation of  both substrate and protease. In particular an irregular Golgi sub-compartmental 
localisation of SPPL3 on conditions of its over-expression (see 5.2.3) could very well explain 
why the protease encounters and cleaves substrates that are hardly affected by endogenous 
SPPL3 (Fig. 5.8b). To test this hypothesis, subsequent studies should exactly define the sub-
cellular compartment harbouring endogenous and over-expressed SPPL3, ideally by 
immunocytochemistry and biochemical cell fractionation. In parallel, sub-cellular localisation of 
the numerous newly identified Golgi substrates of SPPL3 should be examined and in particular 
it needs to be tested whether and to what extent their localisation is altered upon SPPL3 knock-
down as well as upon over-expression of catalytically active but also mutant SPPL3.
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 Abbreviations
For description of  protein and nucleic acid sequences abbreviations were used according to international 
recommendations described in Eur J Biochem (1984), 138, 9-37, and Eur J Biochem (1985), 150, 1-5, respectively. 
Other abbreviations used in this study are listed in the following.
Aβ  amyloid β
ACTH  adrenocorticotropic hormone
AD  Alzheimer's disease
ADAM  a disintegrin and metalloprotease
AICD  APP ICD
APH-1  anterior pharynx defective 1
APP  amyloid precursor protein
ATF6  activating transcription factor 6
β3GnT1  β1,3 N-acetylglucosaminyltransferase 1
β3GalT6  β1,3 galactosyltransferase 6
β4GalT1  β1,4 galactosyltransferase 1
BACE1  β-site of APP cleaving enzyme 1
BLAST  basic local alignment search tool
BSA  bovine serum albumin
BMDC  bone marrow-derived DC
CD  cluster of differentiation
CDG  congenital disorder of glycosylation
CHAPS  3-[(3-Cholamidopropyl)dimethylammonio]-1-propanesulphonate
CHAPSO 3-[(3-cholamidopropyl)dimethylammonio]-2-hydroxy-1-propanesulfonate
CHO (cells) chinese hamster ovary (cells)
CMD  congenital muscular dystrophy
COG  conserved oligomeric Golgi
Con A  Concanavalin A
CS  chrondroitin sulphate
CTF  C-terminal fragment
DAPT  N-[N-(3,5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester
DC  dendritic cell
DMSO  dimethylsulphoxide
DNA  deoxyribonucleic acid
DS  dermatan sulphate
DTT  dithiothreitol
ECL  enhanced chemiluminescence
ECM  extracellular matrix
EGF  epidermal growth factor
EM  electron microscopy
Endo H  endo-β-N-acetylglucosaminidase H
ER  endoplasmic reticulum
ERAD  ER-associated degradation
FACS  fluorescence-activated cell sorting
FAD  familial AD
FCS  fetal calf serum
FasL  Fas ligand
! Abbreviations! 165
FIV  feline immunodeficiency virus
FV  foamy virus
FVenv   FV envelope glycoprotein
GAG  glycosaminoglycan
GME  glycan-modifying enzyme
GnT  N-acetylglucosaminyltransferase
GO  gene ontology
gp160  HIV env glycoprotein
GSI  γ-secretase inhibitor
GT  glycosyltransferase
HEK (cells) human enbryonic kidney (cells)
HIV  human immunodeficiency virus
HO-1  heme oxygenase-1
HS  heparan sulphate
HS6ST  heparan sulphate 6-O sulphotransferase
I-CLiP  intramembrane-cleaving protease
ICD  intracellular domain
IRHD  iRhom homology domain
IL-15  interleukin-15
KS  keratan sulphate
LP  leader peptide
LacNAc  N-acetyllactosamine
LB  lysogeny broth
mAb  monoclonal antibody
MALDI-TOF matrix-assisted laser desorption/ionisation time-of-flight
Man I  α-mannosidase I
MEF  murine embryonic fibroblast
MHC  major histocompatibility complex
mRNA  messenger RNA
mut  mutant
NC  Nitrocellulose
NCT  Nicastrin
NCTim  immature NCT
NCTmat  mature NCT
NDST  bifunctional heparan sulphate N-deacetylase/N-sulphotransferase
NICD  Notch ICD
NK (cell)  natural killer (cell)
NP-40  Nonidet P-40
NTF  N-terminal fragment
pAb  polyclonal antibody
PAGE  polyacrylamide gel electrophoresis
PARL  presenilin-associated, rhomboid-like
PBS  phosphate-buffered saline
PC  pro-protein convertase
PCR  polymerase chain reaction
PEN-2  presenilin enhancer 2
PFA  paraformaldehyde
PFP  pre-flagellin peptidase
PHA-L  phytohaemagglutinin L
PNGase F peptide:N-glycosidase F
166! Abbreviations
PS1/2  presenilin 1/2
PSI-BLAST position-specific iterated BLAST
PSH  presenilin/SPP homologue
PVDF  polyvinylidene fluoride
RIP  regulated intramembrane proteolysis
RNA  ribonucleic acid
S1P  site-1 protease
S2P  site-2 protease
SAGE  submerged agarose gel electrophoresis
sAPP  secreted/soluble APP
SCAP  SREBP cleavage-activating protein
SDM  site-directed mutagenesis
SDS  sodium dodecyl sulphate
shRNA  short hairpin RNA
siRNA  small interfering RNA
SPECS  secretome protein enrichment with click sugars
SPP  signal peptide peptidase
SPPL  signal peptide peptidase-like
SREBP  sterol regulatory element binding protein
ST3Gal1 β-galactoside α2,3 sialyltransferase 1
ST6Gal1 β-galactoside α2,6 sialyltransferase 1
SU  surface subunit
TAE  Tris acetate
TBS  Tris-buffered saline
TCA  trichloroacetic acid
TCR  T cell receptor
TFPP  type IV pre-pilin peptidases
TfR1  transferrin receptor 1
TGN  trans Golgi network
TM  transmembrane subunit 
TMD  transmembrane domain
TMEM106B transmembrane protein 106B
TNFα  tumour necrosis factor α
wt  wild-type
WWS  Walker-Warburg syndrome
XylT  xylosyltransferase
(Z-LL)2 ketone 1,3-di-(N-carboxybenzoyl-L-leucyl-L-leucyl)-amino acetone
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Abstract
Protein N-glycosylation is involved in a variety of physiological and pathophysiological processes such as 
autoimmunity, tumour progression and metastasis. Signal peptide peptidase-like 3 (SPPL3) is an 
intramembrane-cleaving aspartyl protease of the GxGD-type. Its physiological function, however, has 
remained enigmatic, since presently no physiological substrates have been identiﬁed. We demonstrate 
that SPPL3 alters the pattern of cellular N-glycosylation by triggering the proteolytic release of active site-
containing ectodomains of glycosidases and glycosyltransferases such as N-acetylglucosaminyl-
transferase V, α-mannosidase I, β1,3 N-acetylglucosaminyltransferase 1 and β1,4 galactosyltransferase 
1. Cleavage of these enzymes leads to a reduction in their cellular activity. In line with that, reduced 
expression of SPPL3 results in a hyperglycosylation phenotype whereas elevated SPPL3 expression 
causes hypoglycosylation. Thus, SPPL3 plays a central role in an evolutionary highly conserved 
posttranslational process in eukaryotes. 
Keywords
Glycosyltransferases/GxGD aspartyl proteases/protein glycosylation/signal peptide peptidase like-3 
(SPPL3)/protein glycosylation
Introduction
Signal peptide peptidase-like 3 (SPPL3) is a multi-pass transmembrane protein that is highly conserved 
among multi-cellular eukaryotes and belongs to the family of intramembrane-cleaving GxGD proteases 
(Voss et al, 2013). Together with its mammalian paralogues, signal peptide peptidase (SPP) and the 
signal peptide peptidase-like (SPPL) proteases SPPL2a, SPPL2b and SPPL2c, it was ﬁrst identiﬁed by 
database queries in 2002 (Weihofen et al, 2002; Ponting et al, 2002; Grigorenko et al, 2002). Notably, all 
members of the SPP/SPPL family share characteristic structural features and catalytic motifs with the 
presenilins, the catalytically active subunits of the γ-secretase complex (Voss et al, 2013). The two 
catalytic aspartate residues required for the proteolytic activity of SPP/SPPL proteases are embedded in 
conserved YD and GxGD amino acid motifs in transmembrane domain (TMD) 6 and TMD7, respectively 
(Voss et al, 2013). Mutagenesis of either aspartate residue inactivates the respective SPP/SPPL 
(Weihofen et al, 2002; Fluhrer et al, 2006; Friedmann et al, 2006; Kirkin et al, 2007; Voss et al, 2012). In 
contrast to presenilins, which exclusively accept type I transmembrane substrates (Kopan & Ilagan, 
2004), SPP/SPPLs seem to be selective towards transmembrane substrates in type II orientation 
(Weihofen et al, 2002; Friedmann et al, 2004; Nyborg et al, 2004). While recent studies on SPP, SPPL2a 
and SPPL2b  identiﬁed substrates of these proteases in vitro and in vivo and consequently gave a ﬁrst 
impression of the physiological function of these family members (reviewed in (Voss et al, 2013)), the 
physiological function of SPPL3 has remained completely enigmatic. Highly conserved orthologues of 
mammalian SPPL3, however, are found in most multi-cellular eukaryotes pointing to a fundamental 
cellular function of SPPL3 (Voss et al, 2013). SPPL3 most likely adopts the nine TMD topology conserved 
among GxGD proteases (Friedmann et al, 2004), localises to the Golgi network (Friedmann et al, 2006) 
and is not glycosylated (Friedmann et al, 2004). Recently, we described the ﬁrst SPPL3 substrate in a cell 
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culture model system, conﬁrming the assumption that SPPL3 indeed is proteolytically active (Voss et al, 
2012). 
In eukaryotic organisms, N-glycan synthesis is initiated in the ER resulting in high-mannose type glycans 
attached to the luminal domain of secretory and membrane proteins (Kornfeld & Kornfeld, 1985). Within 
the medial- and trans-Golgi network numerous glycosyltransferase and glycosidases compete for these 
high-mannose type precursor glycans converting them into higher-order, complex N-glycans (Sears & 
Wong, 1998; Moremen et al, 2012). Most glycosyltransferases are single-span type II transmembrane 
proteins with a short N-terminal cytoplasmic tail. Their large C-terminal ectodomain that harbours the 
glycosyltransferase activity faces the lumen of the Golgi (Paulson & Colley, 1989; Sears & Wong, 1998; 
Varki et al, 2009).
Secreted glycosyltransferases were observed in conditioned media of cultured cells (Elhammer & 
Kornfeld, 1986; Saito et al, 2002; El-Battari et al, 2003), but also in bodily ﬂuids (Kim et al, 1972a; 1972b; 
Elhammer & Kornfeld, 1986; Kitazume et al, 2009) and tissues (Weinstein et al, 1987). Secretion of the 
catalytically active glycosyltransferase domain has been discussed to negatively regulate cellular protein 
glycosylation, since the crucially required nucleotide- or lipid-linked sugar donor substrates that 
exclusively occur intracellularly are not available for secreted glycosyltransferases (Paulson & Colley, 
1989; Ohtsubo & Marth, 2006; Varki et al, 2009). Secretion is generally believed to be due to proteolytic 
cleavage within the so called stem region that tethers the catalytic glycosyltransferase ectodomain to its 
membrane anchor (Paulson & Colley, 1989; Ohtsubo & Marth, 2006; Varki et al, 2009). However, the 
exact nature of the protease(s) involved in this process remains controversial. The sialyltransferase 
ST6Gal1, for instance, was initially described to be released by a cathepsin D-like protease (Lammers & 
Jamieson, 1988; McCaffrey & Jamieson, 1993). Others identiﬁed the β-site amyloid precursor protein-
cleaving enzyme 1 (BACE1) as protease responsible for ST6Gal1 cleavage in cultured cells (Kitazume et 
al, 2001) and, to a certain extent, in vivo (Kitazume et al, 2005). Secretion of the N-
acetylglucosaminyltransferase V (GnT-V) was suggested to be mediated by the γ-secretase complex 
(Nakahara et al, 2006). 
Using Sppl3 knockout mice as well as human and murine cell lines, we identify SPPL3 as a new 
fundamental mediator of glycosyltransferase secretion. SPPL3 controls the proteolytic release of the 
ectodomain of various glycosyltransferases and glycosidases, most likely by direct cleavage, and 
consequently alters cellular N-glycosylation. Therefore, we deﬁne the protease responsible for proteolytic 
cleavage of glycan-modifying enzymes and provide the ﬁrst insight into the physiological function of 
SPPL3.
Results
SPPL3 expression affects glycosylation pattern of endogenous cellular glycoproteins
Analysis of cell lysates obtained from T-RexTM-293 (HEK293) cells stably expressing SPPL3 under a 
doxycycline-inducible promoter revealed a markedly reduced molecular weight of mature Nicastrin, a 
complexly N-glycosylated γ-secretase component (Haass, 2004) (Fig. 1A). In addition, the molecular 
weight of other endogenous glycoproteins, for instance N-cadherin, SPPL2a and Lamp2, was similarly 
affected in cells expressing proteolytically active SPPL3 compared to non-induced cells (Fig. 1A). 
Notably, expression of the catalytically inactive SPPL3 D200N/D271N mutant (SPPL3 DD/NN) had no 
effect on the molecular weight of these glycoproteins (Fig. 1A), indicating that proteolytic activity of 
! Appendix! 199
SPPL3 is crucially required for the observed molecular weight changes. Doxycycline treatment of non-
transfected HEK293 cells had no effect on the molecular weight of the respective glycoproteins analysed 
(Fig. E1). In contrast to SPPL3 overexpression, siRNA-mediated SPPL3 knockdown induced a slight 
increase in the molecular weight of various glycoproteins compared to cells transfected with non-targeting 
control siRNAs or untransfected cells (Fig. 1B). Importantly, solely the molecular weight of the mature, 
complexly glycosylated variant of Nicastrin was changed by alterations in SPPL3 expression levels, while 
the immature variant remained unaffected (Fig. 1A & B). Moreover, non-glycosylated proteins such as the 
ER chaperone calnexin were not affected by alterations in SPPL3 expression levels (Fig. 1A & B). We 
consequently hypothesised that SPPL3 interferes with cellular N-glycosylation, resulting in a reduced 
extent of N-glycan modiﬁcations, i.e. hypoglycosylation, upon SPPL3 overexpression and a more 
extensive N-glycan modiﬁcation, i.e. hyperglycosylation, upon reduction of SPPL3 expression. To support 
this hypothesis, lysates from HEK293 cells expressing SPPL3 were subjected to enzymatic 
deglycosylation by peptide:N-glycosidase F (PNGase F) or endoglycosidase H (Endo  H) (Fig.1C). As 
expected, the hypoglycosylation phenotype induced by SPPL3 overexpression was completely abolished 
by treatment with PNGase F, but was still detectable after treatment with Endo H (Fig. 1C). Moreover, 
glycoproteins in SPPL3 overexpressing cells remained Endo H-resistant, indicating that SPPL3 
selectively interferes with complex N-glycosylation. To verify this, we treated cells with the plant alkaloid 
kifunensine (Fig. 1D) which is a potent inhibitor of cellular α-mannosidase I activity and, accordingly, 
blocks generation of both hybrid- and complex-type N-glycans (Elbein et al, 1990). As expected, 
kifunensine treatment completely eliminated generation of mature glycoproteins and SPPL3 failed to 
decrease the molecular weight of glycoproteins in kifunensine-treated cells (Fig. 1D), demonstrating that 
SPPL3 interferes with complex N-glycosylation occurring in the medial- and trans-Golgi network following 
modiﬁcation by α-Man I but not with early steps of ER-based N-glycan assembly.
Sppl3-deﬁcient mice exhibit a hyperglycosylation phenotype
To address whether a similar function of SPPL3 is apparent under physiological conditions, we analysed 
glycoproteins in tissue homogenates of Sppl3-deﬁcient mice and littermate controls. On a mixed C57BL/
6;129S5 background Sppl3-deﬁcient mice are viable and present with a rather mild phenotype that is 
characterised by growth retardation and hematologic abnormalities as well as sterility in male 
homozygous mice (Tang et al, 2010). Similar to our observations upon SPPL3 knockdown (Fig. 1B), the 
molecular weight of mature Nicastrin and SPPL2a slightly increased in brain (Fig. 2A), lung (Fig. 2B), 
spleen (Fig. 2C) and immortalized mouse embryonic ﬁbroblasts (MEFs) (Fig. 2D) obtained from Sppl3-/- 
mice compared to Sppl3+/+ littermate controls. In addition to these rather ubiquitously expressed 
glycoproteins, glycoproteins expressed in a tissue-speciﬁc manner, for instance N-cadherin in brain (Fig. 
2A) or CD68 in spleen (Fig. 2C), similarly displayed a hyperglycosylation phenotype in Sppl3-/- mice, 
suggesting that SPPL3 has a rather global effect on cellular N-glycosylation. Similar to hypoglycosylation 
in SPPL3 overexpressing cells, hyperglycosylation in brain homogenates of Sppl3-/- mice and in Sppl3-/- 
MEFs was absent after treatment with PNGase F (Fig. E2A & B). Taken together, these data demonstrate 
that SPPL3 expression inﬂuences complex cellular N-glycosylation not only in a cellular model system but 
also in vivo.
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SPPL3 mediates secretion of GnT-V
In light of the results obtained upon kifunensine treatment (Fig. 1D), we reasoned that SPPL3 affects N-
glycosylation either by interfering with α-mannosidase I activity or another glycan-modifying enzyme 
downstream of α-mannosidase I. In addition, the molecular weight changes observed upon SPPL3 
expression in HEK293 cells (Fig. 1a) were rather substantial. Thus, it is likely that SPPL3 does not 
exclusively affect terminal glycan modiﬁcations as a deregulation of these would not lead to such 
pronounced differences in molecular weight of glycoproteins. We rather assumed that SPPL3 interferes 
with N-acetylglucosaminyl (GlcNAc) branching and/or the generation of N-acetyllactosamine moieties 
(Fig. 3A). 
Accordingly, we investigated whether SPPL3 directly or indirectly affects cellular levels of 
glycosyltransferases implicated in these processes. We found that SPPL3 profoundly affects GnT-V 
(gene name: MGAT5), which is involved in GlcNAc branching (Fig. 3A). GnT-V levels in both supernatant 
and lysate were strongly reduced following transfection with a MGAT5-speciﬁc siRNA pool (Fig. 3B), 
demonstrating that the GnT-V signal obtained in Western Blot was speciﬁc and that endogenous GnT-V is 
secreted in HEK293 cells. Upon siRNA-mediated knockdown of SPPL3, secretion of endogenous GnT-V 
was markedly reduced and the protein strongly accumulated intracellularly (Fig. 3B). Moreover, cellular 
GnT-V, which itself is known to be complexly glycosylated (Kamar et al, 2004), was found to shift to a 
slightly higher molecular weight, indicating that SPPL3 knockdown also induces GnT-V 
hyperglycosylation (Fig. 3B). In contrast, doxycycline-induced SPPL3 overexpression, yet not doxycycline 
treatment per se, caused GnT-V hypoglycosylation accompanied by a strong reduction of cellular GnT-V 
levels (Fig. 3B  & Fig. E3). Similar results were obtained from HEK293 cells co-expressing exogenous 
GnT-V and either SPPL3 wt (Fig. 3C) or a SPPL3-speciﬁc shRNA (Fig. 3D). In HEK293 cells over-
expressing GnT-V we observed two distinct GnT-V species, immature, EndoH-sensitive GnT-V and 
complex glycosylated, mature GnT-V (Fig. 3C, D & Fig. E4). Exogenous co-expression of active SPPL3 
and GnT-V resulted in slightly increased GnT-V secretion and reduction of intracellular mature GnT-V, 
while immature GnT-V remained unaffected (Fig. 3C). Moreover, SPPL3 overexpression induced 
hyperglycosylation of secreted GnT-V but did not affect the molecular weight of immature GnT-V (Fig. 
3C). Catalytically inactive SPPL3 did not affect levels of secreted and intracellular GnT-V (Fig. 3C). In 
contrast, shRNA mediated knock-down of SPPL3 slightly reduced secretion of exogenous GnT-V and 
induced hyperglycosylation exclusively of the mature intracellular GnT-V species (Fig. 3D). This received 
additional support from pulse-chase experiments performed in cells expressing epitope-tagged GnT-V 
that were either co-expressing catalytically active SPPL3 (Fig. E5A) or were transfected with SPPL3- 
speciﬁc siRNA (Fig. E5B). Taken together, this suggests that SPPL3 acts on GnT-V most likely in the 
Golgi, where both GnT-V (Chen et al, 1995) and SPPL3 (Friedmann et al, 2006) may co-localise. Next, 
we examined cellular GnT-V levels and GnT-V secretion in SPPL3-/- MEFs (Fig. 3E). As expected, GnT-V 
was more abundant in lysates from Sppl3-/- MEF than in wild-type control cells and its secretion was 
almost completely abolished in Sppl3-deﬁcient cells (Fig. 3E).
To ﬁnally investigate whether SPPL3 also modulates cellular GnT-V activity, we performed lectin blots 
(Fig. 3F). Both mature and immature Nicastrin immunoprecipitated from HEK293 cells expressing active 
SPPL3 were detected by Concanavalin A, which has a broad reactivity towards mannose-containing 
glycans (Cummings & Etzler, 2009). Strikingly, reactivity towards PHA-L, a leucoagglutinin that 
predominantly binds N-glycans that harbour the GlcNAcβ1,6Man motif generated by GnT-V activity 
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(Cummings & Kornfeld, 1982), was strongly reduced in cells over-expressing SPPL3 (Fig. 3F, lane 4) 
compared to cell with endogenous SPPL3 levels (Fig. 3F, lane 2). To control for speciﬁcity of lectin 
binding, cells were treated with kifunensine, which resulted in impaired complex glycosylation of mature 
Nicastrin. As expected, immature Nicastrin was only detected by ConA but not by PHA-L. In contrast, 
mature Nicastrin from non-treated cells was readily detected by both lectins (Fig. 3F). This indicates that, 
upon SPPL3 expression, glycans on mature Nicastrin are less extensively modiﬁed by GnT-V. To 
investigate whether this generally applies, we isolated secreted glycoproteins from cells overexpressing 
SPPL3 and control cells, isolated attached N-glycans and analysed the latter by liquid chromatography-
mass spectrometry (LCMS, Fig. 3G, E6 and Suppl. Tab. 1). Differences between both samples became 
already apparent in LC chromatograms (Fig. E6A). Subsequent analysis of N-glycan species by mass 
spectrometry revealed that, as expected from previous experiments (Fig. 1D), SPPL3 overexpression 
was not associated with marked changes in high mannose or hybrid N-glycans (Fig. 3G & Suppl. Tab. 1). 
It did, however, affect the relative abundance of complex N-glycan species. Cells overexpressing SPPL3 
were found to secrete glycoproteins more extensively modiﬁed with complex bi-antennary as well as 
bisected complex bi-antennary N-glycans. These N-glycan species are expected to accumulate when 
GnT-V activity is impaired (Fig. 3A) (Lee et al, 2012). Moreover, under these conditions, tri-antennary and 
tetra-antennary N-glycans were less abundant on secreted glycoproteins. Since GnT-V activity 
contributes to the generation of tri-antennary and tetra-antennary N-glycans (Fig. 3A), this further 
demonstrates that reduction in intracellular GnT-V levels observed following SPPL3 over-expression 
(Fig. 3A & B) is also associated with impaired cellular GnT-V activity.
GnT-V secretion results from proteolytic cleavage 
In order to conﬁrm that GnT-V secretion is due to proteolytic cleavage (Fig. 4A), we co-expressed N-
terminally Flag- and C-terminally V5-tagged GnT-V and SPPL3 wt (Fig. 4B). The secreted variant of the 
epitope-tagged GnT-V retained its anti-V5 immunoreactivity, yet was not anti-Flag reactive, demonstrating 
that it had been N-terminally truncated (Fig. 4B). In addition, we determined the cleavage site within GnT-
V using a GnT-V expression construct that lacks the bulk of the GnT-V ectodomain and allows for 
puriﬁcation and mass spectrometric analysis of secreted, GnT-V-derived peptides (Fig. E7). In 
conditioned supernatants from cells expressing this construct we detected ﬁve individual peptides with N-
termini between residues L29 and T33 at the lumenal membrane interface. As demonstrated before 
(Nakahara et al, 2006), one of the most abundant peptides originates from proteolytic cleavage between 
L30 and H31. Since it was previously suggested that γ-secretase is responsible for the release of GnT-V 
in a pancreas carcinoma cell line (Nakahara et al, 2006), we treated HEK293 cells with the potent γ
−secretase inhibitors (GSIs) L-685,458 (Shearman et al, 2000) or N-[N-(3,5-diﬂuorophenacetyl)-L-alanyl]-
S-phenylglycine t-butyl ester (DAPT) (Dovey et al, 2001). Both GSIs efﬁciently interfered with γ-secretase 
activity, as demonstrated by the drastically impaired secretion of endogenous Aβ, a well-established γ-
secretase cleavage product (Haass, 2004), and the intracellular accumulation of APP C-terminal 
fragments, the corresponding γ-secretase substrates (Haass, 2004), in a concentration-dependent 
fashion (Fig. 4C). We failed, however, to detect an inhibitor concentration-dependent reduction of GnT-V 
secretion and a concomitant intracellular GnT-V accumulation (Fig. 4C). Moreover, endogenous 
glycoproteins were not hyperglycosylated in PS1/PS2 double-deﬁcient MEFs that lack the catalytically 
active γ-secretase subunits (Fig. 4D) as observed in Sppl3-/- cells (Fig. 2D & Fig. 4D). Instead, we 
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observed a mild hypoglycosylation on endogenous glycoproteins in these MEFs compared to control cells 
that could be due to a slightly higher SPPL3 expression in the PS1/PS2 double-deﬁcient MEFs (Fig. 4D). 
Finally, we did not observe a reduction of GnT-V secretion in PS1/2 double-deﬁcient MEFs (Fig. 4E), 
while GnT-V secretion was clearly impaired in Sppl3-/- cells (Fig. 3E). In sum, this clearly demonstrates 
that alterations in cellular N-glycosylation observed before (Figs. 1-4) are not linked to γ-secretase 
activity. Instead, our data suggest that the secretion of GnT-V is due to proteolytic cleavage of GnT-V by 
SPPL3. 
SPPL3 mediates secretion of other glycan-modifying enzymes
Assuming that SPPL3 over-expression in HEK293 cells results in hypoglycosylation solely due to the loss 
of intracellular GnT-V activity, we expected that SPPL3 over-expression would phenocopy a siRNA-
mediated knockdown of GnT-V. As expected, both SPPL3 over-expression and GnT-V knockdown 
resulted in hypoglycosylation of endogenous glycoproteins, but the extent of glycoprotein molecular 
weight changes were more drastic upon SPPL3 over-expression (Fig. 5A). This observation suggested 
that GnT-V is not the only glycan-modifying enzyme affected by SPPL3. Indeed, we found that β1,3 N-
acetylglucosaminyltransferase 1 (β3GnT1, gene name: B3GNT1) and β1,4 galactosyltransferase 1 
(β4GalT1, gene name: B4GALT1) were affected by SPPL3 in a manner resembling its effect on GnT-V. 
SPPL3 over-expression caused hypoglycosylation of secreted β3GnT1 (Fig 5B & E8A) and β4GalT1 
(Fig. 5D) accompanied by a reduction of cellular β3GnT1 (Fig. 5B  & E8A) or β4GalT1 (Fig. 5D) levels, 
respectively. Upon SPPL3 knockdown (Fig. 5B, 5D & E8A) as well as in lysates from Sppl3-/- MEF (Fig. 
5C & 5E) intracellular β3GnT1 and β4GalT1 accumulated and secretion of β4GalT1 was strongly 
reduced (Fig.   5B, 5D, 5E & E8A). In addition, SPPL3 over-expression resulted in an statistically 
signiﬁcant increase in secretion of α-Man I (gene name: MAN1B1) (Fig. 5F & Fig. E8B).
Taken together, our results demonstrate that SPPL3 alters cellular N-glycosylation, most likely by directly 
cleaving several glycosyltransferases and glycosidases to release their active site-containing ectodomain 
and thus reducing their respective intracellular activity.
Discussion
Proteolytic secretion of a number of distinct glycosyltransferases is a well-established concept (Paulson & 
Colley, 1989; Ohtsubo & Marth, 2006; Varki et al, 2009) and has been previously observed in cell culture 
as well as in vivo (Kim et al, 1972a; 1972b; Elhammer & Kornfeld, 1986; Weinstein et al, 1987; Saito et al, 
2002; El-Battari et al, 2003). However, the protease(s) involved in this process have not been 
unambiguously identiﬁed and the physiological implications of proteolytic glycosyltransferase secretion 
are unclear.
In the present study, we identify ER-/Golgi-resident type II-oriented glycan-modifying enzymes as a novel 
substrate class for SPPL3. Recently, we reported that SPPL3, unlike γ-secretase (Struhl & Adachi, 2000), 
SPP (Lemberg & Martoglio, 2002), and SPPL2b  (Martin et al, 2009), can cleave a viral full-length 
membrane protein substrate without previous shortening of its ectodomain (i.e. shedding) and thus is, in 
contrast to all other members of the GxGD protease family, capable of acting like a sheddase. Since most 
glycosyltransferases and glycosidases are type II transmembrane proteins, which are the preferred 
substrates for proteolytic cleavage by SPP/SPPL proteases (reviewed in (Voss et al, 2013)), it is very 
likely that SPPL3 may directly mediate, shedding of glycosyltransferases and glycosidases. This notion, 
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however, requires further experimental validation, ideally in an in vitro setting that is devoid of any other 
cellular factors than SPPL3 and the respective substrate.
Another unresolved question is to what extent proteolytic cleavage affects glycosyltransferase activity in 
vivo. Isolated soluble glycosyltransferases retain their catalytic activity in vitro when reactions are 
supplemented with nucleotide-conjugated monosaccharides (Elhammer & Kornfeld, 1986), but in vivo 
nucleotide-conjugated monossacharides are only present intracellularly. Accordingly, secretion of the 
active site-containing glycosyltransferase domain is discussed as a potential mechanism to regulate the 
extent of cellular glycan modiﬁcations (Paulson & Colley, 1989; Ohtsubo & Marth, 2006; Varki et al, 2009). 
Here, we demonstrate that SPPL3 alters N-glycosylation in a cell culture model but also in living animals 
by mediating the proteolytic release of glycosyltransferases and glycosidases. While, under physiological 
conditions, glycosyltransferase secretion is in equilibrium with membrane-bound glycosyltransferase, 
ensuring a particular pattern of glycan modiﬁcations (Fig. 6a), over-expression of SPPL3 reduces the 
amount of catalytically active glycosyltransferases within the Golgi compartment causing 
hypoglycosylation of cellular glycoproteins (Fig. 6b). In case of α-Man I and overexpressed GnT-V this 
reduction of active enzyme in cell lysates and the concomitant effect of hypoglycosylation is accompanied 
by a strong increase of glycosidase secretion. Secretion of endogenous GnT-V, β4GalT1 and β3GnT1, 
however, was only marginally increased under these conditions, indicating that a certain amount of 
glycosyltransferases released from Golgi compartments may rather be subjected to intracellular 
degradation than being secreted. In contrast, reduced levels of endogenous SPPL3 strongly diminish 
glycosyltransferase secretion and catalytically active glycosyltransferases accumulate within the Golgi 
compartment resulting in more extensive modiﬁcation of cellular N-glycans, i.e. hyperglycosylation (Fig. 
6c). In line with this, we were able to show using LCMS that SPPL3 over-expression was accompanied 
by reduction in tri-antennary and tetra-antennary N-glycans. Consequently, SPPL3 functions as a 
mediator of cellular N-glycosylation, providing the ﬁrst insight into one possible physiological function of 
this GxGD intramembrane protease. 
Using a truncated GnT-V model substrate, we mapped the cleavage site of SPPL3 within a peptide 
stretch predicted to localise to the membrane border of GnT-V. One of the major cleavage sites (L30-H31) 
had previously been identiﬁed by N-terminal sequence analysis of puriﬁed secreted GnT-V, but was 
attributed to a cleavage by the γ-secretase complex (Nakahara et al, 2006). γ-secretase is generally 
considered to selectively cleave type I transmembrane protein substrates with a rather short ectodomain 
(Steiner et al, 2008; Hemming et al, 2008; Haapasalo & Kovacs, 2011). Nonetheless, we tested whether 
inhibition of γ-secretase affects secretion of endogenous GnT-V. Two potent GSIs, which are not cross-
reactive with SPPL3 (Voss et al, 2012), however, did not impact on GnT-V secretion. Moreover, while we 
observed neither impaired GnT-V secretion nor alterations in N-glycosylation in γ-secretase-deﬁcient 
MEFs, both phenotypic abnormalities were apparent in Sppl3-/- MEF cells. Since secretion of GnT-V was 
not completely abolished in SPPL3-/- MEFs, it is, however, possible that other proteases also marginally 
contribute to the secretion of GnT-V. 
SPPL3 is found in multicellular organisms, including plants, arthropods, and mammals (Voss et al, 2013). 
In addition, its degree of conservation is extraordinarily high (e.g. human and murine SPPL3 proteins are 
> 99.7% identical), suggesting it was evolved to fulﬁl a fundamentally important physiological function in 
multicellular organisms. N-glycosylation is such a fundamental physiological process. Complex N-glycans 
are critically involved in various physiological processes including, for instance the regulation of cell-to-
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cell interactions and cell signalling - processes that are essentially required for multi-cellularity (Ohtsubo & 
Marth, 2006). While defects in Golgi N-glycosylation, are well tolerated and often phenotypically 
unapparent in cultured cells, they have often been associated with overt phenotypic abnormalities in 
murine genetic models but also in inherited human diseases (Lowe & Marth, 2003). On a mixed C57BL/
6;129S5 background, Sppl3-deﬁcient animals feature a rather mild phenotype (Tang et al, 2010), though 
they are not obtained at expected Mendelian ratios (data not shown). Interestingly, when backcrossed to 
the C57BL/6 background, we failed to obtain viable homozygous knockout animals suggesting that 
Sppl3deﬁciency leads to embryonic or early post-natal lethality (data not shown). Hence, we assume that 
SPPL3 orchestrates cellular N-glycosylation in multicellular organisms, but the respective phenotype of 
SPPL3 deﬁciency strongly depends on strain-dependent modiﬁer alleles, a phenomenon also observed in 
animals lacking GnT-II or GnT-V (Wang et al, 2001; Dennis et al, 2002). Presently, however, we cannot 
exclude that SPPL3 fulﬁls additional biological functions that could likewise lead to the observed 
phenotypic abnormalities.
Moreover, glycosylation plays a fundamental role in the pathophysiology of human diseases (Ohtsubo & 
Marth, 2006; Dennis et al, 2009), for instance in cancer progression and metastasis (Dennis et al, 1999). 
GlcNAc branching and cellular hexoseamine metabolism in particular have emerged as important cellular 
processes recently and deregulation has been linked to human developmental defects or other disorders 
(Lau & Dennis, 2008; Dennis et al, 2009; Grigorian et al, 2009). GnT-V expression, for instance, is up-
regulated in tumours and, consequently, PHA-L reactivity is higher in such tumours (reviewed in (Dennis 
et al, 1999)). Moreover, high GnT-V expression levels correlate with the metastatic potential and poor 
prognosis in colorectal carcinoma (Murata et al, 2000). On the other hand, loss of β1,6GlcNAc branching 
results in hyperreactive T cells and autoimmune disorders in mice (Demetriou et al, 2001). Importantly, all 
these observations are thought to be intricately linked to the generation of poly-N-acetyllactosamine 
binding motifs that allow recruitment of a given glycoprotein into the glycoprotein-galectin lattice (Dennis 
et al, 2009). Therefore, it is particularly interesting that we identiﬁed GnT-V, β3GnT1 and β4GalT1, which 
are all implicated in the generation of poly-N-acetyllactosamine-carrying N-glycans, as SPPL3 substrates. 
GnT-V generates N-glycans preferably modiﬁed by poly-N-acetyllactosamines (van den Eijnden et al, 
1988; Ujita et al, 1999) and β3GnT1 (Sasaki et al, 1997), together with β4GalT1 (Ujita et al, 2000), 
elongates these sugar chains. 
In summary, we identify a family of biological substrates of SPPL3, providing a ﬁrst insight into the 
physiological function of this GxGD intramembrane protease. SPPL3 emerges as mediator of cellular N-
glycosylation in mammals, as it appears to control the cellular availability of glycosyltransferases and 
glycosidases for N-glycan elaboration by facilitating their proteolytic liberation. Therefore, it is tempting to 
speculate that other Golgi glycosyltransferases may similarly be subject to endoproteolysis mediated by 
SPPL3 and that SPPL3 may interfere with disease processes in which cellular glycosylation is 
dysregulated.
Materials and methods:
Antibodies, lectins, and other reagents
Monoclonal antibodies directed against human SPPL3 (clone 7F9) and SPPL2a (clone 6E9) as well as a 
polyclonal antibody directed against murine SPPL2a were described previously (Behnke et al, 2011; Voss 
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et al, 2012; Schneppenheim et al, 2013). The monoclonal (2D8) and polyclonal (3552 & 6687) anti-Aβ 
antibodies have been described elsewhere (Shirotani et al, 2007; Yamasaki et al, 2006; Steiner et al, 
2000) as well as the polyclonal anti-PS1 antibody (rabbit pAb, 2953) (Walter et al, 1997). Other antibodies 
used in this study were obtained from commercial sources as follows: Anti-Nicastrin (rabbit pAb, N1660, 
Sigma-Aldrich, St. Louis, USA), anti-Nicastrin (mouse mAb, clone 35, BD Biosciences, Franklin Lanes, 
USA), anti-human Lamp2 (mouse mAb, clone H4B4, Developmental Studies Hybridoma Bank, University 
of Iowa, USA), anti-human Lamp2 (rabbit pAb, ab37024, Abcam, Cambridge, UK), anti-mouse Lamp2 
(mouse mAb, clone ABL-93, Developmental Studies Hybridoma Bank), anti-N-cadherin (mouse mAb, 
clone 10C32, BD Biosciences), anti-GnT-V (mouse mAb, clone 706824, R&D Systems, McKinley Place, 
USA), anti-CD68 (rat mAb, FA-11, AbD serotec, Düsseldorf, Germany), anti-V5 (mouse mAb, R960-25, 
Life Technologies, Carlsbad, USA), anti-Flag (rabbit mAb, F7425, Sigma), anti-Calnexin (rabbit pAb, Enzo 
Life Sciences, Farmingdale, USA), anti-B3GNT1 (mouse mAb, clone 724057, R&D Systems), anti-
MAN1B1 (mouse mAb, clone 30-Y, Santa Cruz Biotechnology (Dallas, USA), anti-B4GALT1 (goat pAb, 
AF3609, R&D Systems). Horseradish peroxidase (HRP)-conjugated secondary antibodies were 
purchased from Promega (Madison, USA) and Dianova (Hamburg, Germany). For immunoblotting, all 
antibodies were diluted in phosphate buffered saline (PBS) containing 0.5% (v/v) Tween-20 (PBS-T) and 
supplemented with 2% (w/v) Tropix® I-BLOCK™ blocking reagent (Applied Biosystems, Life 
Technologies, Carlsbad, USA). The HRP-conjugated anti-HA antibody 3F10 was from Roche Diagnostics 
(Rotkreuz, Switzerland). Biotinylated lectins and HRP-conjugated streptavidin were obtained from Vector 
Laboratories (Burlingame, USA). Kifunensine was purchased from Santa Cruz Biotechnology and was 
dissolved in double-distilled water. The γ-secretase inhibitors DAPT and L-685,458, were from Enzo Life 
Sciences and Calbiochem (Darmstadt, Germany), respectively. All protease inhibitors were dissolved in 
DMSO.
Molecular cloning and cDNA constructs
The cDNA that encodes SPPL3 is based on Genbank RefSeq NM_139015.4. Mutations to generate 
SPPL3 D200N/D271N were introduced by site-directed mutagenesis (primer sequences are available 
upon request) as described earlier (Voss et al, 2012). SPPL3 D200N/D271N containing a C-terminal HA-
tag (YPYDVPDYA) was subcloned into the EcoRI and XhoI sites of pcDNA 4/TO A (Invitrogen). Human 
MGAT5 coding sequences were purchased from Source BioScience (Nottingham, UK), PCR-ampliﬁed 
and sub-cloned using XhoI and KpnI restriction enzymes into pcDNA3.1hygro+ (Life Technologies). To 
obtain tagged full-length GnT-V, an N-terminal Flag (DYKDDDDK) epitope tag after the initiating 
methionine residue and a C-terminal in-frame V5 (GKPIPNPLLGLDST) epitope tag, respectively, were 
introduced using PCR ampliﬁcation. Tagged GnT-V was subcloned into pcDNA3.1hygro+ using XhoI and 
KpnI. All primer sequences are available upon request and all cloned expression constructs were 
sequenced veriﬁed prior to experimental use.
Cell lines and cell culture experiments
All cells were cultured in DMEM GlutaMAX™ media (Life Technologies) supplemented with L-glutamine 
(Life Technologies), 10% (v/v) fetal calf serum (Sigma-Aldrich) and 1% (v/v) penicillin/streptomycin (Life 
Technologies). Stably transfected HEK293 cells expressing SPPL3 under the control of a doxycycline-
inducible promoter have been described before (Martin et al, 2008). To obtain stable cell lines expressing 
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SPPL3 D200N/D271N T-RexTM-293 (Invitrogen) were transfected with the respective plasmid DNA as 
described above. Transfection of cells was carried out using Lipofectamine 2000 (Invitrogen) according to 
the manufacturer’s instructions, and single cell clones were generated by selection in 200 µg/ml zeocine 
(Invitrogen). To induce expression of SPPL3, cells were incubated with 1 µg/ml doxycycline (BD 
Biosciences) added to the cell culture medium for at least 48 h. T-RexTM-293-derived clonal cell lines that 
express plasmids encoding SPPL3-, SPPL2a- and non-targeting shRNAs (Sigma-Aldrich), respectively, 
or epitope-tagged Flag-GnT-V-V5 were generated as described before (Martin et al, 2008). PS1/PS2 
double-deﬁcient MEFs that lack active γ-secretase were described elsewhere (Herreman et al, 2003) and 
were kindly provided by Dr Bart de Strooper. Transient transfections with plasmid DNA were carried out 
using Lipofectamin 2000 (Life Technologies) according to the manufacturer’s instructions. To achieve 
transient knock-downs, T-RexTM-293 cells were reversely transfected with siGENOME SMARTpools 
(Thermo Scientiﬁc, Waltham, USA) targeting human SPPL3 (#M-006042-02), B3GNT1 (#M-012307-01), 
B4GALT1 (#M-012965-00) or MGAT5 (#M-011334-01) (all dissolved in RNAse-free water (Qiagen, 
Hilden, Germany)) at a ﬁnal concentration of 20 nM using Lipofectamin RNAiMax™ (Life Technologies) 
according to the manufacturer’s instructions. To collect conditioned supernatants, the respective culture 
media were removed from cells after 24 h or 48 h and cleared from detached cells by centrifugation or 
0.2 µm ﬁltration. Protease inhibitor treatment was performed for 16 h at the concentrations indicated. To 
inhibit complex- and hybrid-type N-glycosylation, cultured cells were treated with kifunensine at a ﬁnal 
concentration of 4 μg/ml for 48 h. To detect secretion of endogenous Aβ, cells were incubated in serum-
free Optimem™ + GlutaMAX™ (Life Technologies) over night. To enrich for secreted factors by 
trichloroacetic acid (TCA) precipitation, cells were washed twice and then incubated in pre-warmed 
Optimem™ + GlutaMAX™. Following harvest, 1/5 volume 100% (w/v) TCA was added, samples were 
mixed and incubated on ice for 1 h. Following centrifugation (13,000 rpm, 4°C, 30 min), supernatants 
were discarded and pellets washed twice with cold acetone. Dried pellets were re-suspended in non-
reducing sample buffer and normalised to lysate protein content prior to loading.
Mice, tissue homogenates, and MEFs
The genetrap  mouse line C57BL/6;129S5-Sppl3Gt(OST279815)Lex/Mmucd was obtained from the Mutant 
Mouse Regional Resource Center (MMRRC) at the University of California at Davis, CA, USA. These 
mice were described earlier (Tang et al, 2010) and have generously been made available to the research 
community by Genentech, Inc., and Lexicon Pharmaceuticals, Inc. These mice were inter-crossed to 
maintain the C57BL/6;129S5 hybrid background. Age- and sex-matched animals were sacriﬁced and 
indicated organs were removed and snap-frozen on dry ice. Thawed organs were cut into pieces and 
homogenised in ice-cold buffer (5 mM Tris x HCl, pH 7.4, 250 mM sucrose, 5 mM EGTA, supplemented 
with protease inhibitor mix (1:500, Sigma)), ﬁrst using a Wheaton tissue grinder (Thermo Scientiﬁc), then 
23G needles. Homogenates were centrifuged for 5  min  at  5,000  rpm in a tabletop centrifuge. The 
supernatants were again subjected to centrifugation (13,000 rpm, 1 h, 4oC). Pellets were re-suspended in 
homogenisation buffer containing 2%  (v/v) Triton X-100 and incubated on ice for 30 min. Lysates were 
cleared from cell debris by centrifugation (13,000  rpm, 1  h, 4°C) and subjected to SDS-PAGE and 
Western blotting. MEFs were obtained from mice that had been backcrossed to the C57BL/6 background 
for ﬁve generations. Heterozygous mice were mated and embryos were removed at E13.5. Cells were 
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taken into culture and immortalised as described earlier (Xu, 2005). All animals and derived cells were 
genotyped by PCR (primer sequences are available upon request).
Immunoblotting, lectin blotting, enzymatic deglycosylation and immunoprecipitation
Cells were harvested on ice and lysed in ice-cold STE buffer (150 mM NaCl, 50 mM Tris (pH 7.6), 2 mM 
EDTA) supplemented with 1% (v/v) NP-40 and 1% (v/v) Triton X-100 and protease inhibitor mix (1:500). 
Protein concentrations in lysates were determined using the BCA assay (Interchim, Montluçon, France) 
and, prior to loading on gels, samples were normalised accordingly. For lectin blotting, membranes were 
ﬁrst incubated in 5% (w/v) BSA in PBS-T over-night. Biotin and streptavidin blocking was performed using 
a commercial kit (Vector Laboratories) according to the manufacturer’s instructions. Membranes were 
incubated with the respective biotinylated lectin (2 µg/ml in lectin buffer (10 mM HEPES, pH 7.5, 150 mM 
NaCl, 0.1 mM Ca2+, 0.08% (w/v) NaN3) for one hour at room temperature. Following three washing steps 
(10 min each with PBS-T), blots were incubated with a streptavidin-HRP conjugate (2 µg/ml, diluted in 
PBS-T) at room temperature for 30 min. After three additional washing steps, blots were developed using 
conventional ECL chemistry (GE Healthcare, Chalfont St Giles, UK). For enzymatic deglycosylation, 
proteins in cell lysates were denatured in glycoprotein denaturation buffer (New England Biolabs, Ipswich, 
USA) supplemented with 1% (w/v) SDS by incubation at 95°C for 10 min. Samples were diluted tenfold 
with deglycosylation buffer (50 mM Na2HPO4, pH 7.2, 12 mM EDTA, 0.4% (v/v) NP-40) and digested with 
endoglycosidase H (Endo  H) (Roche) or peptide:N-glycosidase F (PNGase F) (Roche) overnight. 
PNGase F removes all N-glycans irrespective of their exact structure and composition (Maley et al, 1989), 
while Endo  H only removes high-mannose and hybrid but not complex glycan structures from 
glycoproteins (Maley et al, 1989). Immunoprecipitations, gel electrophoresis, and immunoblotting were 
carried out as described previously (Krawitz et al, 2005; Fluhrer et al, 2006). Immunoblots and lectin blots 
were developed using ECL™ or ECL™ Prime chemistry (GE Healthcare, Chalfont StGiles, UK) and X-ray 
ﬁlms.
N-glycan analysis by nanoLCMS
One day after plating of cells, SPPL3 over-expression was induced by supplementing culture medium 
with doxycycline as described earlier. 48 h later cells were washed twice with pre-warmed, serum-free 
DMEM and incubated in serum-free DMEM supplemented with doxycycline for another 72 h to collect 
secreted glycoproteins. Conditioned supernatants were harvested and detached cells were removed by 
centrifugation. Supernatants were concentrated roughly 40-fold by centrifugation (4,200 rpm at 4°C) in an 
ultraﬁltration unit with a molecular weight cut-off of 5,000 (Vivaspin, Sartorius, Göttingen, Germany). 
Concentrated proteins were collected by TCA precipitation as detailed earlier. Dried pellets were 
resuspended in PBS and transferred into ultraﬁltration vials with a molecular weight cut-off of 10,000 
(Vivaspin, Sartorius, Göttingen, Germany). Samples were washed and buffer was exchanged to 
denaturation solution (6 M Guanidine hydrochloride, 50 mM Tris HCl and 5 mM EDTA) by centrifugation. 
Samples were reduced (16 mM dithiothreitol, DTT) for 15 min at 37°C followed by alkylation (30 mM 
iodoacetamide) for 1  hour at 37°C in the ultraﬁltration units. Denaturation solution was subsequently 
removed by centrifugation and samples were diluted in PBS. N-glycans were released by digestion with 
PNGaseF which was conducted for 17 h at 37°C. Released N-glycans were eluted by centrifugation and 
desalted using 96-well PGC (porous graphitized carbon) plates (Thermo Scientiﬁc, Waltham, USA). PGC 
208! Appendix
resin was conditioned with 70% (v/v) acetonitrile (ACN); 0.1% (v/v) triﬂuoroacetic acid (TFA) and 
equilibrated with 0.1% (v/v) TFA in water. After sample application resin was washed with 0.1% (v/v) TFA 
in water. N-glycans were eluted with 40% (v/v) ACN; 0.1% (v/v) TFA and dried using vacuum 
centrifugation. Dried N-glycans were resuspended in water (10  µl) and 2-aminobenzoic acid (2-AA) 
labelling solution (15 µl; 50 mg/ml 2-AA; 80 mg/ml picoline borane in 70:30 DMSO: acetic acid (v/v)). 
Reductive amination was performed at 37°C for 17 h. Excess label was removed by gelﬁltration using 
Sephadex G-10 columns (GE Healthcare). NanoLCMS analysis of 2-AA N-glycans was performed as 
described earlier (Higel et al, 2014).
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Figure legends:
Figure 1 - SPPL3 expression affects cellular N-glycosylation. 
A SPPL3 overexpression results in a reduced molecular weight of glycoproteins. Electrophoretic mobility 
of the endogenous glycoproteins Nicastrin (NCT), N-cadherin (N-cad), SPPL2a, and Lamp2 was studied 
in whole cell lysates of HEK293 cells by Western blotting following separation by SDS-PAGE. Expression 
of either HA-tagged catalytically active SPPL3 (wt) or an inactive SPPL3 mutant (DD/NN) was induced by 
doxycycline treatment (+ Dox) for 72 h. Cells not treated with doxycycline (- Dox) were used as controls. 
In cells expressing catalytically active SPPL3 the glycoproteins analysed displayed a reduced molecular 
weight. Note that only mature (NCTmat) but not immature (NCTim) Nicastrin is affected. Treatment of 
parental HEK293 cells with doxycycline had no effect on glycoprotein electrophoretic mobility (Fig. E1).
B SPPL3 knockdown results in a slightly higher molecular weight of endogenous glycoproteins. Lysates 
of non-transfected (none) HEK293 cells as well as of HEK293 cells transfected with non-targeting (ctrl) or 
SPPL3-targeting siRNA pools were analysed for electrophoretic mobility of endogenous glycoproteins as 
described in A. Reduction of SPPL3 protein levels was accompanied by a slight increase in glycoprotein 
molecular weight. 
C Alterations in glycoprotein molecular weight induced by SPPL3 overexpression are due to altered N-
glycosylation. Whole cell lysates from SPPL3-expressing HEK293 cells (+ Dox) and non-induced control 
cells (- Dox) were deglycosylated using peptide:N-glycosidase F (PNGase F) or endoglycosidase H 
(Endo H) prior to analysis by SDS-PAGE and immunoblotting. Non-treated cell lysates served as control 
(untreated). Arrows and/or brackets indicate the respective glycosylated (glyc) and deglycosylated 
(deglyc) protein species. SPPL3 overexpression had no impact on the molecular weight of deglycosylated 
proteins. Note that anti-Lamp2 (H4B4) immunoreactivity was lost following complete N-glycosylation. N-
deglycosylated Lamp2 was detected using another anti-Lamp2 antibody (ab37024).
D Kifunensine treatment abolishes the effect of SPPL3 overexpression on cellular N-glycosylation. 
HEK293 cells overexpressing SPPL3 (+ Dox) were treated with solvent (control) or kifunensine for 16h to 
block complex N-glycosylation. Non-transfected as well as non-induced (- Dox) cells served as control. 
Electrophoretic mobility of the indicated endogenous glycoproteins was monitored as described in A. 
Upon kifunensine treatment, endogenous glycoproteins were less extensively glycosylated and migrated 
faster. SPPL3 failed to further reduce the glycoprotein molecular weight.
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In all panels, Calnexin was used as a loading control. Antibodies used to visualize the respective proteins 
in Western blot are indicated.
Figure 2 - Sppl3-deﬁcient mice exhibit a hyperglycosylation phenotype. 
A, B, C Electrophoretic mobility of selected endogenous glycoproteins in brain A, lung B and spleen C 
homogenates obtained from Sppl3-deﬁcient (-/-) mice was analysed by SDS-PAGE and subsequent 
immunoblotting. Age- and sex-matched wt (+/+) and heterozygous (+/-) littermates served as controls. As 
assessed by Western blotting (second panel from the bottom), SPPL3 protein expression was absent in 
homogenates of all tissues from Sppl3-/- animals and was reduced in the heterozygous mouse. Note that, 
in all tissues analysed, glycoproteins such as mature Nicastrin (NCTmat), Lamp2 and SPPL2a but also 
tissue-speciﬁc glycoproteins such as N-cadherin (N-cad) in brain and CD68 in spleen exhibited a higher 
molecular weight in Sppl3-deﬁcient animals compared to control animals. Note that, the molecular weight 
of immature Nicastrin (NCTim) was not altered in Sppl3-/- tissues.
D Analysis of glycoprotein molecular weight in immortalised MEF derived from a Sppl3-deﬁcient embryo 
(-/-). MEF derived from wt (+/+) and heterozygous (+/-) littermates served as controls. Total cell lysates 
were analysed as described in Fig. 1A. Similar to tissue homogenates, glycoproteins displayed a higher 
molecular weight in cultured Sppl3-deﬁcient cells compared to control cells.
In all panels, Calnexin was used as a loading control. Antibodies used to visualize the respective proteins 
in Western blot are indicated. 
Figure 3 - SPPL3 affects secretion of the N-acetylglucosaminyltransferase GnT-V. 
A Schematic overview of Golgi asparagine (Asn)-linked N-glycan processing and GlcNAc branching 
resulting in the generation of high-mannose, hybrid and complex N-glycans (grey boxes). The latter types 
of glycans are subsequently subjected to terminal modiﬁcation (not depicted). Kifunensine interferes with 
N-glycosylation by blocking α-mannosidase I (α-Man I) activity. After modiﬁcation by α-mannosidase II (α-
Man II) glycoproteins gain Endo H-resistance. Mannose (Man) residues are depicted as green circles. N-
acetylglucosaminyltransferases (GnTs) attach N-acetylglucosamine (GlcNAc) residues (blue squares) to 
the core mannose residues in speciﬁc stereochemical conﬁgurations (red). Modiﬁed after (Sears & Wong, 
1998) and (Stanley et al, 2009).
B SPPL3 affects secretion of endogenous GnT-V. HEK293 cells were transfected with non-targeting (ctrl), 
SPPL3-speciﬁc or MGAT5-speciﬁc siRNA pools (20 nM each). SPPL3 over-expression was induced by 
doxycycline (+ Dox). GnT-V levels were examined by SDS-PAGE and Western blotting in conditioned 
supernatants (sGnT-V) and whole cell lysates (GnT-V). Cellular SPPL3 levels were similarly analysed.
C & D SPPL3 affects secretion of over-expressed GnT-V. GnT-V was transiently transfected C into 
HEK293 cells stably over-expressing catalytically active SPPL3 (wt) or the inactive SPPL3 D200N/D271N 
mutant (DD/NN) or D into cells that stably expressed non-targeting (ctrl), SPPL2a- or SPPL3-speciﬁc 
shRNAs. GnT-V levels were analysed in conditioned supernatants (sGnT-V) and lysates (GnT-V) as 
described in B. Note that under over-expression conditions, two GnT-V species were detected, mature 
GnT-V (GnT-Vmat) and immature GnT-V (GnT-Vim) (see Fig. E4). n.t., not transfected.
E GnT-V secretion is impaired in Sppl3-deﬁcient MEF cells. GnT-V levels were monitored in whole cell 
lysates and in TCA-precipitated conditioned supernatants of Sppl3-deﬁcient (-/-) MEFs and wt (+/+) 
controls as described in B. 
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F SPPL3 over-expression reduces lectin binding. Nicastrin (NCT) was immunoprecipitated from HEK293 
cells over-expressing catalytically active SPPL3 following doxycycline induction (+ Dox) and from non-
induced control cells (- Dox). Immunoprecipitates were visualized either with an anti-Nicastrin monoclonal 
antibody or the biotinylated lectins, Concanavalin A (ConA) and PHA-L, respectively. Note that PHA-L 
only detected mature Nicastrin (NCTmat), and that PHA-L reactivity was reduced in cells over-expressing 
SPPL3. Kifunensine-treated (+ KF) cells were used as a control and lacked PHA-L-reactive N-glycans.
G SPPL3 over-expression reduces GnT-V-mediated glycan branching. N-glycans on secreted 
glycoproteins from HEK293 cells (empty bars) and cells over-expressing SPPL3 (hatched bars) following 
doxycycline induction were analysed by liquid chromatography-mass spectrometry. Bar graphs depict the 
relative abundance of the indicated N-glycan species. Bar graphs are colour-coded and the assigned 
individual N-glycan species are listed in Suppl. Tab. 1 accordingly.
In panels B  to F, Calnexin was used as a loading control. Antibodies and lectins used to visualize the 
respective proteins in Western blots are indicated. 
Figure 4 - GnT-V secretion in HEK293 cells occurs via a SPPL3-dependent proteolytic mechanism. 
A Similar to most Golgi glycosyltransferases, GnT-V is a type II membrane protein. It comprises a short 
cytosolic N-terminus, a TMD, a luminal stem region and the luminal catalytic ectodomain. Its secretion is 
likely mediated by proteolytic cleavage (scissors) at the TMD/stem region boundary.
B GnT-V secretion occurs via a proteolytic mechanism. HEK293 cells were stably transfected with N-
terminally Flag-tagged and C-terminally V5-tagged GnT-V (Flag-GnT-V-V5). In lysates, mature (GnT-Vmat) 
and immature (GnT-Vim) species of Flag-GnT-V-V5 were detected by Western blotting. Intracellular GnT-
Vmat was reduced and soluble GnT-V (sGnT-V) enriched in conditioned supernatants of cells co-
expressing SPPL3 (+ Dox). Note that sGnT-V was detected using the ectodomain-speciﬁc mAb  and an 
anti-V5 antibody but was not reactive with antibodies directed against the N-terminal Flag tag, suggesting 
that sGnT-V lacks an intact Flag tag. n.t., not transfected, *, unspeciﬁc band.
C GnT-V secretion is not affected by GSI treatment. HEK293 cells were treated for 16 h with the GSIs 
DAPT and L-685,458 at the concentrations indicated. Vehicle-treated cells (DMSO) served as control. 
GnT-V levels were monitored by Western blotting in conditioned supernatants (sGnT-V) and in cell lysates 
(GnT-V). To control for γ-secretase inhibition, β-amyloid precursor protein (APP) processing by γ-
secretase was monitored. To this end, total secreted amyloid-β  peptide (Aβ) was immunoprecipitated (IP) 
from conditioned supernatants. Immunoprecipitates were analysed by Western blotting. Levels of full-
length APP and APP C-terminal fragments (APP CTF) were likewise monitored in cell lysates. GSI 
treatment led to a concentration-dependent reduction in Aβ secretion and a concomitant intracellular 
accumulation of APP CTF indicating that APP processing by γ-secretase was blocked. Note, however, 
that GnT-V secretion was altered following GSI treatment. The increase in secreted Aβ at low GSI 
concentrations has been observed before (Shen & Kelleher, 2007).
D Loss of γ-secretase activity does not induce hyperglycosylation. Glycoproteins were analysed in PS1/
PS2-deﬁcient (-/-) and control (+/+) MEFs and compared to Sppl3-deﬁcient (-/-) MEFs as described in Fig. 
1A. Note that PS1/PS2-/- MEFs display a mild hypoglycosylation phenotype which could be explained by 
the slightly higher SPPL3 expression compared to the respective control.
E GnT-V levels were analysed in lysates (GnT-V) and TCA-precipitated conditioned supernatants (sGnT-
V) of PS1/PS2-/- MEFs and of control cells as described in Fig. 3E. Note that GnT-V secretion was not 
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abrogated by loss of γ-secretase activity whereas loss of SPPL3 was associated with a marked reduction 
in secretion of GnT-V. 
Figure 5 - SPPL3 similarly affects other glycosyltransferases and glycosidases.
A Loss of GnT-V expression does not phenocopy SPPL3 over-expression. HEK293 cells transiently 
transfected with non-targeting (ctrl), SPPL3-speciﬁc or MGAT5-speciﬁc siRNA pools (20 nM each) and 
HEK293 cells over-expressing SPPL3 (+ Dox) were analysed for electrophoretic mobility of endogenous 
mature Nicastrin (NCTmat), N-cadherin (N-cad), SPPL2a, and Lamp2 as described in Fig. 1A. Note, that 
hypoglycosylation induced by SPPL3 overexpression is more pronounced compared to transfection with 
MGAT5-speciﬁc siRNAs suggesting that GnT-V is not the only SPPL3 substrate contributing to SPPL3 
effects on N-glycosylation.
B SPPL3 affects secretion of β1,3 N-acetylglucosaminyltransferase 1 (β3GnT1). HEK293 cells were 
transfected with B3GNT1-speciﬁc, non-targeting (ctrl) or SPPL3-speciﬁc siRNA pools as in A. β3GnT1 
levels were analysed by immunoblotting in conditioned supernatants (sβ3GnT1) and cell lysates 
(β3GnT1). β3GnT1 strongly accumulated intracellularly following siRNA-mediated SPPL3 knockdown in 
HEK293 cells and sβ3GnT1 secretion was signiﬁcantly decreased (see also quantiﬁcation in Fig. E7 A). 
Overexpression of SPPL3 in doxycycline-induced cells (+ Dox) resulted in a reduction of β3GnT1 in 
cellular lysates. Antibody staining was speciﬁc as β3GnT1 as well as sβ3GnT1 levels were reduced in 
cells transfected with a B3GNT1-speciﬁc siRNA pool. 
C β3GnT1 accumulates in Sppl3-deﬁcient MEFs. β3GnT1 levels were monitored by Western blotting in 
whole lysates (β3GnT1) obtained from Sppl3-deﬁcient (-/-) or wt control (+/+) MEFs. In Sppl3-/- MEFs, 
β3GnT1 strongly accumulated intracellularly. 
D SPPL3 affects secretion of β1,4 galactosyltransferase 1 (β4GalT1). The experiment was conducted as 
in B, yet a siRNA pool targeting B4GALT1 was used to control for antibody speciﬁcity. Intracellular 
β4GalT1 levels and levels of secreted β4GALT1 (sβ4GalT1) were monitored by Western blotting using a 
speciﬁc antibody. Note that SPPL3 knockdown reduced β4GalT1 secretion while intracellular β4GalT1 
accumulated intracellularly. SPPL3 overexpression reduced intracellular β4GalT1 levels.
E β4GalT1 secretion is impaired in Sppl3-deﬁcient MEFs. β4GalT1 and sβ4GalT1 levels were monitored 
in lysates and TCA-precipitated conditioned supernatants obtained from Sppl3-deﬁcient (-/-) or wt control 
(+/+) MEFs by Western blotting.
F SPPL3 affects secretion of α-mannosidase I (α-Man I). In a setting similar to B, intracellular (α-Man I) 
and secreted (sα-Man  I) levels of α-Man I were analysed in lysates and conditioned supernatants, 
respectively. Note that SPPL3 knockdown led to a mild intracellular accumulation of α-Man I and soluble 
α-Man I strongly accumulated in the supernatant of cells over-expressing SPPL3 (see also quantiﬁcation 
in Fig. E7 B&C).
Antibodies used to visualise the respective proteins in Western blots are indicated. 
Figure 6 - Model depicting the effect of SPPL3 on glycosyltransferase secretion and cellular N-
glycosylation.
A  Membrane-tethered glycosyltransferases (GT, green) mature in the Golgi stacks (bold arrows) and are 
destined to catalyse protein glycosylation in particular subcompartments (depicted here: generation of a 
tri-antennary N-glycan, e.g. by GnT-V activity) leading to a speciﬁc glycosylation proﬁle on a particular 
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glycoprotein (purple). Under physiological conditions, the endogenous SPPL3 pool (red) facilitates 
proteolytic liberation of a certain fraction of the Golgi glycosyltransferases from their membrane anchor 
resulting in their subsequent secretion (soluble glycosyltransferases, sGT).
B More abundant SPPL3 protein in the Golgi, e.g. upon over-expression, results in a substantially larger 
fraction of glycosyltransferase turned over proteolytically, leading to enhanced glycosyltransferase 
secretion and loss of intracellular glycosyltransferase activity. Consequently and as proteolytic cleavage 
occurs prematurely, glycans are not modiﬁed by the given glycosyltransferase (depicted here: no tri-
antennary N-glycans) resulting in a hypoglycosylation phenotype.
C In cells lacking SPPL3, glycosyltransferase secretion is impaired as glycosyltransferases are not 
endoproteolysed. Hence, active glycosyltransferases accumulate in their destined compartment, resulting 
in more extensively glycan modiﬁcation (depicted here: only triantennary N-glycans) and a 
hyperglycosylation phenotype.
Expanded View legends:
Figure E1. Doxycycline treatment per se does not affect cellular glycorptoteins. This ﬁgure depicts 
the very same experiment shown in Fig. 1A of the main text version. As a control, it includes non-
transfected HEK293 cells (untransf.) that were treated with doxycycline (+ Dox) in the same manner as 
cells overexpressing SPPL3 to exclude that the effects observed following induction of SPPL3 
overexpression in a clonal derivative of these cells are due to the doxycycline treatment per se. 
Figure E2. Hyperglycosylation phenotype in Sppl3-/- tissues and MEF is abolished by enzymatic 
deglycosylation. Brain homogenates A from a Sppl3-deﬁcient mouse (-/-) and a wild-type (+/+) littermate 
control or whole cell lysates from immortalized MEFs obtained from a Sppl3-deﬁcient (-/-) embryos and 
wild-type (+/+) control B were subjected to enzymatic deglycosylation with peptide:N-glycosidase F 
(PNGase F), endoglycosidase H (Endo H) prior to analysis by SDS-PAGE and Western blotting. Controls 
were left untreated. The indicated N-glycosylated (glyc) proteins were analysed. Complexly glycosylated 
mature Nicastrin (NCTglyc), N-cadherin (N-cadglyc) and SPPL2a (SPPL2aglyc) are resistant to Endo H 
treatment and display a higher apparent molecular weight in brain tissue obtained from a Sppl3-/- animal 
compared to the Sppl3+/+ control. Upon PNGase F digestion, no difference in the molecular weight of N-
deglycosylated protein species (NCTdeglyc, N-caddeglyc and SPPL2adeclyc) between brain homogenates and 
MEF from Sppl3-deﬁcient (-/-) and wt controls (+/+) was detectable. Antibodies used to visualize the 
respective proteins in Western blots are indicated. 
Figure E3. Endogenous GnT-V, β3GnT1 and α-Man I levels are not altered by doxycycline 
treatment per se. Intracellular levels of GnT-V, β3GnT1 and α-Man I were monitored by Western blotting 
in total lysates of non-transfected control HEK293 cells and of cells overexpressing catalytically active 
SPPL3 following doxycycline treatment (+ Dox). Note that doxycycline treatment of non-transfected 
control cells does not affect intracellular levels of the indicated glycosyltransferases excluding that 
doxycycline treatment per se causes the alterations in glycosyltransferase levels.
Figure E4. Upon GnT-V overexpression immature GnT-V is detected in cellular lysates. Cell lysates 
of HEK293 cells transiently overexpressing GnT-V were subjected to enzymatic deglycosylation with 
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peptide:N-glycosidase F (PNGase F), endoglycosidase H (Endo H) or were left untreated prior to analysis 
by SDS-PAGE and Western blotting. Note that the higher molecular weight GnT-V species (GnT-Vmat) is 
resistant to Endo H treatment and was only deglycosylated by PNGase F, demonstrating that this species 
is complexly glycosylated and likely localises to post-ER compartments. In contrast, the lower molecular 
weight GnT-V species (GnT-Vim) is deglycosylated by Endo H as well as PNGase F treatment and, thus, 
harbours no complex N-glycans. Antibodies used to visualize the respective proteins in Western blots are 
indicated.
Figure E5. Effect of SPPL3 on GnT-V secretion and maturation. Intracellular and secreted levels of 
pulse-labelled Flag-GnT-V-V5 were analysed in cells overexpressing catalytically active SPPL3 and in 
control cells (A) or in cells transfected with SPPL3-speciﬁc or non-targeting siRNA pools (B). Three days 
after doxycycline-mediated induction of exogenous SPPL3 expression (A) and 4 days after transfection 
with siRNA pools (20 nM, B) cells were starved for 3 hours in serum-, methionine- and cysteine-free 
DMEM. For metabolic labelling, cells were incubated for 10 min in in serum-, methionine- and cysteine-
free DMEM supplemented with [35 S] methione/[35 S] cysteine (ca. 85 µCi/ 6 cm dish; Hartmann Analytics, 
Braunschweig, Germany). Subsequently, cells were incubated for the indicated time periods in DMEM 
supplemented with 10% (v/v) fetal calf serum, 2 mM methionine and 2 mM cysteine. Conditioned 
supernatants were collected and subjected to anti-V5 immunoprecipitation. Cells were washed once with 
ice-cold PBS and lysed. Lysates cleared by centrifugation were subjected to immunoprecipitations as 
indicated. Immunoprecipitates were separated by SDS-PAGE and transferred to PVDF membranes for 
documentation by autoradiography. Note that pulse-labelled immature intracellular GnT-V was not 
affected by SPPL3 over-expression, while under these conditions GnT-V secretion was strongly promoted 
and intracellular mature GnT-V was hardly detectable. siRNA mediated knockdown of SPPL3 reduced 
GnT-V secretion and cuased hyperglycosylation of the mature intracellular GnT-V species.
Figure E6. N-glycan analysis by liquid chromatography-mass spectrometry. A Liquid chromatogram 
of N-glycans released by PNGase  F digestion from secreted glycoproteins that were collected from 
HEK293 control cells (bottom) and cells overexpressing SPPL3 upon doxycycline induction (top). N-
glycan species assigned are colour-coded as in Fig. 3G  and Suppl. Tab. 1. B Expression controls. SPPL3 
overexpression was tested in lysates from cells analysed in Fig. 3G, Suppl. Tab. 1 and A. In addition, 
Nicastrin running behaviour was analyzed and, as expected (Fig. 1A), SPPL3 overexpression was 
associated with an increased electrophoretic mobility of mature Nicastrin (NCTmat), but not of immature 
Nicastrin (NCTim). 
Figure E7. Determination of SPPL3 cleavage sites within GnT-V. A Schematic presentation of the 
epitope-tagged GnT-V N-terminal fragment (NTF) model substrate comprising amino acids 2 to 61 of the 
GnT-V holoprotein and an N-terminal V5 as well as a C-terminal Flag epitope tag. Amino acids are 
depicted using the one letter code, the predicted TMD (amino acids 14 to 30 (Shoreibah et al, 1993)) is 
illustrated in grey. At the very C-terminus an alanine-proline motif was added to prevent degradation of 
liberated fragments by exopeptidases. To generate this expression construct, the GnT-V NTF coding 
sequence was ampliﬁed by PCR and tags were introduced via the respective primers (sequences 
available upon request). The PCR fragment was subcloned via XhoI and KpnI into pcDNA3.1hygro (+) 
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(Invitrogen). The expression construct was then transiently transfected into cells as indicated in B. B 
Mass spectrometric analysis of GnT-V NTF cleavage products secreted into conditioned supernatants of 
HEK293 cells (top  panels) or HEK293 cells stably transfected with either SPPL3 wt (middle panels) or the 
SPPL3 D200N/D271N (DD/NN) mutant. Conditioned media of cells indicated were collected after 4 h and 
GnT-V NTF cleavage products were puriﬁed by immunoprecipitation using anti-Flag M2-conjugated 
agarose beads. Following agitation at 4°C overnight, beads were washed three times with IP/MS buffer 
(0.1% N-octylglucoside 10 mM Tris-HCl, pH 8.0, 5 mM EDTA, 140 mM NaCl) and three times with sterile 
water. Eluted peptides were analysed by MALDI-TOF MS as described earlier (Fukumori et al, 2010) with 
a ACTH (7 to 38) reference peptide to obtain relative peak intensities. SPPL3 wt or DD/NN expression 
was achieved by supplementing media with doxycycline (induced) and the respective uninduced cells 
were used as controls. Mass spectrometric analysis revealed ﬁve peptides (coloured and numbered (1 to 
5) arrowheads) that mapped to the GnT-V NTF and were absent in immunoprecipitates of untransfected 
control cells. The very same peptides were more abundant in conditioned supernatants of SPPL3 wt-
overexpressing cells but not of mutant SPPL3-expressing cells. C Overview of peptide fragments 
assigned to the peaks detected. obs. mass, observed mass. calc. mass, calculated mass.
Figure E8. Quantiﬁcation of SPPL3 effects on β3GnT1 and α-Man I secretion. Effects of SPPL3 
expression levels on sβ3GnT1 (A), sα-Man I (B) and cellular α-Man I (C) described in Fig. 5 of the main 
text were quantiﬁed. Respective Western Blot panels depicting the particular protein quantiﬁed in lysates 
or in TCA-precipitated conditioned supernatants (sup) as well as the respective Calnexin controls are 
shown (upper panels). (B) and (C) were obtained from the same samples, therefore the Calnexin panel is 
identical. For quantiﬁcation, Western blot signals from three independent experiments were acquired 
digitally using the LAS 4000 (Fujiﬁlm, Japan). sβ3GnT1, sα-Man I and α-Man I signals, respectively, were 
quantiﬁed using the MultiGauge software (Fujiﬁlm) and normalized to Calnexin Western blots signals 
obtained from cell lysates. Reference samples (non-targeting siRNA-transfected cells (ctrl) and cells not 
treated with doxycycline (- Dox), respectively) were set to 1. Statistical analysis using the two-tailed, 
unpaired t-test was conducted with the Graphpad Prism software. n.s., not signiﬁcant, p  > 0.05, *, p  ≤ 
0.05, ***, p ≤ 0.001. Error bars depict SEM (n = 3).
Suppl. Tab. 1. Overview of N-glycans identiﬁed by liquid chromatography-mass spectrometry in 
HEK293 cells and cells overexpressing SPPL3. The table summarises all N-glycan species identiﬁed, 
their calculated and observed masses as well as their relative abundance on secreted glycoproteins 
obtained from HEK293 control cells and cells over-expressing SPPL3. N-glycans are colour-coded as 
indicated and this code is also used in Fig. 3G and Fig. E6.
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